

PCT


WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁶ : C07D 471/04, 403/10, 405/14, 409/14, 413/14, 417/14, 487/04, A61K 31/435, 31/50</p>	<p>A1</p>	<p>(11) International Publication Number: WO 95/16687 (43) International Publication Date: 22 June 1995 (22.06.95)</p>
<p>(21) International Application Number: PCT/US94/14112 (22) International Filing Date: 8 December 1994 (08.12.94) (30) Priority Data: 08/168,564 16 December 1993 (16.12.93) US 08/324,631 18 October 1994 (18.10.94) US 08/347,528 5 December 1994 (05.12.94) US (71) Applicant: ABBOTT LABORATORIES [US/US]; CHAD 0377/AP6D-2, 100 Abbott Park Road, Abbott Park, IL 60064-3500 (US). (72) Inventors: SUMMERS, James, B., Jr.; 1955 St. Andrews Drive, Libertyville, IL 60048 (US). DAVIDSEN, Steven, K.; 1002 Gracewood, Libertyville, IL 60048 (US). CURTIN, Michael, L.; 2205 Rolling Ridge Lane, Linden- hurst, IL 60046 (US). HEYMAN, H., Robin; 400 North McClurg Court, Chicago, IL 60610 (US). SHEPPARD, George, S.; 300 Laurel Avenue, Wilmette, IL 60091 (US). XU, Lianhong; 219 Adler Drive, Libertyville, IL 60048 (US). CARRERA, George, M., Jr.; 9379 Bay Colony Drive, Des Plaines, IL 60016 (US). GARLAND, Robert, B.; 2529 Walters Avenue, Northbrook, IL 60062 (US).</p>		<p>(74) Agents: JANSSEN, Jerry, F. et al.; Abbott Laboratories, CHAD 0377/AP6D-2, 100 Abbott Park Road, Abbott Park, IL 60064-3500 (US). (81) Designated States: AU, CA, JP, KR, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i></p>

(54) Title: PLATELET ACTIVATING FACTOR ANTAGONISTS: IMIDAZOPYRIDINE INDOLES



(57) Abstract

The present invention relates to compounds of formula (I) and the pharmaceutically acceptable salts thereof which are potent antagonists of PAF and are useful in the treatment of PAF-related disorders including asthma, shock, respiratory distress syndrome, acute inflammation, transplanted organ rejection, gastrointestinal ulceration, allergic skin diseases, delayed cellular immunity, parturition, fetal lung maturation, and cellular differentiation.

BEST AVAILABLE COPY

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				


PLATELET ACTIVATING FACTOR ANTAGONISTS: IMIDAZOPYRIDINE INDOLES

Technical Field

5 This invention relates to compounds having pharmacological activity, to compositions containing these compounds, and to a medical method of treatment employing the compounds and compositions. More particularly, this invention concerns certain indolecarbonyl pyridylpyrrolothiazole compounds and their salts which have platelet activating factor (PAF) antagonist activity, to pharmaceutical
10 compositions containing these compounds, and to a method of treating PAF-mediated disorders.

Background of the Invention

Platelet activating factor (PAF) is a phospholipid released from human and
15 other animal cells and is an acetylglceryl ether of phosphorylcholine as represented by the following formula:




20 where n is 15 or 17.

PAF is physiologically active and causes contraction of the airway smooth muscle, increased vascular permeability, platelet aggregation, hypotension, and the like. It is now recognized as a powerful mediator of inflammation and may play a physiological or pathobiological role in a variety of clinical conditions, such as asthma
25 and pulmonary dysfunction, acute inflammation, transplanted organ rejection, shock, thrombosis, anaphylaxis, gastrointestinal ulceration, allergic skin diseases, retinal and corneal diseases, chemically induced liver cirrhosis, and ovimplantation in pregnancy. Accordingly, compounds possessing PAF antagonistic effects should be of value in the treatment of any of the above conditions.

2

Summary of the Invention

The present invention provides, in its principal aspect, compounds having PAF antagonist activity of formula I:




or the pharmaceutically acceptable salt thereof where R^1 is one or more groups independently selected from the group consisting of (a) hydrogen, (b) halogen, (c) hydroxy, (d) cyano, (e) alkyl of one to six carbon atoms, (f) alkynyl of two to four carbon atoms, (g) alkoxy of one to six carbon atoms, (h) alkanoyl of one to seven carbon atoms, (i) $-COOR^6$, where R^6 is hydrogen, alkyl of one to ten carbon atoms, or phenylalkyl where the alkyl portion is of one to four carbon atom, (j) phenyl, optionally substituted with (j-1) alkyl of one to six carbon atoms, (j-2) alkoxy of one to six carbon atoms, (j-3) halogen, (j-4) $-NR^4R^5$, where R^4 and R^5 are independently selected from hydrogen and alkyl of one to six carbon atoms, or R^4 and R^5 together with the nitrogen atom to which they are attached form a pyrrolidinyl, piperidinyl, piperazinyl, or morpholinyl ring, (j-5) $-COOR^6$, (j-6) $-CONR^4R^5$, or (j-7) $-SO_2NR^4R^5$, (k) $-C(O)NR^4R^5$, (l) $-OC(O)NR^4R^5$, (m) $-NHC(O)NR^4R^5$, (n) 2- or 3-furyl, (o) 2- or 3-thienyl, (p) 2-, 4-, or 5-thiazolyl, (q) 2-, 3-, or 4-pyridyl, (r) 2-, or 4-pyrimidyl, (s) phenylalkyl, in which the alkyl portion contains one to six carbon atoms and the phenyl moiety is optionally substituted with halogen, alkyl of one to six carbon atoms, or alkoxy of one to six carbon atoms, (t) benzoyl, optionally substituted with halogen, alkyl of one to six carbon atoms, or alkoxy of one to six carbon atoms, (u) phenoxy, optionally substituted with halogen, alkyl of one to six carbon atoms, or alkoxy of one to six carbon atoms, (v) phenylalkyloxy, in which the alkyl portion contains from one to six carbon atoms and the phenyl moiety is optionally substituted with halogen, alkyl of one to six carbon atoms, or alkoxy of one to six carbon atoms, and (w) phenylalkanoyl, in which the alkanoyl portion contains one to seven carbon atoms and the phenyl moiety is optionally substituted with halogen, alkyl of one to six carbon atoms, or alkoxy of from one to six carbon atoms.

3

R^2 is selected from the group consisting of (a) hydrogen, (b) alkyl of one to six carbon atoms, (c) $-(CH_2)_pCOOR^6$, where p is 0, 1, 2, 3, or 4, (d) $-(CH_2)_qNR^4R^5$, where q is 2, 3, or 4, (e) $-(CH_2)_pCOR^6$, (f) $-(CH_2)_qOR^6$, (g) $-(CH_2)_pSO_2R^6$, (h) $-(CH_2)_pSO_2NR^4R^5$, (i) $-(CH_2)_pCONR^7R^8$, where R^7 and R^8 are independently selected from (i-1) hydrogen, (i-2) alkyl of one to six carbon atoms, (i-3) $-(CH_2)_rCOOR^6$, where r is 1, 2, 3, or 4, (i-4) $-(CH_2)_rNR^4R^5$, (i-5) $-(CH_2)_rOH$, (i-6) $-(CH_2)_rSO_2R^6$, and (i-7) $-(CH_2)_rSO_2NR^4R^5$, (j) $-(CH_2)_pCN$, (k) $-(CH_2)_p-1H$ -tetrazol-5-yl, (l) $-CONHNH_2$, and (m) phenylalkyl wherein the alkyl portion is of one to four carbon atoms, and the phenyl moiety is optionally substituted with halogen, alkyl of one to six carbon atoms, or alkoxy of from one to six carbon atoms, or R^7 and R , taken together with the nitrogen atom to which they are attached, for a pyrrolidinyll or morpholinyl ring.

R^3 is selected from the group consisting of hydrogen and alkyl of from one to six carbon atoms, and L^1 is selected from the group consisting of

- (a) $>C=O$, (b) , (c) $>C=NNR^9R^{10}$, where R^9 , and R^{10} are independently selected from hydrogen, alkyl of one to six carbon atoms, alkoxycarbonyl of two to six carbon atoms, aminocarbonyl, alkylaminocarbonyl of two to six carbon atoms, dialkylaminocarbonyl in which the alkyl groups are independently of one to six carbon atoms, alkanoyl of one to six carbon atoms, and phenyl, optionally substituted with halogen, alkyl of one to six carbon atoms, or alkoxy of from one to six carbon atoms, (d) $>C=NOR^9$, (e) $>S(O)_n$, where n is 1 or 2, and (e) $-NHSO_2-$.

Ar^1 is a valence bond or a radical of formula









where Y is O, S, or $-CH=CH-$, Z is N or CH, and R^{11} is selected from the group consisting of hydrogen, alkyl of one to six carbon atoms, alkenyl of two to six carbon atoms, alkoxy of one to six carbon atoms, and halogen.

L^2 is a valence bond or straight-chain alkylene of one to six carbon atoms, optionally substituted with one or more groups selected from (a) alkyl of one to six carbon atoms, (b) alkenyl of two to six carbon atoms, (c) alkoxycarbonyl of one to six carbon atoms, (d) alkoxy of one to six carbon atoms, (e) alkylthio of one to six carbon




4

- atoms, (f) alkoxyalkyl in which the alkoxy and alkyl portions are independently one to six carbon atoms, (g) alkylthioalkyl in which the alkyl portions are independently one to six carbon atoms, (h) phenylalkyl wherein the alkyl portion is one to six carbon atoms and where the phenyl ring is optionally substituted with alkyl of one to six carbon atoms, haloalkyl of one to six carbon atoms, alkoxy of one to six carbon atoms, hydroxy, or halogen, and (i) thiophenyl where the phenyl ring is optionally substituted with alkyl of one to six carbon atoms, haloalkyl of one to six carbon atoms, alkoxy of one to six carbon atoms, hydroxy, or halogen, provided that L^2 is optionally substituted alkyl when Ar^1 is a valence bond.


10 Ar^2 is selected from the group consisting of



15



5



, and

where Z is defined above, and R¹³ is selected from the group consisting of (a) alkyl of one to six carbon atoms, (b) alkenyl of two to six carbon atoms, (c) alkoxy of one to six carbon atoms, (d) alkylthio of one to six carbon atoms, (e) alkoxyalkyl in which the alkoxy and alkyl portions are independently one to six carbon atoms, (f) alkylthioalkyl in which the alkyl portions are independently one to six carbon atoms, (g) haloalkyl, (h) phenylalkyl wherein the alkyl portion is of one to six carbon atoms and the phenyl ring is optionally substituted with alkyl of one to six carbon atoms, (i) cycloalkyl of three to eight carbon atoms, and (j) thiophenyl where the phenyl ring is optionally substituted with alkyl of one to six carbon atoms, haloalkyl of one to six carbon atoms, alkoxy of one to six carbon atoms, hydroxy, or halogen. R¹⁴ and R¹⁵ are independently selected from the group consisting of (a) hydrogen, (b) alkyl of one to six carbon atoms, (c) alkenyl of two to six carbon atoms, (d) halogen, (e) cyano, (f) carboxyl, (g) alkoxycarbonyl of from two to six carbon atoms, (h) aminocarbonyl, (i) alkylaminocarbonyl of one to six carbon atoms, (j) dialkylaminocarbonyl in which the alkyl groups are independently one to six carbon atoms, (k) alkanoyl, (l) hydroxyalkyl, (m) haloalkyl, (n) alkoxy of one to six carbon atoms, (o) alkylthio of one to six carbon atoms, (p) alkylsulfinyl of one to six carbon atoms, (q) alkylsulfonyl of one to six carbon atoms, (r) amino, (s) alkonylamino, and (t) nitro, or R¹⁴ and R¹⁵, together with the carbon atoms to which they are attached define a phenyl ring or 5- to 7-membered cycloalkylene ring.

Compounds of the present invention may exhibit stereoisomerism by virtue of the presence of one or more asymmetric or chiral centers in the compounds. The present invention contemplates the various stereoisomers and mixtures thereof. Desired enantiomers are obtained by chiral synthesis from commercially available chiral starting materials by methods well known in the art, or may be obtained from mixtures of the enantiomers by resolution using known techniques.

In another aspect, the present invention provides pharmaceutical compositions useful for the treatment of PAF-mediated disorders comprising a therapeutically effective amount of a compound of formula I above in combination with a pharmaceutically acceptable carrier.

5 In another aspect, the present invention provides a method of inhibiting PAF activity by administering to a host mammal in need of such treatment an effective amount of a PAF-inhibiting compound having structure I above.

In yet another aspect of the present invention, there is provided a method of treating PAF-mediated disorders including asthma, shock, respiratory distress
10 syndrome, acute inflammation, delayed cellular immunity, parturition, fetal lung maturation, and cellular differentiation by administering to a host mammal in need of such treatment a therapeutically effective amount of a compound of structure I above.

Detailed Description of the Invention

15

Definitions of Terms

As used throughout this specification and the appended claims, the following terms have the meanings specified.

The term "alkyl" refers to a monovalent group derived from a straight or branched chain saturated hydrocarbon by the removal of a single hydrogen atom.

20 Alkyl groups are exemplified by methyl, ethyl, *n*- and *iso*-propyl, *n*-, *sec*-, *iso*- and *tert*-butyl, and the like.

The term "alkylamino" refers to a group having the structure -NHR' wherein R' is alkyl, as previously defined. Examples of alkylamino include methylamino, ethylamino, *iso*-propylamino and the like.

25 The term "alkylaminocarbonyl" refers to an alkylamino group, as previously defined, attached to the parent molecular moiety through a carbonyl group. Examples of alkylaminocarbonyl include methylamino-carbonyl, ethylaminocarbonyl, *iso*-propylaminocarbonyl and the like.

The term "alkylthio" refers to an alkyl group, as defined above, attached to the
30 parent molecular moiety through a sulfur atom and includes such examples as methylthio, ethylthio, propylthio, *n*-, *sec*- and *tert*-butylthio and the like.

The term "alkanoyl" represents an alkyl group, as defined above, attached to the parent molecular moiety through a carbonyl group. Alkanoyl groups are exemplified by formyl, acetyl, propionyl, butanoyl and the like.

The term "alkanoylamino" refers to an alkanoyl group, as previously defined, attached to the parent molecular moiety through a nitrogen atom. Examples of alkanoylamino include formamido, acetamido, and the like.

The term "N-alkanoyl-N-alkylamino" refers to an alkanoyl group, as previously defined, attached to the parent molecular moiety through an aminoalkyl group. Examples of N-alkanoyl-N-alkylamino include N-methylformamido, N-methyl-acetamido, and the like.

The terms "alkoxy" or "alkoxyl" denote an alkyl group, as defined above, attached to the parent molecular moiety through an oxygen atom. Representative alkoxy groups include methoxyl, ethoxyl, propoxyl, butoxyl, and the like.

The term "alkoxyalkoxyl" refers to an alkyl group, as defined above, attached through an oxygen to an alkyl group, as defined above, attached in turn through an oxygen to the parent molecular moiety. Examples of alkoxyalkoxyl include methoxymethoxyl, methoxyethoxyl, ethoxyethoxyl and the like.

The term "alkoxyalkyl" refers to an alkoxy group, as defined above, attached through an alkylene group to the parent molecular moiety.

The term "alkoxycarbonyl" represents an ester group; i.e. an alkoxy group, attached to the parent molecular moiety through a carbonyl group such as methoxycarbonyl, ethoxycarbonyl, and the like.

The term "alkenyl" denotes a monovalent group derived from a hydrocarbon containing at least one carbon-carbon double bond by the removal of a single hydrogen atom. Alkenyl groups include, for example, ethenyl, propenyl, butenyl, 1-methyl-2-buten-1-yl and the like.

The term "alkylene" denotes a divalent group derived from a straight or branched chain saturated hydrocarbon by the removal of two hydrogen atoms, for example methylene, 1,2-ethylene, 1,1-ethylene, 1,3-propylene, 2,2-dimethylpropylene, and the like.

The term "alkenylene" denotes a divalent group derived from a straight or branched chain hydrocarbon containing at least one carbon-carbon double bond. Examples of alkenylene include $-\text{CH}=\text{CH}-$, $-\text{CH}_2\text{CH}=\text{CH}-$, $-\text{C}(\text{CH}_3)=\text{CH}-$, $-\text{CH}_2\text{CH}=\text{CHCH}_2-$, and the like.

The term "alkynylene" refers to a divalent group derived by the removal of two hydrogen atoms from a straight or branched chain acyclic hydrocarbon group containing a carbon-carbon triple bond. Examples of alkynylene include $-\text{CH}\equiv\text{CH}-$, $-\text{CH}\equiv\text{CH}-\text{CH}_2-$, $-\text{CH}\equiv\text{CH}-\text{CH}(\text{CH}_3)-$, and the like.

8.

The term "aryl" is used herein to mean substituted and unsubstituted aromatic carbocyclic radicals and substituted and unsubstituted heterocyclic aromatic radicals including, but not limited to, phenyl, 1-naphthyl or 2-naphthyl, fluorenyl, pyridyl, quinolyl, thienyl, thiazolyl, pyrimidyl, indolyl, and the like.

5 The term "heterocyclic aromatic" is used herein to refer to 5- and 6-membered aromatic rings having in the ring one, two, or three heteroatoms selected from N, O, and S, and also including benzo fused analogs of these 5- and 6-membered heterocyclic aromatic rings including, but not limited to pyridyl, quinolyl, furyl, benzofuryl, thienyl, thiazolyl, pyrimidyl, indolyl, and the like.

10 The term "cycloalkyl" denotes a monovalent group derived from a monocyclic or bicyclic saturated carbocyclic ring compound by the removal of a single hydrogen atom. Examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, bicyclo[2.2.1]heptanyl, and bicyclo[2.2.2]octanyl.

The term "cycloalkylene" refers to a divalent group derived from a saturated carbocyclic hydrocarbon by the removal of two hydrogen atoms, for example cyclopentylene, cyclohexylene, and the like.

15 The term "carbocyclic aryl" denotes a monovalent carbocyclic ring group derived by the removal of a single hydrogen atom from a monocyclic or bicyclic fused or non-fused ring system obeying the " $4n + 2$ p electron" or Huckel aromaticity rule. Examples of carbocyclic aryl groups include phenyl, 1- and 2-naphthyl, biphenyl, fluorenyl, and the like.

20 The term "(carbocyclic aryl)alkyl" refers to a carbocyclic aryl ring group as defined above, attached to the parent molecular moiety through an alkylene group. Representative (carbocyclic aryl)alkyl groups include phenylmethyl, phenylethyl, phenylpropyl, 1-naphthylmethyl, and the like.

25 The term "carbocyclic aryloxyalkyl" refers to a carbocyclic aryl group, as defined above, attached to the parent molecular moiety through an oxygen atom and thence through an alkylene group. Such groups are exemplified by phenoxymethyl, 1- and 2-naphthyloxymethyl, phenoxyethyl and the like.

30 The term "(carbocyclic aryl)alkoxyalkyl" denotes a carbocyclic aryl group as defined above, attached to the parent molecular moiety through an alkoxyalkyl group. Representative (carbocyclic aryl)alkoxyalkyl groups include phenylmethoxymethyl, phenylethoxymethyl, 1- and 2-naphthylmethoxyethyl, and the like.

35 "Carbocyclic arylthioalkyl" represents a carbocyclic aryl group as defined above, attached to the parent molecular moiety through a sulfur atom and thence

through an alkylene group and are typified by phenylthiomethyl, 1- and 2-naphthylthioethyl and the like.

The term "dialkylamino" refers to a group having the structure -NR'R" wherein R' and R" are independently selected from alkyl, as previously defined.

- 5 Additionally, R' and R" taken together may optionally be -(CH₂)_{kk}- where kk is an integer of from 2 to 6. Examples of dialkylamino include, dimethylamino, diethylaminocarbonyl, methylethylamino, piperidino, and the like.

- The term "haloalkyl" denotes an alkyl group, as defined above, having one, two, or three halogen atoms attached thereto and is exemplified by such groups as
10 chloromethyl, bromoethyl, trifluoromethyl, and the like.

The term "hydroxyalkyl" represents an alkyl group, as defined above, substituted by one to three hydroxyl groups with the proviso that no more than one hydroxy group may be attached to a single carbon atom of the alkyl group.

- The term "phenoxy" refers to a phenyl group attached to the parent molecular
15 moiety through an oxygen atom.

The term "phenylthio" refers to a phenyl group attached to the parent molecular moiety through a sulfur atom.

The term "pyridyloxy" refers to a pyridyl group attached to the parent molecular moiety through an oxygen atom.

- 20 The term "metabolically cleavable group" denotes a group which is cleaved *in vivo* to yield the parent molecule of the structural formulae indicated above wherein M is hydrogen. Examples of metabolically cleavable groups include -COR, -COOR, -CONRR and -CH₂OR radicals where R is selected independently at each occurrence from alkyl, trialkylsilyl, carbocyclic aryl or carbocyclic aryl substituted with one or
25 more of C₁-C₄ alkyl, halogen, hydroxy or C₁-C₄ alkoxy. Specific examples of representative metabolically cleavable groups include acetyl, methoxycarbonyl, benzoyl, methoxymethyl and trimethylsilyl groups.

- By "pharmaceutically acceptable salt" it is meant those salts which are, within the scope of sound medical judgement, suitable for use in contact with the tissues of
30 humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, S. M Berge, *et al.* describe pharmaceutically acceptable salts in detail in *J. Pharmaceutical Sciences*, 1977, 66: 1-19. The salts can be prepared *in situ* during the final isolation and purification of
35 the compounds of the invention, or separately by reacting the free base function with a suitable organic acid. Representative acid addition salts include acetate, adipate,

10

alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphersulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptonate, glycerophosphate, hemisulfate, heptonate, hexanoate, hydrobromide, hydrochloride, hydroiodide, 2-
5 hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, toluenesulfonate, undecanoate, valerate salts, and the like. Representative alkali or
10 alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like, as well as nontoxic ammonium, quaternary ammonium, and amine cations, including, but not limited to ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, ethylamine, and the like.


15 The terms "PAF-related disorders" and "PAF-mediated disorders" are used herein to mean disorders related to PAF or mediated by PAF, including asthma, shock, respiratory distress syndromes, acute inflammation, gastric ulceration, transplant organ rejection, psoriasis, allergic skin disease, ischemia and reperfusion injury, delayed cellular immunity, parturition, fetal lung maturation, and cellular
20 differentiation.

Preferred Embodiments

In one preferred embodiment, the compounds of this invention are represented by formula I wherein R^3 is hydrogen; L^1 is $>C=O$ or $-SO_2-$; R^1 is one or more
25 groups independently selected from the group consisting of (a) hydrogen, (b) halogen, (c) alkyl of one to six carbon atoms, (d) alkynyl of two to four carbon atoms, (e) alkoxy of one to six carbon atoms, (f) $-COOR^6$ where R^6 is hydrogen or alkyl of one to six carbon atoms, (g) phenyl, optionally substituted with alkyl of one to six carbon atoms, alkoxy of one to six carbon atoms, or halogen, (h) phenylalkyl where the alkyl
30 portion contains one to six carbon atoms and the phenyl moiety is optionally substituted with alkyl of one to six carbon atoms, alkoxy of one to six carbon atoms, or halogen, (i) phenoxy optionally substituted with halogen, alkyl of one to six carbon atoms, or alkoxy of one to six carbon atoms, and (j) $-OC(O)NR^4R^5$; L^2 is a valence bond or methylene;







35

11


 Ar^1 is

wherein Y is O, S, or $-\text{CH}=\text{CH}-$, Z is N or CH, and R^{11} ; and Ar^2 is selected from the group consisting of

5



, and



10

, wherein R^{13} is methyl and R^{14} and R^{15} are hydrogen.

In another preferred embodiment, the compounds of this invention are represented by formula I wherein Ar^1 is a valence bond and L^2 is straight-chain alkylene of one to six carbon atoms.

15

In another preferred embodiment, the compounds of this invention are represented by formula I wherein R^1 is hydrogen, $-\text{COOR}^6$ where R^6 is hydrogen or alkyl of one to six carbon atoms, 4-fluorophenyl, phenylmethyl, or 4-fluorophenoxy; R^2 is *N,N*-dimethylcarbamoyl or 2-ethoxyethyl; L^1 is $>\text{C}=\text{O}$ or $-\text{SO}_2-$; Ar^1 is a valence bond, and L^2 is straight-chain alkylene of one to six carbon atoms.

In the most preferred embodiment the compounds of this invention are represented by formula I wherein R^1 is selected from the group consisting of hydrogen, $-COOR^6$ where R^6 is hydrogen or alkyl of one to six carbon atoms, alkynyl of two to four carbon atoms, 4-fluorophenyl, phenylmethyl, or 4-fluorophenoxy; R^2 is *N,N*-dimethylcarbamoyl or 2-ethoxyethyl; L^1 is $>C=O$ or $-SO_2-$; Ar^1 is phenyl or phenyl substituted with alkyl of one to six carbon atoms, alkoxy of one to six carbon atoms, or halogen, L^2 is methylene; and R^3 and Ar^2 are defined immediately above.

- Compounds contemplated as falling within the scope of this invention include, but are not limited to:
- 6-(4-fluorophenyl)-3-{4-[(1H-2-methylbenzimidazolyl)methyl]benzoyl}indole,
 - 1-*N,N*-dimethylcarbamoyl-6-(4-fluorophenyl)-3-{4-[(1H-2-methylbenzimidazolyl)methyl]benzoyl}indole,
 - 6-(4-fluorophenyl)-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole,
 - 1-*N,N*-dimethylcarbamoyl-6-(4-fluorophenyl)-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole,
 - 1-*N,N*-dimethylcarbamoyl-6-(4-fluorophenyl)-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole hydrochloride,
 - 6-(4-fluorophenyl)-3-{4-[(3H-2-methylimidazo[4.5-c]pyrid-3-yl)methyl]benzoyl}indole,
 - 1-*N,N*-dimethylcarbamoyl-6-(4-fluorophenyl)-3-{4-[(3H-2-methylimidazo[4.5-c]pyrid-3-yl)methyl]benzoyl}indole,
 - 1-*N,N*-dimethylcarbamoyl-6-(4-fluorophenyl)-3-[4-(5H-2-methylimidazo[4.5-c]pyrid-5-ylmethyl)benzoyl]indole,
 - 6-(4-fluorophenyl)-3-[4-(1H-2-methylimidazo[4.5-c]pyridyl)benzoyl]indole,
 - 1-*N,N*-dimethylcarbamoyl-6-(4-fluorophenyl)-3-[4-(1H-2-methylimidazo[4.5-c]pyrid-1-yl)benzoyl]indole,
 - 6-(4-fluorophenyl)-3-{3-[(1H-2-methylimidazo[4.5-c]pyridyl)methyl]benzoyl}indole,
 - 1-*N,N*-dimethylcarbamoyl-6-(4-fluorophenyl)-3-{3-[(1H-2-methylimidazo[4.5-c]pyridyl)methyl]benzoyl}indole,
 - 3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole,
 - 1-*N,N*-dimethylcarbamoyl-3-{4-[(1H-2-methylimidazo[4.5-c]pyridyl)methyl]benzoyl}indole,

13

- 3-[4-(5H-2-methylimidazo[4.5-c]pyrid-5-ylmethyl)benzoyl]indole,
1-*N,N*-dimethylcarbamoyl-3-[4-(5H-2-methylimidazo[4.5-c]pyrid-5-ylmethyl)benzoyl]indole,
3-{3-[(1H-2-methylimidazo[4.5-c]pyridyl)methyl]benzoyl}indole,
5 1-*N,N*-dimethylcarbamoyl-3-{3-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole,
3-{3-[(3H-2-methylimidazo[4.5-c]pyridyl)methyl]benzoyl}indole,
1-*N,N*-dimethylcarbamoyl-3-{3-[(3H-2-methylimidazo[4.5-c]pyridyl)methyl]benzoyl}indole,
10 3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)]benzoyl}indole,
1-*N,N*-dimethylcarbamoyl-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)benzoyl}indole,
1-*N,N*-dimethylcarbamoyl-6-(4-fluorophenyl)-3-[(3H-2-methylimidazo[4.5-c]pyrid-3-yl)methylcarbonyl]indole,
15 1-*N,N*-dimethylcarbamoyl-6-(4-fluorophenyl)-3-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methylcarbonyl]indole,
1-*N,N*-dimethylcarbamoyl-3-[(3H-2-methylimidazo[4.5-c]pyrid-3-yl)methylcarbonyl]indole,
1-*N,N*-dimethylcarbamoyl-3-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methylcarbonyl]indole,
20 1-*N,N*-dimethylcarbamoyl-3-{4-[(3H-2-methylimidazo[4.5-b]pyrid-3-yl)methyl]benzoyl}indole,
1-*N,N*-dimethylcarbamoyl-3-{4-[(1H-2-methylimidazo[4.5-b]pyrid-1-yl)methyl]benzoyl}indole,
25 1-*N,N*-dimethylcarbamoyl-3-{4-[1H-2-trifluoromethylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole,
1-*N,N*-dimethylcarbamoyl-3-{4-[1H-imidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole,
1-*N,N*-dimethylcarbamoyl-3-{4-[1H-2-(2-propyl)imidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole,
30 1-*N,N*-dimethylcarbamoyl-3-{4-[1H-2-phenylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole,
1-*N,N*-dimethylcarbamoyl-3-{4-[1H-2-ethylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole,
35 3-{3-[(5H-2-methylimidazo[4.5-c]pyrid-5-yl)methyl]benzoyl}indole,

- 1-*N,N*-dimethylcarbamoyl-3-{3-[(5*H*-2-methylimidazo[4.5-*c*]pyrid-5-yl)methyl]benzoyl}indole,
1-*p*-toluenesulfonyl-6-(4-fluorophenyl)-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyridyl)methyl]benzoyl}indole,
5 1-*N,N*-dimethylcarbamoyl-6-(4-fluorophenyl)-3-[(3*H*-2-methylimidazo[4.5-*c*]pyrid-3-yl)pent-5-ylcarbonyl]indole,
1-*N,N*-dimethylcarbamoyl-6-(4-fluorophenyl)-3-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)pent-5-ylcarbonyl]indole,
1-*N,N*-dimethylcarbamoyl-6-(4-fluorophenyl)-3-[(5*H*-2-methylimidazo[4.5-*c*]pyrid-5-yl)pent-5-ylcarbonyl]indole,
10 1-*N,N*-dimethylcarbamoyl-6-(4-fluorophenoxy)-3-{4-[(3*H*-2-methylimidazo[4.5-*c*]pyrid-3-yl)methyl]benzoyl}indole,
1-*N,N*-dimethylcarbamoyl-6-(4-fluorophenoxy)-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole,
15 1-*N,N*-dimethylcarbamoyl-5-phenylmethoxy-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole,
1-*N,N*-dimethylcarbamoyl-6-(4-methoxyphenyl)-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole,
1-*N,N*-dimethylcarbamoyl-6-(pyrid-3-yl)-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole,
20 1-*N,N*-dimethylcarbamoyl-6-bromo-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole,
1-*N,N*-dimethylcarbamoyl-6-chloro-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole,
25 1-*N,N*-dimethylcarbamoyl-5-methoxy-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole,
1-*N,N*-dimethylcarbamoyl-6-(4-fluorophenyl)-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyloxime}indole,
1-*N,N*-dimethylcarbamoyl-6-(4-fluorophenyl)-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoylhydrazone}indole,
30 1-methyl-6-(4-fluorophenyl)-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole,
1-*tert*-butyloxycarbonyl-6-(4-fluorophenyl)-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole,
35 1-methoxycarbonyl-6-(4-fluorophenyl)-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole,

15

- 1-phenoxy carbonyl-6-(4-fluorophenyl)-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole,
1-carbamoyl-6-(4-fluorophenyl)-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole,
5 1-N-methylcarbamoyl-6-(4-fluorophenyl)-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole,
1-N-phenyl-N-methylcarbamoyl-6-(4-fluorophenyl)-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole,
1-(N-methyl-N-(dimethylaminoethyl))carbamoyl-6-(4-fluorophenyl)-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole,
10 1-N-(2-hydroxyethyl)carbamoyl-6-(4-fluorophenyl)-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole,
1-hydrazinocarbonyl-6-(4-fluorophenyl)-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole,
15 1-N-carboxymethylcarbamoyl-6-(4-fluorophenyl)-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole,
1-N-(2-(imidazol-4-yl)ethyl)carbamoyl-6-(4-fluorophenyl)-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole,
1-(2-hydroxyethyl)-6-(4-fluorophenyl)-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole,
20 1-(2-aminoethyl)-6-(4-fluorophenyl)-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole,
1-(2-methanesulfonylaminoethyl)-6-(4-fluorophenyl)-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole,
25 1-(2-sulfamylethyl)-6-(4-fluorophenyl)-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole,
1-(2-carbomethoxyethyl)-6-(4-fluorophenyl)-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole,
1-(2-carboethoxyethyl)-6-(4-fluorophenyl)-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole,
30 1-(2-carboxyethyl)-6-(4-fluorophenyl)-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole,
1-(2-tert-butoxycarbonylaminoethyl)-6-(4-fluorophenyl)-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole,
35 1-cyanomethyl-6-(4-fluorophenyl)-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole,

- 1-carboxymethyl-6-(4-fluorophenyl)-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole,
1-N-methylcarbamoylmethyl-6-(4-fluorophenyl)-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole,
5 1-(1H-tetrazol-5-ylmethyl)-6-(4-fluorophenyl)-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole,
1-methanesulfonyl-6-(4-fluorophenyl)-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole,
1-ethanesulfonyl-6-(4-fluorophenyl)-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole,
10 1-phenylsulfonyl-6-(4-fluorophenyl)-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole,
1-N,N-dimethylsulfamyl-6-(4-fluorophenyl)-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole,
15 1-N,N-dimethylcarbamoyl-6-phenylmethyl-3-{4-[(3H-2-methylimidazo[4.5-c]pyrid-3-yl)methyl]benzoyl}indole,
1-N,N-dimethylcarbamoyl-6-phenylmethyl-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole,
1-N,N-dimethylcarbamoyl-4-methoxycarbonyl-3-{4-[(3H-2-methylimidazo[4.5-c]pyrid-3-yl)methyl]benzoyl}indole,
20 1-N,N-dimethylcarbamoyl-4-methoxycarbonyl-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole,
1-N,N-dimethylcarbamoyl-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]phenylsulfonyl}indole,
25 1-(morpholin-4-ylcarbonyl)-6-(4-fluorophenyl)-3-{4-[(1H-2-methylimidazo[4.5-c]pyridyl)methyl]benzoyl}indole,
1-(N,N-dimethylcarbamoylmethyl)-6-(4-fluorophenyl)-3-{4-[(1H-2-methylimidazo[4.5-c]pyridyl)methyl]benzoyl}indole,
1-N,N-dimethylcarbamoyl-6-(4-fluorophenyl)-3-{5-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]thien-2-oyl}indole,
30 1-N,N-dimethylcarbamoyl-6-(4-fluorophenyl)-3-{5-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]fur-2-oyl}indole,
1-N,N-dimethylcarbamoyl-6-(4-fluorophenyl)-3-{4-[(3H-2-methylimidazo[4.5-c]pyrid-3-yl)methyl]thiazo-2-oyl}indole,
35 1-N,N-dimethylcarbamoyl-6-(4-fluorophenyl)-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]thiazo-2-oyl}indole,

- 1-methyl-3-{4-[(1H-2-methylimidazo[4,5-c]pyrid-1-yl)methyl]phenylsulfonylamino}indole,
4,7-dimethoxycarbonyl-3-{4-[(1H-2-methylimidazo[4,5-c]pyrid-1-yl)methyl]benzoyl}indole,
5 4,7-dimethyl-3-{4-[(1H-2-methylimidazo[4,5-c]pyrid-1-yl)methyl]benzoyl}indole,
4,7-dimethyl-3-{4-[(3H-2-methylimidazo[4,5-c]pyrid-3-yl)methyl]benzoyl}indole,
7-benzyloxy-3-{4-[(1H-2-methylimidazo[4,5-c]pyrid-1-yl)methyl]benzoyl}indole,
7-(4-fluorophenyl)-3-{4-[(1H-2-methylimidazo[4,5-c]pyrid-1-yl)methyl]benzoyl}indole,
10 6-(4-fluorophenyl)-3-{N-[3-(1H-2-methylimidazo[4,5-c]pyrid-1-yl)propyl]sarcosyl}indole-1-carboxylic acid dimethyl amide,
1-N,N-dimethylcarbamoyl-4-methoxycarbonyl-3-{3-fluoro-4-[(1H-2-methylimidazo[4,5-c]pyrid-1-yl)methyl]benzoyl}indole,
1-N,N-dimethylcarbamoyl-6-benzyloxy-3-{3-fluoro-4-[(1H-2-methylimidazo[4,5-c]pyrid-1-yl)methyl]benzoyl}indole,
15 1-N,N-dimethylcarbamoyl-4-methoxycarbonyl-3-{5-[(1H-2-methylimidazo[4,5-c]pyrid-1-yl)methyl]thien-2-oyl}indole,
1-N,N-dimethylcarbamoyl-6-(4-fluorophenyl)-3-{4-[(1H-2-methylimidazo[4,5-c]pyrid-1-yl)methyl]phenylaminocarbonyl}indole hydrochloride,
20 1-N,N-dimethylcarbamoyl-5-(4-fluorophenyl)-3-{4-[(1H-2-methylimidazo[4,5-c]pyrid-1-yl)methyl]benzoyl}indole,
1-N,N-dimethylcarbamoyl-6-(4-fluorophenyl)-3-{4-[(1H-2-methylimidazo[4,5-c]pyrid-1-yl)methyl]phenylsulfonyl}indole,
1-N,N-dimethylcarbamoyl-4-bromo-3-{4-[(1H-2-methylimidazo[4,5-c]pyrid-1-yl)methyl]benzoyl}indole,
25 1-N,N-dimethylcarbamoyl-4-acetyl-3-{4-[(1H-2-methylimidazo[4,5-c]pyrid-1-yl)methyl]benzoyl}indole,
1-N,N-dimethylcarbamoyl-4-(fur-2-yl)-3-{4-[(1H-2-methylimidazo[4,5-c]pyrid-1-yl)methyl]benzoyl}indole,
30 1-N,N-dimethylcarbamoyl-4-(benzo[b]fur-2-yl)-3-{4-[(1H-2-methylimidazo[4,5-c]pyrid-1-yl)methyl]benzoyl}indole,
1-N,N-dimethylcarbamoyl-4-(trimethylsilylethynyl)-3-{4-[(1H-2-methylimidazo[4,5-c]pyrid-1-yl)methyl]benzoyl}indole,
1-N,N-dimethylcarbamoyl-4-ethynyl-3-{4-[(1H-2-methylimidazo[4,5-c]pyrid-1-yl)methyl]benzoyl}indole,
35

- 4-(4-fluorophenyl)-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole,
1-*N,N*-dimethylcarbamoyl-4-chloro-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole,
5 1-*N,N*-dimethylcarbamoyl-4-fluoro-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole,
1-*N,N*-dimethylcarbamoyl-2-methyl-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole,
1,4-di-*N,N*-dimethylcarbamoyl-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole,
10 1-*N,N*-dimethylcarbamoyl-5-methoxycarbonyl-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole,
1-*N,N*-dimethylcarbamoyl-4-methoxycarbonyl-6-(4-fluorophenyl)-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole,
15 4-methoxycarbonyl-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole,
4-methoxycarbonyl-1-(pyrrolidin-1-ylcarbonyl)-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole,
1-*N,N*-dimethylcarbamoyl-4-benzoyloxycarbonyl-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole,
20 1-*N,N*-dimethylcarbamoyl-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole-4-carboxylic acid,
1-*N,N*-dimethylcarbamoyl-4-(*N*-nonylcarbamoyl)-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole,
25 1-*N,N*-dimethylcarbamoyl-4-(dec-1-yloxycarbonyl)-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole,
1-*N,N*-dimethylcarbamoyl-4-methoxy-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole,
1-*N,N*-dimethylcarbamoyl-4-methyl-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole,
30 1-*N,N*-dimethylcarbamoyl-4-methoxycarbonyl-3-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)hex-6-ylcarbonyl]indole,
1-*N,N*-dimethylcarbamoyl-4-methoxycarbonyl-3-{4-[(1H-2-methylbenzimidazolyl)methyl]benzoyl}indole,
35 4-methoxycarbonyl-1-(pyrrolidin-1-ylcarbonyl)-3-{4-[(1H-2-methylbenzimidazolyl)methyl]benzoyl}indole,

- 1-*N,N*-dimethylcarbamoyl-4-methoxycarbonyl-3-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)pent-5-ylcarbonyl]indole,
1-*N,N*-dimethylcarbamoylmethyl-4-methoxycarbonyl-3-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)pent-5-ylcarbonyl]indole,
5 1-*N,N*-dimethylcarbamoyl-4-methoxycarbonyl-3-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)pent-5-ylcarbonyl]indole,
1-*N,N*-dimethylcarbamoyl-4-methoxycarbonyl-3-{4-[(2-methyl-4-(3*H*)quinazolinone-3-yl)methyl]benzoyl}indole,
1-(2-ethoxyethyl)-4-methoxycarbonyl-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole,
10 1-*N,N*-dimethylsulfamoyl-4-methoxycarbonyl-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole,
1-*N,N*-dimethylsulfamoyl-4-methoxycarbonyl-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole,
15 1-acetoxymethyl-4-methoxycarbonyl-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole,
1-(2-propanesulfonyl)-4-methoxycarbonyl-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole,
1-(1-pinacolyl)-4-methoxycarbonyl-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole,
20 1-carbamoyl-4-methoxycarbonyl-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole,
1-*N*-methylcarbamoyl-4-methoxycarbonyl-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole,
25 1-(2-ethoxyethyl)-4-chloro-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole,
1-*N,N*-dimethylcarbamoyl-4-methoxycarbonyl-3-{3-methoxy-4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole,
1-*N,N*-dimethylcarbamoyl-4-methoxycarbonyl-3-{3-methoxy-4-[(3*H*-2-methylimidazo[4.5-*c*]pyrid-3-yl)methyl]benzoyl}indole,
30 1-*N,N*-dimethylcarbamoyl-4-methoxycarbonyl-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]phenylsulfonyl}indole,
1-*N,N*-dimethylcarbamoyl-4-methoxycarbonyl-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]phenylsulfonyl}indole,
35 1-*N,N*-dimethylcarbamoyl-4-ethynyl-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole,

- 1-*N,N*-dimethylcarbamoyl-4-hydroxy-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole,
- 1-*N,N*-dimethylcarbamoyl-6-bromo-4-methoxycarbonyl-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole,
- 5 1-*N,N*-dimethylcarbamoyl-6-(benzo[*b*]fur-2-yl)-4-methoxycarbonyl-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole,
- 1-*N,N*-dimethylcarbamoyl-6-(fur-2-yl)-4-methoxycarbonyl-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole,
- 10 1-*N,N*-dimethylcarbamoyl-4-(*N,N*-dimethylaminocarbonyloxy)-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole,
- 1-*N,N*-dimethylcarbamoyl-4-(*N,N*-dimethylaminocarbonylamino)-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole,
- 1-*N,N*-dimethylcarbamoyl-4-cyano-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole hydrochloride,
- 15 1-*N,N*-dimethylcarbamoyl-4-methoxycarbonyl-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole,
- 1-*N,N*-dimethylcarbamoyl-4-chloro-3-{4-[(1*H*-2-methylimidazo[4.5-*b*]pyrid-1-yl)methyl]benzoyl}indole,
- 20 1-*N,N*-dimethylcarbamoyl-4-methoxycarbonyl-3-{4-[(3*H*-2-methylimidazo[4.5-*b*]pyrid-3-yl)methyl]benzoyl}indole,
- 1-*N,N*-dimethylcarbamoyl-4-methoxycarbonyl-3-{4-[(1*H*-2-methylimidazo[4.5-*b*]pyrid-1-yl)methyl]benzoyl}indole,
- 1-*N,N*-dimethylcarbamoyl-4-methoxycarbonyl-3-{4-[(5*H*-2-methylimidazo[4.5-*c*]pyrid-5-yl)methyl]benzoyl}indole,
- 25 1-*N,N*-dimethylcarbamoyl-4-methoxycarbonyl-3-{4-[1-(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)eth-1-yl]benzoyl}indole,
- 1-*N,N*-dimethylcarbamoyl-4-methoxycarbonyl-3-{4-[1-(1*H*-imidazo[4.5-*c*]pyrid-1-yl)eth-1-yl]benzoyl}indole,
- 1-*N,N*-dimethylcarbamoyl-4-methoxycarbonyl-3-{4-[(1*H*-2-methyl-5-, and 6-
- 30 chlorobenzimidazolyl)methyl]benzoyl}indole,
- 1-*N,N*-dimethylcarbamoyl-4-chloro-3-{4-[(1*H*-2-methyl-5-, and 6-chlorobenzimidazolyl)methyl]benzoyl}indole,
- 1-(2-ethoxyethyl)-4-methoxycarbonyl-3-{4-[(1*H*-2-methyl-5-, and 6-chlorobenzimidazolyl)methyl]benzoyl}indole,
- 35 1-(pyrrolidin-1-ylcarbonyl)-4-methoxycarbonyl-3-{4-[(1*H*-2-methyl-5-, and 6-chlorobenzimidazolyl)methyl]benzoyl}indole,

- 1-*N,N*-dimethylcarbamoyl-4-methoxycarbonyl-3-{4-[(1*H*-2-(trifluoromethyl)benzimidazolyl)methyl]benzoyl}indole,
1-*N,N*-dimethylcarbamoyl-4-methoxycarbonyl-3-{4-[(1*H*-2-methyl-5- and 6-methylbenzimidazolyl)methyl]benzoyl}indole,
5 1-*N,N*-dimethylcarbamoyl-4-methoxycarbonyl-3-{4-[(1*H*-2-methyl-4- and 7-methylbenzimidazolyl)methyl]benzoyl}indole,
1-*N,N*-dimethylcarbamoyl-4-methoxycarbonyl-3-{4-[(1*H*-2-methyl-5- and 6-methylbenzimidazolyl)methyl]benzoyl}indole,
1-*N,N*-dimethylcarbamoyl-4-methoxycarbonyl-3-{4-[(1*H*-2-methyl-5- and 6-nitrobenzimidazolyl)methyl]benzoyl}indole,
10 1-*N,N*-dimethylcarbamoyl-4-methoxycarbonyl-3-{4-[(1*H*-2-methyl-5, 6-dichlorobenzimidazolyl)methyl]benzoyl}indole,
1-*N,N*-dimethylcarbamoyl-4-methoxycarbonyl-3-{4-[(1*H*-2-methyl-5- and 6-methoxycarbonylbenzimidazolyl)methyl]benzoyl}indole,
15 1-(pyrrolidin-1-ylcarbonyl)-4-methoxycarbonyl-3-{4-[(1*H*-2-methyl-5- and 6-methoxycarbonylbenzimidazolyl)methyl]benzoyl}indole,
1-(pyrrolidin-1-ylcarbonyl)-4-methoxycarbonyl-3-{4-[(1*H*-2-methyl-5- and 6-methylbenzimidazolyl)methyl]benzoyl}indole,
1-*N,N*-dimethylcarbamoyl-4-methoxycarbonyl-3-{4-[(3*H*-2, 4, 6-trimethylimidazo[4.5-*c*]pyrid-3-yl)methyl]benzoyl}indole,
20 1-(pyrrolidin-1-ylcarbonyl)-4-methoxycarbonyl-3-{4-[(1*H*-5-trifluoromethyl-2-methylmethylbenzimidazolyl)methyl]benzoyl}indole,
1-*N,N*-dimethylcarbamoyl-4-methoxycarbonyl-3-{4-[(5-oxide-1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole,
25 1-*N,N*-dimethylcarbamoyl-4-methoxycarbonyl-3-{4-[(4-chloro-1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole,
1-*N,N*-dimethylcarbamoyl-4-methoxycarbonyl-3-{4-[(1,5-*H*-2-methylimidazo[4.5-*c*]pyrid-4-one-1-yl)methyl]benzoyl}indole,
1-*N,N*-dimethylcarbamoyl-4-ethoxycarbonyl-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole,
30 1-*N,N*-dimethylcarbamoyl-4-(2-propyloxycarbonyl)-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole,
1-*N,N*-dimethylcarbamoyl-4-methoxycarbonyl-3-{4-[(1*H*-2-methylnaphtho[2,3-*d*]imidazol-1-yl)methyl]benzoyl}indole,
35 1-*N,N*-Dimethylcarbamoyl-4-(*N,N*-dimethylaminocarbonyloxy)-3-{3-fluoro-4-[(1*H*-2-methylimidazo[4,5-*c*]pyrid-1-yl)methyl]benzoyl}indole, and

1-*N,N*-Dimethylcarbamoyl-4-ethynyl-3-{3-fluoro-4-[(1*H*-2-methylimidazo-
[4,5-*c*]pyrid-1-yl)methyl]benzoyl}indole.

Particularly preferred compounds of the present invention are

- 1-*N,N*-dimethylcarbamoyl-4-(*N,N*-dimethylaminocarbonyloxy)-3-{3-fluoro-
4-[(1*H*-2-methylimidazo[4,5-*c*]pyrid-1-yl)methyl]benzoyl}indole,
1-*N,N*-dimethylcarbamoyl-4-ethynyl-3-{3-fluoro-4-[(1*H*-2-methylimidazo-
[4,5-*c*]pyrid-1-yl)methyl]benzoyl}indole,
1-*N,N*-dimethylcarbamoyl-4-ethynyl-3-{4-[(1*H*-2-methylimidazo-
[4,5-*c*]pyrid-1-yl)methyl]benzoyl}indole,
1-*N,N*-dimethylcarbamoyl-4-(*N,N*-dimethylaminocarbonyloxy)-3-{4-
[(1*H*-2-methylimidazo[4,5-*c*]pyrid-1-yl)methyl]benzoyl}indole, and
1-*N,N*-Dimethylcarbamoyl-4-methoxycarbonyl-3-{4-[(1*H*-2-methyl-
imidazo[4,5-*c*]pyrid-1-yl)methyl]benzoyl}indole,
or a pharmaceutically acceptable salt thereof.

PAF Inhibitory Activity of the Compounds of the Present Invention

The ability of representative compounds of the present invention to inhibit PAF activity was determined in an *in vitro* test using the following method.

Citrated whole rabbit blood was obtained from Pel-Freez (Rogers, AR).

- Rabbit platelets were prepared by centrifugation and washing. The platelets were lysed by freeze-thawing and sonication; platelet membranes were prepared by centrifugation and washing. Final membrane preparations were stored frozen in 10 mM Tris/5 mM MgCl₂/2 mM EDTA (TME buffer, pH 7.0) with 0.25 M sucrose added for membrane stabilization.

- The standard PAF receptor binding assay contained 10 µg platelet membrane protein, 0.6 nM [³H]C₁₈-PAF (from Amersham or New England Nuclear; specific activity 120-180 Ci/mmol), with and without test compound, in "binding buffer" consisting of TME with 0.25% bovine serum albumin added (Sigma, RIA grade). The final volume of the assay was 100 µl. The assay was conducted in Millititre-GV™ (Millipore Corp.) filtration plates; incubation time was for 60 minutes at room temperature (22-23°C.). "Specific binding" was operationally defined as the arithmetic difference between "total binding" of 0.6 nM [³H]C₁₈-PAF (in the absence of added PAF) and "nonspecific binding" (in the presence of 1 µM PAF). After the prescribed incubation, platelet membranes were filtered under vacuum and washed with 1 millilitre of "binding buffer". The filters were dried and removed. The bound radioactivity was quantitated with a Berthold TLC-Linear Analyzer model LB2842.

Dose-response curves of inhibition of specific [^3H]C₁₈-PAF binding by test compounds were conducted in triplicate, with at least four doses covering the active range. Experiments were repeated at least once. IC₅₀ values (concentration producing 50% inhibition) were determined by point-to-point evaluation. K_i values of inhibitory binding constants were calculated according to the method of Cheng and Prusoff [Biochem. Pharmacol. 22 (1973) 3099-3108] whereby

$$\begin{aligned}
 K_i &= \frac{IC_{50}}{1 + ([^3\text{H}]\text{PAF}/K_d[^3\text{H}]\text{PAF})} \\
 &= \frac{IC_{50}}{1 + (0.6 \text{ nM}/0.6 \text{ nM})} \\
 &= \frac{IC_{50}}{2}
 \end{aligned}$$

The values of K_i for representative compounds of the present invention appear in Table 1.

Table 1.

Example	K _i (nM) or % Inhibition	Example	K _i (nM) or % Inhibition
2	56	30	342
3	75	31	44
4	2.3	32	10% @ 1.0 μM
6	140	33	29
7	700	90	2.9
9	60	95	130
10	258	96	7.7
11	86	102	10
12	140	107	0.6
13	150	112	150
14	5	122	0.8
16	18% @ 100 μM	126	62
17	422	131	4.7
18	323	135	1.3
19	280	138	2.2
20	26% @ 100 μM	141	20
22	146	143	0.9

24

23	7% @ 1.0 μ M	150	40
24	6% @ 1.0 μ M	156	19
25	14% @ 1.0 μ M	159	9
26	7% @ 1.0 μ M	162	14
27	160	167	450
28	87	174	4
29	494		

Pharmaceutical Compositions

The present invention also provides pharmaceutical compositions which comprise one or more of the compounds of formula I above formulated together with one or more non-toxic pharmaceutically acceptable carriers. The pharmaceutical compositions may be specially formulated for oral administration in solid or liquid form, for parenteral injection, or for rectal administration.

The pharmaceutical compositions of this invention can be administered to humans and other animals orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, or drops), buccally, or as an oral or nasal spray. The term "parenteral" administration as used herein refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.

Pharmaceutical compositions of this invention for parenteral injection comprise pharmaceutically acceptable sterile aqueous or nonaqueous solutions, dispersions, suspensions, or emulsions as well as sterile powders for reconstitution into sterile injectable solutions or dispersions just prior to use. Examples of suitable aqueous and nonaqueous carriers, diluents, solvents, or vehicles include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils (such as olive oil), and injectable organic esters such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of coating materials such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.

These compositions may also contain adjuvants such as preservative, wetting agents, emulsifying agents, and dispersing agents. Prevention of the action of microorganisms may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents such as sugars, sodium chloride, and the like. Prolonged absorption of the injectable pharmaceutical form

may be brought about by the inclusion of agents which delay absorption such as aluminum monostearate and gelatin.

In some cases, in order to prolong the effect of the drug, it is desirable to slow the absorption of the drug from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material with poor water solubility. The rate of absorption of the drug then depends upon its rate of dissolution which, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered drug form is accomplished by dissolving or suspending the drug in an oil vehicle.

Injectable depot forms are made by forming microencapsule matrices of the drug in biodegradable polymers such as polylactide-polyglycolide. Depending upon the ratio of drug to polymer and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions which are compatible with body tissues.

The injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium just prior to use.

Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and/or (a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, (b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose, and acacia, (c) humectants such as glycerol, (d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, (e) solution retarding agents such as paraffin, (f) absorption accelerators such as quaternary ammonium compounds, (g) wetting agents such as, for example, cetyl alcohol and glycerol monostearate, (h) absorbents such as kaolin and bentonite clay, and (i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets and pills, the dosage form may also comprise buffering agents.

Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.

5 The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions which can be used include polymeric
10 substances and waxes.

The active compounds can also be in micro-encapsulated form, if appropriate, with one or more of the above-mentioned excipients.

Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs. In addition to the
15 active compounds, the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethyl formamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and
20 sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.

Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.

25 Suspensions, in addition to the active compounds, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.

30 Compositions for rectal or vaginal administration are preferably suppositories which can be prepared by mixing the compounds of this invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol, or a suppository wax which are solid at room temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.

35 Compounds of the present invention can also be administered in the form of liposomes. As is known in the art, liposomes are generally derived from phospholipids or other lipid substances. Liposomes are formed by mono- or multi-

lamellar hydrated liquid crystals that are dispersed in an aqueous medium. Any non-toxic, physiologically acceptable and metabolizable lipid capable of forming liposomes can be used. The present compositions in liposome form can contain, in addition to a compound of the present invention, stabilizers, preservatives, excipients, and the like.

- 5 The preferred lipids are the phospholipids and the phosphatidyl cholines (lecithins), both natural and synthetic.

Methods to form liposomes are known in the art. See, for example, Prescott, Ed., Methods in Cell Biology, Volume XIV, Academic Press, New York, N.Y. (1976), p. 33 et seq.

- 10 Dosage forms for topical administration of a compound of this invention include powders, sprays, ointments, and inhalants. The active compound is mixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives, buffers, or propellants which may be required. Ophthalmic formulations, eye ointments, powders and solutions are also contemplated as being
15 within the scope of this invention.

- Actual dosage levels of active ingredients in the pharmaceutical compositions of this invention may be varied so as to obtain an amount of the active compound(s) that is effective to achieve the desired therapeutic response for a particular patient, compositions, and mode of administration. The selected dosage level will depend
20 upon the activity of the particular compound, the route of administration, the severity of the condition being treated, and the condition and prior medical history of the patient being treated. However, it is within the skill of the art to start doses of the compound at levels lower than required to achieve the desired therapeutic effect and to gradually increase the dosage until the desired effect is achieved.

- 25 Generally dosage levels of about 0.001 to about 100 mg, more preferably of about 0.01 to about 20 mg, and most preferably about 0.1 to about 10 mg of active compound per kilogram of body weight per day are administered orally to a mammalian patient. If desired, the effective daily dose may be divided into multiple doses for purposes of administration, e.g. two to four separate doses per day.

30

Preparation of Compounds of the Invention

The compounds of this invention can be prepared by a variety of synthetic routes. Representative procedures are outlined as follows. It should be understood that R¹, R², R³, and Ar² as used herein correspond to the groups identified above.


- 35 A general route to the compounds of this invention is shown in Scheme 1. Indolyl zinc reagent 1 is prepared by treatment of the corresponding indole with

28

ethylmagnesium bromide and zinc chloride. Conversion of benzoic acid 2 to the acid chloride by reaction with oxalyl chloride, followed by addition of indolyl zinc reagent 1 forms 3, which is converted to the desired final product as described in PCT/US92/05890 (international publication no. WO 93/1813).

5

Scheme 1




10

Preparation of the intermediate benzoic acid 2 is shown in Scheme 2. 1,2-phenylenediamine is condensed with acetic anhydride to form 2-methylbenzimidazole which is then reacted with benzyl halide 5 (where X is Br, Cl, I, methansulfonyl, or p-toluenesulfonyl), in the presence of base to form 6. Hydrolysis of ester 6 gives benzoic acid 2. Condensation of 3,4-diaminopyridine with acetic anhydride followed by reaction with benzyl halide 5 as described above gives a mixture of 1-, 3-, and 5-substituted imidazo[4,5-c]pyridines (compounds 8, 9, and 10) which are separated by chromatography on silica gel and converted to 2 as described above. Similarly, imidazo[4,5-b]pyridines 12, 13, and 14 are prepared from 2,3-diaminopyridine.

29

Scheme 2




30

An alternative procedure for the preparation of the compounds of this invention is shown in Schemes 3a and b. According to Scheme 3a, 4-(*N*-*tert*-butoxycarbonylaminomethyl)benzoic acid 15, prepared by treatment of 4-

5 (aminomethyl)benzoic acid with di-*tert*-butyldicarbonate and base, is converted to the (aminomethyl)benzoic acid with di-*tert*-butyldicarbonate and base, is converted to the acid chloride and coupled with indolylzinc reagent 1 as described in Scheme 1 to give 16. The group R^2 is then introduced as described in Scheme 1, and the *tert*-butoxycarbonyl group is hydrolyzed with HCl to form amine 18. Reaction of 18 with

10 substituted nitropyridine 19, wherein any one of A, B, C, and D is N, and X is halogen or alkoxy, followed by reduction of the nitro group, preferably by hydrogenolysis catalyzed by palladium on carbon, gives key intermediate 20.

Scheme 3a




15

The conversion of diaminopyridine 20 to the compounds of this invention is shown in Scheme 3b. Reaction of 20 with ethyl(ethoxymethylene)cyanoacetate provides the compounds 21 in which R^{13} is H. Introduction of alkyl groups is accomplished by reaction of 20 with the appropriate anhydride as shown in the preparation of compounds 22 and 24. Compounds of formula 23 are prepared by

20 reaction of 20 with benzoyl chloride.


31
Scheme 3b



- 5 The preparation of the compounds of this invention where Ar¹ is thienyl is shown in Scheme 4. 2-carbomethoxy-5-bromomethylthiophene 25 is prepared from 5-methyl-2-thiophenecarboxylic acid by reaction with diazomethane and *N*-bromosuccinimide. Reaction of imidazopyridine 26, wherein any one of A, B, C, or D is N, with bromomethylthiophene 25 in the presence of potassium *tert*-butoxide and
- 10 DMSO gives 27, which is hydrolyzed to thiophenecarboxylic acid 28 with lithium hydroxide. The desired compound 29 is then prepared from 28 as described in Scheme 1 above.


32

Scheme 4




- 5 The preparation of the compounds of this invention in which Ar¹ is furyl is shown in Scheme 5. 5-acetoxy-2-carboxyethylfuran **30** is hydrolyzed with potassium carbonate in ethanol to give furyl alcohol **31**, which is converted to furyl azide **32** by treatment with methanesulfonyl chloride and lutidine to give the mesylate, followed by displacement with sodium azide. Raney nickel hydrogenolysis of the azide gives
- 10 amine **33**. Reaction of **33** with ethoxynitropyridine **34**, in which any one of A, B, C, or D is nitrogen, followed by reduction with tin(II) chloride gives diamine **36** which is converted to the desired compound **37** as described in Scheme 3b.

33
Scheme 5




- 5 The preparation of compounds in which L^1 is sulfonylamino is outlined in Scheme 6. Heating 1-methylindole and 4-azidomethylphenylsulfonyl azide 38, prepared by reaction of p-toluenesulfonyl chloride with N-bromosuccinimide followed by sodium azide, gives azide 39. Reduction of 39 with triphenylphosphine gives the primary amine 40. Reaction with ethoxynitropyridine 34, in which any one of A, B, C, or D is nitrogen, followed by reduction with tin(II) chloride gives diamine 41 which is converted to the desired compound 42 as described in Scheme 3b.
- 10

34
Scheme 6



- 5 The preparation of compounds in which L^1 is $-SO_2-$ is shown in Scheme 7. According to Scheme 7, the desired substituted indole is reacted with p-tolyldisulfide and sulfonyl chloride in the presence of triethylamine to form 3-(p-tolythio)indole **44**. Reaction of **44** with phenylsulfonyl chloride and KOH gives 1-phenylsulfonylindole derivative **45** which is oxidized to **46** with H_2O_2 in acetic acid. Bromination of **46**
- 10 with *N*-bromosuccinimide and benzoyl peroxide gives bromomethyl compound **47**. Displacement of bromide with potassium bis(*t*-butoxycarbonyl)amide and deprotection with trifluoroacetic acid followed by sodium carbonate gives benzyl amine **49**. Reaction of **49** with ethoxynitropyridine **34**, in which any one of A, B, C, or D is nitrogen, followed by reduction with iron and NH_4Cl gives diamine **51** which
- 15 is converted to imidazopyridine **52** as described in Scheme 3b. The desired final product **53** is then prepared as described in PCT/US92/05890 (international publication no. WO 93/1813).

35
Scheme 7




5

An alternative synthesis of the compounds of the invention which allows for facile introduction of Ar² is shown in Scheme 8. Indole **38** is converted to 1-substituted indole **39** by reaction with base, for example KOH or NaH, and R²X (where X is Br, Cl, I, methanesulfonyl, or p-toluenesulfonyl). Friedel-Crafts acylation of **39** with benzoyl chloride **40** provides 3-benzoylindole **41**. The desired compound

36

42 is prepared by reaction of imidazopyridine 26 (where any one of A, B, C, or D is N) or benzimidazole 26 (where A, B, C, and D are CH) with base, for example NaH, followed by alkylation with 41.

5

Scheme 8

The foregoing may be better understood by the following examples, which are presented for the purpose of illustration and are not intended to limit the scope of the invention.

Example 1

Preparation of 6-(4-fluorophenyl)-3-{4-[(1H-2-methylbenzimidazolyl)methyl]-benzoyl}indole.

15

Step 1: 2-Methylbenzimidazole.

20

A solution of 1,2-diaminobenzene (5.00g, 46.3 mmol) in acetic anhydride (36.5 mL) was heated for 17 hours at 90 °C and then stirred for 17 hours at ambient temperature. The reaction mixture was taken to pH 9 by dropwise addition of NH₄OH, with ice added as necessary to keep the mixture cool, followed by cooling in an ice bath. The resulting precipitate was filtered, rinsed with H₂O, and dried in a vacuum oven to give 5.28 g of 2-methylbenzimidazole as a brown solid.

Step 2: Methyl 4-(1H-2-methylbenzimidazol-1-ylmethyl)benzoate.

To a solution under N₂ of 2-methylbenzimidazole (2.00g, 15.2 mmol), prepared as in step 1, in THF (75.8 mL) was added NaH (437 mg, 18.2 mmol) in one portion. The resulting brown suspension was stirred for one hour at ambient
5 temperature, then cooled to 0 °C and a solution of methyl (4-bromomethyl)benzoate (2.89 g, 12.6 mmol) in THF (14.0 mL) was added dropwise via syringe, after which the ice bath was removed and the reaction mixture was stirred for 17 hours at ambient temperature. The reaction mixture was poured into a mixture of H₂O and ethyl acetate and the layers were separated. The organic phase was washed twice with H₂O, and
10 the aqueous phase was washed three times with ethyl acetate. The combined organic layers were dried over MgSO₄, filtered, and concentrated *in vacuo*. Chromatography on silica gel (5% methanol/CH₂Cl₂) gave methyl 4-(2-methylbenzimidazol-1-ylmethyl)benzoate (2.82 g) as a yellow solid.

Step 3: 4-(2-Methyl-1H-benzimidazolylmethyl)benzoic acid.

To a solution under N₂ of methyl 4-(1H-2-methylbenzimidazol-1-ylmethyl)benzoate (2.72 g, 9.71 mmol) in methanol (21.6 mL) was added 1M aqueous KOH (11.7 mL, 11.7 mmol). The reaction mixture was stirred for 1.33 hours at ambient temperature. Aqueous 1M HCl was added until a pH of about 4 was
20 obtained, and the reaction mixture was concentrated *in vacuo*. The residue was cooled in an ice bath for 30 min and filtered. The resulting tan precipitate was dried in the vacuum oven and the filtrate was extracted twice with ethyl acetate and twice with CH₂Cl₂. The combined extracts were dried over MgSO₄, filtered, and concentrated *in vacuo* to give a tan solid which was combined with the original precipitate to give 2.51
25 g of 4-(1H-2-methylbenzimidazol-1-ylmethyl)benzoic acid.

Step 4: 6-(4-Fluorophenyl)-3-{4-[(1H-2-methylbenzimidazol-1-yl)methyl]benzoyl}indole.

To a suspension of 4-(1H-2-methylbenzimidazol-1-ylmethyl)benzoic acid
30 (1.50 g, 5.63 mmol), prepared as in step 3, in THF (28 mL) was added NaH (195 mg, 8.46 mmol) in a single portion. The reaction mixture was stirred for 10 min, then DMF (85 µL, 1.13 mmol) and oxalyl chloride (953 µL, 11.3 mmol) were added. After stirring for 4 hours at ambient temperature, the reaction mixture was concentrated *in vacuo* to give a gray powder which was placed under N₂ and
35 suspended in CH₂Cl₂ (30 mL). In a separate flask, ethylmagnesium bromide (3M solution in ether, 4.5 mL, 13.5 mmol) was added to a solution of 6-(4-

38

fluorophenyl)indole (2.38 g, 11.3 mmol), prepared as described in WO 93/01813, in CH₂Cl₂ (56 mL). After 15 min, ZnCl₂ (1.0M solution in ether, 13.5 mL, 13.5 mmol) was added and the clear, dark brown solution was stirred for 20 min at ambient temperature. The 6-(4-fluorophenyl)indolylzinc solution was then transferred via
5 cannula to the acid chloride suspension and the resulting light-brown suspension was stirred for 20 hours at ambient temperature. The reaction mixture was quenched with H₂O (20 mL) and filtered. The filtrate layers were separated and the aqueous layer was extracted with CH₂Cl₂ (3x50 mL). The combined organic layers were washed with saturated aqueous NaHCO₃, dried over MgSO₄, filtered, and concentrated *in vacuo* to give a solid. The filter cake was stirred with methanol and filtered again.
10 The filtrate was extracted with CH₂Cl₂ (4x50 mL), and the combined organic layers were washed with saturated aqueous NaHCO₃, dried over MgSO₄, filtered, and concentrated *in vacuo* to give additional solid. The combined solids were purified by chromatography on silica gel (2%, then 5%, then 10% methanol/CH₂Cl₂ to give 6-(4-
15 fluorophenyl)-3-{4-[(1H-2-methylbenzimidazolyl)methyl]benzoyl}indole (539 mg) as a red solid. ¹H NMR (DMSO-d₆, 300 MHz) δ 2.57 (s, 3H), 5.61 (s, 2H), 7.15-7.25 (m, 2H), 7.25-7.35 (m, 3H), 7.5-7.6 (m, 6H), 7.97 (d, 1H, J = 3.0 Hz), 8.28 (d, 1H, J = 8.4 Hz), 12.16 (br s, 1H). MS (DCI/NH₃) m/e 460 (M+H)⁺. Anal calcd for C₃₀H₂₂FN₃O · 0.6H₂O: C, 76.61; H, 4.97; N, 8.93. Found: C, 76.72; H, 4.90;
20 N, 8.95.

Example 2

Preparation of 1-N,N-Dimethylcarbamoyl-6-(4-fluorophenyl)-3-{4-[(1H-2-methylbenzimidazolyl)methyl]benzoyl}indole.

25 To a solution of 6-(4-fluorophenyl)-3-{4-[(1H-2-methylbenzimidazolyl)methyl]benzoyl}indole (200 mg, 0.44 mmol), prepared as in Example 1, in 1:1 THF/DMF (8.0 mL) at 0 °C was added KOH (61 mg, 1.09 mmol). The reaction mixture was stirred for 10 min and dimethylcarbamoyl chloride (60.3 μL, 0.65 mmol) was added via syringe. Stirring was continued for 40 min and then
30 the reaction mixture was partitioned between H₂O (20 mL) and ethyl acetate (20 mL). The aqueous phase was extracted twice with ethyl acetate. The combined organic layers were washed with brine, dried over MgSO₄, filtered, and concentrated *in vacuo*. Pure 6-(4-fluorophenyl)-3-{4-[(1H-2-methylbenzimidazolyl)methyl]benzoyl}indole-1-carboxylic acid dimethylamide (200
35 mg) was obtained by chromatography on silica gel (5% methanol/CH₂Cl₂). ¹H NMR (DMSO-d₆, 300 MHz) δ 2.56 (s, 3H), 3.02 (s, 6H), 5.62 (s, 2H), 7.15-7.25 (m,

39

2H), 7.25-7.35 (m, 4H), 7.5-7.6 (m, 2H), 7.64 (dd, 1H, $J = 8.4, 1.8$ Hz), 7.7-7.8 (m, 2H), 7.8-7.9 (m, 3H), 8.15 (s, 1H), 8.30 (d, 1H, $J = 8.4$ Hz). MS (DCI/ NH_3) m/e 531 ($\text{M}+\text{H}$)⁺. Anal calcd for $\text{C}_{33}\text{H}_{27}\text{FN}_4\text{O}_2 \cdot 0.4\text{H}_2\text{O}$: C, 73.70; H, 5.21; N, 10.42. Found: C, 73.70; H, 5.30; N, 10.40.

5

Example 3

Preparation of 6-(4-Fluorophenyl)-3-{4-[(1H-2-methylimidazo[4,5-c]pyrid-1-yl)methyl]benzoyl}indole.

Step 1: 1H-2-Methylimidazo[4,5-c]pyridine.

10 The desired compound was prepared according to the method of Example 1, step 1, except substituting 3,4-diaminopyridine for 1,2-diaminobenzene.

Step 2: Methyl 4-(1H-2-methylimidazo[4,5-c]pyrid-1-ylmethyl)benzoate.

15 To a solution under N_2 of 1H-2-methylimidazo[4,5-c]pyridine (600 mg, 4.51 mmol), prepared as in step 1, in THF (33 mL) and DMF (11 mL) was added NaH (130 mg, 5.41 mmol) in a single portion. The resulting brown suspension was stirred for one hour at ambient temperature, then cooled to 0 °C and a solution of methyl 4-(bromomethyl)benzoate (1.03 g, 4.51 mmol) in THF (5 mL) was added via syringe. The cold bath was then removed and the reaction mixture stirred for 17 hours at
20 ambient temperature. The reaction mixture was partitioned between pH 7 buffer (40 mL), and ethyl acetate (40 mL). The aqueous phase was extracted with ethyl acetate (2x30 mL), and the combined organic layers were washed with H_2O (5x30 mL), dried over MgSO_4 , filtered, and concentrated *in vacuo* to give a mixture of predominately two products. Chromatography on silica gel gave methyl 4-(1H-2-methylimidazo[4,5-c]pyrid-1-ylmethyl)benzoate (150 mg) and methyl 4-(3H-2-methylimidazo[4,5-c]pyrid-3-ylmethyl)benzoate (95 mg). The original aqueous phase
25 was concentrated *in vacuo* to give a brown solid which was taken up in methanol, dried over MgSO_4 , filtered, and re-concentrated *in vacuo*. Chromatography on silica gel gave methyl 4-(5H-2-methylimidazo[4,5-c]pyrid-5-ylmethyl)benzoate (435 mg).

30

Step 3: 6-(4-Fluorophenyl)-3-{4-[(1H-2-methylimidazo[4,5-c]pyrid-1-yl)methyl]benzoyl}indole.

The desired compound was prepared according to the method of Example 1, steps 3 and 4, except substituting 4-(1H-2-methylimidazo[4,5-c]pyrid-1-ylmethyl)benzoate, prepared as in step 2, for methyl 4-(2-methylbenzimidazol-1-ylmethyl)benzoate. ^1H NMR ($\text{DMSO}-d_6$, 300 MHz) δ 2.60 (s, 3H), 5.65 (s, 2H),
35

40

7.25-7.35 (m, 4H), 7.52 (dd, 1H, J = 8.4, 1.5 Hz), 7.64 (d, 1H, J = 8.7 Hz), 7.7-7.8 (m, 3H), 7.80 (d, 1H, J = 8.1 Hz), 7.97 (s, 1H), 8.28 (d, 1H, J = 8.4 Hz), 8.32 (d, 1H, J = 5.4 Hz), 8.87 (s, 1H), 12.15 (br s, 1H). MS (FAB) m/e 461 (M+1)⁺.
Anal calcd for C₂₉H₂₁FN₄O · 1.2H₂O: C, 72.25; H, 4.89; N, 11.62. Found: C, 72.26; H, 4.72; N, 11.67.

Example 4

Preparation of 1-N,N-Dimethylcarbamoyl-6-(4-fluorophenyl)-3-{4-[(1H-2-methylimidazo[4,5-c]pyrid-1-yl)methyl]benzoyl}indole.

10 Step 1: 6-(4-fluorophenyl)indole-1-carboxylic acid dimethylamide.

To a 0 °C solution of 6-(4-fluorophenyl)indole (2.00 g, 9.48 mmol), prepared as described in WO 93/01813, in THF (50 mL) was added KOH (2.7 g, 47.4 mmol) in a single portion and the cold bath was removed. After stirring for 15 min at ambient temperature, dimethylcarbamoyl chloride (1.3 mL, 14.2 mmol) was added via
15 syringe and the resulting brown suspension was stirred for 4 hours at ambient temperature. The reaction mixture was poured into a mixture of ethyl acetate and saturated aqueous NH₄Cl and the layers were separated. The aqueous phase was extracted twice with ethyl acetate. The combined organic layers were dried over MgSO₄, filtered, and concentrated *in vacuo* to afford 6-(4-fluorophenyl)indole-1-carboxylic acid dimethylamide as a brown solid which was used without further
20 purification.

Step 2: 6-(4-Fluorophenyl)-3-(4-chloromethylbenzoyl)indole-1-carboxylic acid dimethylamide.

25 To a solution of 4-(chloromethyl)benzoyl chloride (804 mg, 4.26 mmol) in CH₂Cl₂ (21 mL) was added AlCl₃ (850 mg, 6.39 mmol) in a single portion, and the yellow solution was stirred for 15 min at ambient temperature. A solution of 6-(4-fluorophenyl)indole-1-carboxylic acid dimethylamide (1.00 g, 3.55 mmol), prepared as in step 1, in CH₂Cl₂ was added dropwise and the dark solution was stirred for 2
30 hours at ambient temperature. Additional AlCl₃ (0.24 g, 1.78 mmol) was added and the reaction mixture was stirred for 0.5 hours. The reaction mixture was poured into a separatory funnel containing ice water and CH₂Cl₂. The layers were separated and the aqueous phase was extracted three times with CH₂Cl₂. The combined organic layers were washed with saturated aqueous NaHCO₃, dried over MgSO₄, filtered,
35 and concentrated *in vacuo*. Pure 6-(4-fluorophenyl)-3-(4-

chloromethylbenzoyl)indole-1-carboxylic acid dimethylamide (294 mg) was obtained by chromatography on silica gel (25%, then 50% ethyl acetate/hexanes).

5 Step 3: 1-N, N-Dimethylcarbamoyl-6-(4-fluorophenyl)-3-{4-[(1H-2-methylimidazo[4,5-c]pyrid-1-yl)methyl]benzoyl}indole.

To a solution of imidazo[4,5-c]pyridine (407 mg, 3.06 mmol) in THF (15 mL) and 1,3-dimethyl-3,4,5,6-tetrahydro-2-1H-pyrimidinone (5 mL) was added NaH (110 mg, 4.59 mmol) in a single portion and the resulting solution was stirred for 1 hour at ambient temperature. In a separate flask, NaBr (630 mg, 6.11 mmol) was added to a solution of 6-(4-fluorophenyl)-3-(4-chloromethylbenzoyl)indole-1-carboxylic acid dimethylamide (1.33 g, 3.06 mmol), prepared as in step 2, in THF (15 mL) and 1,3-dimethyl-3,4,5,6-tetrahydro-2-1H-pyrimidinone (5 mL). The resulting yellow suspension was stirred for 1 hour at ambient temperature, after which the imidazopyridine solution was added dropwise via syringe. The reaction mixture was stirred for 3 hours at ambient temperature and then was partitioned between brine and ethyl acetate. The layers were separated and the aqueous phase was extracted twice with ethyl acetate. The combined organic layers were washed twice with brine, dried over MgSO₄, filtered, and concentrated *in vacuo*. Chromatography on silica gel (2%, then 4% methanol/CH₂Cl₂) provided 1-N, N-dimethylcarbamoyl-6-(4-fluorophenyl)-3-{4-[(1H-2-methylimidazo[4,5-c]pyrid-1-yl)methyl]benzoyl}indole. (228 mg). mp 257-259 °C. ¹H NMR (DMSO-d₆, 300 MHz) δ 2.59 (s, 3H), 3.03 (s, 6H), 5.67 (s, 2H), 7.25-7.35 (m, 4H), 7.6-7.7 (m, 2H), 7.7-7.8 (m, 2H), 7.8-7.9 (m, 3H), 8.15 (s, 1H), 8.30 (d, 1H, J = 8.4 Hz), 8.31 (d, 1H, J = 5.7 Hz), 8.87 (s, 1H). MS (DCI/NH₃) m/e 532 (M+H)⁺. Anal calcd for C₃₂H₂₆FN₅O₂ · 0.8H₂O: C, 70.39; H, 5.09; N, 12.83. Found: C, 70.38; H, 5.39; N, 12.82.

Example 5

Preparation of 1-N, N-Dimethylcarbamoyl-6-(4-fluorophenyl)-3-{4-[(1H-2-methylimidazo[4,5-c]pyrid-1-yl)methyl]benzoyl}indole hydrochloride.

30 To a 0 °C solution of 1-N, N-dimethylcarbamoyl-6-(4-fluorophenyl)-3-{4-[(1H-2-methylimidazo[4,5-c]pyrid-1-yl)methyl]benzoyl}indole (50 mg, 0.09 mmol), prepared as in Example 4, in CH₂Cl₂ (3 mL) was added 2 mL of 4N HCl in dioxane. The resulting yellow solution, which also contained a small amount of yellow oil, was stirred for 15 min at 0 °C and then was concentrated *in vacuo*. CH₂Cl₂ (2 mL) was added to the oily residue and the mixture was sonicated until a fine suspension was obtained. The suspension was diluted with ether and filtered to give 42 mg of 1-N, N-

42

dimethylcarbamoyl-6-(4-fluorophenyl)-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole hydrochloride as a yellow solid. mp 275-278 °C. ¹H NMR (D₃COD, 300 MHz) δ 2.79 (s, 3H), 3.11 (s, 6H), 5.84 (s, 2H), 7.15-7.25 (m, 2H), 7.40 (apparent d, 2H, J = 8.1 Hz), 7.61 (dd, 1H, J = 8.4, 2.3 Hz), 7.65-7.75 (m, 2H), 7.75-7.80 (narrow m, 1H), 7.85-7.90 (m, 2H), 7.99 (s, 1H), 8.19 (d, 1H, J = 6.3 Hz), 8.34 (d, 1H, J = 8.1 Hz), 8.58 (d, 1H, J = 6.3 Hz), 9.26 (s, 1H). Anal calcd for C₃₂H₂₇FN₅O₂Cl · 0.6H₂O: C, 66.40; H, 4.91; N, 12.10. Found: C, 66.40; H, 5.00; N, 12.01.

10

Example 6

Preparation of 6-(4-Fluorophenyl)-3-{4-[(3H-2-methylimidazo[4.5-c]pyrid-3-yl)methyl]benzoyl}indole.

Step 1: Potassium 4-(3H-2-methylimidazo[4.5-c]pyrid-3-ylmethyl)benzoate.

Hydrolysis of methyl 4-(3H-2-methylimidazo[4.5-c]pyrid-3-ylmethyl)benzoate, prepared as in Example 3, step 2, with aqueous KOH in methanol was accomplished as described in Example 1, step 3. After complete consumption of starting material, the reaction mixture was partitioned between H₂O and ethyl acetate. The aqueous phase was washed twice with ethyl acetate and concentrated *in vacuo*. Lyophilization of the crude product gave potassium 4-(3H-2-methylimidazo[4.5-c]pyrid-3-ylmethyl)benzoate.

Step 2: 6-(4-Fluorophenyl)-3-{4-[(3H-2-methylimidazo[4.5-c]pyrid-3-yl)methyl]benzoyl}indole.

To a suspension of potassium 4-(3H-2-methylimidazo[4.5-c]pyrid-3-ylmethyl)benzoate (350 mg, 1.15 mmol), prepared as in step 1, in THF (6 mL) was added DMF (179 μL, 2.3 mmol) and oxalyl chloride (200 μL, 2.30 mmol). The reddish suspension was stirred at ambient temperature for 1.5 hours after gas evolution ceased. The reaction mixture was concentrated *in vacuo* to give a tan paste which was suspended in CH₂Cl₂ (6 mL). A solution of 6-(4-fluorophenyl)indolylzinc (2.30 mmol), prepared as described in Example 1, step 4, was added via cannula and the resulting tan suspension was stirred for 17 hours at ambient temperature. The reaction mixture was quenched with H₂O (50 mL) and the layers were separated. The aqueous phase was extracted with CH₂Cl₂ (2x50 mL) and ethyl acetate (4x50 mL). The combined organic layers were dried over MgSO₄, filtered, and concentrated *in vacuo*. Chromatography on silica gel (2%, then 5%, then 7% methanol/CH₂Cl₂ gave 79 mg of 6-(4-fluorophenyl)-3-{4-[(3H-2-

methylimidazo[4.5-c]pyrid-3-yl)methyl]benzoyl}indole. ¹H NMR (DMSO-d₆, 300 MHz) δ 2.59 (s, 3H), 5.64 (s, 2H), 7.2-7.3 (m, 4H), 7.45-7.55 (m, 1H), 7.63 (dd, 1H, J = 5.4, 1.1 Hz), 7.75-7.80 (m, 2H), 7.91 (s, 1H), 8.2-8.3 (m, 1H), 8.31 (d, 1H, J = 5.4 Hz), 8.87 (s, 1H), 12.08 (br s, 1H). MS (FAB) m/e 461 (M+1)⁺.

5

Example 7

Preparation of 1-N,N-Dimethylcarbamoyl-6-(4-fluorophenyl)-3-{4-[(3H-2-methylimidazo[4.5-c]pyrid-3-yl)methyl]benzoyl}indole.

The desired compound was prepared according to the method of Example 2, except substituting 6-(4-fluorophenyl)-3-{4-[(3H-2-methylimidazo[4.5-c]pyrid-3-yl)methyl]benzoyl}indole, prepared as in Example 6, for 6-(4-fluorophenyl)-3-{4-[(1H-2-methylbenzimidazolyl)methyl]benzoyl}indole. ¹H NMR (DMSO-d₆, 300 MHz) δ 2.63 (s, 3H), 3.03 (s, 6H), 5.73 (s, 2H), 7.25-7.40 (m, 4H), 7.59 (dd, 1H, J = 5.7, 1.0 Hz), 7.65 (dd, 1H, J = 8.1, 1.5 Hz), 7.7-7.8 (m, 2H), 7.8-7.9 (m, 3H), 8.16 (s, 1H), 8.30 (d, J = 8.1 Hz), 8.31 (d, 1H, J = 5.7 Hz), 8.97 (s, 1H). MS (DCI/NH₃) m/e 532 (M+H)⁺. Anal calcd for C₃₂H₂₆FN₅O₂ · 0.9H₂O: C, 70.16; H, 5.11; N, 12.78. Found C, 70.29; H, 5.28; N, 12.27.

15

Example 8

Preparation of 1-N,N-Dimethylcarbamoyl-6-(4-fluorophenyl)-3-[4-(5H-2-methylimidazo[4.5-c]pyrid-5-ylmethyl)benzoyl]indole.

Step 1: 6-(4-Fluorophenyl)-3-[4-(5H-2-methylimidazo[4.5-c]pyrid-5-ylmethyl)benzoyl]indole.

The desired compound was prepared according to the method of Example 6, except substituting 4-(5H-2-methylimidazo[4.5-c]pyrid-5-ylmethyl)benzoate, prepared as in Example 3, step 2, for methyl 4-(3H-2-methylimidazo[4.5-c]pyrid-3-ylmethyl)benzoate.

25

Step 2: 1-N,N-Dimethylcarbamoyl-6-(4-fluorophenyl)-3-[4-(5H-2-methylimidazo[4.5-c]pyrid-5-ylmethyl)benzoyl]indole.

30

The desired compound was prepared according to the method of Example 2, except substituting 6-(4-fluorophenyl)-3-[4-(5H-2-methylimidazo[4.5-c]pyrid-5-ylmethyl)benzoyl]indole, prepared as in step 1, for 6-(4-fluorophenyl)-3-{4-[(1H-2-methylbenzimidazolyl)methyl]benzoyl}indole. ¹H NMR (DMSO-d₆, 300 MHz) δ 2.52 (s, 3H), 3.02 (s, 6H), 5.77 (s, 2H), 7.25-7.35 (m, 2H), 7.57 (apparent d, 2H, J = 8.4 Hz), 7.6-7.7 (m, 2H), 7.7-7.8 (m, 2H), 7.80-7.85 (narrow m, 1H), 7.89

35

44

(apparent d, 2H, J = 8.4 Hz), 8.16 (s, 1H), 8.21 (dd, 1H, J = 6.9, 1.8 Hz), 8.31 (d, 1H, 8.4 Hz), 9.00 (d, 1H, J = 1.2 Hz). MS (DCI/NH₃) m/e 532 (M+H)⁺.

Example 9

5 Preparation of 6-(4-Fluorophenyl)-3-[4-(1H-2-methylimidazo[4,5-c]pyrid-1-yl)benzoyl]indole.

Step 1: 4-(N-3-nitropyrid-4-ylamino)benzonitrile.

To a solution under N₂ of 3-nitro-4-chloropyridine (4.63 g, 29.2 mmol), prepared as described by Wright, G. C., *J. Heterocyclic Chem.* **1976**, *13*, 601, and
10 Kruger, S. and Mann, F.G., *J. Chem. Soc.* **2 1955**, 758, in absolute ethanol (100 mL) was added 4-aminobenzonitrile (3.45 g, 29.2 mmol) and the resulting purple-brown solution was stirred for 17 hours at ambient temperature, during which time it became a green-brown suspension. The reaction mixture was poured into cold 10% aqueous NH₄OH and filtered. The solid was suspended in ethanol (75 mL) and
15 heated for 10 min on the steam bath. The suspension was cooled to ambient temperature and filtered to give 4-(N-3-nitropyrid-4-ylamino)benzonitrile as a bright-yellow solid.

Step 2: 4-(N-3-Aminopyrid-4-ylamino)benzonitrile.

20 Catalytic hydrogenation (2 atm H₂, 10% Pd/C) of 4-(N-3-nitropyrid-4-ylamino)benzonitrile (6.17 g) in 1:1 methanol/CH₂Cl₂ gave 4-(N-3-aminopyrid-4-ylamino)benzonitrile.

Step 3: 4-(1H-2-Methylimidazo[4,5-c]pyrid-1-yl)benzonitrile.

25 A mixture of 4-(N-3-aminopyrid-4-ylamino)benzonitrile (5.20 g, 24.7 mmol), prepared as in step 2, acetic anhydride (16 mL, 169 mmol), and acetic acid (16 mL) was warmed to 95 °C and stirred for 2 hours. The reaction mixture was cooled to ambient temperature and concentrated *in vacuo*. The residue was azeotroped with benzene to give a brown solid. The brown solid was mixed with 10% aqueous
30 NH₄Cl and extracted with CH₂Cl₂ (3x75 mL). The combined organic extracts were dried over MgSO₄, filtered, and concentrated *in vacuo* to give 4-(1H-2-methylimidazo[4,5-c]pyrid-1-yl)benzonitrile (6.38 g) as a yellow solid which was used without further purification.

Step 4: Methyl 4-(1H-2-methylimidazo[4,5-c]pyrid-1-yl)benzoate.

HCl gas was bubbled for 10 minutes into a flask containing 100 mL of methanol and cooled in an ice/acetone bath, during which time the solution temperature rose to 37 °C. The solution temperature was allowed to come down to -5 °C and a solution of 4-(1H-2-methylimidazo[4,5-c]pyrid-1-yl)benzonitrile (5.30 g, 22.6 mmol) in methanol (50 mL) was added dropwise over 15 min. The reaction was warmed slowly to ambient temperature and stirred for 65 hours. The milky white reaction mixture was cooled in an ice/water bath and H₂O (100 mL) was added dropwise. The resulting clear-yellow suspension was stirred for 3 hours at ambient temperature and again cooled in an ice/water bath. Solid Na₂CO₃ was added until a pH of 8 was achieved and the white suspension was warmed to ambient temperature. Water was added until a clear solution was obtained and the solution was extracted with CH₂Cl₂ (3x600 mL). The combined organic extracts were dried over Na₂SO₄, filtered, and concentrated *in vacuo* to give methyl 4-(1H-2-methylimidazo[4,5-c]pyrid-1-yl)benzoate (5.19 g) as a yellow-white solid.

Step 5: 6-(4-Fluorophenyl)-3-[4-(1H-2-methylimidazo[4,5-c]pyrid-1-yl)benzoyl]indole.

The desired compound was prepared according to the method of Example 1, steps 3 and 4, except substituting 4-(1H-2-methylimidazo[4,5-c]pyrid-1-yl)benzoate for methyl 4-(1H-2-methylbenzimidazol-1-ylmethyl)benzoate. ¹H NMR (DMSO-d₆, 300 MHz) δ 2.66 (s, 3H), 7.65 (d, 1H, J = 1.5 Hz), 7.69 (d, 1H, J = 1.5 Hz), 7.82-7.91 (c, 3H), 8.05 (bs, 1H), 8.25 (s, 1H), 8.28 (s, 1H), 8.36 (s, 1H), 8.55 (d, 1H, J = 6 Hz), 8.69-8.80 (c, 5H), 9.24 (s, 1H). IR (KBr) 3140, 1600, 1560, 1500, 1470, 1450, 1430, 1400, 1380, 13250, 1300, 1250, 1230, 1200, 890, 850, 810, 710. MS (DCI/NH₃) m/e 447 (M+H)⁺, 281, 238, 212, 130, 117 cm⁻¹. Anal calcd for C₂₈H₂₂FN₄O_{2.5}: C, 71.02; H, 4.68; N, 11.84. Found: C, 70.86; H, 4.65; N, 12.26.

Example 10

Preparation of 1-N,N-Dimethylcarbamoyl-6-(4-fluorophenyl)-3-[4-(1H-2-methylimidazo[4,5-c]pyrid-1-yl)benzoyl]indole.

The desired compound was prepared according to the method of Example 2, except substituting 6-(4-fluorophenyl)-3-[4-(1H-2-methylimidazo[4,5-c]pyrid-1-yl)benzoyl]indole, prepared as in Example 9, for 6-(4-fluorophenyl)-3-{4-[(1H-2-methylbenzimidazolyl)methyl]benzoyl}indole, and using K₂CO₃/DMSO instead of

KOH/THF,DMF. mp 307.0-307.5 °C. ¹H NMR (DMSO-d₆, 300 MHz) δ 2.59 (s, 3H), 3.10 (s, 6H), 7.30-7.40 (c, 2H), 7.61-7.72 (c, 2H), 7.73-7.88 (c, 5H), 8.05-8.16 (c, 2H), 8.30-8.41 (c, 2H), 8.96 (s, 1H), 9.08 (bd, 1H, J = 10.5 Hz). IR (KBr) 1700, 1640, 1600, 1520, 1480, 1440, 1390, 1220, 1180, 1090, 1020, 990, 920 cm⁻¹. MS (DCI/NH₃) m/e 518 (M+H)⁺.

Example 11

Preparation of 6-(4-Fluorophenyl)-3-{3-[(1H-2-methylimidazo[4,5-c]pyrid-1-yl)methyl]benzoyl}indole.

10 Step 1: Methyl 3-(1H-2-methylimidazo[4,5-c]pyrid-1-ylmethyl)benzoate.

To a solution of 1H-2-methylimidazo[4,5-c]pyridine (3.00 g, 22.5 mmol), prepared as in Example 3, step 1, in THF (165 mL) was added DMF (55 mL) and NaH (95%, 650 mg, 27.0 mmol). The resulting brown suspension was stirred for 1 hour at ambient temperature, then cooled in an ice bath and a solution of methyl 3-(bromomethyl)benzoate (5.18 g, 22.6 mmol) in THF (25 mL) was added dropwise over 10 min. The reaction mixture was stirred for 15 min at 0 °C, then the cold bath was removed and stirring was continued at ambient temperature for 17 hours. The reaction mixture was poured into H₂O (200 mL) and the aqueous phase was extracted with ethyl acetate (3x250 mL). The combined organic layers were dried over Na₂SO₄, filtered, and concentrated *in vacuo* to give 3.95 g of gummy solid. Chromatography on silica gel (2%, then 4%, then 10% methanol/CH₂Cl₂) gave methyl 3-(1H-2-methylimidazo[4,5-c]pyrid-1-ylmethyl)benzoate (620 mg), methyl 3-(3H-2-methylimidazo[4,5-c]pyrid-3-ylmethyl)benzoate (790 mg), and methyl 3-(5H-2-methylimidazo[4,5-c]pyrid-5-ylmethyl)benzoate (1.50 g).

25

Step 2: 6-(4-Fluorophenyl)-3-{3-[(1H-2-methylimidazo[4,5-c]pyrid-1-yl)methyl]benzoyl}indole.

The desired compound was prepared according to the method of Example 1, steps 3 and 4, except substituting methyl 3-(1H-2-methylimidazo[4,5-c]pyrid-1-ylmethyl)benzoate, prepared as in step 1, for 4-(1H-2-methylbenzimidazol-1-ylmethyl)benzoate. mp 194.4-196.4 °C. ¹H NMR (DMSO-d₆, 300 MHz) δ 2.60 (s, 3H), 5.65 (s, 2H), 7.27-7.38 (c, 3H), 7.49-7.56 (c, 2H), 7.70-7.79 (c, 4H), 7.89 (d, 1H, J = 3 Hz), 8.24 (d, 1H, J = 9 Hz), 8.30 (d, 1H, J = 6 Hz), 8.85 (bs, 1H), 12.16 (bs, 1H). IR (KBr) 3160, 2940, 1610, 1580, 1510, 1450, 1400, 1370, 1290, 1240, 1180, 1160, 1040, 920, 900, 840, 810. MS (DCI/NH₃) m/e 461(M+H)⁺,

47

212, 134 cm^{-1} . Anal calcd. for $\text{C}_{29}\text{H}_{21}\text{FN}_4\text{O} \cdot 1.25 \text{ H}_2\text{O}$: C, 72.11; H, 4.9; N, 11.6. Found: C, 72.01; H, 5.17; N, 11.27.

Example 12

5 Preparation of 1-*N,N*-Dimethylcarbamoyl-6-(4-fluorophenyl)-3-{3-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole.

To a solution under N_2 of 6-(4-fluorophenyl)-3-{3-[(1*H*-2-methylimidazo[4.5-*c*]pyridyl)methyl]benzoyl}indole (921 mg, 2.00 mmol), prepared as in Example 11, in DMSO (2.0 mL), was added K_2CO_3 (138 mg, 1.00 mmol) and
10 the resulting dark-yellow suspension was stirred for 30 min at ambient temperature. *N,N*-dimethylcarbamoyl chloride (36.7 μL , 4.00 mmol) was added and stirring was continued for 17 hours. The reaction was quenched with saturated aqueous NH_4Cl (0.60 mL), stirred for 30 min, and concentrated to dryness *in vacuo*. The residue was partitioned between saturated aqueous NH_4Cl and CH_2Cl_2 . A small amount of brine
15 was added and the layers were separated. The aqueous phase was extracted with CH_2Cl_2 . The combined organic layers were dried over Na_2SO_4 , filtered, and concentrated *in vacuo*. Chromatography on silica gel (3% methanol/ CH_2Cl_2) gave 1-*N,N*-dimethylcarbamoyl-6-(4-fluorophenyl)-3-{3-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole (89 mg, 84%). mp. 244.5-245.5 $^\circ\text{C}$. ^1H NMR (DMSO-
20 d_6 , 300 MHz) δ 2.58 (s, 3H), 3.03 (s, 6H), 5.65 (bs, 2H), 7.32 (t, 2H, $J = 7.5$ Hz), 7.40 (bd, 1H, $J = 7.5$ Hz), 7.56 (bt, 1H, $J = 7.5$ Hz), 7.59-7.67 (c, 3H), 7.73-7.83 (c, 4H), 8.02 (s, 1H), 8.24-8.31 (c, 2H), 8.85 (bs, 1H). IR (KBr) 3440, 1700, 1630, 1610, 1580, 1550, 1510, 1480, 1430, 1390, 1230, 1180, 820 cm^{-1} . MS (DCI/ NH_3) m/e 532 ($\text{M}+\text{H}$) $^+$, 134, 106. Anal calcd for $\text{C}_{32}\text{H}_{27}\text{FN}_5\text{O}_2 \cdot 2\text{H}_2\text{O}$: C, 67.7; H, 5.32; N, 12.34. Found C, 67.78; H, 4.93; N, 12.18.

Example 13

Preparation of 3-{4-[(1*H*-2-Methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole.

Step 1: potassium 4-(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl)benzoate.

30 The desired compound was prepared as described in Example 6, step 1, except substituting methyl 4-(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl)benzoate, prepared as in Example 3, step 2, for 4-(3*H*-2-methylimidazo[4.5-*c*]pyrid-3-yl)methyl)benzoate.

35

Step 2: 6-3-{4-[(1H-2-Methylimidazo[4,5-c]pyrid-1-yl)methyl]benzoyl}indole.

The desired compound was prepared according to the method of Example 6, step 2, except substituting potassium 4-(1H-2-methylimidazo[4,5-c]pyrid-1-ylmethyl)benzoate, prepared as in step 1, for potassium 4-(3H-2-methylimidazo[4,5-c]pyrid-3-ylmethyl)benzoate, and preparing the indolylzinc reagent from indole instead of 6-(4-fluorophenyl)indole. ¹H NMR (DMSO-d₆, 300 MHz) δ 2.59 (s, 3H), 5.64 (s, 2H), 7.2-7.3 (m, 4H), 7.45-7.55 (m, 1H), 7.63 (dd, 1H, J = 5.4, 1.1 Hz), 7.75-7.80 (m, 2H), 7.91 (s, 1H), 8.2-8.3 (m, 1H), 8.31 (d, 1H, J = 5.4 Hz), 8.87 (s, 1H), 12.08 (br s, 1H). MS (FAB) m/e 367 (M+1)⁺.

Example 14

Preparation of 1-N,N-Dimethylcarbamoyl-3-{4-[(1H-2-methylimidazo[4,5-c]pyrid-1-yl)methyl]benzoyl}indole.

The desired compound was prepared according to the method of Example 2, except substituting 3-[4-(1H-2-methylimidazo[4,5-c]pyrid-1-ylmethyl)benzoyl]indole, prepared as in Example 13, for 6-(4-fluorophenyl)-3-{4-[(1H-2-methylbenzimidazolyl)methyl]benzoyl}indole. ¹H NMR (DMSO-d₆, 300 MHz) δ 2.59 (s, 3H), 3.00 (s, 6H), 5.66 (s, 2H), 7.25-7.45 (m, 4H), 7.6-7.7 (m, 2H), 7.8-7.9 (m, 2H), 8.10 (s, 1H), 8.2-8.3 (m, 1H), 8.31 (d, 1H, J = 5.7 Hz), 8.87 (s, 1H). MS (FAB) m/e 438 (M+1)⁺. Anal calcd for C₂₆H₂₃N₅O₂ · 0.7H₂O: C, 69.38; H, 5.46; N, 15.56. Found: C, 69.69; H, 5.60; N, 14.96.

Example 15

Preparation of 3-[4-(5H-2-Methylimidazo[4,5-c]pyrid-5-ylmethyl)benzoyl]indole.

The desired compound was prepared according to the method of Example 1, steps 3 and 4, except substituting methyl 4-(5H-2-methylimidazo[4,5-c]pyrid-5-ylmethyl)benzoate, prepared as in Example 3, step 2, for methyl 4-(1H-2-methylbenzimidazol-1-ylmethyl)benzoate, and substituting indolylzinc for 6-(4-fluorophenyl)indolylzinc. ¹H NMR (DMSO-d₆, 300 MHz) δ 2.55 (s, 3H), 5.81 (s, 2H), 7.2-7.3 (m, 2H), 7.50-7.55 (m, 1H), 7.56 (d, 2H, J = 8.1 Hz), 7.71 (d, 1H, J = 6.6 Hz), 7.81 (d, 2H, J = 8.7 Hz), 7.91 (d, 1H, J = 3.0 Hz), 8.2-8.3 (m, 1H), 8.32 (dd, 1H, J = 6.6, 1.5 Hz), 12.21 (br s, 1H). MS (DCI/NH₃) m/e 367 (M+H)⁺.

Example 16Preparation of 1-*N,N*-Dimethylcarbamoyl-3-[4-(5*H*-2-methylimidazo[4.5-*c*]pyrid-5-ylmethyl)benzoyl]indole.

The desired compound was prepared according to the method of Example 2,
5 except substituting 3-[4-(5*H*-2-methylimidazo[4.5-*c*]pyrid-5-ylmethyl)benzoyl]indole,
prepared as in Example 15, for 6-(4-fluorophenyl)-3-{4-[(1*H*-2-
methylbenzimidazolyl)methyl]benzoyl}indole. ¹H NMR (DMSO-*d*₆, 300 MHz) δ
2.52 (s, 3H), 3.00 (s, 6H), 5.76 (s, 2H), 7.3-7.4 (m, 2H), 7.5-7.65 (m, 4H), 7.8-
7.9 (m, 2H), 8.11 (s, 1H), 8.15-8.30 (m, 2H), 8.99 (s, 1H). MS (DCI/NH₃) *m/e*
10 438 (M+H)⁺.

Example 17Preparation of 3-{3-[(1*H*-2-Methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole.

The desired compound was prepared according to the method of Example 1,
15 steps 3 and 4, except substituting methyl 3-(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-
ylmethyl)benzoate, prepared as in Example 11, step 1, for 4-(1*H*-2-
methylbenzimidazol-1-ylmethyl)benzoate, and preparing the indolylzinc reagent from
indole instead of 6-(4-fluorophenyl)indole. mp 246.1-247.3 °C. ¹H NMR (DMSO-
*d*₆, 300 MHz) δ 2.60 (s, 3H), 5.64 (s, 2H), 7.19-7.30 (c, 2H), 7.32(bd, 1H, *J* = 7.5
20 Hz), 7.48-7.54 (c, 2H), 7.57 (bs, 1H), 7.62 (dd, 1H, *J* = 6.1 Hz), 7.72 (bd, 1H, *J* =
7.5 Hz), 7.83 (s, 1H), 8.18-8.22 (c, 1H), 8.30 (d, 1H, *J* = 6 Hz), 8.85 (s, 1H),
12.06 (bs, 1H). IR (KBr) 1610, 1580, 1520, 1490, 1440, 1390, 1370, 1340, 1290,
1180, 1170, 1150, 1030, 890, 830, 750 cm⁻¹. MS (DCI/NH₃) *m/e* 367 (M+H)⁺,
118.

-25-

Example 18Preparation of 1-*N,N*-Dimethylcarbamoyl-3-{3-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole.

The desired compound was prepared according to the method of Example 2,
30 except substituting 3-{3-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-
yl)methyl]benzoyl}indole, prepared as in Example 17, for 6-(4-fluorophenyl)-3-{4-
[(1*H*-2-methylbenzimidazolyl)methyl]benzoyl}indole. mp 192-194 °C. ¹H NMR
(DMSO-*d*₆, 300 MHz) δ 2.59 (s, 3H), 3.01 (s, 6H), 5.64 (s, 2H), 7.32-7.43 (c,
3H), 7.51-7.66 (c, 4H), 7.79 (bd, 1H, *J* = 7.5 Hz), 7.98 (s, 1H), 8.21-8.32 (c, 2H),
35 8.85 (bs, 1H). IR (KBr) 3440, 1700, 1630, 1610, 1580, 1530, 1480, 1450, 1390,

50

1230, 1180, 1160, 1080, 1030, 760 cm^{-1} . MS (DCI/ NH_3) m/e 438 ($\text{M}+\text{H}$)⁺, 296, 118.

Example 19

5 Preparation of 3-{3-[(3H-2-Methylimidazo[4,5-c]pyrid-3-yl)methyl]benzoyl}indole.

The desired compound was prepared according to the method of Example 17, except substituting methyl 3-(3H-2-methylimidazo[4,5-c]pyrid-3-ylmethyl)benzoate, prepared as in Example 11, step 1, for methyl 3-(1H-2-methylimidazo[4,5-c]pyrid-1-ylmethyl)benzoate. mp 210-212 °C. ¹H NMR (DMSO- d_6 , 300 MHz) δ 2.63 (s, 3H), 5.71 (s, 2H), 7.20-7.30 (c, 2H), 7.37 (bd, 1H, $J = 7.5$ Hz), 7.49-7.59 (c, 3H), 7.60 (bs, 1H), 7.72 (bd, 1H, $J = 7.5$ Hz), 7.84 (s, 1H), 8.19-8.25 (c, 1H), 8.30 (d, 1H, $J = 6$ Hz), 8.88 (s, 1H), 12.09 (bs, 1H). IR (KBr) 1610, 1580, 1520, 1510, 1470, 1460, 1450, 1400, 1370, 1310, 1230, 1170, 830, 750 cm^{-1} . MS (DCI/ NH_3) m/e 367 ($\text{M}+\text{H}$)⁺, 134, 118. Anal calcd for $\text{C}_{23}\text{H}_{19.5}\text{N}_4\text{O}_{1.75}$: C, 72.7; H, 5.17; N, 14.75. Found: C, 72.38; H, 4.87; N, 14.66.

Example 20

Preparation of 1-N,N-Dimethylcarbamoyl-3-{3-[(3H-2-methylimidazo[4,5-c]pyrid-3-yl)methyl]benzoyl}indole.

20 The desired compound was prepared according to the method of Example 2, except substituting 3-{3-[(3H-2-methylimidazo[4,5-c]pyrid-3-yl)methyl]benzoyl}indole, prepared as in Example 19, for 6-(4-fluorophenyl)-3-{4-[(1H-2-methylbenzimidazolyl)methyl]benzoyl}indole. mp 134-136 °C. ¹H NMR (DMSO- d_6 , 300 MHz) δ 2.63 (s, 3H), 3.02 (s, 6H), 5.70 (s, 2H), 7.32-7.44 (c, 3H), 7.52-7.58 (c, 2H), 7.64 (d, 1H, $J = 4.5$ Hz), 7.68 (s, 1H), 7.79 (d, 1H, $J = 4.5$ Hz), 8.01 (s, 1H), 8.24 (d, 1H, $J = 4.5$ Hz), 8.29 (d, 1H, $J = 3.0$ Hz), 8.86 (s, 1H). IR (KBr) 1700, 1630, 1610, 1580, 1530, 1505, 1450, 1390, 1310, 1230, 1190, 1180, 1080, 830, 780 cm^{-1} . MS (DCI/ NH_3) m/e 438 ($\text{M}+\text{H}$)⁺. Anal calcd for $\text{C}_{26}\text{H}_{26}\text{FN}_5\text{O}_{3.5}$: C, 67.22; H, 5.64; N, 15.08. Found: C, 67.25; H, 5.25; N, 14.89.

Example 21

Preparation of 3-{4-[1H-2-Methylimidazo[4,5-c]pyrid-1-yl]}benzoyl}indole.

The desired compound was prepared according to the method of Example 9, except preparing the indolylzinc reagent from indole instead of 6-(4-fluorophenyl)indole. mp 239.5-240.5 °C. ¹H NMR (DMSO- d_6 , 300 MHz) δ 2.58 (s, 3H), 7.26-7.32 (c, 2H), 7.34 (dd, 1H, $J = 1, 6$ Hz), 7.53-7.58 (c, 1H), 7.72-

51

7.80 (c, 2H), 8.01-8.07 (c, 2H), 8.07-8.11 (c, 1H), 8.29-8.93 (c, 1H), 8.95 (d, 1H, J = 6 Hz), 8.95 (s, 1H), 12.17 (bs, 1H). IR (KBr) 3160, 1600, 1575, 1565, 1510, 1490, 1430, 1380, 1210, 895 cm⁻¹. MS (DCI/NH₃) m/e 353 (M+H)⁺, 281, 253, 130, 118.

5

Example 22

Preparation of 1-N,N-Dimethylcarbamoyl-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)]benzoyl}indole.

The desired compound was prepared according to the method of Example 2, except substituting 3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)]benzoyl}indole, prepared as in Example 21, for 6-(4-fluorophenyl)-3-{4-[(1H-2-methylbenzimidazolyl)methyl]benzoyl}indole. mp 241.1-241.7 °C. ¹H NMR (DMSO-d₆, 300 MHz) δ 2.58 (s, 3H), 3.06 (s, 6H), 7.35 (dd, 1H, J = 1.5, 6Hz), 7.39-7.45 (c, 2H), 7.64-7.69 (c, 1H), 7.76-7.83 (c, 2H), 8.08-8.14 (c, 2H), 8.28 (s, 1H), 8.32-8.39 (c, 2H), 8.96 (bs, 1H). MS (DCI/NH₃) m/e 424 (M+H)⁺.

15

Example 23

Preparation of 1-N,N-Dimethylcarbamoyl-6-(4-fluorophenyl)-3-[(3H-2-methylimidazo[4.5-c]pyrid-3-yl)methylcarbonyl]indole.

Step 1: 1-Chloro-2-[6-(4-fluorophenyl)indol-3-yl]ethanone.

A solution under N₂ of 6-(4-fluorophenyl)indole (10.0 g, 47.4 mmol), prepared as described in WO 93/01813, in dioxane (36 mL) and pyridine (5.8 mL, 71.8 mmol) was heated to 60 °C and a solution of chloroacetyl chloride (5.7 mL, 71.1 mmol) in dioxane (12.5 mL) was added dropwise over 1 hour. The reaction mixture was stirred for 1 hour at 60 °C, then cooled to ambient temperature and poured into a mixture of H₂O (200 mL) and ether (50 mL). The resulting orange precipitate was filtered and dried. Recrystallization from ethanol, followed by rinsing with cold ether gave 1-chloro-2-[6-(4-fluorophenyl)indol-3-yl]ethanone (2.8 g) as an orange solid.

25

Step 2: 1-Chloro-2-[1-N,N-dimethylcarbamoyl-6-(4-fluorophenyl)indol-3-yl]ethanone.

30

The desired compound was prepared according to the method of Example 2, except substituting 1-chloro-2-[6-(4-fluorophenyl)indol-3-yl]ethanone, prepared as in step 1, for 6-(4-fluorophenyl)-3-{4-[(1H-2-methylbenzimidazolyl)methyl]benzoyl}indole.

35

Step 3: 1-N, N-Dimethylcarbamoyl-6-(4-fluorophenyl)-3-[(3H-2-methylimidazo[4.5-c]pyrid-3-yl)methylcarbonyl]indole

To a solution under N₂ of 1H-2-methylimidazo[4,5-c]pyridine (372 mg, 2.80 mmol), prepared as in Example 3, step 1, in a mixture of THF (13.2 mL) and 1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinole (DMPU, 4.4 mL) was added NaH (81 mg, 3.36 mmol) and the resulting yellow suspension was stirred for 50 min at ambient temperature. In a separate flask, a mixture of 1-chloro-2-[1-N, N-dimethylcarbamoyl-6-(4-fluorophenyl)indol-3-yl]ethanone (1.00 g, 2.80 mmol), prepared as in step 2, and NaBr (577 mg, 5.60 mmol) in THF (13.2 mL) was cooled to 0 °C. The imidazopyridine/NaH suspension was then added via syringe, and the orange solution was warmed slowly to ambient temperature and stirred for 17 hours. The reaction mixture was partitioned between H₂O (75 mL) and ethyl acetate (75 mL). The layers were separated and the aqueous phase was washed with ethyl acetate (2x75 mL), and the combined organic extracts were washed with H₂O (2x75 mL). The combined aqueous extracts were extracted twice with ethyl acetate. The combined organic layers were dried over MgSO₄, filtered, and concentrated *in vacuo*. Chromatography on silica gel (8% methanol/CH₂Cl₂) gave 1-N, N-dimethylcarbamoyl-6-(4-fluorophenyl)-3-[(3H-2-methylimidazo[4.5-c]pyrid-3-yl)methylcarbonyl]indole (92.6 mg). ¹H NMR (DMSO-d₆, 300 MHz) δ 2.54 (s, 3H), 3.15 (s, 6H), 5.99 (s, 2H), 7.25-7.35 (m, 2H), 7.58 (d, 1H, J = 5.4 Hz), 7.64 (dd, 1H, J = 8.1, 1.2 Hz), 7.7-7.8 (m, 2H), 7.87 (s, 1H), 8.19 (d, 1H, J = 8.1 Hz), 8.30 (d, 1H, J = 5.4 Hz), 8.84 (s, 1H), 8.95 (s, 1H). MS (DCI/NH₃) m/e 456 (M+H)⁺. Anal calcd for C₂₆H₂₂FN₅O₂ · 1.7H₂O: C, 64.24; H, 5.27; N, 14.41. Found: C, 64.58; H, 5.20; N, 13.81.

Example 24

Preparation of 1-N, N-Dimethylcarbamoyl-6-(4-fluorophenyl)-3-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methylcarbonyl]indole.

The desired compound (58.3 mg) was obtained from the chromatography described in Example 23. ¹H NMR (DMSO-d₆, 300 MHz) δ 2.52 (s, 3H), 3.15 (s, 6H), 5.93 (s, 2H), 7.25-7.35 (m, 2H), 7.56 (d, 1H, J = 5.4 Hz), 7.63 (d, 1H, J = 9.3 Hz), 7.7-7.8 (m, 2H), 7.89 (s, 1H), 8.19 (d, 1H, J = 8.4 Hz), 8.28 (d, 1H, 5.7 Hz), 8.86 (s, 1H), 8.95 (s, 1H). MS (DCI/NH₃) m/e 456 (M+H)⁺. Anal calcd for C₂₆H₂₂FN₅O₂ · 2H₂O: C, 63.53; H, 5.33; N, 14.25. Found: C, 63.62; H, 5.04; N, 13.93.

53

Example 25

Preparation of 1-N,N-Dimethylcarbamoyl-3-[(3H-2-methylimidazo[4.5-c]pyrid-3-yl)methylcarbonyl]indole.

The desired compound was prepared according to the method of Example 23, except substituting indole for 6-(4-fluorophenyl)indole and separating the isomers by chromatography on silica gel using 5% methanol/CH₂Cl₂ instead of 8% methanol/CH₂Cl₂. ¹H NMR (DMSO-d₆, 300 MHz) δ 2.52 (s, 3H), 3.12 (s, 6H), 5.97 (s, 2H), 7.3-7.45 (m, 2H), 7.55-7.60 (m, 1H), 7.65-7.70 (m, 1H), 8.14 (d, 1H, J = 7.8 Hz), 8.29 (dd, 1H, J = 5.4, 1.2 Hz), 8.23 (s, 1H), 8.92 (s, 1H). MS (DCI/NH₃) m/e 362 (M+H)⁺.

Example 26

Preparation of 1-N,N-Dimethylcarbamoyl-3-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methylcarbonyl]indole.

The desired compound was obtained in the chromatography described in Example 25. ¹H NMR (DMSO-d₆, 500 MHz) δ 2.52 (s, 3H), 3.12 (s, 6H), 5.90 (s, 2H), 7.30-7.45 (m, 2H), 7.54 (dd, 1H, J = 5.4, 1.2 Hz), 7.67 (d, 1H, 8.1 Hz), 8.14 (d, 1H, J = 7.2 Hz), 8.27 (d, 1H, J = 5.4 Hz), 8.85 (s, 1H), 8.91 (s, 1H). MS (FAB) m/e 362 (M+1)⁺. Anal calcd for C₂₀H₁₉N₅O₂ · 1.1H₂O: C, 63.01; H, 5.61; N, 18.37. Found: C, 63.25; H, 5.61; N, 18.03.

Example 27

Preparation of 1-N,N-Dimethylcarbamoyl-3-{4-[(3H-2-methylimidazo[4.5-b]pyrid-3-yl)methyl]benzoyl}indole.Step 1: 1H-2-Methylimidazo[4.5-b]pyridine.

A solution of 2,3-diaminopyridine (10.0 g, 91.7 mmol) in acetic anhydride (83.4 mL, 888 mmol) was heated at 140 °C for 18.5 hours. The black solution was then cooled to ambient temperature and stirred for 17 hours. The reaction mixture was cooled in an ice bath and a solution of NaOH (70.8 g, 1.77 mol) in H₂O (200 mL) was added dropwise to bring the reaction to pH 9. The reaction mixture was poured into ethyl acetate (200 mL) and the layers were separated. The organic phase was washed with H₂O (2x100 mL), dried over MgSO₄, filtered, and concentrated *in vacuo*. The aqueous phase was transferred to a continuous extraction vessel and extracted with ethyl acetate for 17 hours. The resulting ethyl acetate solution was combined with the product from above and concentrated *in vacuo*. Chromatography

on silica gel (10% methanol/CH₂Cl₂ gave 5.07 g of 1H-2-methylimidazo[4,5-b]pyridine.

Step 2: Methyl 4-(3H-2-methylimidazo[4,5-b]pyrid-3-ylmethyl)benzoate.

- 5 To a solution under N₂ of 1H-2-methylimidazo[4,5-b]pyridine (3.00 g, 22.6 mmol), prepared as in step 1, in THF (113 mL) and DMF (25 mL) was added NaH (758 mg, 31.6 mmol). The resulting suspension was stirred for 1 hour at ambient temperature, then cooled to 0 °C and a solution of methyl (4-bromomethyl)benzoate (6.20 g, 27.1 mmol) in THF (30 mL) was added via cannula. The cold bath was removed and the reaction mixture was stirred for 70 hours at ambient temperature. The reaction mixture was partitioned between H₂O (100 mL) and ethyl acetate (200 mL). The organic phase was extracted with H₂O (75 mL), and the combined aqueous phases were extracted with ethyl acetate (3x150 mL). The combined organic phases were dried over MgSO₄, filtered, and concentrated *in vacuo*. Chromatography on silica gel (2%, then 5%, then 7% methanol/CH₂Cl₂) gave methyl 4-(3H-2-methylimidazo[4,5-b]pyrid-3-ylmethyl)benzoate (2.89 g), methyl 4-(1H-2-methylimidazo[4,5-b]pyrid-1-ylmethyl)benzoate (1.36 g), and methyl 4-(4H-2-methylimidazo[4,5-b]pyrid-4-ylmethyl)benzoate (1.16 g).

20 Step 3: 3-{4-[(3H-2-Methylimidazo[4,5-b]pyrid-3-yl)methyl]benzoyl}indole.

The desired compound was prepared according to the method of Example 15, except substituting methyl 3-(3H-2-methylimidazo[4,5-b]pyrid-3-ylmethyl)benzoate, prepared as in step 2, for methyl 4-(5H-2-methylimidazo[4,5-c]pyrid-5-ylmethyl)benzoate.

25

Step 4: 1-N,N-Dimethylcarbamoyl-3-{4-[(3H-2-methylimidazo[4,5-b]pyrid-3-yl)methyl]benzoyl}indole.

The desired compound was prepared according to the method of Example 2, except substituting 3-{4-[(3H-2-methylimidazo[4,5-b]pyrid-1-

- 30 yl)methyl]benzoyl}indole, prepared as in step 3, for 6-(4-fluorophenyl)-3-{4-[(1H-2-methylbenzimidazolyl)methyl]benzoyl}indole. ¹H NMR (DMSO-d₆, 300 MHz) δ 2.57 (s, 3H), 3.00 (s, 6H), 5.63 (s, 2H), 7.28 (dd, 1H, J = 8.1, 5.1 Hz), 7.3-7.4 (m, 4H), 7.6-7.7 (m, 1H), 7.83 (apparent d, 2H, J = 7.8 Hz), 8.00 (dd, 1H, J = 7.8, 1.2 Hz), 8.11 (s, 1H), 8.2-8.3 (m, 1H), 8.30-8.35 (m, 1H). MS (DCI/NH₃) m/e 438 (M+H)⁺.
- 35

Example 28

Preparation of 1-*N,N*-Dimethylcarbamoyl-3-{4-[(1*H*-2-methylimidazo[4,5-*b*]pyrid-1-yl)methyl]benzoyl}indole.

The desired compound was prepared according to the method of Example 27, except substituting methyl 4-(1*H*-2-methylimidazo[4,5-*b*]pyrid-1-ylmethyl)benzoate, prepared as in Example 27, step 2, for methyl 4-(3*H*-2-methylimidazo[4,5-*b*]pyrid-3-ylmethyl)benzoate. ¹H NMR (DMSO-*d*₆, 300 MHz) δ 2.61 (s, 3H), 3.00 (s, 6H), 5.66 (s, 2H), 7.22 (dd, 1H, *J* = 8.1, 4.8 Hz), 7.30-7.45 (m, 4H), 7.63 (d, 1H, *J* = 8.1 Hz), 7.84 (apparent d, 2H, *J* = 8.1 Hz), 7.98 (d, 1H, *J* = 8.1 Hz), 8.10 (s, 1H), 8.25-8.30 (m, 1H), 8.35-8.40 (m, 1H). MS (DCI/NH₃) *m/e* 438 (M+H)⁺. Anal calcd for C₂₆H₂₃N₅O₂ · 1.9H₂O: C, 66.20; H, 5.73; N, 14.85. Found: C, 66.49; H, 5.46; N, 14.34.

Example 29

Preparation of 1-*N,N*-Dimethylcarbamoyl-3-{4-[1*H*-2-trifluoromethylimidazo[4,5-*c*]pyrid-1-yl)methyl]benzoyl}indole.Step 1: 4-(*N-tert*-Butoxycarbonylaminomethyl)benzoic acid

To a solution of 4-aminomethylbenzoic acid (11.1 g, 73.4 mmol) in 1N aqueous NaOH (100 mL) was added THF (100 mL) and di-*tert*-butyldicarbonate (16.8 g, 77.1 mmol). The reaction mixture was stirred for 2 hours at ambient temperature, then acidified to pH 2 and extracted 3 times with ethyl acetate. The combined organic layers were dried over MgSO₄, filtered, and concentrated *in vacuo* to give 4-(*N-tert*-butoxycarbonylaminomethyl)benzoic acid (18.3 g) as white crystals which was used without further purification.

Step 2: 3-[4-(*N-tert*-Butoxycarbonylaminomethyl)benzoyl]indole.

To a 0 °C solution of 4-(*N-tert*-butoxycarbonylaminomethyl)benzoic acid (5.07 g, 20.2 mmol) in CHCl₃ was added DMF (200 μL) and oxalyl chloride (1.94 mL, 22.2 mmol). The cold bath was removed and the reaction mixture was stirred for 2 hours at ambient temperature, after which it was concentrated *in vacuo*. The residue was taken up in CH₂Cl₂ and added to a solution of indolylzinc (50.5 mmol, prepared as described in Example 1, step 4, except substituting indole for 6-(4-fluorophenyl)indole). The reaction mixture was stirred for 16 hours at ambient temperature, then quenched with saturated aqueous NH₄Cl and partitioned between CH₂Cl₂ and saturated aqueous NH₄Cl. The solids were filtered off and rinsed with CH₂Cl₂. The layers were separated and the organic phase was dried over MgSO₄.

filtered, and concentrated *in vacuo*. Pure 3-[4-(*N*-*tert*-butoxycarbonylaminomethyl)benzoyl]indole (3.10 g) was obtained by chromatography on silica gel (60% ether/hexanes, then 60% ethyl acetate/hexanes).

5 Step 3: 1-*N,N*-Dimethylcarbamoyl-3-[4-(*N*-*tert*-butoxycarbonylaminomethyl)-benzoyl]indole.

Sodium hydride (60% dispersion in mineral oil, 251 mg, 6.29 mmol) was washed twice with hexanes and added to a solution of 3-[4-(*N*-*tert*-butoxycarbonylaminomethyl)benzoyl]indole (1.00g, 2.86 mmol), prepared as in step
10 2, in THF (40 mL). After stirring for 10 min, dimethylcarbamoyl chloride (315 μ L, 3.43 mmol) was added and the reaction mixture was stirred for 10 min. The reaction mixture was poured into saturated aqueous NH_4Cl and extracted three times with ethyl acetate. The combined organic layers were dried over MgSO_4 , filtered, and concentrated *in vacuo*. Chromatography on silica gel gave 1-*N,N*-
15 dimethylcarbamoyl-3-[4-(*N*-*tert*-butoxycarbonylaminomethyl)benzoyl]indole (870 mg, 72%).

Step 4: 1-*N,N*-Dimethylcarbamoyl-3-(4-aminomethylbenzoyl)indole.

To a solution of 1-*N,N*-dimethylcarbamoyl-3-[4-(*N*-*tert*-butoxycarbonylaminomethyl)benzoyl]indole (870 mg, 2.07 mmol), prepared as in
20 step 3, in ethyl acetate (10 mL) was added 3N aqueous HCl (2 mL). The reaction mixture was stirred for 17 hours at ambient temperature, and an additional 4 mL of 3N aqueous HCl was added. The reaction mixture was stirred for a further 10 hours and then was adjusted to pH 1 and extracted three times with ethyl acetate. The combined
25 organic extracts were washed with H_2O , and the aqueous layers were combined, adjusted to pH 12, and extracted three times with CH_2Cl_2 . The CH_2Cl_2 extracts were combined, dried over Na_2SO_4 , filtered, and concentrated *in vacuo* to give 620 mg of 1-*N,N*-dimethylcarbamoyl-3-(4-aminomethylbenzoyl)indole which was used without further purification.

30

Step 5: 1-*N,N*-Dimethylcarbamoyl-3-[4-(*N*-3-nitropyridin-4-yl)aminomethyl-benzoyl]indole.

To a solution of 1-*N,N*-dimethylcarbamoyl-3-(4-aminomethylbenzoyl)indole (0.620g, 1.93 mmol), prepared as in step 4, in THF (10 mL) was added triethylamine
35 (403 μ L, 2.90 mmol) and 3-nitro-4-chloropyridine (0.300g, 1.93 mmol), prepared as described by Wright, G. C., *J. Heterocyclic Chem.* 1976, 13, 601, and Kruger, S.

and Mann, F.G., *J. Chem. Soc.* 2 1955, 758. The reaction mixture was heated for 17 hours at 45 °C, then additional 3-nitro-4-chloropyridine (40 mg) was added and heating was continued for 2 hours at which all to the starting material was consumed. The reaction mixture was poured into a mixture of saturated aqueous NH₄Cl and brine and the aqueous phase was extracted twice with CH₂Cl₂. The combined organic layers were dried over MgSO₄, filtered, and concentrated *in vacuo*. Chromatography on silica gel (60% ethyl acetate/hexanes, then 10% methanol/CH₂Cl₂) gave 1-*N,N*-dimethylcarbamoyl-3-[4-(*N*-3-nitropyridin-4-yl)aminomethylbenzoyl]indole. (903 mg).

Step 6: 1-*N,N*-Dimethylcarbamoyl-3-[4-(*N*-3-aminopyridin-4-yl)aminomethylbenzoyl]indole.

A mixture of 1-*N,N*-dimethylcarbamoyl-3-[4-(*N*-3-nitropyridin-4-yl)aminomethylbenzoyl]indole (141 mg), prepared as in step 5, and 10% palladium on activated carbon (40 mg) in 5:1 ethanol/CH₂Cl₂ (10 mL) was stirred under 1 atmosphere of hydrogen for 4 hours. The reaction mixture was filtered through a pad of celite and the filtrate was concentrated *in vacuo* to give 131 mg of 1-*N,N*-dimethylcarbamoyl-3-[4-(*N*-3-aminopyridin-4-yl)aminomethylbenzoyl]indole which was used without further purification.

Step 7: 1-*N,N*-Dimethylcarbamoyl-3-[4-[1H-2-trifluoromethylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl]indole.

A mixture of 1-*N,N*-dimethylcarbamoyl-3-[4-(*N*-3-aminopyridin-4-yl)aminomethylbenzoyl]indole (131 mg), prepared as in step 6, trifluoroacetic anhydride (1.0 mL), and trifluoroacetic acid (0.5 mL) was heated at 45 °C for 17 hours. The reaction mixture was cooled to ambient temperature and concentrated *in vacuo*. Chromatography on silica gel (ethyl acetate) gave 1-*N,N*-dimethylcarbamoyl-3-[4-[1H-2-trifluoromethylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl]indole (107 mg, 68% yield for steps 4 and 5). ¹H NMR (DMSO-d₆, 300 MHz) δ 2.99 (s, 6H), 5.89 (s, 2H), 7.30 (d, 2H, J = 8.7 Hz), 7.32-7.42 (m, 2H), 7.61-7.63 (m, 1H), 7.84 (d, 2H, J = 8.7 Hz), 7.85-7.88 (m, 1H), 8.08 (s, 1H), 8.23-8.26 (m, 1H), 8.58 (d, 1H, J = 6 Hz). MS (DCI/NH₃) m/e 492 (M+H)⁺, 409, 306. Anal calcd for C₂₆H₂₀F₃N₅O₂ · 1.25 CF₃CO₂H: C, 53.99; H, 3.37; N, 11.04. Found: C, 53.76; H, 3.55; N, 11.10.

Example 30Preparation of 1-*N,N*-Dimethylcarbamoyl-6-3-{4-[1H-imidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole.

To a solution of 1-*N,N*-dimethylcarbamoyl-3-[4-(*N*-3-aminopyridin-4-yl)aminomethylbenzoyl]indole (44.9 mg, 0.11 mmol), prepared as in Example 29, step 5, in acetic acid (1.5 mL) was added ethyl (ethoxymethylene)cyanoacetate (27.6 mg, 0.16 mmol). The reaction mixture was heated at 90 °C for 4 hours, then cooled to ambient temperature and concentrated *in vacuo*. 1-*N,N*-dimethylcarbamoyl-6-3-{4-[1H-imidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole (15.6 mg) was isolated by thin layer chromatography (10% methanol/CH₂Cl₂). ¹H NMR (DMSO-d₆, 300 MHz) δ 9.19 (s, 1H), 8.47 (d, 1H, J = 5.7 Hz), 8.38 (m, 1H), 8.11 (s, 1H), 7.86 (2H, d, J = 8.4 Hz), 7.73 (s, 1H), 7.53 (m, 1H), 7.40 (m, 2H), 7.31 (m, 3H), 5.49 (s, 2H), 3.08 (s, 6H). MS (DCI/NH₃) m/e 424 (M+H)⁺, 306, 120.

Example 31Preparation of 1-*N,N*-Dimethylcarbamoyl-3-{4-[1H-2-(2-propyl)imidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole.Step 1: 1-*N,N*-Dimethylcarbamoyl-3-[4-(*N*-3-(2-propyl)aminopyridin-4-yl)-*N*-(2-propyl)aminomethylbenzoyl]indole.

The desired compound (66.4 mg) was prepared according to the method of Example 29, step 6, except substituting isobutyric anhydride and isobutyric acid for trifluoroacetic anhydride and trifluoroacetic acid.

Step 2: 1-*N,N*-Dimethylcarbamoyl-3-{4-[1H-2-(2-propyl)imidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole-1-carboxylic acid dimethylamide.

A solution of 1-*N,N*-dimethylcarbamoyl-3-[4-(*N*-3-(2-propyl)aminopyridin-4-yl)-*N*-(2-propyl)aminomethylbenzoyl]indole (62.5 mg) in trifluoroacetic acid (1.0 mL) was heated at 70 °C for 17 hours. The reaction mixture was cooled to ambient temperature and concentrated *in vacuo*. 1-*N,N*-dimethylcarbamoyl-3-{4-[1H-2-(2-propyl)imidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole (50.6 mg) was obtained by thin layer chromatography (7% methanol/CH₂Cl₂). ¹H NMR (DMSO-d₆, 300 MHz) δ 1.31 (d, 6H, J = 6.8 Hz), 3.01 (s, 6H), 3.47 (m, 1H), 5.92 (2H, s), 7.31 (d, 2H, J = 8.4 Hz), 7.32-7.42 (m, 2H), 7.62 (d, 1H, J = 7.5 Hz), 7.86 (d, 2H, J = 8.4 Hz), 8.04 (s, 1H), 8.23 (d, 1H, J = 7.5 Hz), 8.29 (d, 1H, J = 6.4 Hz), 8.69 (d, 1H, J = 6.4 Hz), 9.49 (s, 1H). MS (DCI/NH₃) m/e 466 (M+H)⁺, 162. Anal calcd for

$C_{28}H_{27}N_5O_2 \cdot 2.25H_2O$: C, 66.45; H, 6.24; N, 12.73. Found: C, 66.80; H, 6.27; N, 13.84.

Example 32

5 Preparation of 1-N,N-Dimethylcarbamoyl-3-{4-[1H-2-phenylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole.

To a solution of 1-N,N-dimethylcarbamoyl-3-[4-(N-3-aminopyridin-4-yl)aminomethylbenzoyl]indole (38 mg), prepared as in Example 29, step 5, in CH_2Cl_2 was added triethylamine and benzoyl chloride. The reaction mixture was stirred for 20 hours at ambient temperature and was then partitioned between CH_2Cl_2 and 10 saturated aqueous $NaHCO_3$. The organic phase was dried over $MgSO_4$, filtered, and concentrated *in vacuo*. Pure 1-N,N-dimethylcarbamoyl-3-{4-[1H-2-phenylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole (21 mg, 41%) was obtained by thin layer chromatography (10% methanol/ CH_2Cl_2). 1H NMR ($CDCl_3$, 300 MHz) δ 3.09 (s, 6H), 5.58 (s, 2H), 7.20 (d, 2H, J = 8.5 Hz), 7.24 (d, 1H, J = 6 Hz), 15 7.36-7.44 (m, 2H), 7.50-7.58 (m, 4H), 7.71 (dd, 2H, J = 7.8, 2.2 Hz), 7.79 (s, 1H), 7.85 (d, 2H, J = 8.5 Hz), 8.38-8.41 (m, 1H), 8.46 (d, 1H, J = 5.4 Hz), 9.21 (s, 1H). MS (DCI/ NH_3) m/e 500 (M+H)⁺, 318.

Example 33

20 Preparation of 1-N,N-Dimethylcarbamoyl-3-{4-[1H-2-ethylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole.

The desired compound (66.4 mg) was prepared according to the method of Example 29, step 6, except substituting propionic anhydride and propionic acid for trifluoroacetic anhydride and trifluoroacetic acid. 1H NMR (DMSO- d_6 , 300 MHz) δ 25 1.32 (t, 3H, J = 7.5 Hz), 2.91 (q, 2H, J = 7.5 Hz), 2.99 (s, 6H), 5.66 (s, 2H), 7.28 (d, 2H, J = 8.1 Hz), 7.32-7.42 (m, 2H), 7.62 (d, 2H, J = 6 Hz), 7.83 (d, 2H, J = 8.1 Hz), 8.09 (s, 1H), 8.25 (dd, 1H, J = 6.3, 2.1 Hz), 8.31 (d, 1H, J = 6.3 Hz), 8.91 (s, 1H). MS (DCI/ NH_3) m/e 452 (M+H)⁺, 306. Anal calcd for $C_{27}H_{25}N_5O_2 \cdot 1H_2O$: C, 69.06; H, 5.79; N, 14.91. Found: C, 69.07; H, 5.71; N, 14.76.

30

Example 34

Preparation of 1-N,N-Dimethylcarbamoyl-3-{3-[(5H-2-methylimidazo[4.5-c]pyrid-5-yl)methyl]benzoyl}indole.

The desired compound was prepared according to the method of Example 17, 35 except substituting methyl 3-(5H-2-methylimidazo[4,5-c]pyrid-5-ylmethyl)benzoate, prepared as in Example 11, step 1, for methyl 3-(1H-2-methylimidazo[4,5-c]pyrid-1-

60

ylmethyl)benzoate. mp 230-232 °C. ¹H NMR (DMSO-d₆, 300 MHz) δ 2.50 (s, 3H), 5.75 (s, 2H), 7.20-7.30 (c, 2H), 7.50-7.60 (c, 4H), 7.76 (d, 1H, J = 4.5 Hz), 7.88 (s, 1H), 7.91(d, 1H, J = 1.5 Hz), 8.20-8.23 (c, 2H), 9.00(s, 1H), 12.10 (bs,1H). IR (KBr) 1630, 1580, 1530, 1500, 1445, 1370, 1320, 1235, 1180, 1150
5 cm⁻¹. MS (DCI/NH₃) m/e 367 (M+H)⁺, 134, 118.

Example 35

Preparation of 1-N,N-Dimethylcarbamoyl-3-{3-[(5H-2-methylimidazo[4.5-c]pyrid-5-yl)methyl]benzoyl}indole.

10 The desired compound was prepared according to the method of Example 2, except substituting 3-{3-[(5H-2-methylimidazo[4.5-c]pyrid-5-yl)methyl]benzoyl}indole, prepared as in Example 34, for 6-(4-fluorophenyl)-3-{4-[(1H-2-methylbenzimidazolyl)methyl]benzoyl}indole. mp 194.4-196.4 °C. ¹H NMR (DMSO-d₆, 300 MHz) δ 3.01 (s, 6H), 5.74 (s, 2H), 7.38 (dm, 2H, J = 7.5, 1.5
15 Hz), 7.55-7.62 (c, 2H), 7.62-7.71 (c, 2H), 7.83 (dt, 1H, J = 1, 7.5 Hz), 7.92 (bs, 1H), 8.07 (s, 1H), 8.19-8.28 (c, 2H), 9.00 (bs, 1H). IR (KBr) 1690, 1630, 1600, 1580, 1530, 1470, 1450, 1390, 1310, 1230, 1190, 1170, 1120, 1080 cm⁻¹. MS (DCI/NH₃) m/e 438 (M+H)⁺. Anal calcd for C₂₆H₂₈N₅O_{4.5}: C, 64.71; H, 5.85; N, 14.52. Found: C, 64.59; H, 5.45; N, 14.30.

20

Example 36

Preparation of 1-N,N-dDimethylcarbamoyl-6-(4-fluorophenyl)-3-[(3H-2-methylimidazo[4.5-c]pyrid-3-yl)pent-5-ylcarbonyl]indole.

25 Step 1: 6-Bromo-1-[6-(4-fluorophenyl)-1-N,N-dimethylcarbamoylindol-3-yl]hexanone.

To a solution of 6-bromohexanoyl chloride (596 μL, 3.9 mmol) in CH₂Cl₂ was added AlCl₃ (1.00g, 7.8 mmol) in a single portion and the reaction mixture was stirred for 1 hour at ambient temperature. A solution of 6-(4-fluorophenyl)-1-N,N-dimethylcarbamoylindole (1.00 g, 3.55 mmol), prepared as in Example 4, step 1, in
30 CH₂Cl₂ (5 mL) was added dropwise and the solution was stirred for 1 hour at ambient temperature. The reaction mixture was partitioned between H₂O and CH₂Cl₂. The layers were separated and the aqueous phase was extracted twice with CH₂Cl₂. The combined organic layers were washed with saturated aqueous NaHCO₃, dried over MgSO₄, filtered, and concentrated *in vacuo*. Chromatography
35 on silica gel (CH₂Cl₂) gave 6-chloro-1-[6-(4-fluorophenyl)-1-N,N-dimethylcarbamoylindol-3-yl]hexanone (1.57 g) as an off-white solid.

Step 2: 1-N, N-Dimethylcarbamoyl-6-(4-fluorophenyl)-3-[(3H-2-methylimidazo[4,5-c]pyrid-3-yl)pent-5-ylcarbonyl]indole.

The desired compounds were prepared according to the method of Example 23, step 2, except substituting 6-chloro-1-[6-(4-fluorophenyl)-1-N, N-dimethylcarbamoylindol-3-yl]hexanone, prepared as in step 1, for 1-chloro-2-[1-N, N-dimethylcarbamoyl-6-(4-fluorophenyl)indol-3-yl]ethanone. Chromatography on silica gel (2%, then 3%, then 4%, then 15% methanol/CH₂Cl₂) gave 1-N, N-dimethylcarbamoyl-6-(4-fluorophenyl)-3-[(3H-2-methylimidazo[4,5-c]pyrid-3-yl)pent-5-ylcarbonyl]indole (137 mg). ¹H NMR (DMSO-d₆, 300 MHz) δ 1.35-1.45 (m, 2H), 1.65-1.75 (m, 2H), 1.75-1.85 (m, 2H), 2.59 (s, 3H), 2.92 (t, 2H, J = 7.4 Hz), 3.07 (s, 6H), 4.29 (t, 2H, J = 7.4 Hz), 7.25-7.35 (m, 2H), 7.50 (dd, 1H, J = 5.4, 1.0 Hz), 7.59 (dd, 1H, J = 8.4, 1.8 Hz), 7.7-7.8 (m, 4H), 8.25-8.35 (m, 2H), 8.58 (d, 1H, J = 1.0 Hz). MS (DCI/NH₃) m/e 512 (M+H)⁺.

Example 37

Preparation of 1-N, N-Dimethylcarbamoyl-6-(4-fluorophenyl)-3-[(1H-2-methylimidazo[4,5-c]pyrid-1-yl)pent-5-ylcarbonyl]indole.

The desired compound (184 mg) was obtained from the chromatography described in Example 36, step 2. ¹H NMR (DMSO-d₆, 300 MHz) δ 1.30-1.45 (m, 2H), 1.65-1.85 (m, 4H), 2.58 (s, 3H), 2.91 (t, 2H, J = 7.4 Hz), 3.06 (s, 6H), 4.22 (t, 2H, J = 7.4 Hz), 7.25-7.35 (m, 2H), 7.5-7.6 (m, 2H), 7.7-7.8 (m, 3H), 8.2-8.3 (m, 2H), 8.58 (s, 1H), 8.78 (d, 1H, J = 1.0 Hz). MS (DCI/NH₃) m/e 512 (M+H)⁺. Anal calcd for C₃₀H₃₀FN₅O₂ · 0.8H₂O: C, 68.50; H, 6.05; N, 13.31. Found: C, 68.52; H, 5.99; N, 13.26.

Example 38

Preparation of 1-N, N-Dimethylcarbamoyl-6-(4-fluorophenyl)-3-[(5H-2-methylimidazo[4,5-c]pyrid-5-yl)pent-5-ylcarbonyl]indole.

The desired compound (431 mg) was obtained in the chromatography described in Example 36, step 2. ¹H NMR (DMSO-d₆, 300 MHz) δ 1.3-1.4 (m, 2H), 1.65-1.75 (m, 2H), 1.9-2.0 (m, 2H), 2.51 (s, 1H), 2.93 (t, 2H, J = 7.4 Hz), 3.07 (s, 6H), 4.42 (t, 2H, 7.1 Hz), 7.2-7.3 (m, 2H), 7.5-7.6 (m, 2H), 7.7-7.8 (m, 3H), 8.05 (dd, 1H, J = 6.7, 1.3 Hz), 8.28 (d, 1H, J = 8.4 Hz), 8.58 (s, 1H), 8.78 (d, 1H, J = 1.3 Hz). MS (DCI/NH₃) m/e 512 (M+H)⁺.

Example 39

Preparation of 1-*N,N*-Dimethylcarbamoyl-6-(4-fluorophenoxy)-3-{4-[(3H-2-methylimidazo[4.5-c]pyrid-3-yl)methyl]benzoyl}indole.

The desired compound was prepared according to the method of Example 4, except substituting 6-(4-fluorophenoxy)indole for 6-(4-fluorophenyl)indole. Chromatography on silica gel (2%, then 3%, then 4% methanol/CH₂Cl₂) gave 1-*N,N*-dimethylcarbamoyl-6-(4-fluorophenoxy)-3-{4-[(3H-2-methylimidazo[4.5-c]pyrid-3-yl)methyl]benzoyl}indole. ¹H NMR (DMSO-d₆, 300 MHz) δ 2.62 (s, 3H), 2.97 (s, 6H), 5.72 (s, 2H), 7.05-7.15 (m, 3H), 7.2-7.3 (m, 3H), 7.35 (apparent d, 2H, J = 8.4 Hz), 7.59 (dd, 1H, J = 5.4, 1.2 Hz), 7.85 (apparent d, 2H, J = 8.4 Hz), 8.08 (s, 1H), 8.23 (d, 1H, J = 8.7 Hz), 8.31 (d, 1H, J = 5.7 Hz), 8.90 (d, 1H, 1.2 Hz). MS (DCI/NH₃) m/e 548 (M+H)⁺.

Example 40

Preparation of 1-*N,N*-Dimethylcarbamoyl-6-(4-fluorophenoxy)-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole.

The desired compound was obtained in the chromatography described in Example 39. ¹H NMR (DMSO-d₆, 300 MHz) δ 2.59 (s, 3H), 2.97 (s, 6H), 5.66 (s, 2H), 7.05-7.10 (m, 3H), 7.2-7.3 (m, 3H), 7.30 (apparent d, 2H, J = 8.4 Hz), 7.63 (dd, 1H, J = 5.7, 1.0 Hz), 7.84 (apparent d, 2H, J = 8.4 Hz), 8.08 (s, 1H), 8.23 (d, 1H, J = 8.4 Hz), 8.31 (d, 1H, J = 5.7 Hz), 8.87 (s, 1H). MS (DCI/NH₃) m/e 548 (M+H)⁺. Anal calcd for C₃₂H₂₆N₅O₃F: C, 67.52; H, 5.03; N, 12.30. Found: C, 67.57; H, 4.79; N, 12.01.

Example 41

Preparation of 1-*N,N*-Dimethylcarbamoyl-6-phenylmethyl-3-{4-[(3H-2-methylimidazo[4.5-c]pyrid-3-yl)methyl]benzoyl}indole.

The desired compound was prepared according to the method of Example 4, except substituting 6-phenylmethylindole for 6-(4-fluorophenyl)indole. 1-*N,N*-dimethylcarbamoyl-6-phenylmethyl-3-{4-[(3H-2-methylimidazo[4.5-c]pyrid-3-yl)methyl]benzoyl}indole was isolated by chromatography on silica gel (3%, then 4%, then 5% methanol/CH₂Cl₂). ¹H NMR (DMSO-d₆, 300 MHz) δ 2.62 (s, 3H), 2.98 (s, 6H), 4.08 (s, 2H), 5.71 (s, 2H), 7.1-7.3 (m, 6H), 7.33 (apparent d, 2H, J = 7.8 Hz), 7.49 (s, 1H), 7.58 (dd, 1H, J = 5.4, 1.0 Hz), 7.83 (apparent d, 2H, J = 8.7 Hz), 8.04 (s, 1H), 8.14 (d, 1H, J = 8.1 Hz), 8.31 (d, 1H, J = 5.4 Hz), 8.88 (d, 1H, J = 1.0 Hz). MS (DCI/NH₃) m/e 528 (M+H)⁺.

Example 42

Preparation of 1-*N,N*-Dimethylcarbamoyl-6-phenylmethyl-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole.

The desired compound was isolated in the chromatography described in

- 5 Example 41. ¹H NMR (DMSO-*d*₆, 300 MHz) δ 2.58 (s, 3H), 2.98 (s, 6H), 4.08 (s, 2H), 5.65 (s, 2H), 7.15-7.30 (m, 8H), 7.49 (s, 1H), 7.62 (dd, 1H, *J* = 5.4, 1.2 Hz), 7.82 (apparent d, 2H, *J* = 8.1 Hz), 8.03 (s, 1H), 8.14 (d, 1H, *J* = 8.1 Hz), 8.31 (d, 1H, *J* = 5.4 Hz), 8.86 (d, 1H, *J* = 1.0 Hz). MS (DCI/NH₃) *m/e* 528 (M+H)⁺.

10

Example 43

Preparation of 1-*N,N*-Dimethylcarbamoyl-4-methoxycarbonyl-3-{4-[(3*H*-2-methylimidazo[4.5-*c*]pyrid-3-yl)methyl]benzoyl}indole.

Step 1: 4-methoxycarbonylindole.

- 15 To a 0 °C solution of indole-4-carboxylic acid (1.00g, 6.21 mmol) in ether (60 mL) was added diazomethane (0.3M solution in ether, 24.8 mL, 7.45 mmol) and the reaction mixture was stirred for 0.5 hours at 0 °C. An additional 20 mL of diazomethane solution was then added and stirring was continued for 1 hour at 0 °C. The reaction mixture was quenched with formic acid (1.0 mL) and concentrated *in vacuo* to give 4-methoxycarbonylindole (1.1 g) as an off white powder.

20

Step 2: 1-*N,N*-Dimethylcarbamoyl-4-methoxycarbonyl-3-{4-[(3*H*-2-methylimidazo[4.5-*c*]pyrid-3-yl)methyl]benzoyl}indole.

- The desired compound was prepared according to the method of Example 4, except substituting 4-methoxycarbonylindole, prepared as in step 1, for 6-(4-fluorophenylindole). 1-*N,N*-dimethylcarbamoyl-4-methoxycarbonyl-3-{4-[(3*H*-2-methylimidazo[4.5-*c*]pyrid-3-yl)methyl]benzoyl}indole was isolated by chromatography on silica gel (3%, then 5%, then 6% methanol/CH₂Cl₂). ¹H NMR (DMSO-*d*₆, 300 MHz) δ 2.60 (s, 3H), 3.02 (s, 6H), 3.47 (s, 3H), 5.70 (s, 2H), 7.32 (apparent d, 2H, *J* = 8.1 Hz), 7.4-7.5 (m, 1H), 7.56 (dd, 1H, *J* = 2.1, 1.0 Hz), 7.56-7.58 (m, 1H), 7.85 (apparent d, 2H, *J* = 8.1 Hz), 7.86 (dd, 1H, *J* = 8.1, 1.2 Hz), 8.11 (s, 1H), 8.30 (d, 1H, *J* = 5.7 Hz), 8.86 (d, 1H, *J* = 1.0 Hz). MS (DCI/NH₃) *m/e* 496 (M+H)⁺. Anal calcd for C₂₈H₂₅N₅O₄ · 1.8 H₂O: C, 63.70; H, 5.46; N, 13.26. Found: C, 63.68; H, 5.12; N, 12.95.

35

64

Example 44

Preparation of 1-*N,N*-Dimethylcarbamoyl-4-methoxycarbonyl-3-{4-[(1*H*-2-methylimidazo[4,5-*c*]pyrid-1-yl)methyl]benzoyl}indole.

The desired compound was isolated in the chromatography described in

- 5 Example 43. ¹H NMR (DMSO-d₆, 300 MHz) δ 2.57 (s, 3H), 3.02 (s, 6H), 3.47 (s, 3H), 5.64 (s, 2H), 7.28 (apparent d, 2H, J = 8.4 Hz), 7.4-7.5 (m, 1H), 7.55-7.60 (m, 2H), 7.84 (apparent d, 2H, J = 8.4 Hz), 7.86 (dd, 1H, J = 8.4, 1.2 Hz), 8.10 (s, 1H), 8.30 (d, 1H, J = 5.7 Hz), 8.86 (d, 1H, J = 1.0 Hz). MS (DCI/NH₃) m/e 496 (M+H)⁺. Anal calcd for C₂₈H₂₅N₅O₄ · 1.9 H₂O: C, 63.48; H, 5.48; N, 13.22.
- 10 Found: C, 63.69; H, 5.08; N, 12.73.

Example 45

Preparation of 1-*N,N*-Dimethylcarbamoyl-5-phenylmethoxy-3-{4-[(1*H*-2-methylimidazo[4,5-*c*]pyrid-1-yl)methyl]benzoyl}indole.

- 15 The desired compound is prepared according to the method of Example 4, except substituting 5-benzyloxyindole for 6-(4-fluorophenyl)indole.

Example 46

Preparation of 1-*N,N*-Dimethylcarbamoyl-6-(4-methoxyphenyl)-3-{4-[(1*H*-2-methylimidazo[4,5-*c*]pyrid-1-yl)methyl]benzoyl}indole.

- 20 The desired compound is prepared according to the method of Example 4, except substituting 6-(4-methoxyphenyl)indole, prepared as described in WO 93/01813, for 6-(4-fluorophenyl)indole.

Example 47

Preparation of 1-*N,N*-Dimethylcarbamoyl-6-(pyrid-3-yl)-3-{4-[(1*H*-2-methylimidazo[4,5-*c*]pyrid-1-yl)methyl]benzoyl}indole.

- 25 The desired compound is prepared according to the method of Example 4, except substituting 6-(pyrid-3-yl)indole, prepared as described in WO 93/01813, for
- 30 6-(4-fluorophenyl)indole.

65

Example 48

Preparation of 1-*N,N*-Dimethylcarbamoyl-6-bromo-3-{4-[(1*H*-2-methylimidazo[4,5-*c*]pyrid-1-yl)methyl]benzoyl}indole.

5 The desired compound is prepared according to the method of Example 4, except substituting 6-bromoindole for 6-(4-fluorophenyl)indole.

Example 49

Preparation of 1-*N,N*-Dimethylcarbamoyl-6-chloro-3-{4-[(1*H*-2-methylimidazo[4,5-*c*]pyrid-1-yl)methyl]benzoyl}indole.

10 The desired compound is prepared according to the method of Example 4, except substituting 6-chloroindole for 6-(4-fluorophenyl)indole.

Example 50

Preparation of 1-*N,N*-Dimethylcarbamoyl-5-methoxy-3-{4-[(1*H*-2-methylimidazo[4,5-*c*]pyrid-1-yl)methyl]benzoyl}indole.

15 The desired compound is prepared according to the method of Example 4, except substituting 5-methoxyindole for 6-(4-fluorophenyl)indole.

Example 51

20 Preparation of 1-*N,N*-Dimethylcarbamoyl-6-(4-fluorophenyl)-3-{5-[(1*H*-2-methylimidazo[4,5-*c*]pyrid-1-yl)methyl]thien-2-oyl}indole.

Step 1: 5-Methyl-2-carboxymethylthiophene.

25 The desired compound was prepared according to the method of Example 43, step 1, except substituting 5-methyl-2-thiophenecarboxylic acid for indole-4-carboxylic acid.

Step 2: 5-Bromomethyl-2-carboxymethylthiophene.

30 To a solution of *N*-bromosuccinimide (5.94 g, 33 mmol) in hexanes (16 mL) was added 5-methyl-2-carboxymethylthiophene (5.0 g, 32 mmol), prepared as in step 1, followed by 1 drop of perchloric acid. The reaction mixture was stirred for 22 hours at ambient temperature and then partitioned between ethyl acetate and saturated aqueous NaHSO_3 solution. The organic phase was dried over Na_2SO_4 , filtered, and concentrated *in vacuo* to give 6.17 g of 5-bromomethyl-2-carboxymethylthiophene as a yellow oil.

35

Step 3: 5-[(1H-2-Methylimidazo[4,5-c]pyrid-1-yl)methyl]-2-carboxymethylthiophene.

To a solution of 1H-2-methylimidazo[4,5-c]pyridine (2.00 g, 15 mmol), prepared as in Example 3, step 1, in DMSO (150 mL) was added potassium *tert*-butoxide (1.7 g, 17 mmol) and the reaction mixture was stirred until all of the base dissolved (~15 min). After a further 5 min, 5-bromomethyl-2-carboxymethylthiophene (4.0 g, 17 mmol), prepared as in step 2, was added. The reaction mixture was stirred for 2 hours at ambient temperature and then partitioned between ethyl acetate (2 L), and 1:1 pH 7 buffer/brine (1 L). The organic phase was dried over MgSO₄, filtered, and concentrated *in vacuo*. Chromatography on silica gel (3%, then 4%, then 5% methanol/CH₂Cl₂) gave 5-[(1H-2-methylimidazo[4,5-c]pyrid-1-yl)methyl]-2-carboxymethylthiophene.

Step 4: 5-[(1H-2-Methylimidazo[4,5-c]pyrid-1-yl)methyl]-2-thiophenecarboxylic acid.

To a solution of 5-[(1H-2-methylimidazo[4,5-c]pyrid-1-yl)methyl]-2-carboxymethylthiophene (0.360 g, 1.25 mmol) in THF (15 mL) and H₂O (2 mL) was added lithium hydroxide hydrate (0.114 g, 2.70 mmol). The reaction mixture was stirred for 6 hours at ambient temperature and then quenched with 4N HCl/dioxane (1 mL) and partitioned between ethyl acetate and H₂O. The aqueous phase was extracted with CH₂Cl₂. The combined organic layers were dried over MgSO₄, filtered, and concentrated *in vacuo* to give 5-[(1H-2-methylimidazo[4,5-c]pyrid-1-yl)methyl]-2-thiophenecarboxylic acid (0.46 g) as an oil.

Step 5: 6-(4-Fluorophenyl)-3-{5-[(1H-2-methylimidazo[4,5-c]pyrid-1-yl)methyl]thien-2-oyl}indole.

The desired compound was prepared according to the method of Example 1, step 4, except substituting 5-[(1H-2-methylimidazo[4,5-c]pyrid-1-yl)methyl]-2-thiophenecarboxylic acid, prepared as in step 4, for 4-(1H-2-methylbenzimidazol-1-ylmethyl)benzoic acid.

Step 6: 1-N, N-dimethylcarbamoyl-6-(4-fluorophenyl)-3-{5-[(1H-2-methylimidazo[4,5-c]pyrid-1-yl)methyl]thien-2-oyl}indole.

The desired compound was prepared according to the method of Example 2, except substituting 6-(4-fluorophenyl)-3-{5-[(1H-2-methylimidazo[4,5-c]pyrid-1-yl)methyl]thien-2-oyl}indole, prepared as in step 5, for 6-(4-fluorophenyl)-3-{4-[(1H-2-methylbenzimidazolyl)methyl]benzoyl}indole. mp 200-203 C. ¹H NMR

67

(CDCl₃, 300 MHz) δ 9.06 (s, 1H), 8.44 (d, 1H, J = 5.6 Hz), 8.32 (d, 1H, J = 8.5 Hz), 7.94 (s, 1H), 7.71 (d, 1H, J = 1.5 Hz), 7.64 (d, 1H, J = 3.6 Hz), 7.58 (m, 3H), 7.32 (d, 1H, J = 4.5 Hz), 7.14 (t, 2H, J = 8.8 Hz), 6.92 (d, 1H, J = 3.3 Hz), 5.54 (s, 2H), 3.12 (s, 6H), 2.73 (s, 3H). MS (DCI/NH₃) m/e 538 (M+H)⁺, 205.

5

Example 52

Preparation of 1-N,N-Dimethylcarbamoyl-6-(4-fluorophenyl)-3-{5-[1H-2-methylimidazo[4,5-c]pyrid-1-yl)methyl]fur-2-oyl}indole.

Step 1: 5-hydroxymethyl-2-carboethoxyfuran.

10 A solution of 5-acetoxymethyl-2-ethoxycarbonylfuran (Maybridge Chemical Co., Ltd., Tintagel, Cornwall, UK., 0.54 g, 2.5 mmol) and K₂CO₃ (0.352 g, 2.6 mmol) in 5:1 THF/H₂O (30 mL), was stirred for 17 hours at ambient temperature. The reaction mixture was concentrated *in vacuo* and the residue partitioned between CH₂Cl₂ and saturated aqueous NaHCO₃. The organic phase was dried over MgSO₄,
15 filtered, and concentrated *in vacuo* to give 5-hydroxymethyl-2-carboethoxyfuran (0.32 g) as a yellow liquid which was used without further purification.

Step 2: 5-Methanesulfonyloxymethyl-2-carboethoxyfuran.

20 To a 0 °C solution of 5-hydroxymethyl-2-carboethoxyfuran (2.94 g, 17.3 mmol), prepared as in step 1, in CH₂Cl₂ (50 mL) was added 2,6-lutidine (2.50 mL, 21.5 mmol) and methanesulfonyl chloride (1.50 mL, 19.0 mmol). The reaction mixture was stirred for 40 min at 0 °C, then the cold bath was removed and stirring was continued for 2 hours. The reaction mixture was extracted with 1N aqueous HCl and saturated aqueous NaHCO₃, and the organic phase was dried over MgSO₄,
25 filtered, and concentrated *in vacuo* to give 5-methanesulfonyloxymethyl-2-carboethoxyfuran (4.0 g) as a yellow oil which was used without further purification.

Step 3: 5-Azidomethyl-2-carboxyethylfuran.

30 To a suspension of NaN₃ (1.3 g, 20 mmol) in CH₃CN (50 mL) was added the 5-methanesulfonyloxymethyl-2-carboethoxyfuran (4.0 g, 16 mmol) obtained in step 2, and the suspension was warmed to 60 °C and heated for 68 hours. The reaction mixture was cooled to ambient temperature and extracted with saturated aqueous NaHCO₃ and CH₂Cl₂. The aqueous phase was extracted with ethyl acetate. The combined organic layers were dried over MgSO₄, filtered, and concentrated *in vacuo*
35 to give 5-azidomethyl-2-carboxyethylfuran (3.6 g) as an orange oil.

68

Step 4: 5-Aminomethyl-2-carboxyethylfuran.

Treatment of a solution in ethanol (50 mL) at ambient temperature of 5-azidomethyl-2-carboxyethylfuran (585 mg, 3.00 mmol), prepared as in step 3, with Raney nickel 2800 and 4 atmospheres of H₂ for 24 hours, followed by filtration of the reaction mixture and concentration *in vacuo* gave 5-aminomethyl-2-carboxyethylfuran (0.50 g) as a yellow oil.

Step 5: 5-[N-(3-Nitropyrid-4-yl)aminomethyl]-2-carboxyethylfuran.

The desired compound was prepared by heating a solution in CH₃CN of 5-aminomethyl-2-carboxyethylfuran with 4-ethoxy-3-nitropyridine.

Step 6: 5-[N-(3-aminopyrid-4-yl)aminomethyl]-2-carboxyethylfuran.

The desired compound was prepared by reduction of 5-[N-(3-nitropyrid-4-yl)aminomethyl]-2-carboxyethylfuran, prepared as in step 5, with tin(II) chloride.

Step 7: 5-[(1H-2-Methylimidazo[4.5-c]pyrid-1-yl)methyl]-2-ethoxycarbonylfuran.

The desired compound was prepared by reaction of 5-[N-(3-aminopyrid-4-yl)aminomethyl]-2-carboxyethylfuran, prepared as in step 6, with acetic anhydride and acetic acid as described in Example 3, step 1.

Step 8: 1-N,N-Dimethylcarbamoyl-6-(4-fluorophenyl)-3-{5-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]fur-2-oyl}indole.

The desired compound was prepared according to the method of Example 51, steps 4-6, except substituting 5-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]-2-ethoxycarbonylfuran, prepared as in step 7, for 5-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]-2-carboxymethylthiophene. ¹H NMR (CDCl₃, 300 MHz) δ 9.03 (s, 1H), 8.44 (d, 1H J = 6 Hz), 8.32 (d, 1H, J = 8 Hz), 8.04 (s, 1H), 7.71 (d, 1H, J = 2 Hz), 7.64 (d, 1H, J = 4 Hz), 7.58 (m, 2H), 7.32 (d, 1H, J = 4.5 Hz), 7.14 (t, 2H, J = 8.8 Hz), 6.82 (d, 1H, J = 3 Hz), 6.52 (d, 1H, J = 3 Hz), 5.45 (s, 2H), 3.07 (s, 6H), 2.73 (s, 3H). MS (DCI/NH₃) m/e 522 (M+H)⁺, 171.

Example 53

Preparation of 1-*N,N*-Dimethylcarbamoyl-6-(4-fluorophenyl)-3-{4-[(3H-2-methylimidazo[4.5-c]pyrid-3-yl)methyl]thiazo-2-oyl}indole.

Step 1: 4-Chloromethyl-2-ethoxycarbonylthiazole.

5 A mixture of ethyl thiioxamate (1.0 g, 7.5 mmol) and 1,3-dichloroacetone (1.0 g, 8.3 mmol) in ethanol (25 mL) was heated at reflux for 15 hours. The reaction mixture was cooled to ambient temperature and concentrated *in vacuo*. The residue was partitioned between CH₂Cl₂ and saturated aqueous NaHCO₃. The organic phase was washed with brine, dried over MgSO₄, filtered, and concentrated *in vacuo* to give
10 an orange oil. 4-chloromethyl-2-ethoxycarbonylthiazole was obtained as a yellow oil by chromatography on silica gel (10% ether/hexanes).

Step 2: Potassium 4-chlormethyl-2-thiazocarboxylate.

15 To a solution of 4-chloromethyl-2-ethoxycarbonylthiazole (354 mg, 1.73 mmol), prepared as in step 1, in ethanol (10 mL) was added KOH (116 mg, 2.07 mmol). The reaction mixture was stirred for 1 hour at ambient temperature, then concentrated *in vacuo* and azeotroped twice with THF to give potassium 4-chlormethyl-2-thiazocarboxylate.

20 Step 3: 4-Chloromethyl-2-thiazocarbonyl chloride.

The desired compound is prepared by treatment of a suspension of potassium 4-chlormethyl-2-thiazocarboxylate in THF/DMF with oxalyl chloride.

25 Step 4: 1-*N,N*-Dimethylcarbamoyl-6-(4-fluorophenyl)-3-{4-[(3H-2-methylimidazo[4.5-c]pyrid-3-yl)methyl]thiazo-2-oyl}indole.

The desired compound is prepared according to the method of Example 4, except substituting 4-chloromethyl-2-thiazocarbonyl chloride, prepared as in step 3, for 4-chloromethylbenzoyl chloride.

30

Example 54

Preparation of 1-*N,N*-Dimethylcarbamoyl-6-(4-fluorophenyl)-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]thiazo-2-oyl}indole.

The desired compound is isolated by chromatography on silica gel from the mixture of products formed in Example 53, step 4.

35

Example 55

Preparation of 1-*N,N*-Dimethylcarbamoyl-6-(4-fluorophenyl)-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyloxime}indole.

The desired compound is prepared by reaction of 1-*N,N*-dimethylcarbamoyl-6-(4-fluorophenyl)-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole, prepared as in Example 4, with hydroxylamine hydrochloride and pyridine in ethanol as described in WO 93/01813.

Example 56

Preparation of 1-*N,N*-Dimethylcarbamoyl-6-(4-fluorophenyl)-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoylhydrazone}indole.

The desired compound is prepared by treatment of 1-*N,N*-dimethylcarbamoyl-6-(4-fluorophenyl)-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole, prepared as in Example 4, with hydrazine as described in WO 93/01813.

Example 57

Preparation of 1-*N,N*-Dimethylcarbamoyl-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]phenylsulfonyl}indole.

Step 1: 3-(4-methylthiophenyl)indole.

To a -10 °C solution of indole (5.85 g, 50 mmol) in CH₂Cl₂ (50 mL) was added triethylamine (7.0 mL, 50 mmol). In a separate flask a solution of p-tolyldisulfide (6.16 g, 25 mmol) in CH₂Cl₂ (50 mL) was cooled to -20 °C and sulfonyl chloride (2.0 mL, 25 mmol) was added over 10 min. The cold bath was removed and the reaction mixture was stirred for 1 hour and then was added to the indole/triethylamine solution over 15 min. The resulting solution was warmed to ambient temperature and stirred for 17 hours. The reaction mixture was washed with H₂O and brine, dried over MgSO₄, filtered, and concentrated *in vacuo*. The residue was taken up in toluene and filtered through a plug of silica gel. The filtrate was diluted with an equal volume of hexanes and the resulting solid was collected to give 4.43 g of the desired material. The mother liquors were concentrated *in vacuo* and the residue was purified by chromatography on silica gel (10% ethyl acetate/hexanes). The material from the chromatography was combined with the original solid and recrystallized from toluene/hexanes to give 7.41 g (62% yield) of 3-(4-methylthiophenyl)indole. mp 125-126.4 °C.

Step 2: 1-Phenylsulfonyl-3-(4-methylthiophenyl)indole.

To a solution of 3-(4-methylthiophenyl)indole (7.34 g, 30.7 mmol), prepared as in step 1, in dimethoxyethane (75 mL) was added powdered KOH (85%, 7.01 g, 125 mmol) and benzenesulfonyl chloride (4.25 mL, 33.3 mmol). A white precipitate
5 formed immediately and the reaction mixture became quite warm. The reaction mixture was stirred for 1 hour during which time it cooled to ambient temperature. Water (50 mL) was added and the mixture was extracted with ethyl acetate. The organic phase was washed with H₂O and brine, dried over Na₂SO₄, filtered, and concentrated *in vacuo*. 1-phenylsulfonyl-3-(4-methylthiophenyl)indole (8.89 g, 76%
10 yield) was obtained by chromatography on silica gel (10%, then 20% ethyl acetate/hexanes).

Step 3: 1-Phenylsulfonyl-3-(4-methylphenylsulfonyl)indole.

To a solution of 1-phenylsulfonyl-3-(4-methylthiophenyl)indole (8.89 g, 23.4
15 mmol) in glacial acetic acid (15 mL) was added 30% H₂O₂ solution (2.45 g, 72 mmol) and the resulting 2-phase mixture was heated at reflux for 30 min during which time it became a solid mass. The reaction mixture was cooled to ambient temperature and diluted with H₂O and ethyl acetate and the solid was filtered off. The filtrate layers were separated and the organic phase was washed with saturated aqueous
20 NaHCO₃, H₂O, and brine, dried over Na₂SO₄, filtered, and concentrated *in vacuo*. The residue was triturated with ethyl acetate/ether and the resulting solid was combined with the solid obtained above and recrystallized from ethyl acetate to give 8.15 g of 1-phenylsulfonyl-3-(4-methylphenylsulfonyl)indole. mp 188.9-189.7 °C.

Step 4: 1-Phenylsulfonyl-3-[(4-bromomethyl)phenylsulfonyl]indole.

To a suspension of 1-phenylsulfonyl-3-(4-methylphenylsulfonyl)indole (7.33 g, 17.8 mmol) and *N*-bromosuccinimide (3.20 g, 17.9 mmol) in CCl₄ (750 mL) was added benzoyl peroxide (100 mg, 0.40 mmol) and the reaction mixture was warmed to reflux, during which time it became homogenous. The reaction mixture was heated
30 for 3 hours at reflux, cooled to ambient temperature, stirred for 17 hours, and concentrated *in vacuo*. Pure (1.14 g, mp 194-195.5 °C), and 75% pure (3.74 g) 1-phenylsulfonyl-3-[(4-bromomethyl)phenylsulfonyl]indole was obtained by chromatography on silica gel (20%, then 30%, then 50% CH₂Cl₂/toluene) followed by recrystallization from toluene/hexanes.

Step 5: 1-Phenylsulfonyl-3-[(4-(di-*tert*-butoxycarbonyl)aminomethyl)phenylsulfonyl]indole.

To a suspension in DMF (10 mL) of potassium bis(*tert*-butoxycarbonyl)amide (1.78 g, 6.99 mmol), prepared as described by Allan, R.D., et al, *J. Chem. Soc. Perkin Trans. I*, **1983**, 2983, was added a solution of 1-phenylsulfonyl-3-[(4-bromomethyl)phenylsulfonyl]indole (2.8 g, 5.7 mmol), prepared as in step 4, in DMF (12 mL). The reaction mixture was heated at 50 °C for 2 hours, then cooled to ambient temperature and diluted with ethyl acetate (20 mL). The suspension was filtered and the filtrate concentrated *in vacuo*. The residue was taken up in ethyl acetate and washed with 1N aqueous NaHSO₄, H₂O, 5% aqueous NaHCO₃, H₂O, and brine, dried over Na₂SO₄, filtered, and concentrated *in vacuo*. Chromatography on silica gel (1:1 toluene/CH₂Cl₂, then CH₂Cl₂, then 5% ethyl acetate/CH₂Cl₂), followed by recrystallization from toluene/hexanes gave 1-phenylsulfonyl-3-[(4-(di-*tert*-butoxycarbonyl)aminomethyl)phenylsulfonyl]indole (3.10 g, 85% yield). mp 175.5-177 °C.

Step 6: 1-Phenylsulfonyl-3-[(4-aminomethyl)phenylsulfonyl]indole.

A mixture of 1-phenylsulfonyl-3-[(4-(di-*tert*-butoxycarbonyl)aminomethyl)phenylsulfonyl]indole (3.00 g, 4.79 mmol), prepared as in step 5, CH₂Cl₂ (5 mL), and trifluoroacetic acid (5 mL) was stirred for 45 min at ambient temperature. The reaction mixture was concentrated *in vacuo* and the residue partitioned between ethyl acetate (150 mL) and 1M aqueous Na₂CO₃. The aqueous phase was extracted twice with ethyl acetate. The combined organic layers were washed with H₂O and brine, and concentrated *in vacuo* to give 1-phenylsulfonyl-3-[(4-aminomethyl)phenylsulfonyl]indole (2.10 g) which was used without further purification.

Step 7: 3-[(4-(*N*-3-Nitropyrid-4-yl)aminomethyl)phenylsulfonyl]indole.

A solution of 1-phenylsulfonyl-3-[(4-aminomethyl)phenylsulfonyl]indole (2.10 g, 4.79 mmol), prepared in step 6, and 4-ethoxy-3-nitropyridine (0.894 g, 5.31 mmol) in ethanol (20 mL) and triethylamine (1 mL) was heated at reflux for 70 hours. The reaction mixture was cooled to ambient temperature and diluted with ethyl acetate (250 mL). The organic phase was washed twice with H₂O and once with brine. The combined aqueous washings were extracted with ethyl acetate. The combined organic layers were dried over Na₂SO₄, filtered, and concentrated *in vacuo*. Chromatography on silica gel (ethyl acetate, then 0.2% ethanol/ethyl acetate) followed by

recrystallization from ethyl acetate/ether gave 3-[(4-(*N*-3-nitropyrid-4-yl)aminomethyl)phenylsulfonyl]indole (350 mg, 23% yield). mp 97-102 °C.

Step 8: 3-{4-[(1*H*-2-Methylimidazo[4.5-*c*]pyrid-1-yl)methyl]phenylsulfonyl}indole.

- 5 A mixture of iron powder (140 mg), 3-[(4-(*N*-3-nitropyrid-4-yl)aminomethyl)phenylsulfonyl]indole (483 mg, 0.88 mmol), 1M aqueous NH₄Cl (5 mL), and CH₃CN (10 mL) was heated at reflux for 2 hours. The reaction mixture was filtered hot and the filter cake was rinsed with hot methanol. The filtrate was concentrated to a volume of ~2 mL. The liquid was decanted and the residue dried to
- 10 give crude 3-[(4-(*N*-3-aminopyrid-4-yl)aminomethyl)phenylsulfonyl]indole (670 mg). To this material was added acetic acid (3 mL) and acetic anhydride (3 mL) and the mixture was heated at reflux for 2 hours. The reaction mixture was concentrated *in vacuo* and the residue partitioned between 4N aqueous NH₄OH and ethyl acetate/CH₂Cl₂. The organic phase was washed with H₂O and brine, dried over
- 15 Na₂SO₄, filtered, and concentrated *in vacuo*. Chromatography on silica gel (7%, then 10% methanol/CH₂Cl₂) followed by recrystallization from methanol/H₂O gave 3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]phenylsulfonyl}indole (327 mg). mp 291-293 °C.

- 20 Step 9: 1-*N,N*-Dimethylcarbamoyl-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]phenylsulfonyl}indole.

- The desired compound was prepared according to the method of Example 2, except substituting 3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]phenylsulfonyl}indole, prepared as in step 8, for 6-(4-fluorophenyl)-3-{4-[(1*H*-2-methylbenzimidazolyl)methyl]benzoyl}indole, and substituting 1,2-
- 25 dimethoxyethane for THF/DMF. ¹H NMR (CDCl₃, 300 MHz) δ 2.54 (s, 3H), 3.09 (s, 6H), 5.36 (s, 2H), 7.10 (dd, 1H, J=6.0, 0.9 Hz), 7.12 (d, 2H, J=8.4 Hz), 7.29 (td, 1H, J=7.5, 1.5 Hz), 7.58 (dt, 1H, J=8.4, 2.4 Hz), 7.87 (dt, 1H, J=7.5, 2.4 Hz), 7.95 (t, 1H, J=1.8 Hz), 7.96 (s, 1H), 7.99 (t, 1H, J=1.8 Hz), 8.33 (d, 1H, J=6.0), 9.01 (s, 1H). MS (DCI/NH₃) m/e 474 (M+H)⁺. Anal Calcd for C₂₅H₂₃N₅O₃S · 0.5H₂O: C, 52.65; H, 5.26, N, 13.53. Found C, 62.29; H, 5.31; N, 13.71. S: calcd 6.19, found 6.22.
- 30

Example 58

Preparation of 1-Methyl-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]phenylsulfonylamino}indole.

Step 1: 1-Methyl-3-[4-(azidomethyl)phenylsulfonylamino]indole.

5 A mixture of 4-azidomethylphenylsulfonyl azide (2.93 g, 12.3 mmol), prepared by reaction of *p*-toluenesulfonyl chloride with *N*-bromosuccinimide followed by sodium azide, and 1-methylindole was heated at 55 °C for 6 hours. Pure 1-methyl-3-[4-(azidomethyl)phenylsulfonylamino]indole was obtained by chromatography on silica gel (1:1 CH₂Cl₂/hexanes, then CH₂Cl₂, then 1.5% methanol/CH₂Cl₂).

10 Step 1: 1-Methyl-3-[4-(aminomethyl)phenylsulfonylamino]indole.

To a solution of 1-methyl-3-[4-(azidomethyl)phenylsulfonylamino]indole (674 mg, 1.97 mmol), prepared as in step 1, in 8:2 THF/H₂O (10 mL) was added triphenylphosphine (1.03 g, 3.9 mmol) and the reaction mixture was stirred for 17
15 hours at ambient temperature. The reaction mixture was concentrated *in vacuo* and the residue was partitioned between ethyl acetate and brine. The organic phase was dried over Na₂SO₄, filtered, and concentrated *in vacuo* to give 1-methyl-3-[4-(aminomethyl)phenylsulfonylamino]indole (1.68 g) as a yellow-orange foam.

20 Step 3: 1-Methyl-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]phenylsulfonylamino}indole.

The desired compound is prepared according to the method of Example 52, steps 5-8, except substituting 1-methyl-3-[4-(aminomethyl)phenylsulfonylamino]indole, prepared as in step 2, for 5-aminomethyl-
25 2-carboxyethylfuran.

Example 59

Preparation of 1-*p*-Toluenesulfonyl-6-(4-fluorophenyl)-3-{4-[(1H-2-methylimidazo[4.5-c]pyridyl)methyl]benzoyl}indole.

30 The desired compound was prepared according to the method of Example 4, except substituting *p*-toluenesulfonyl chloride for *N,N*-dimethylcarbamoyl chloride. ¹H NMR (DMSO-d₆, 300 MHz) δ 2.32 (s, 3H), 2.61 (s, 3H), 5.69 (s, 2H), 7.30-7.45 (m, 6H), 7.64 (dd, 1H, *J* = 5.4, 1.2 Hz), 7.70 (dd, 1H, *J* = 8.4, 1.8 Hz), 7.7-7.8 (m, 2H), 7.91 (apparent d, 2H, *J* = 8.4 Hz), 8.05-8.10 (m, 3H), 8.21 (d, 1H, *J* = 9.0 Hz), 8.27 (s, 1H), 8.33 (d, 1H, *J* = 5.4 Hz), 8.88 (d, 1H, *J* = 1.2 Hz). MS
35

75

(DCI/NH₃) m/e 615 (M+H)⁺. Anal calcd for C₃₆H₂₇FN₄O₃S · 1.4H₂O: C, 67.57; H, 4.69; N, 8.76. Found: C, 67.55; H, 4.51; N, 8.72.

Example 60

5 Preparation of 1-(Morpholin-4-ylcarbonyl)-6-(4-fluorophenyl)-3-{4-[(1H-2-methylimidazo[4.5-c]pyridyl)methyl]benzoyl}indole.

The desired compound was prepared according to the method of Example 2, except substituting 6-(4-fluorophenyl)-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole for 6-(4-fluorophenyl)-3-{4-[(1H-2-methylbenzimidazolyl)methyl]benzoyl}indole, and substituting 4-morpholinecarbonyl
10 chloride for *N,N*-dimethylcarbamoyl chloride. ¹H NMR (DMSO-d₆, 300 MHz) δ 2.60 (s, 3H), 3.5-3.6 (m, 4H), 3.6-3.7 (m, 4H), 5.67 (s, 2H), 7.3-7.4 (m, 4H), 7.6-7.7 (m, 2H), 7.7-7.8 (m, 2H), 7.87 (apparent d, 2H, J = 8.1 Hz), 7.85-7.90 (narrow m, 1H), 8.12 (s, 1H), 8.30 (d, 1H, J = 8.4 Hz), 8.32 (d, 1H, J = 5.4
15 Hz), 8.87 (s, 1H). MS (DCI/NH₃) m/e 574 (M+H)⁺.

Example 61

Preparation of 1-(*N,N*-Dimethylcarbamoylmethyl)-6-(4-fluorophenyl)-3-{4-[(1H-2-methylimidazo[4.5-c]pyridyl)methyl]benzoyl}indole.

20 The desired compound was prepared according to the method of Example 2, except substituting 6-(4-fluorophenyl)-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole for 6-(4-fluorophenyl)-3-{4-[(1H-2-methylbenzimidazolyl)methyl]benzoyl}indole, and substituting *N,N*-dimethylchloroacetamide for *N,N*-dimethylcarbamoyl chloride. ¹H NMR (DMSO-d₆,
25 300 MHz) δ 2.60 (s, 3H), 2.84 (s, 3H), 3.09 (s, 3H), 5.76 (s, 2H), 7.25-7.35 (m, 4H), 7.56 (dd, 1H, J = 8.4, 1.8 Hz), 7.76 (apparent d, 2H, J = 8.4 Hz), 7.7-7.8 (m, 3H), 7.92 (s, 1H), 8.30 (d, 1H, J = 8.1 Hz), 8.31 (d, 1H, J = 5.4 Hz), 8.87 (s, 1H). MS (DCI/NH₃) m/e 546 (M+H)⁺.

30


35

76

The compounds represented in Table 3 are prepared from 6-(4-fluorophenyl)-3-{4-[(1H-2-methylimidazo[4,5-c]pyridyl)methyl]benzoyl}indole by the methods described in Examples 59-61 and WO 93/01813.













5

Table 3








Example	R ²
62	-CH ₃
63	
64	
65	
66	
67	
68	

77

69	
70	
71	
72	
73	
74	
75	
76	
77	
78	
79	
80	

78

81	
82	
83	
84	
85	
86	-SO ₂ CH ₃
87	-SO ₂ CH ₂ CH ₃
88	-SO ₂ C ₆ H ₅
89	-SO ₂ N(CH ₃) ₂

Example 90

Preparation of 4,7-Dimethoxycarbonyl-3-{4-[(1H-2-methylimidazo[4,5-c]pyrid-1-yl)methyl]benzoyl}indole.

5 Step 1: 4,7-Dimethoxycarbonylindole.

To a solution under N₂ of dimethyl nitroterephthlate (10.0 g, 41.8 mmol) in dry, freshly distilled THF (420 mL) at -45 to -40 °C was added vinylmagnesium bromide (1.0 M in THF, 125 mL, 125 mmol) over 10 minutes and the reaction mixture was stirred for an additional 40 minutes. The reaction was quenched with saturated aqueous NH₄Cl and extracted twice with ether. The combined ether extracts were dried over Na₂SO₄, filtered, and concentrated *in vacuo* to give 11.9 g of orange oil and yellow granular solid. Chromatography on silica gel (3:1 hexane/ethyl acetate) gave 4,7-dimethoxycarbonylindole (1.90 g) as a bright-yellow waxy solid.

Trituration of the mixed fractions with hexane-ethyl acetate gave an additional 0.66 g of product.

Step 2: 4,7-Dimethoxycarbonyl-3-(4-chloromethylbenzoyl)indole.

5 To a solution under N₂ of 4,7-dimethoxycarbonylindole (1.87 g, 8.02 mmol) in CH₂Cl₂ (135 mL) was added ethylmagnesium bromide (3.0 M in ether, 2.70 mL, 8.10 mmol) over 5 minutes. The resulting red-orange suspension was stirred for 10 minutes at ambient temperature and ZnCl₂ (1.0M in ether, 24.1 mL, 24.1 mmol) was added quickly via syringe. After stirring for 20 minutes, during which time the
10 reaction mixture turned to a light-green suspension, a solution of 4-chloromethylbenzoyl chloride in CH₂Cl₂ (35 mL) was added over 5 minutes. The reaction mixture was stirred for 3 days at ambient temperature and then was poured into saturated aqueous NH₄Cl. The layers were separated and the aqueous phase was extracted twice with CH₂Cl₂. The combined organic layers were washed with brine,
15 dried over Na₂SO₄, filtered, and concentrated *in vacuo* to give a clear-orange oil (3.57 g). Chromatography on silica gel (99:1, then 97:3 CH₂Cl₂/acetone) gave a clear-yellow oil which partially crystallized on standing. Azeotroping with CH₂Cl₂ gave 4,7-dimethoxycarbonyl-3-(4-chloromethylbenzoyl)indole as a yellow solid (0.85 g, 28%).

20

Step 3: 4,7-Dimethoxycarbonyl-3-{4-[(1H-2-methylimidazo[4,5-c]pyrid-1-yl)methyl]benzoyl}indole.

To a 0 °C solution under N₂ of 1H-2-methylimidazo[4,5-c]pyridine, (0.32 g, 2.4 mmol) prepared as in Example 3, step 1, in THF (8.0 mL) and DMPU (1,3-
25 dimethyl-3,4,5,6-tetrahydro-1H-pyridin-2-one, 2.75 mL) was added NaH (95%, 0.23 g, 2.2 mmol), and the mixture was stirred for 30 minutes. In a separate reaction vessel, NaBr (0.23 g, 2.2 mmol) was added to a solution of 4,7-dimethoxycarbonyl-3-(4-chloromethylbenzoyl)indole (0.83 g, 2.2 mmol) in THF (8.5 mL) and DMPU (1.75 mL). The sodium anion solution was then added to the indole/NaBr solution
30 via cannula over 5 minutes, and the reaction mixture was stirred overnight at ambient temperature. The reaction mixture was partitioned between ethyl acetate and saturated aqueous NH₄Cl. The organic phase was washed with H₂O and brine, dried over Na₂SO₄, filtered, and concentrated *in vacuo* to give a viscous, clear-orange oil (1.1 g). Chromatography on silica gel (40:1, then 20:1, then 12:1 CHCl₃/methanol) gave a
35 bright-yellow oil. Azeotroping with CH₂Cl₂ gave 4,7-dimethoxycarbonyl-3-{4-[(1H-2-methylimidazo[4,5-c]pyrid-1-yl)methyl]benzoyl}indole (40 mg) as a bright-yellow

solid. ^1H NMR (CDCl_3 , 300 MHz) δ 2.63 (s, 3H), 3.72 (s, 3H), 4.02 (s, 3H), 5.41 (s, 2H), 7.14 (d, 2H, $J = 8.5$ Hz), 7.20 (d, 1H, $J = 5.5$ Hz), 7.62 (d, 1H, $J = 7.7$ Hz), 7.70 (d, 1H, $J = 2.9$ Hz), 7.86 (d, 2H, $J = 8.5$ Hz), 8.01 (d, 1H, $J = 8.1$ Hz), 8.40 (d, 1H, $J = 4.8$ Hz), 9.05 (s, 1H), 10.58 (s, 1H). MS (DCI/ NH_3) m/e 483 (M+H) $^+$. IR (microscope) 1163 (s), 1198 (m), 1280 (s), 1433 (m), 1520 (m), 1610 (m), 1637 (m), 1721 (s), 2952 (w), 3362 (br) cm^{-1} . Anal calcd for $\text{C}_{27}\text{H}_{22}\text{N}_4\text{O}_5 \cdot 0.35 \text{H}_2\text{O} \cdot 0.65 \text{CH}_2\text{Cl}_2$: C, 61.05; H, 4.45; N, 10.30. Found: C, 61.29; H, 4.53; N, 9.91.

10

Example 91Preparation of 4,7-Dimethyl-3-{4-[(1H-2-methylimidazo[4,5-c]pyrid-1-yl)methyl]benzoyl}indole.

The desired compound was prepared according to the method of Example 90, except substituting 4,7-dimethylindole, prepared as described by Dalton, *et al.*, *Aust. J. Chem.*, **1968**, 21, 2053, for 4,7-dimethoxycarbonylindole. mp 146-151 $^\circ\text{C}$. ^1H NMR ($\text{DMSO}-d_6$, 500 MHz) δ 2.45 (s, 3H), 2.52 (s, 3H), 2.59 (s, 3H), 5.63 (s, 2H), 6.85 (d, 1H, $J = 7.3$ Hz), 6.94 (d, 1H, $J = 7.1$ Hz), 7.27 (d, 2H, $J = 8.3$ Hz), 7.59 (d, 1H, $J = 5.4$ Hz), 7.60 (s, 1H), 7.80 (d, 2H, $J = 8.3$ Hz), 8.30 (d, 1H, $J = 5.6$ Hz), 8.86 (s, 1H), 11.85 (s, 1H). MS (DCI/ NH_3) m/e 395 (M+H) $^+$. IR (microscope) 885 (m), 1222 (m), 1299 (m), 1350 (m), 1391 (m) cm^{-1} . Anal calcd for $\text{C}_{25}\text{H}_{22}\text{N}_4\text{O} \cdot 1.2 \text{H}_2\text{O}$: C, 72.17; H, 5.91; N, 13.46. Found: C, 72.06; H, 5.64; N, 13.55.

Example 92Preparation of 4,7-Dimethyl-3-{4-[(3H-2-methylimidazo[4,5-c]pyrid-3-yl)methyl]benzoyl}indole.

The desired compound was separated by chromatography (30:1, then 20:1, then 14:1, then 11:1, then 10:1 CHCl_3 , methanol) from the 1H isomer prepared in Example 91. mp 219-225 $^\circ\text{C}$. ^1H NMR ($\text{DMSO}-d_6$, 500 MHz) δ 2.46 (s, 3H), 2.53 (s, 3H), 2.62 (s, 3H), 5.70 (s, 2H), 6.85 (d, 1H, $J = 7.3$ Hz), 6.94 (d, 1H, $J = 7.3$ Hz), 7.32 (d, 2H, $J = 8.3$ Hz), 7.58 (dd, 1H, $J = 0.8, 5.5$ Hz), 7.61 (s, 1H), 7.81 (d, 2H, $J = 8.3$ Hz), 8.30 (d, 1H, $J = 5.4$ Hz), 8.86 (d, 1H, $J = 0.7$ Hz), 11.85 (s, 1H). MS (DCI/ NH_3) m/e 395 (M+H) $^+$, 412 (M+ NH_4) $^+$. IR cm^{-1} (microscope) 881 (m), 1162 (m), 1215 (m), 1346 (s), 1381 (m). Anal calcd for $\text{C}_{25}\text{H}_{22}\text{N}_4\text{O} \cdot 0.8 \text{H}_2\text{O}$: C, 73.44; H, 5.82; N, 13.70. Found: C, 73.18; H, 5.50; N, 13.45.

Example 93Preparation of 7-Benzyloxy-3-{4-[(1H-2-methylimidazo[4,5-c]pyrid-1-yl)methyl]benzoyl}indole.

5 The desired compound was prepared according to the method of Example 90, except substituting 7-benzyloxyindole for 4,7-dimethoxycarbonylindole. ¹H NMR (DMSO-d₆, 300 MHz) δ 2.59 (s, 3H), 5.30 (s, 2H), 5.63 (s, 2H), 6.93 (d, 1H, J = 7.7 Hz), 7.13 (t, 1H, J = 7.9 Hz), 7.28 (d, 2H, J = 8.1 Hz), 7.32-7.46 (c, 3H), 7.54-7.60 (c, 2H), 7.62 (d, 1H, J = 5.1 Hz), 7.71 (d, 1H, J = 2.2 Hz), 7.76 (d, 2H, J = 8.5 Hz), 7.80 (d, 1H, J = 8.1 Hz), 8.30 (d, 1H, J = 5.2 Hz), 8.87 (s, 1H), 12.24 (d, 1H, J = 2.6 Hz). MS (DCI/NH₃) m/e 473 (M+H)⁺. IR, cm⁻¹ (microscope) 738 (m), 1219 (m), 1248 (m), 1278 (m), 1436 (s). Anal calcd for C₃₀H₂₄N₄O₂ · 1.2 H₂O: C, 72.92; H, 5.38; N, 11.34. Found: C, 72.97; H, 5.30; N, 11.05.

Example 94Preparation of 7-(4-Fluorophenyl)-3-{4-[(1H-2-methylimidazo[4,5-c]pyrid-1-yl)methyl]benzoyl}indole.

20 The desired compound was prepared according to the method of Example 90, except substituting 7-(4-fluorophenyl)indole, prepared as described by Carrera, G.M., and Sheppard, G.S., *Synlett*, **1994**, 93, for 4,7-dimethoxycarbonylindole. ¹H NMR (DMSO-d₆, 300 MHz) δ 2.59 (s, 3H), 5.64 (s, 2H), 7.26 (dd, 1H, J = 1.3, 7.2 Hz), 7.30 (d, 2H, J = 8.1 Hz), 7.33 (t, 1H, J = 7.6 Hz), 7.37 (t, 2H, J(F-Hortho, Hortho-Hmeta) = 9.0 Hz), 7.61 (dd, 1H, J = 1.1, 5.5 Hz), 7.64 (dd, 2H, J(F-Hmeta, Hortho-Hmeta) = 5.5, 8.8 Hz), 7.76 (d, 1H, J = 3 Hz), 7.78 (d, 2H, J = 8.5 Hz), 8.26 (dd, 1H, J = 1.1, 7.7 Hz), 8.30 (d, 1H, J = 5.5 Hz), 8.86 (s, 1H), 11.90 (d, 1H, J = 2.6 Hz). MS (DCI/NH₃) m/e 461 (M+H)⁺. IR, cm⁻¹ (microscope) 800 (m), 1174 (m), 1225 (s), 1374 (m), 1395 (m). Anal calcd for C₂₉H₂₄N₄OF · 0.75 H₂O: C, 73.48; H, 4.78; N, 11.82. Found: C, 73.60; H, 4.38; N, 11.79.

Example 95Preparation of 6-(4-Fluorophenyl)-3-{N-[3-(1H-2-methylimidazo[4,5-c]pyrid-1-yl)propyl]sarcosyl}indole-1-carboxylic acid dimethyl amide.Step 1: N-tert-butoxycarbonyl-3-bromopropylamine.

35 To a 0 °C solution of 3-bromopropylamine hydrobromide (10.0 g, 45.7 mmol) in 1:1 aqueous dioxane was added triethylamine (12.8 mL, 91.8 mmol), di-tert-

82

butyldicarbonate (20.2 g, 92.6 mmol), and saturated aqueous NaHCO₃ (3 mL). The cold bath was removed and the reaction mixture was stirred for 3.5 hours. The reaction mixture was extracted three times with ethyl acetate. The combined organic extracts were washed with 10% aqueous citric acid and brine, dried over Na₂SO₄,
5 filtered, and concentrated *in vacuo*. Chromatography on silica gel (10:1, then 6:1, then 3:1 hexane, ethyl acetate) gave *N-tert*-butoxycarbonyl-3-bromopropylamine (21.1 g, 79%) as a clear yellow oil.

10 Step 2: 1-(3-*N-tert*-Butoxycarbonylaminoprop-1-yl)-1H-2-methylimidazo[4,5-
c]pyridine.

To a solution under N₂ of 1H-2-methylimidazo[4,5-*c*]pyridine, (2.00 g, 15.0 mmol) prepared as in Example 3, step 1, in THF (35 mL) and DMF (2.0 mL) was added NaH (95%, 0.42 g, 16.6 mmol) over 15 minutes and the reaction mixture was stirred for 80 minutes. The resulting suspension was cooled in an ice-water bath and
15 a solution of *N-tert*-butoxy-3-bromopropylamine (3.93 g, 16.5 mmol), prepared as in step 1, in THF (5.0 mL) was added via cannula. The cold bath was removed, DMF (20 mL) was added to make a homogenous solution, and the reaction mixture was stirred overnight at ambient temperature. The reaction mixture was diluted with ethyl acetate and poured into water. The layers were separated and the organic phase was
20 washed with ethyl acetate. The aqueous phase was extracted with ethyl acetate. The combined organic extracts were dried over Na₂SO₄, filtered, and concentrated *in vacuo* to give 5.5 g of a dark oil. Chromatography on silica gel (20:1, then 10:1 CHCl₃, methanol) gave 1-(3-*N-tert*-butoxycarbonylaminoprop-1-yl)-1H-2-methylimidazo[4,5-*c*]pyridine (0.58 g) which was contaminated with 8-10% of the
25 3H isomer.

Step 3: 1-(3-Aminoprop-1-yl)-1H-2-methylimidazo[4,5-*c*]pyridine.

To a 0 °C solution of 1-(3-*N-tert*-butoxycarbonylaminoprop-1-yl)-1H-2-methylimidazo[4,5-*c*]pyridine (0.33 g, 1.1 mmol), prepared as in step 2, in CH₂Cl₂
30 (8.8 mL) was added dropwise trifluoroacetic acid (2.20 mL, 28.6 mmol). The cold bath was removed and the reaction mixture was stirred for 20 minutes. The reaction mixture was carefully added to saturated aqueous NaHCO₃ (20 mL). The acidic aqueous phase (pH = 2) was taken to pH = 12-13 with 15% aqueous NaOH. The layers were combined and added to a liquid-liquid continuous extractor and extracted
35 into CH₂Cl₂ for 18 hours. Concentration *in vacuo* gave 1-(3-aminoprop-1-yl)-1H-2-methylimidazo[4,5-*c*]pyridine (0.27 g).

Step 4: 1-(3-*N*-Formylaminoprop-1-yl)-1H-2-methylimidazopyridine.

The desired compound was prepared by reaction of the 1-(3-aminoprop-1-yl)-1H-2-methylimidazo[4,5-*c*]pyridine (0.27 g, 1.1 mmol) prepared in step 3 with ethyl formate according to the method of DeCosta *et al.*, *J. Med. Chem.*, **1994**, *37*, 314. Distillation was replaced by chromatography on silica gel (10:1 CHCl₃, methanol + 1% of 29% aqueous NH₄OH, then 7:1 CHCl₃, methanol + 1% of 29% aqueous NH₄OH) gave 1-(3-*N*-formylaminoprop-1-yl)-1H-2-methylimidazopyridine (0.23 g, 96% yield from step 3).

Step 5: 1-(3-*N*-Methylaminoprop-1-yl)-1H-2-methylimidazopyridine.

The desired compound (0.21 g) was prepared by reduction of 1-(3-*N*-formylaminoprop-1-yl)-1H-2-methylimidazopyridine (0.21 g, 0.96 mmol), prepared as in step 4, with LAH according to the method of DeCosta *et al.*, *J. Med. Chem.*, **1992**, *35*, 38, except substituting DME for THF to give 1-(3-*N*-methylaminoprop-1-yl)-1H-2-methylimidazopyridine as a bright yellow oil which was used without further purification.

Step 6: 6-(4-Fluorophenyl)-3-{N-[3-(1H-2-methylimidazo[4.5-*c*]pyrid-1-yl)propyl]sarcosyl}indole.

To a solution under N₂ of the 1-(3-*N*-methylaminoprop-1-yl)-1H-2-methylimidazopyridine (0.21 g) prepared in step 5 and *N,N*-diisopropylethylamine (0.52 mL, 3.0 mmol) in DMF (1 mL) was added a solution in 1:1 DMF, THF (6 mL) of 3-chloroacetyl-6-(4-fluorophenyl)indole (0.18 g, 0.62 mmol), prepared as in Example 23, step 1, and the reaction mixture was stirred overnight at ambient temperature. The reaction mixture was diluted with ethyl acetate and extracted twice with aqueous 1N NaOH. The organic phase was dried over Na₂SO₄, filtered, and concentrated *in vacuo* to give a clear orange foam. Chromatography on silica gel (50:1 CHCl₃, methanol + 0.5% NH₄OH, then 20:1 CHCl₃, methanol + 0.5% NH₄OH, then 10:1 CHCl₃, methanol + 0.5% NH₄OH) to give 6-(4-fluorophenyl)-3-{N-[3-(1H-2-methylimidazo[4.5-*c*]pyrid-1-yl)propyl]sarcosyl}indole (21 mg) as an orange, oily foam.

84

Step 7: 6-(4-Fluorophenyl)-3-{N-[3-(1H-2-methylimidazo[4,5-c]pyrid-1-yl)propyl]sarcosyl}indole-1-carboxylic acid dimethyl amide.

The desired compound was prepared as an 85:15 mixture of the 1H and 3H isomers by reaction of 6-(4-fluorophenyl)-3-{3-[*N*-methyl-*N*-methylcarbonyl-(1H-2-methylimidazo[4,5-c]pyrid-1-yl)amino]prop-1-yl}indole, prepared as in step 6, with KOH and *N,N*-dimethylcarbonyl chloride in THF/DMF as described in Example 2.

¹H NMR (DMSO-d₆, 300 MHz) δ 1.96 (quintet, 2H, J = 7.0 Hz), 2.32 (s, 3H), 2.47-2.56 (c, 2H), 2.59 (s, 3H), 3.05 (s, 6H), 3.76 (s, 2H), 4.25 (t, 2H, J = 7.2 Hz), 7.30 (t, 2H, J(F-Hortho, Hortho-Hmeta) = 8.8 Hz), 7.57 (dd, 1H, J = 0.7, 5.5 Hz), 7.60 (dd, 1H, J = 1.5, 8.5 Hz), 7.74 (dd, 2H, J(F-Hmeta, Hortho-Hmeta) = 5.5, 8.8 Hz), 7.79 (d, 1H, J = 1.1 Hz), 8.24 (d, 1H, J = 5.5 Hz), 8.30 (d, 1H, J = 8.1 Hz), 8.66 (s, 1H), 8.78 (s, 1H). MS (DCI/NH₃) m/e 527 (M+H)⁺. IR, cm⁻¹ (microscope) 822 (m), 1160 (m), 1177 (m), 1391 (s), 1480 (m). Anal calcd for C₃₀H₃₁N₆O₂F · 0.6 H₂O · 0.2 Et₂O: C, 66.99; H, 6.24; N, 15.22. Found: C, 67.22; H, 6.00; N, 14.87.

Example 96

Preparation of 1-*N,N*-Dimethylcarbonyl-4-methoxycarbonyl-3-{3-fluoro-4-[(1H-2-methylimidazo[4,5-c]pyrid-1-yl)methyl]benzoyl}indole.

Step 1: 4-methoxycarbonyl-3-(3-fluoro-4-methylbenzoyl)indole.

The desired compound was prepared according to the method of Example 90, step 2, except substituting 4-methoxycarbonylindole for 4,7-dimethoxycarbonylindole, and substituting 3-fluoro-4-methylbenzoyl chloride, prepared by reaction of 3-fluoro-4-methylbenzoic acid with thionyl chloride, for 4-chloromethylbenzoyl chloride.

Step 2: 1-*N,N*-Dimethylcarbonyl-4-methoxycarbonyl-3-(3-fluoro-4-methylbenzoyl)indole.

The desired compound was prepared by reaction of 4-methoxycarbonyl-3-(3-fluoro-4-methylbenzoyl)indole, prepared as in step 1, with KOH and *N,N*-dimethylcarbonyl chloride in THF as described in Example 2.

85

Step 3: 1-*N,N*-Dimethylcarbamoyl-4-methoxycarbonyl-3-(3-fluoro-4-bromomethylbenzoyl)indole.

The desired compound was prepared by heating a solution in CCl₄ of *N,N*-dimethylcarbamoyl-4-methoxycarbonyl-3-(3-fluoro-4-methylbenzoyl)indole, prepared
5 as in step 2, *N*-bromosuccinimide, and catalytic AIBN.

Step 4: 1-*N,N*-Dimethylcarbamoyl-4-methoxycarbonyl-3-{3-fluoro-4-[(1*H*-2-methylimidazo[4,5-*c*]pyrid-1-yl)methyl]benzoyl}indole.

The desired compound was prepared according to the method of Example 90,
10 step 3, except substituting *N,N*-dimethylcarbamoyl-4-methoxycarbonyl-3-(3-fluoro-4-bromomethylbenzoyl)indole, prepared as in step 3, for 4,7-dimethoxycarbonyl-3-(4-chloromethylbenzoyl)indole. ¹H NMR (DMSO-*d*₆, 300 MHz) δ 8.86 (s, 1H), 8.31-8.29 (d, 1H, *J* = 4.4 Hz), 8.19 (s, 1H), 7.88-7.85 (d, 1H, *J* = 8.5 Hz), 7.71-7.69 (d, 1H, *J* = 4.4 Hz), 7.66-7.63 (d, 1H, *J* = 4.4 Hz), 7.59-7.56 (d, 1H, *J* = 4.4
15 Hz), 7.49-7.46 (d, 1H, *J* = 8.1 Hz), 7.16-7.10 (t, 1H, *J* = 7.8 Hz), 5.69 (s, 2H), 3.51 (s, 3H), 3.34 (s, 6H), 2.62 (s, 3H). MS (DCI/NH₃) *m/e* 514 (M+H)⁺. Anal calcd for C₂₈H₂₄FN₅O₄ · 0.5 CH₂Cl₂: C, 61.56; H, 4.53; N, 12.13. Found: C, 61.55; H, 4.51; N, 12.28.

Example 97

20 Preparation of 1-*N,N*-Dimethylcarbamoyl-6-benzyloxy-3-{4-[(1*H*-2-methylimidazo[4,5-*c*]pyrid-1-yl)methyl]benzoyl}indole.

The desired compound was prepared according to the method of Example 90, except substituting 6-benzyloxyindole for 4-methoxycarbonylindole. ¹H NMR (DMSO-*d*₆, 300 MHz) δ 8.86 (s, 1H), 8.31-8.29 (d, 1H, *J* = 5.1 Hz), 8.13-8.10 (d,
25 1H, *J* = 8.8 Hz), 7.95 (s, 1H), 7.83-7.80 (d, 2H, *J* = 5.0 Hz), 7.50-7.47 (d, 2H, *J* = 5.0 Hz), 7.43-7.37 (t, 1H, *J* = 6.9 Hz), 7.35-7.33 (d, 2H, *J* = 5.5 Hz), 7.30-7.26 (d, 2H, *J* = 7.8 Hz), 7.18 (s, 1H), 7.09-7.06 (d, 1H, *J* = 5.5 Hz), 5.56 (s, 2H), 5.17 (s, 2H), 2.95 (s, 6H), 2.59 (s, 3H). MS (DCI/NH₃) *m/e* 544 (M+H)⁺. Anal calcd for C₃₃H₂₉N₅O₃ · 1.5 H₂O: C, 69.45; H, 5.65; N, 12.27. Found: C, 69.45; H, 5.57;
30 N, 11.64.

86

Example 98

Preparation of 1-*N,N*-Dimethylcarbamoyl-4-methoxycarbonyl-3-{5-[(1*H*-2-methylimidazo[4,5-*c*]pyrid-1-yl)methyl]thien-2-yl}indole.

Step 1: 1-*N,N*-Dimethylcarbamoyl-4-methoxycarbonyl-3-(5-bromomethylthien-2-yl)indole.

5

The desired compound was prepared according to the method of Example 96, steps 1-3, except substituting 5-methylthiophene-2-carboxylic acid for 3-fluoro-4-methylbenzoic acid.

Step 2: 1-*N,N*-Dimethylcarbamoyl-4-methoxycarbonyl-3-(5-azidomethylthien-2-yl)indole.

10

To a solution of 1-*N,N*-dimethylcarbamoyl-4-methoxycarbonyl-3-(5-bromomethylthien-2-yl)indole (2.8 g, 6.2 mmol), prepared as in step 1, in CH₃CN (10 mL) was added sodium azide (0.77 g, 11.8 mmol) and benzyltrimethylammonium chloride (0.10 g, 0.40 mmol). The reaction mixture was stirred for 3.5 hours at ambient temperature and then was partitioned between CH₂Cl₂ and saturated aqueous NaHCO₃. The organic phase was washed with brine, dried over MgSO₄, filtered, and concentrated *in vacuo* to give 1-*N,N*-dimethylcarbamoyl-4-methoxycarbonyl-3-(5-azidomethylthien-2-yl)indole (2.18 g) as a yellow foam which was used without further purification.

15

20

Step 3: 1-*N,N*-Dimethylcarbamoyl-4-methoxycarbonyl-3-(5-aminomethylthien-2-yl)indole.

To a solution of SnCl₂ (4.73 g, 25 mmol) in methanol (70 mL) was added in 2-mL portions a solution in methanol (30 mL) of the 1-*N,N*-dimethylcarbamoyl-4-methoxycarbonyl-3-(5-azidomethylthien-2-yl)indole prepared in step 2. The reaction mixture was stirred at ambient temperature for 5 hours and then was concentrated *in vacuo*. The residue was partitioned between CH₂Cl₂ and saturated aqueous NaHCO₃. The organic phase was dried over MgSO₄, filtered, and concentrated *in vacuo* to give a yellow foam (1.60 g). Chromatography on silica gel (1% triethylamine, 99% CH₂Cl₂, then 1% triethylamine, 3% methanol, 94% CH₂Cl₂) gave 1-*N,N*-dimethylcarbamoyl-4-methoxycarbonyl-3-(5-aminomethylthien-2-yl)indole (0.95 g) as a tan foam.

25

30

35

87

Step 4: 1-*N,N*-Dimethylcarbamoyl-4-methoxycarbonyl-3-[5-(*N*-3-nitropyridin-4-yl)aminomethylthien-2-oyl]indole.

To a solution of 1-*N,N*-dimethylcarbamoyl-4-methoxycarbonyl-3-(5-aminomethylthien-2-oyl)indole (0.896 g, 2.33 mmol) in CH₃CN (5 mL) was added 4-ethoxy-3-nitropyridine (0.428 g, 2.55 mmol) and the reaction mixture was heated at reflux for 17 hours, then the solvent was removed in vacuo and the residue heated at 100 °C for 2 hours. The reaction mixture was then put under high vacuum to give 1-*N,N*-dimethylcarbamoyl-4-methoxycarbonyl-3-[5-(*N*-3-nitropyridin-4-yl)aminomethylthien-2-oyl]indole as a brown foam which was used without further purification.

Step 5: 1-*N,N*-Dimethylcarbamoyl-4-methoxycarbonyl-3-[5-(*N*-3-aminopyridin-4-yl)aminomethylthien-2-oyl]indole.

To a solution of SnCl₂ in methanol (30 mL) was added in 2 mL portions a solution in 2:1 methanol, CH₂Cl₂ of the 3-[5-(*N*-3-nitropyridin-4-yl)aminomethylthien-2-oyl]indole prepared in step 4 (1.18 g), and the reaction mixture was stirred for 3 hours at ambient temperature. The reaction mixture was partitioned between CH₂Cl₂ and saturated aqueous NaHCO₃. The resulting emulsion was filtered after which layers formed. The layers were separated and the organic phase was dried over MgSO₄, filtered, and concentrated *in vacuo* to give 1-*N,N*-dimethylcarbamoyl-4-methoxycarbonyl-3-[5-(*N*-3-aminopyridin-4-yl)aminomethylthien-2-oyl]indole (1.73 g) which was used without further purification.

Step 6: 1-*N,N*-Dimethylcarbamoyl-methoxycarbonyl-3-{5-[(1*H*-2-methylimidazo[4,5-*c*]pyrid-1-yl)methyl]thien-2-oyl}indole.

A mixture of the 1-*N,N*-dimethylcarbamoyl-4-methoxycarbonyl-3-[5-(*N*-3-aminopyridin-4-yl)aminomethylthien-2-oyl]indole prepared in step 5, acetic acid (20 mL), and acetic anhydride (20 mL) were stirred overnight at reflux. The reaction mixture was cooled to ambient temperature, quenched by dropwise addition of methanol (30 mL), and concentrated *in vacuo*. The residue was partitioned between saturated aqueous NaHCO₃ and CH₂Cl₂. The organic phase was dried over MgSO₄, filtered, and concentrated *in vacuo* to give 0.83 g of red-brown gum. Chromatography on silica gel (99:1 CH₂Cl₂, triethylamine, then 97:2:1 CH₂Cl₂, methanol, triethylamine) gave 1-*N,N*-dimethylcarbamoyl-methoxycarbonyl-3-{5-

[(1H-2-methylimidazo[4,5-c]pyrid-1-yl)methyl]thien-2-oyl}indole (0.14 g) as a brown solid.

Step 7: 1-N,N-Dimethylcarbamoyl-methoxycarbonyl-3-{5-[(1H-2-

5 methylimidazo[4,5-c]pyrid-1-yl)methyl]thien-2-oyl}indole hydrochloride.

A solution of 1-N,N-dimethylcarbamoyl-methoxycarbonyl-3-{5-[(1H-2-methylimidazo[4,5-c]pyrid-1-yl)methyl]thien-2-oyl}indole (0.125 g), prepared in step 6, in THF was swirled with activated carbon and filtered. To the filtrate was added 4 M HCl/dioxane (0.07 mL). 1-N,N-dimethylcarbamoyl-methoxycarbonyl-3-{5-[(1H-2-methylimidazo[4,5-c]pyrid-1-yl)methyl]thien-2-oyl}indole hydrochloride (71 mg)
10 was isolated as a light brown powder by filtration. ¹H NMR (DMSO-d₆, 300 MHz) δ 8.84 (s, 1H), 8.36 (d, 1H, J = 6 Hz), 8.30 (s, 1H), 7.97 (dd, 1H, J = 1, 9 Hz), 7.73 (dd, 1H, J = 1, 6 Hz), 7.68 (d, 1H, J = 5 Hz), 7.57 (dd, 1H, J = 1, 7 Hz), 7.46 (m, 1H), 7.22 (d, 1H, J = 5 Hz), 5.84 (s, 2H), 3.54 (s, 3H), 3.04 (s, 6H), 2.68 (s,
15 3H). MS (DCI/NH₃) m/e 502 (M+H)⁺, 371, 151. IR cm⁻¹ (microscope) 3400 (br), 2970, 2950, 2600, 1700, 1640, 1515, 1485. Anal calcd for C₂₅H₂₃N₅O₄S · HCl · C₄H₁₀O · 1.5 H₂O: C, 56.37; H, 5.83; N, 10.96. Found: C, 56.22; H, 6.05; N, 11.08.

Example 99

20 Preparation of 1-N,N-Dimethylcarbamoyl-6-(4-fluorophenyl)-3-{4-[(1H-2-methylimidazo[4,5-c]pyrid-1-yl)methyl]phenylaminocarbonyl}indole hydrochloride.
Step 1: 4-(1H-2-Methylimidazo[4,5-c]pyrid-1-yl)methyl)nitrobenzene.

To a suspension in CH₃CN (700 mL) of 1H-2-methylimidazo[4,5-c]pyridine (5.04 g, 37.9 mmol), prepared as in Example 3, step 1, was added tris[2-(2-methoxyethoxy)ethyl]amine (1.3 mL, 4.1 mmol) and KOH (10.6 g, 190 mmol). The
25 suspension was stirred at ambient temperature for 90 minutes and then 4-nitrobenzyl bromide (8.23 g, 38.1 mmol) was added and stirring was continued for 2 hours. The reaction mixture was partitioned between ethyl acetate and pH 7 buffer. The organic phase was dried over MgSO₄, filtered, and concentrated *in vacuo*. Chromatography
30 on silica gel (5% methanol/CH₂Cl₂) gave 4-(1H-2-methylimidazo[4,5-c]pyrid-1-yl)methyl)nitrobenzene (1.07 g) as a tan solid.

Step 2: 4-(1H-2-Methylimidazo[4,5-c]pyrid-1-yl)methyl)aniline.

A suspension of 4-(1H-2-methylimidazo[4,5-c]pyrid-1-yl)methyl)nitrobenzene
35 (1.04 g, 3.9 mmol), prepared as in step 1, and SnCl₂ (3.25 g, 19.9 mmol) in 8:2 ethyl acetate, methanol (100 mL) was stirred vigorously for two hours at ambient

temperature. The reaction mixture poured into 1N aqueous NaOH and extracted twice with ethyl acetate and once with CH₂Cl₂. The combined organic layers were dried over MgSO₄, filtered, and concentrated *in vacuo* to give 0.91 g of an orange foam. The foam was dissolved in 30 mL of methanol and SnCl₂ (3.7 g) was added.
5 After stirring for 3 hours, the reaction was worked up as above to give 0.79 g of 4-(1H-2-methylimidazo[4,5-c]pyrid-1-ylmethyl)aniline as an orange oil.

Step 3: 6-(4-Fluorophenyl)indole-2-carboxaldehyde.

The desired compound was prepared by Vilsmeier formylation of 6-(4-fluorophenyl)indole using DMF and oxalyl chloride.
10

Step 4: 1-N, N-Dimethylcarbamoyl-6-(4-fluorophenyl)indole-2-carboxaldehyde.

The desired compound was prepared by reaction of 6-(4-fluorophenyl)indole-2-carboxaldehyde with KOH and *N,N*-dimethylcarbamoyl chloride in THF/DMF as described in Example 2.
15

Step 5: 6-(4-Fluorophenyl)indole-2-carboxylic acid.

To a solution in THF (25 mL) and *tert*-butyl alcohol (70 mL) of 1-*N,N*-dimethylcarbamoyl-6-(4-fluorophenyl)indole-2-carboxaldehyde, prepared as in step 4,
20 was added 2-methyl-2-butene (2M in THF, 8 mL, 16 mmol), followed by a solution of NaClO₂ (1.2 g, 13 mmol) and NaH₂PO₄ (2.4 g, 17 mmol) in H₂O (20 mL). After stirring overnight at ambient temperature, a solution of NaClO₂ (0.25 g) and NaH₂PO₄ (0.50 g) in H₂O (10 mL) was added and the reaction mixture was stirred
25 for 2 hours. The organic solvents were stripped off *in vacuo* and the residue was extracted with ether. The aqueous phase was taken to pH 3 with concentrated HCl, the water was decanted, and the residue was taken up in ethyl acetate. The ethyl acetate solution was dried over MgSO₄, filtered, and concentrated *in vacuo* to give a dark-brown oil (0.53 g). The oil was dissolved in THF and treated with activated carbon. Filtration and concentration *in vacuo* gave 6-(4-fluorophenyl)indole-2-carboxylic acid (0.426 g, 93%) as a red solid.
30

Step 6: 1-N, N-Dimethylcarbamoyl-6-(4-fluorophenyl)-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]phenylaminocarbonyl}indole.

To a solution in THF (6 mL) of 6-(4-fluorophenyl)indole-2-carboxylic acid
35 (0.103 g, 0.32 mmol), prepared as in step 5, was added diisopropylethylamine (0.10 mL, 0.57 mmol) and bis(2-oxo-3-oxazolidinyl)phosphinic chloride (0.095 g, 0.37

90

mmol), and the reaction mixture was stirred at ambient temperature for 15 minutes. A solution of 4-(1H-2-methylimidazo[4,5-c]pyrid-1-ylmethyl)aniline (0.108 g, 0.45 mmol), prepared as in step 2, in THF (4 mL) was added and the reaction mixture was stirred for 15 hours at ambient temperature. The reaction mixture was partitioned
5 between CH₂Cl₂ and saturated aqueous NaHCO₃. The organic phase was dried over Na₂SO₄, filtered, and concentrated in vacuo to give a tan solid (0.165 g). Chromatography on silica gel (7% methanol, ethyl acetate) gave a mixture of desired compound and starting aniline. Gradient elution on the HPLC (5% to 90% acetonitrile/H₂O with 1% trifluoroacetic acid) gave 1-*N,N*-dimethylcarbamoyl-6-(4-fluorophenyl)-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]phenylaminocarbonyl}indole (13 mg).
10

Step 7: 1-*N,N*-Dimethylcarbamoyl-6-(4-fluorophenyl)-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]phenylaminocarbonyl}indole hydrochloride.

15 The desired compound was prepared by treating a solution of 1-*N,N*-dimethylcarbamoyl-6-(4-fluorophenyl)-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]phenylaminocarbonyl}indole, prepared as in step 6, in CH₂Cl₂/CDCl₃ with 4N HCl/dioxane. ¹H NMR (CDCl₃, 300 MHz) δ 8.97 (s, 1H), 8.38 (d, 1H, J = 6 Hz), 8.06 (d, 1H, J = 7 Hz), 7.97 (s, 1H), 7.92 (s, 1H), 7.70 (s, 1H), 7.59 (d, 2H, J = 7 Hz), 7.53 (m, 2H), 7.46 (m, 1H), 7.09 (m, 2H), 6.99 (d, 2H, J = 7 Hz), 5.27
20 (s, 2H, 3.05 (s, 6H), 2.59 (s, 3H). MS (DCI/NH₃) m/e 547 (M+H)⁺.

Example 100

Preparation of 1-*N,N*-Dimethylcarbamoyl-5-(4-fluorophenyl)-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole.

25 The desired compound was prepared according to the method of Example 4, except substituting 5-(4-fluorophenyl)indole for 6-(4-fluorophenyl)indole, and using KI instead of NaBr in step 3. mp 198-203 °C. ¹H NMR (CDCl₃, 300 MHz) δ 2.63 (s, 3H), 3.10 (s, 6H), 5.41 (s, 2H), 7.12 (d, 1H, J = 8.4 Hz), 7.15 (t, 2H, J = 8.4 Hz), 7.20 (d, 1H, J = 6.0 Hz), 7.58 (d, 2H, J = 1.5 Hz), 7.61 (d, 1H, J = 5.1 Hz),
30 7.64 (d, 1H, J = 5.1 Hz), 7.76 (s, 1H), 7.83 (d, 2H, J = 8.4 Hz), 8.38 (d, 1H, J = 6.0 Hz), 8.57 (t, 1H, J = 1.3 Hz), 9.06 (s, 1H). MS (DCI/NH₃) m/e 532 (M+H)⁺. Anal calcd for C₃₂H₂₆N₅O₂F · 0.3 C₄H₈O₂: C, 71.46; H, 5.13; N, 12.55. Found: C, 71.58; H, 5.17; N, 12.77.

35

Example 101

Preparation of 1-*N,N*-Dimethylcarbamoyl-6-(4-fluorophenyl)-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]phenylsulfonyl}indole.

Step 1: 3-(4-Methylthiophenyl)-6-(4-fluorophenyl)indole.

5 The desired compound was prepared according to the method of Example 57, step 1, except substituting 6-(4-fluorophenyl)indole for indole.

Step 2: 1-*tert*-Butoxycarbonyl-3-(4-methylthiophenyl)-6-(4-fluorophenyl)indole.

10 To a suspension in CH₃CN (40 mL) of 3-(4-methylthiophenyl)-6-(4-fluorophenyl)indole (6.75 g, 20.2 mmol), prepared as in step 1, was added di-*tert*-butyldicarbonate (4.94 g, 22.6 mmol) and 4-dimethylaminopyridine (250 mg, 2.05 mmol). The reaction mixture was stirred for 15 minutes at ambient temperature during which time significant gas evolution occurred and the reaction mixture became a clear solution. The solvent was removed *in vacuo* and the residue was taken up in ethyl acetate. The ethyl acetate solution was washed with H₂O, 1M aqueous NaHSO₄, H₂O, and brine, dried over Na₂SO₄, filtered, and concentrated *in vacuo*.
15 Chromatography on silica gel (1% then 2% ethyl acetate/hexane), followed by crystallization from ether/hexane gave 1-*tert*-butoxycarbonyl-3-(4-methylthiophenyl)-6-(4-fluorophenyl)indole (8.05 g, 92% yield). mp 123.7-124.4 °C.

20 Step 3: 1-*tert*-Butoxycarbonyl-3-(4-methylphenylsulfonyl)-6-(4-fluorophenyl)indole.

 To a 0 °C solution in CH₂Cl₂ (200 mL) of 1-*tert*-butoxycarbonyl-3-(4-methylthiophenyl)-6-(4-fluorophenyl)indole (8.03 g, 18.5 mmol), prepared as in step 1, was added 3-chloroperbenzoic acid (80%, 8.2 g, 38 mmol). The cold bath was removed and the reaction mixture was stirred for 1 hour. Aqueous 2N Na₂CO₃ (50 mL) was added and the layers separated. The organic phase was washed with H₂O, dried over Na₂SO₄, filtered, and concentrated *in vacuo*. Chromatography on silica gel (10%, then 20% ethyl acetate/hexane), followed by crystallization from ether/hexane gave 1-*tert*-butoxycarbonyl-3-(4-methylphenylsulfonyl)-6-(4-fluorophenyl)indol
25 (5.99 g), mp 134.6-135.3 °C.
30

Step 4: 1-*N,N*-Dimethylcarbamoyl-6-(4-fluorophenyl)-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]phenylsulfonyl}indole.

 The desired compound was prepared according to the method of Example 56,
35 steps 4-9, except substituting 1-*tert*-butoxycarbonyl-3-(4-methylphenylsulfonyl)-6-(4-fluorophenyl)indol, prepared as in step 3, for 1-phenylsulfonyl-3-[(4-

bromomethyl)phenylsulfonyl]indole. ^1H NMR (CDCl_3 , 300 MHz) δ 2.54 (s, 3H), 3.13 (s, 6H), 5.37 (s, 2H), 7.11 (d, 2H, $J = 8.4$ Hz), 7.13 (d, 2H, $J = 8.4$ Hz), 7.14 (d, 1H, $J = 8.4$ Hz), 7.47-7.58 (c, 3H), 7.75 (d, 1H, $J = 1.5$ Hz), 7.92 (d, 1H, $J = 8.4$ Hz), 8.00 (d, 2H, $J = 8.4$ Hz), 8.35 (d, 1H, $J = 3.6$ Hz), 9.03 (s, 1H). MS (DCI/ NH_3) m/e 568 ($\text{M}+\text{H}$) $^+$. Anal calcd for $\text{C}_{31}\text{H}_{26}\text{N}_5\text{O}_3\text{SF} \cdot 0.40$ ethyl acetate: C, 64.95; H, 4.88; N, 11.62. Found: C, 64.85; H, 4.73; N, 11.72.

Example 102

Preparation of 1-*N,N*-Dimethylcarbamoyl-4-bromo-3-{4-[(1*H*-2-methylimidazo[4,5-
10 c]pyrid-1-yl)methyl]benzoyl}indole.

Step 1: 1-*N,N*-Dimethylcarbamoyl-4-bromo-3-(4-chloromethylbenzoyl)indole.

The desired compound was prepared according to the method of Example 4, steps 1 and 2, except substituting 4-bromoindole for 6-(4-fluorophenyl)indole.

15 Step 2: 1-*N,N*-Dimethylcarbamoyl-4-bromo-3-(4-azidomethylbenzoyl)indole.

To a solution in DMF (40 mL) of 1-*N,N*-dimethylcarbamoyl-4-bromo-3-(4-chloromethylbenzoyl)indole (12.54 g, 31 mmol), prepared as in Step 1, was added sodium azide (2.15 g, 33 mmol). The reaction mixture was stirred for 3 hours at ambient temperature and then was diluted with H_2O and extracted twice with ethyl acetate. The combined organic extracts were washed twice with H_2O , once with
20 brine, dried over Na_2SO_4 , filtered, and concentrated *in vacuo* to give 1-*N,N*-dimethylcarbamoyl-4-bromo-3-(4-azidomethylbenzoyl)indole (16.0 g) which was used without further purification.

25 Step 3: 1-*N,N*-Dimethylcarbamoyl-4-bromo-3-(4-aminomethylbenzoyl)indole.

To a solution of the 1-*N,N*-dimethylcarbamoyl-4-bromo-3-(4-azidomethylbenzoyl)indole prepared in step 2 (16.0 g) in THF (60 mL) was added triphenylphosphine (8.7 g, 33 mmol) and H_2O (30 mL) and the reaction mixture was stirred overnight at ambient temperature. The reaction mixture was evaporated to dryness and the residue was dissolved in THF (100 mL). 4N HCl/dioxane (8 mL)
30 was added followed by ether (100 mL) to form a gummy solid which was left standing overnight. The liquid was decanted and the solid was dissolved in H_2O . The aqueous solution was extracted with ethyl acetate. The ethyl acetate extract was discarded and the aqueous phase was made basic with aqueous 2N Na_2CO_3 and
35 extracted three times with ethyl acetate. The combined organic extracts were washed with H_2O and brine, dried over Na_2SO_4 , filtered, and concentrated *in vacuo* to give 1-

N,N-dimethylcarbamoyl-4-bromo-3-(4-aminomethylbenzoyl)indole (13.65 g) which was used without further purification.

5 Step 4: 1-*N,N*-Dimethylcarbamoyl-4-bromo-3-(4-(*N*-3-nitropyridin-4-yl)aminomethylbenzoyl)indole.

A mixture of the 1-*N,N*-dimethylcarbamoyl-4-bromo-3-(4-aminomethylbenzoyl)indole prepared in step 3 (13.65 g) and 4-ethoxy-3-nitropyridine (5.10 g, 30.3 mmol) in CH₃CN (50 mL) was heated at reflux for 50 hours during which time 46 mL of solvent distilled out. To the thick residue was added toluene (50 mL) and the mixture was heated at a rate such that 21 mL of solvent distilled off over 2 hours. The reaction mixture was cooled to ambient temperature and diluted with ethyl acetate (30 mL). The solution was placed directly on a silica gel column and eluted with 50%, then 80% ethyl acetate/toluene to give 1-*N,N*-dimethylcarbamoyl-4-bromo-3-(4-(*N*-3-nitropyridin-4-yl)aminomethylbenzoyl)indole (6.76 g), mp 173.5-174.5 °C after crystallization from ethyl acetate/ether.

Step 5: 1-*N,N*-Dimethylcarbamoyl-4-bromo-3-{4-[(1*H*-2-methylimidazo[4,5-*c*]pyrid-1-yl)methyl]benzoyl}indole.

The desired compound (4.72 g), was prepared according to the method of Example 57, step 8, except substituting 1-*N,N*-dimethylcarbamoyl-4-bromo-3-(4-(*N*-3-nitropyridin-4-yl)aminomethylbenzoyl)indole, prepared as in step 4, for 3-[(4-(*N*-3-nitropyrid-4-yl)aminomethyl)phenylsulfonyl]indole and crystallization from CH₂Cl₂/ethyl acetate. mp 232.5-234 °C. ¹H NMR (DMSO-*d*₆, 300 MHz) δ 2.56 (s, 3H), 3.01 (s, 6H), 5.63 (s, 2H), 7.27 (d, 2H, *J* = 8.4 Hz), 7.28 (t, 1H, *J* = 8.4 Hz), 7.47 (dd, 1H, *J* = 8.4, 0.3 Hz), 7.57 (dd, 1H, *J* = 5.7, 0.3 Hz), 7.69 (dd, 1H, *J* = 8.4, 0.3 Hz), 7.86 (d, 2H, *J* = 8.4 Hz), 8.03 (s, 1H), 8.38 (d, 1H, *J* = 5.7 Hz), 8.84 (d, 1H, *J* = 0.3 Hz). MS (DCI/NH₃) *m/e* 516, 518 (M+H)⁺. Anal calcd for C₂₆H₂₂N₅O₂Br: C, 60.47; H, 4.29; N, 13.56. Found: C, 60.21; H, 4.29; N, 13.38.

30 **Example 103**

Preparation of 1-*N,N*-Dimethylcarbamoyl-4-acetyl-3-{4-[(1*H*-2-methylimidazo[4,5-*c*]pyrid-1-yl)methyl]benzoyl}indole.

To a 20-mL pressure bottle were added 1-*N,N*-dimethylcarbamoyl-4-bromo-3-{4-[(1*H*-2-methylimidazo[4,5-*c*]pyrid-1-yl)methyl]benzoyl}indole (212 mg, 0.41 mmol), prepared as in Example 102, tetrakis(triphenylphosphine)palladium(0) (27 mg, 0.023 mmol), butyl vinyl ether (208 mg, 2.1 mmol), triethylamine (87 mg, 0.86

mmol), and dioxane (5 mL). The bottle was flushed thoroughly with N₂, sealed, and heated at 130 °C for 24 hours. The reaction mixture was cooled to ambient temperature and placed directly on a silica gel column eluting with 7% methanol, CH₂Cl₂ to give 193 mg of the intermediate enol ether. The enol ether was stirred for 5 30 minutes in 90% trifluoroacetic acid. The reaction mixture was diluted with H₂O and concentrated *in vacuo*. The residue was partitioned between 5% aqueous NaHCO₃ and CH₂Cl₂. The organic phase was washed with H₂O and brine, dried over Na₂SO₄, filtered, and concentrated *in vacuo*. 1-*N,N*-dimethylcarbamoyl-4-acetyl-3-
10 {4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole (131 mg) was obtained by chromatography on silica gel (8% methanol/CH₂Cl₂). ¹H NMR (DMSO-d₆, 300 MHz) δ 2.40 (s, 3H), 2.58 (s, 3H), 3.03 (s, 6H), 5.64 (s, 2H), 7.27 (d, 2H, J = 8.4 Hz), 7.45 (dd, 1H, J = 7.8, 8.1 Hz), 7.57 (dd, 1H, J = 7.8, 0.6 Hz), 7.59 (d, 1H, J = 6.6 Hz), 7.84 (d, 2H, J = 8.4 Hz), 7.84 (dd, 1H, J = 8.1, 0.6 Hz), 8.09 (s, 1H), 8.30 (d, 1H, J = 6.6 Hz), 8.87 (s, 1H). MS (DCI/NH₃) m/e 480
15 (M+H)⁺. Anal calcd for C₂₈H₂₅N₅O₃ · 1.4 H₂O: C, 66.63; H, 5.55; N, 13.87. Found: C, 66.75; H, 5.70; N, 13.87.

Example 104

Preparation of 1-*N,N*-Dimethylcarbamoyl-4-(fur-2-yl)-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole.

20 To a 20-mL pressure bottle were added tri(*n*-butyl)-(fur-2-yl)stannane (160 mg, 0.45 mmol), 1-*N,N*-dimethylcarbamoyl-4-bromo-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole (153 mg, 0.30 mmol), prepared as in Example 102, tetrakis(triphenylphosphine)palladium(0) (21 mg, 0.018
25 mmol), and dioxane (5 mL). The bottle was flushed thoroughly with N₂, sealed, and heated at 115 °C for 2.5 hours. The reaction mixture was cooled to ambient temperature, filtered, and concentrated *in vacuo*. The residue was chromatographed on silica gel (7% methanol, CH₂Cl₂). The resulting material was taken up in ethyl acetate, and the solution was warmed, diluted with ether, filtered, and concentrated *in vacuo*. Chromatography on silica gel twice (5% methanol/CH₂Cl₂) gave pure 1-*N,N*-
30 dimethylcarbamoyl-4-(fur-2-yl)-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole (94 mg). ¹H NMR (DMSO-d₆, 300 MHz) δ 2.53 (s, 3H), 3.03 (s, 6H), 5.57 (s, 2H), 6.17 (dd, 1H, J = 3.9, 3.6 Hz), 6.36 (dd, 1H, J = 3.9, 0.9 Hz), 7.13 (d, 2H, J = 8.7 Hz), 7.26 (dd, 1H, J = 2.4, 0.9 Hz), 7.34 (dd, 1H, J = 8.4, 2.1 Hz), 7.39 (t, 1H, J = 8.4 Hz), 7.57 (dd, 1H, J = 6.3, 1.2 Hz), 7.66 (dd,
35 1H, J = 8.4, 2.1 Hz), 7.67 (d, 2H, J = 8.7 Hz), 8.01 (s, 1H), 8.31 (d, 1H, J = 6.3

95

Hz), 8.86 (s, 1H). MS (DCI/NH₃) m/e 504 (M+H)⁺. Anal calcd for C₃₀H₂₅N₅O₃ · 0.2 ethyl acetate · 0.2 H₂O: C, 70.49; H, 5.19; N, 13.35. Found: C, 70.30; H, 5.10; N, 13.30.

Example 105

5 Preparation of 1-*N,N*-Dimethylcarbamoyl-4-(benzo[b]fur-2-yl)-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole.

The desired compound was prepared according to the method of Example 104, except substituting tri(*n*-butyl)-(benzo[b]fur-2-yl)stannane for tri(*n*-butyl)-(fur-2-yl)stannane. ¹H NMR (DMSO-d₆, 300 MHz) δ 2.49 (s, 3H), 3.07 (s, 6H), 5.47 (s, 2H), 6.87 (s, 1H), 6.91 (dd, 1H, J = 7.8, 1.2 Hz), 6.98 (d, 2H, J = 8.7 Hz), 7.04 (dd, 1H, J = 6.0, 1.2 Hz), 7.08 (td, 1H, J = 6.0, 1.2 Hz), 7.33 (dt, 1H, J = 9.3, 1.2 Hz), 7.47 (t, 1H, J = 7.8 Hz), 7.50 (dd, 1H, J = 6.0, 1.2 Hz), 7.55 (dd, 1H, J = 6.6, 1.2 Hz), 7.58 (d, 2H, J = 8.7 Hz), 7.78 (dd, 1H, J = 9.3, 1.2 Hz), 8.10 (s, 1H), 8.32 (d, 1H, J = 6.6 Hz), 8.87 (s, 1H). Anal calcd for C₃₄H₂₇N₅O₃ · 0.4 ethyl acetate · 0.5 H₂O: C, 71.52; H, 5.26; N, 11.71. Found: C, 71.43; H, 5.35; N, 11.67.

Example 106

20 Preparation of 1-*N,N*-Dimethylcarbamoyl-4-(trimethylsilylethynyl)-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole.

The desired compound was prepared by heating a mixture of trimethyl-(trimethylsilylethynyl)stannane (58 mg, 0.232 mmol), 1-*N,N*-dimethylcarbamoyl-4-bromo-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole (100 mg, 0.194 mmol), prepared as in Example 102, tetrakis(triphenylphosphine)palladium(0) (16 mg), and toluene (7 mL) were heated in a pressure bottle at 120 °C for 4 hours as described in Example 103. The reaction mixture was cooled to ambient temperature, filtered, and concentrated *in vacuo*. Chromatography on silica gel (CH₂Cl₂, then 5% methanol/CH₂Cl₂) gave 1-*N,N*-dimethylcarbamoyl-4-(trimethylsilylethynyl)-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole (58 mg). ¹H NMR (DMSO-d₆, 300 MHz) δ 0.00 (s, 9H), 2.60 (s, 3H), 3.05 (s, 6H), 5.68 (s, 2H), 7.33 (d, 2H, J = 9 Hz), 7.37-7.40 (m, 1H), 7.62 (d, 1H, J = 6 Hz), 7.70-7.78 (m, 1H), 7.90 (d, 2H, J = 9 Hz), 8.04 (s, 1H), 8.33 (d, 1H, J = 6 Hz), 8.88 (s, 1H). MS (DCI/NH₃) m/e 534 (M+H)⁺. Anal calcd for C₃₁H₃₁N₅O₂Si · 0.75 H₂O: C, 67.83; H, 5.94; N, 12.41. Found: C, 68.04; H, 5.98; N, 12.79.

Example 107Preparation of 1-*N,N*-Dimethylcarbamoyl-4-ethynyl-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole.

- To a solution in 40:20 THF/CH₃CN of 1-*N,N*-dimethylcarbamoyl-4-(trimethylsilylethynyl)-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole (0.39 g, 0.73 mmol), prepared as in Example 106, was added CsF (0.56 g, 3.66 mmol) and the reaction mixture was stirred for 16 hours at ambient temperature. The reaction mixture was filtered and the filtrate was washed with brine, dried over MgSO₄, filtered, and concentrated *in vacuo* to give 1-*N,N*-dimethylcarbamoyl-4-ethynyl-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole (0.29 g). ¹H NMR (DMSO-*d*₆, 300 MHz) δ 2.55 (s, 3H), 3.00 (s, 6H), 4.04 (s, 1H), 5.64 (s, 2H), 7.25 (d, 2H, *J* = 9 Hz), 7.30-7.42 (m, 2H), 7.58 (d, 1H, *J* = 6 Hz), 7.73 (d, 1H, *J* = 9 Hz), 7.85 (d, 2H, *J* = 9 Hz), 8.04 (s, 1H), 8.29 (d, 1H, *J* = 6 Hz), 8.86 (s, 1H). MS (DCI/NH₃) *m/e* 462 (M+H)⁺.
- Anal calcd for C₂₈H₂₃N₅O₂ · 2.0 H₂O: C, 67.21; H, 5.20; N, 13.53. Found: C, 67.59; H, 5.46; N, 14.07.

Example 108Preparation of 4-(4-Fluorophenyl)-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole.

- To a solution in DMF (6 mL) of 1-*N,N*-dimethylcarbamoyl-4-bromo-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole (200 mg, 0.38 mmol), prepared as in Example 102, was added tetrakis(triphenylphosphine)palladium(0) (22 mg) and the solution was stirred for 30 minutes. A solution of 4-fluorophenylboronic acid (80 mg, 0.57 mmol) in DMF (2 mL) was added, followed by saturated aqueous NaHCO₃ (4 mL). The reaction mixture was stirred at 90 °C for 4 hours and 40 °C for 48 hours. Additional tetrakis(triphenylphosphine)palladium(0) (22 mg) was added and the reaction mixture was stirred at 115 °C for 4 hours. The reaction mixture was cooled to ambient temperature, diluted with H₂O, and extracted three times with ethyl acetate. The combined organic layers were dried over MgSO₄, filtered, and concentrated *in vacuo*. Chromatography on silica gel (5% methanol/CH₂Cl₂) gave 4-(4-fluorophenyl)-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole as a white solid (111 mg). ¹H NMR (DMSO-*d*₆, 300 MHz) δ 2.60 (s, 3H), 3.04 (s, 6H), 5.58 (s, 2H), 6.85 (t, 2H, *J* = 9 Hz), 7.05-7.13 (m, 5H), 7.43 (t, 1H, *J* = 9 Hz), 7.50 (d, 2H, *J* = 9 Hz), 7.60 (d, 1H, *J* = 6 Hz), 7.68 (d, 1H, *J* = 9 Hz), 8.01 (s, 1H), 8.30 (bs, 1H),

97

8.88 (bs, 1H). MS (DCI/NH₃) m/e 532 (M+H)⁺. Anal calcd for C₃₂H₂₆N₅O₂F: 0.75 H₂O: C, 70.51; H, 5.08; N, 12.84. Found: C, 70.23; H, 5.16; N, 12.54.

Example 109

5 Preparation of 1-*N,N*-Dimethylcarbamoyl-4-chloro-3-{4-[(1*H*-2-methylimidazo[4,5-*c*]pyrid-1-yl)methyl]benzoyl}indole.

Step 1: 4-Chloro-3-(4-chloromethylbenzoyl)indole.

The desired compound was prepared according to the method of Example 90, step 2, except substituting 4-chloroindole for 4,7-dimethoxycarbonylindole.

10

Step 2: 1-*N,N*-Dimethylcarbamoyl-4-chloro-3-(4-chloromethylbenzoyl)indole.

The desired compound was prepared by reaction of 4-chloro-3-(4-chloromethylbenzoyl)indole, prepared as in step 1, with KOH and *N,N*-dimethylcarbamoyl chloride in THF/DMF as described in Example 2.

15

Preparation of 1-*N,N*-Dimethylcarbamoyl-4-chloro-3-{4-[(1*H*-2-methylimidazo[4,5-*c*]pyrid-1-yl)methyl]benzoyl}indole.

The desired compound was prepared according to the method of Example 90, step 3, except substituting 1-*N,N*-dimethylcarbamoyl-4-chloro-3-(4-chloromethylbenzoyl)indole, prepared as in step 2, for 4,7-dimethoxycarbonyl-3-(4-chloromethylbenzoyl)indole. ¹H NMR (DMSO-d₆, 300 MHz) δ 2.56 (s, 3H), 3.01 (s, 6H), 5.65 (s, 2H), 7.28 (d, 2H, J = 8.4 Hz), 7.25-7.40 (m, 2H), 7.59 (dd, 1H, J = 6.0, 1.2 Hz), 7.65 (dd, 1H, J = 7.8, 1.2 Hz), 7.86 (d, 2H, J = 8.1 Hz), 8.05 (s, 1H), 8.29 (d, 1H, J = 5.4 Hz), 8.85 (s, 1H). MS (DCI/NH₃) m/e 472 (M+H)⁺.

25 Anal calcd for C₂₆H₂₂ClN₅O₂ · 1.3 H₂O: C, 63.04; H, 5.01; N, 14.14. Found: C, 62.92; H, 4.62; N, 13.97.

Example 110

Preparation of 1-*N,N*-Dimethylcarbamoyl-4-fluoro-3-{4-[(1*H*-2-methylimidazo[4,5-*c*]pyrid-1-yl)methyl]benzoyl}indole.

30 The desired compound was prepared according to the method of Example 109, except substituting 4-fluoroindole for 4-chloroindole. ¹H NMR (DMSO-d₆, 300 MHz) δ 2.57 (s, 3H), 3.00 (s, 6H), 5.66 (s, 2H), 7.08 (dd, 1H, J = 11.1, 6.9 Hz), 7.29 (d, 2H, J = 8.4 Hz), 7.37 (dt, 1H, J = 8.1, 5.1 Hz), 7.46 (d, 1H, J = 7.8 Hz), 7.62 (dd, 1H, J = 5.7, 1.0 Hz), 7.86 (d, 2H, J = 8.7 Hz), 8.04 (s, 1H), 8.31 (d, 35 1H, J = 5.4 Hz), 8.87 (s, 1H). MS (DCI/NH₃) m/e 456 (M+H)⁺. Anal calcd for

98

$C_{26}H_{22}FN_5O_2 \cdot 0.2$ ethyl acetate $\cdot 0.8 H_2O$: C, 66.03; H, 5.21; N, 14.37. Found: C, 66.16; H, 5.27; N, 14.08.

Example 111

Preparation of 1-*N,N*-Dimethylcarbamoyl-2-methyl-3-{4-[(1*H*-2-methylimidazo[4,5-
c]pyrid-1-yl)methyl]benzoyl}indole.

The desired compound was prepared according to the method of Example 109, except substituting 2-methylindole for 4-chloroindole. 1H NMR (DMSO- d_6 , 300 MHz) δ 2.35 (s, 3H), 2.57 (s, 3H), 5.64 (s, 2H), 6.99 (dt, 1H, $J = 8.1, 1.0$ Hz), 7.11 (dt, 1H, $J = 8.1, 1.0$ Hz), 7.2-7.3 (m, 3H), 7.38 (d, 1H, $J = 8.1$ Hz), 7.58 (d, 2H, $J = 8.1$ Hz), 7.55-7.65 (m, 1H), 8.31 (d, 1H, $J = 5.4$ Hz), 8.86 (s, 1H). MS (DCI/ NH_3) m/e 381 ($M+H$) $^+$. Anal calcd for $C_{24}H_{20}N_4O \cdot 0.4 H_2O$: C, 74.36; H, 5.41; N, 14.45. Found: C, 74.25; H, 5.35; N, 14.4.

Example 112

Preparation of 1,4-di-*N,N*-Dimethylcarbamoyl-3-{4-[(1*H*-2-methylimidazo[4,5-
c]pyrid-1-yl)methyl]benzoyl}indole.

The desired compound was prepared according to the method of Example 109, except substituting 4-*N,N*-dimethylcarbamoylindole for 4-chloroindole. 1H NMR (DMSO- d_6 , 300 MHz) δ 2.58 (s, 3H), 2.76 (s, 3H), 2.82 (s, 3H), 3.01 (s, 6H), 5.65 (s, 2H), 7.15 (dd, 1H, $J = 7.2, 1$ Hz), 7.28 (apparent d, 2H, $J = 8.4$ Hz), 7.35-7.45 (m, 1H), 7.62 (d, 1H, $J = 5.4$ Hz), 7.67 (apparent d, 2H, $J = 8.4$ Hz), 8.04 (s, 1H), 8.30 (d, 1H, $J = 5.4$ Hz), 8.86 (s, 1H). MS (DCI/ NH_3) m/e 509 ($M+H$) $^+$. Anal calcd for $C_{29}H_{28}N_6O_3 \cdot 1.4 H_2O$: C, 65.52; H, 5.82; N, 15.74. Found: C, 65.59; H, 6.02; N, 14.58.

Example 113

Preparation of 1-*N,N*-Dimethylcarbamoyl-5-methoxycarbonyl-3-{4-[(1*H*-2-methylimidazo[4,5-
c]pyrid-1-yl)methyl]benzoyl}indole.

The desired compound was prepared according to the method of Example 109, except substituting 5-methoxycarbonylindole for 4-chloroindole. 1H NMR (DMSO- d_6 , 300 MHz) δ 2.65 (s, 3H), 3.08 (s, 6H), 3.96 (s, 3H), 5.44 (s, 2H), 7.19 (d, 2H, $J = 8.1$ Hz), 7.29 (d, 1H, $J = 5.7$ Hz), 7.57 (d, 1H, $J = 9.0$ Hz), 7.78 (s, 1H), 7.84 (d, 2H, $J = 8.1$ Hz), 8.11 (dd, 1H, $J = 9.0, 1.5$ Hz), 8.42 (d, 1H, $J = 5.7$ Hz), 9.05 (d, 1H, $J = 1.5$ Hz), 9.06 (s, 1H). MS (DCI/ NH_3) m/e 513 ($M+NH_4$) $^+$. Anal calcd for $C_{28}H_{25}N_5O_4 \cdot 0.7 EtOAc$: C, 66.39; H, 5.54; N, 12.57. Found: C, 66.36; H, 5.20; N, 12.47.

Example 114**Preparation of 1-*N,N*-Dimethylcarbamoyl-4-methoxycarbonyl-6-(4-fluorophenyl)-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole.**

The desired compound was prepared according to the method of Example 109, except substituting 4-methoxycarbonyl-6-(4-fluorophenyl)indole for 4-chloroindole. ¹H NMR (DMSO-*d*₆, 300 MHz) δ 2.57 (s, 3H), 3.04 (s, 6H), 3.48 (s, 3H), 5.64 (s, 2H), 7.25-7.35 (m, 4H), 7.59 (d, 1H, *J* = 6.4 Hz), 7.75-7.80 (m, 3H), 7.85 (apparent d, 2H, *J* = 8.1 Hz), 8.04 (d, 1H, *J* = 1.7 Hz), 8.14 (s, 1H), 8.30 (d, 1H, *J* = 5.2 Hz), 8.85 (s, 1H). MS (DCI/NH₃) *m/e* 590 (M+H)⁺. Anal calcd for C₃₄H₂₈N₅O₄F · 1.4 H₂O: C, 66.42; H, 5.05; N, 11.39. Found: C, 66.41; H, 4.96; N, 10.91.

Example 115**Preparation of 4-Methoxycarbonyl-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole.**

To a 0 °C solution in methanol (4 mL) of 1-*N,N*-dimethylcarbamoyl-4-methoxycarbonyl-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole, (164 mg, 0.33 mmol), prepared as in Example 44, was added aqueous 1*N* NaOH (0.9 mL, 0.9 mmol) and the reaction mixture was stirred for 1 hour. The reaction mixture was partitioned between CH₂Cl₂ and saturated aqueous NH₄Cl. The aqueous phase was acidified with 1*N* aqueous HCl and extracted 4 times with CH₂Cl₂. The combined organic layers were dried over MgSO₄, filtered, and concentrated *in vacuo* to give 4-methoxycarbonyl-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole (140 mg) as a white solid. ¹H NMR (DMSO-*d*₆, 300 MHz) δ 2.58 (s, 3H), 3.51 (s, 3H), 5.63 (s, 2H), 7.2-7.35 (m, 3H), 7.40 (dd, 1H, *J* = 7.3, 1.1 Hz), 7.60 (dd, 1H, *J* = 5.5, 1.1 Hz), 7.69 (dd, 1H, *J* = 8.1, 1.1 Hz), 7.79 (apparent d, 2H, *J* = 8.1 Hz), 7.89 (s, 1H), 8.30 (d, 1H, *J* = 5.6 Hz), 8.86 (s, 1H), 12.17 (br s, 1H). MS (DCI/NH₃) *m/e* 425 (M+H)⁺.

Example 116**Preparation of 4-Methoxycarbonyl-1-(pyrrolidin-1-ylcarbonyl)-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole.**

To a 0 °C solution in 1:1 THF/DMF (2 mL) of 4-methoxycarbonyl-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole (111 mg, 0.26 mmol), prepared as in Example 115 was added NaH (9.0 mg, 0.39 mmol). After 5 minutes, 1-pyrrolidine carbonyl chloride (42 mg, 0.31 mmol) was added and the yellow suspension was stirred for 1 hour at 0 °C. The reaction mixture was partitioned

100

between ethyl acetate and brine. The aqueous phase was extracted twice with ethyl acetate. The combined organic layers were washed twice with H₂O, dried over MgSO₄, filtered, and concentrated *in vacuo*. Chromatography on silica gel gave 4-methoxycarbonyl-1-(pyrrolidin-1-ylcarbonyl)-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole (101 mg) as a white solid. ¹H NMR (DMSO-d₆, 300 MHz) δ 1.7-1.8 (br m, 4H), 2.57 (s, 3H), 3.46 (s, 3H), 3.5-3.6 (br m, 4H), 5.64 (s, 2H), 7.28 (apparent d, 2H, J = 8.4 Hz), 7.4-7.5 (m, 1H), 7.55-7.65 (m, 2H), 7.85 (apparent d, 2H, J = 8.4 Hz), 7.98 (dd, 1H, J = 8.4, 1.2 Hz), 8.19 (s, 1H), 8.30 (d, 1H, J = 5.4 Hz), 8.86 (s, 1H). MS (DCI/NH₃) m/e 522 (M+H)⁺.

Example 117

Preparation of 1-N,N-Dimethylcarbamoyl-4-benzyloxycarbonyl-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole.

The desired compound was prepared according to the method of Example 109, except substituting 4-benzyloxycarbonylindole for 4-chloroindole. ¹H NMR (DMSO-d₆, 300 MHz) δ 2.6 (s, 3H), 3.01 (s, 6H), 5.01 (s, 2H), 5.67 (s, 2H), 7.0-7.2 (m, 5H), 7.29 (apparent d, 2H, J = 8.1 Hz), 7.4-7.5 (m, 1H), 7.6-7.7 (m, 2H), 7.86 (apparent d, 2H, J = 8.4 Hz), 8.10 (s, 1H), 8.31 (d, 1H, J = 5.4 Hz), 8.87 (s, 1H). MS (DCI/NH₃) m/e 572 (M+H)⁺. Anal calcd for C₃₄H₂₉N₅O₄ · 1.1 H₂O: C, 69.05; H, 5.32; N, 11.84. Found: C, 69.27; H, 5.29; N, 11.26.

Example 118

Preparation of 1-N,N-Dimethylcarbamoyl-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole-4-carboxylic acid.

The desired compound (46 mg) was prepared by hydrogenolysis (1 atm H₂, 10% palladium on carbon, 7:3 methanol, CH₂Cl₂) of 1-N,N-dimethylcarbamoyl-4-benzyloxycarbonyl-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole, prepared as in Example 117. ¹H NMR (DMSO-d₆, 300 MHz) δ 2.55 (s, 3H), 3.02 (s, 6H), 5.62 (s, 2H), 7.25 (d, 2H, J = 8.4 Hz), 7.4-7.5 (m, 1H), 7.55-7.65 (m, 2H), 7.81 (d, 2H, J = 8.4 Hz), 7.8-7.9 (m, 1H), 8.03 (s, 1H), 8.30 (d, 1H, J = 5.7 Hz), 8.85 (s, 1H), 12.62 (br s, 1H). MS (DCI/NH₃) m/e 482 (M+H)⁺.

Example 119Preparation of 1-*N,N*-Dimethylcarbamoyl-4-(*N*-nonylcarbamoyl)-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole.

To a suspension of 1-*N,N*-dimethylcarbamoyl-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole-4-carboxylic acid (100 mg, 0.21 mmol), prepared as in Example 118, was added 1-aminononane (46 μ L, 0.25 mmol), and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (48 mg, 0.25 mmol), and the resulting clear solution was stirred for 24 hours at ambient temperature. The reaction mixture was partitioned between CH₂Cl₂ and brine. The aqueous phase was extracted with CH₂Cl₂. The combined organic layers were dried over MgSO₄, filtered, and concentrated *in vacuo*. The residue was purified directly by reverse-phase HPLC (25-60% CH₃CN/H₂O with 0.1% trifluoroacetic acid) to give 1-*N,N*-dimethylcarbamoyl-4-(*N*-nonylcarbamoyl)-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole (33 mg). ¹H NMR (DMSO-*d*₆, 300 MHz) δ 0.85 (t, 3H, *J* = 6.3 Hz), 1.1-1.3 (m, 14H), 2.57 (s, 3H), 2.82 (q, 2H, *J* = 6.3 Hz), 3.01 (s, 6H), 5.62 (s, 2H), 7.25 (d, 2H, *J* = 8.1 Hz), 7.29 (dd, 1H, *J* = 7.5, 1.0 Hz), 7.3-7.4 (m, 1H), 7.61 (d, 1H, *J* = 5.4 Hz), 7.71 (dd, 1H, *J* = 8.1, 1.0 Hz), 7.77 (d, 2H, *J* = 8.1 Hz), 7.97 (s, 1H), 8.16 (t, 1H, *J* = 5.4 Hz), 8.30 (d, 1H, *J* = 5.7 Hz), 8.86 (s, 1H). MS (DCI/NH₃) *m/e* 607 (M+H)⁺.

Example 120Preparation of 1-*N,N*-Dimethylcarbamoyl-4-(dec-1-yloxy carbonyl)-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole.

To a solution in DMF (4 mL) of 1-*N,N*-dimethylcarbamoyl-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole-4-carboxylic acid (200 mg, 0.42 mmol), prepared as in Example 118, was added NaHCO₃ (70 mg, 0.83 mmol) and decyl bromide (0.43 mL, 2.07 mmol). The resulting white suspension was stirred for 72 hours at ambient temperature and then partitioned between CH₂Cl₂ and brine. The aqueous phase was extracted twice with CH₂Cl₂. The combined organic layers were dried over MgSO₄, filtered, and concentrated *in vacuo*. Chromatography on silica gel (10% methanol/CH₂Cl₂) gave 1-*N,N*-dimethylcarbamoyl-4-(dec-1-yloxy carbonyl)-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole (65 mg). ¹H NMR (DMSO-*d*₆, 300 MHz) δ 0.83 (t, 3H, *J* = 6.6 Hz), 1.0-1.35 (m, 16H), 2.57 (s, 3H), 3.02 (s, 6H), 3.90 (t, 2H, *J* = 6.6 Hz), 5.64 (s, 2H), 7.30 (d, 2H, *J* = 8.1 Hz), 7.4-7.5 (m, 1H), 7.5-7.6 (m, 2H), 7.86 (dd, 1H, *J* = 8.1, 1.2 Hz), 7.88 (d, 2H, *J* = 8.4 Hz), 8.10 (s, 5.7 Hz), 8.29 (d, 1H, *J* = 5.7 Hz), 8.85 (s, 1H).

102

MS (DCI/NH₃) m/e 622 (M+H)⁺. Anal calcd for C₃₇H₄₃N₅O₄ · 0.4 H₂O: C, 70.65; H, 7.11; N, 10.90. Found: C, 70.65; H, 7.02; N, 11.13.

Example 121

5 Preparation of 1-N,N-Dimethylcarbamoyl-4-methoxy-3-{4-[(1H-2-methylimidazo[4,5-c]pyrid-1-yl)methyl]benzoyl}indole.

The desired compound was prepared according to the method of Example 109, except substituting 4-methoxyindole for 4-chloroindole. ¹H NMR (DMSO-d₆, 300 MHz) δ 2.6 (s, 3H), 3.03 (s, 6H), 3.49 (s, 3H), 5.63 (s, 2H), 6.7 (d, 1H, J = 7.5 Hz), 7.18-7.3 (m, 4H), 7.63 (d, 1H, J = 6 Hz), 7.74 (d, 2H, J = 7.5 Hz), 7.85 (s, 1H), 8.31 (d, 1H, J = 6 Hz), 8.88 (s, 1H). MS (DCI/NH₃) m/e 468 (M⁺). Anal calcd for C₂₇H₂₅N₅O₃ · 0.75 H₂O: C, 67.41; H, 5.55; N, 14.55. Found: C, 67.71; H, 5.34; N, 13.64.

Example 122

15 Preparation of 1-N,N-Dimethylcarbamoyl-4-methyl-3-{4-[(1H-2-methylimidazo[4,5-c]pyrid-1-yl)methyl]benzoyl}indole.

The desired compound was prepared according to the method of Example 109, except substituting 4-methylindole for 4-chloroindole. ¹H NMR (DMSO-d₆, 300 MHz) δ 2.57 (s, 3H), 2.96 (s, 6H), 5.64 (s, 2H), 7.05 (d, 1H, J = 6 Hz), 7.25 (d, 1H, J = 6 Hz), 7.27-7.32 (m, 2H), 7.45 (d, 1H, J = 6 Hz), 7.58 (d, 1H, J = 3 Hz), 7.83 (d, 1H, J = 3 Hz), 7.85 (d, 2H, J = 6 Hz), 8.30 (d, 1H, J = 3 Hz), 8.84 (s, 1H). MS (DCI/NH₃) m/e 452 (M+H)⁺. Anal calcd for C₂₇H₂₅N₅O₂ · 0.5 H₂O: C, 70.56; H, 5.73; N, 14.73. Found: C, 70.41; H, 5.69; N, 15.20.

Example 123

25 Preparation of 1-N,N-Dimethylcarbamoyl-4-methoxycarbonyl-3-[(1H-2-methylimidazo[4,5-c]pyrid-1-yl)hex-6-ylcarbonyl]indole.

The desired compound was prepared according to the method of Example 109, except substituting 4-methoxycarbonylindole for 4-chloroindole, and 7-bromoheptanoyl chloride for 4-bromomethylbenzoyl chloride. ¹H NMR (DMSO-d₆, 300 MHz) δ 1.25-1.45 (m, 4H), 1.6-1.8 (m, 4H), 2.57 (s, 3H), 2.87 (t, 2H, J = 7.4 Hz), 3.05 (s, 3H), 3.73 (s, 3H), 4.20 (t, 2H, J = 7.4 Hz), 7.4-7.45 (narrow m, 2H), 7.56 (dd, 1H, J = 5.4, 0.6 Hz), 7.7-7.8 (complex m, 1H), 8.25 (d, 1H, J = 5.4 Hz), 8.59 (s, 1H), 8.79 (d, 1H, J = 0.6 Hz). MS (DCI/NH₃) m/e 490 (M+H)⁺. Anal calcd for C₂₇H₃₁N₅O₄ · 0.6 H₂O: C, 64.81; H, 6.49; N, 14.00. Found: C, 64.91; H, 6.32; N, 13.92.

103

Example 124

Preparation of 1-*N,N*-Dimethylcarbamoyl-4-methoxycarbonyl-3-{4-[(1*H*-2-methylbenzimidazolyl)methyl]benzoyl}indole.

- The desired compound was prepared according to the method of Example 109, except substituting 2-methylbenzimidazole for 1*H*-2-methylimidazo[4,5-*c*]pyridine. ¹H NMR (DMSO-*d*₆, 300 MHz) δ 2.54 (s, 3H), 3.02 (s, 6H), 3.47 (s, 3H), 5.59 (s, 2H), 7.1-7.2 (m, 2H), 7.26 (d, 2H, *J* = 8.1 Hz), 7.4-7.6 (m, 4H), 7.8-7.9 (m, 3H), 8.10 (s, 1H). MS (DCI/NH₃) *m/e* 495 (M+H)⁺.

10

Example 125

Preparation of 4-Methoxycarbonyl-1-(pyrrolidin-1-ylcarbonyl)-3-{4-[(1*H*-2-methylbenzimidazolyl)methyl]benzoyl}indole.

- The desired compound was prepared according to the method of Example 109, except substituting 1-pyrrolidine carbonyl chloride for *N,N*-dimethylcarbamoyl chloride in step 2, and substituting 2-methylbenzimidazole for 1*H*-2-methylimidazo[4,5-*c*]pyridine in step 3. ¹H NMR (DMSO-*d*₆, 300 MHz) δ 1.8-1.9 (m, 4H), 2.54 (s, 3H), 3.46 (s, 3H), 3.5-3.6 (m, 4H), 5.60 (s, 2H), 7.1-7.2 (complex m, 2H), 7.27 (d, 2H, *J* = 8.4 Hz), 7.4-7.6 (m, 4H), 7.84 (d, 2H, *J* = 8.1 Hz), 7.97 (dd, 1H, *J* = 8.4, 1.2 Hz), 8.18 (s, 1H). MS (DCI/NH₃) *m/e* 521 (M+H)⁺. Anal calcd for C₃₁H₂₈N₄O₄ · 0.1 H₂O · 0.4 CH₂Cl₂: C, 67.79; H, 5.25; N, 10.07. Found: C, 67.70; H, 5.11; N, 9.97.

20

Example 126

Preparation of 1-*N,N*-Dimethylcarbamoyl-4-methoxycarbonyl-3-[(1*H*-2-methylimidazo[4,5-*c*]pyrid-1-yl)pent-5-ylcarbonyl]indole.

- The desired compound was prepared according to the method of Example 109, except substituting 4-methoxycarbonylindole for 4-chloroindole, and 6-bromohexanoyl chloride for 4-bromomethylbenzoyl chloride. ¹H NMR (DMSO-*d*₆, 300 MHz) δ 1.3-1.4 (m, 2H), 1.66 (quint, 2H, *J* = 7.5 Hz), 1.77 (quint, 2H, *J* = 7.5 Hz), 2.58 (s, 3H), 2.88 (t, 2H, *J* = 7.2 Hz), 3.04 (s, 6H), 3.70 (s, 3H), 4.21 (t, 2H, *J* = 7.2 Hz), 7.40-7.45 (m, 2H), 7.56 (dd, 1H, *J* = 5.2, 1.1 Hz), 7.8-7.8 (m, 1H), 8.25 (d, 1H, *J* = 5.7 Hz), 8.59 (s, 1H), 8.79 (s, 1H). MS (DCI/NH₃) *m/e* 476 (M+H)⁺. Anal calcd for C₂₆H₂₉N₅O₄ · 0.5 H₂O: C, 64.45; H, 6.24; N, 14.45. Found: C, 64.41; H, 5.99; N, 14.20.

35

104

Example 127

Preparation of 1-*N,N*-Dimethylcarbamoylmethyl-4-methoxycarbonyl-3-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl]indole.

- The desired compound was prepared according to the method of Example 109, except substituting 2-chloro-*N,N*-dimethylacetamide for *N,N*-dimethylcarbamoyl chloride in step 2, and 4-methoxycarbonylindole for 4-chloroindole in step 3. ¹H NMR (DMSO-*d*₆, 300 MHz) δ 2.59 (s, 3H), 2.84 (s, 3H), 3.08 (s, 3H), 3.58 (s, 3H), 5.30 (s, 2H), 5.64 (s, 2H), 7.25-7.45 (m, 4H), 7.6-7.7 (m, 2H), 7.78 (apparent d, 2H, *J* = 8.1 Hz), 7.86 (s, 1H), 8.31 (d, 1H, *J* = 5.4 Hz), 8.86 (s, 1H). MS (DCI/NH₃) *m/e* 510 (M+H)⁺. Anal calcd for C₂₉H₂₇N₅O₄ · 1.5 H₂O: C, 64.91; H, 5.64; N, 13.05. Found: C, 64.75; H, 5.64; N, 13.05.

Example 128

Preparation of 1-*N,N*-Dimethylcarbamoyl-4-methoxycarbonyl-3-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl]indole.

- The desired compound was prepared according to the method of Example 109, except substituting 4-methoxycarbonylindole for 4-chloroindole, and 5-iodopentanoyl chloride for 4-bromomethylbenzoyl chloride. ¹H NMR (DMSO-*d*₆, 300 MHz) δ 1.59-1.70 (m, 2H), 1.75-1.85 (m, 2H), 2.60 (s, 3H), 2.95 (t, 2H, *J* = 9 Hz), 3.04 (s, 3H), 3.60 (s, 3H), 4.28 (t, 2H, *J* = 9 Hz), 7.42 (d, 2H, *J* = 6 Hz), 7.62 (d, 1H, *J* = 6 Hz), 7.74-7.80 (m, 1H), 8.26 (d, 1H, *J* = 6 Hz), 8.60 (s, 1H), 8.80 (s, 1H). MS (DCI/NH₃) *m/e* 462 (M⁺). Anal calcd for C₂₅H₂₇N₅O₄ · 1.0 H₂O: C, 62.63; H, 6.16; N, 14.00. Found: C, 62.61; H, 6.09; N, 14.60.

Example 129

Preparation of 1-*N,N*-Dimethylcarbamoyl-4-methoxycarbonyl-3-{4-[(2-methyl-4-(3*H*)quinazolinone-3-yl)methyl]benzoyl}indole.

Step 1: 1-*N,N*-Dimethylcarbamoyl-4-methoxycarbonyl-3-(4-chloromethylbenzoyl)indole.

- The desired compound was prepared according to the method of Example 109, steps 1 and 2, except substituting 4-carboxymethylcarbonylindole for 4-chloroindole.

Step 2: 1-*N,N*-Dimethylcarbamoyl-4-methoxycarbonyl-3-{4-[(2-methyl-4-(3*H*)quinazolinone-3-yl)methyl]benzoyl}indole.

- To a solution of 2-methyl-4-(3*H*)quinazolinone (120 mg, 0.75 mmol) in DMF (2 mL) was added lithium hexamethyldisilazide (1.0 M in THF, 0.83 mL, 0.83 mmol)

105

and a solution in DMF (2 mL) of 1-*N,N*-dimethylcarbamoyl-4-methoxycarbonyl-3-(4-chloromethylbenzoyl)indole (300 mg, 0.75 mmol), prepared as in step 1, and LiBr (65 mg). The clear-brown solution was stirred for 20 hours at ambient temperature and then was partitioned between saturated aqueous NH₄Cl and ethyl acetate. The aqueous phase was extracted twice with ethyl acetate. The combined organic layers were washed three times with H₂O, dried over MgSO₄, filtered, and concentrated *in vacuo*. Chromatography on silica gel (10%, then 20% acetone/CH₂Cl₂) and reverse phase HPLC (30-65% CH₃CN, H₂O with 0.1% trifluoroacetic acid) gave 1-*N,N*-dimethylcarbamoyl-4-methoxycarbonyl-3-{4-[(2-methyl-4-(3H)quinazolinone-3-yl)methyl]benzoyl}indole (203 mg). ¹H NMR (DMS)-d₆, 300 MHz) δ 2.52 (s, 3H), 3.03 (s, 6H), 3.51 (s, 3H), 5.49 (s, 2H), 7.37 (d, 2H, J = 8.1 Hz), 7.4-7.6 (m, 3H), 7.65 (d, 1H, J = 8.1 Hz), 7.8-7.9 (m, 2H), 7.87 (d, 2H, J = 8.1 Hz), 8.15 (s, 1H), 8.1-8.2 (m, 1H). MS (DCI/NH₃) m/e 523 (M+H)⁺. Anal calcd for C₃₀H₂₆N₄O₅ · 0.3 CH₂Cl₂: C, 66.41; H, 4.89; N, 10.22. Found: C, 66.32; H, 4.97, N, 9.73.

Example 130

Preparation of 1-(2-Ethoxyethyl)-4-methoxycarbonyl-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole.

To a solution in 1:1 THF, DMF (30 mL) of 4-methoxycarbonyl-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole (0.13 g, 0.31 mmol), prepared as in Example 115, was added NaH (95%, 9.3 mg, 0.37 mmol) and the reaction mixture was stirred for 15 minutes. Neat 2-bromoethyl ethyl ether (90%, 87 μL, 0.80 mmol) was added and stirring was continued for 48 hours. The reaction was quenched with saturated aqueous NH₄Cl and extracted twice with ethyl acetate. The combined organic extracts were dried over MgSO₄, filtered, and concentrated *in vacuo*. Chromatography on silica gel gave 1-(2-ethoxyethyl)-4-methoxycarbonyl-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole (83 mg) as a white solid. ¹H NMR (DMSO-d₆, 300 MHz) δ 0.95 (t, 3H, J = 7.5 Hz), 2.58 (s, 3H), 3.35 (q, 2H, J = 6 Hz), 3.55 (s, 3H), 3.68 (t, 2H, J = 6 Hz), 4.45 (t, 2H, J = 6 Hz), 5.65 (s, 2H), 7.28 (d, 2H, J = 9 Hz), 7.34-7.45 (m, 2H), 7.63 (dd, 1H, J = 2, 6 Hz), 7.80 (d, 2H, J = 9 Hz), 7.85 (dd, 1H, J = 2, 8 Hz), 7.94 (s, 1H), 8.33 (d, 1H, J = 6 Hz), 8.87 (s, 1H). MS (DCI/NH₃) m/e 497 (M+H)⁺. Anal calcd for C₂₉H₂₈N₄O₄ · 0.5 H₂O: C, 68.89; H, 5.78; N, 11.08. Found: C, 68.97; H, 5.64; N, 10.82.

106

Example 131

Preparation of 1-*N,N*-Dimethylsulfamoyl-4-methoxycarbonyl-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole.

The desired compound was prepared according to the method of Example 130, except substituting *N,N*-dimethylsulfamoyl chloride for 2-bromoethyl ethyl ether. ¹H NMR (DMSO-*d*₆, 300 MHz) δ 2.57 (s, 3H), 2.88 (s, 6H), 3.44 (s, 3H), 5.65 (s, 2H), 7.28 (d, 2H, J = 9 Hz), 7.53 (d, 1H, J = 9 Hz), 7.60 (d, 1H, J = 6 Hz), 7.68 (d, 1H, J = 8 Hz), 7.85 (d, 2H, J = 9 Hz), 8.08(s, 1H), 8.20 (d, 1H, J = 8 Hz), 8.30 (d, 1H, J = 6 Hz), 8.87(s, 1H). MS (DCI/NH₃) *m/e* 532 (M⁺). Anal calcd for C₂₇H₂₅N₅O₅S · 0.25 H₂O: C, 60.49; H, 4.79; N, 13.06. Found: C, 60.69; H, 5.09; N, 12.87.

Example 132

Preparation of 1-*iso*-Propyl-4-methoxycarbonyl-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole.

The desired compound was prepared according to the method of Example 130, except substituting 1-iodo-2-methylpropane for 2-bromoethyl ethyl ether. ¹H NMR (DMSO-*d*₆, 300 MHz) δ 0.84 (d, 6H, J = 6 Hz), 2.08-2.2 (m, 1H), 2.60 (s, 3H), 3.54 (s, 3H), 4.13 (d, 2H, J = 7 Hz), 5.63 (s, 2H), 7.28 (d, 2H, J = 9 Hz), 7.3-7.45 (m, 2H), 7.63 (d, 1H, J = 6 Hz), 7.80 (d, 2H, J = 9 Hz), 7.85 (d, 1H, J = 9 Hz), 7.98 (s, 1H), 8.33 (d, 1H, J = 6 Hz), 8.87(s, 1H). MS (DCI/NH₃) *m/e* 481 (M+H)⁺. Anal calcd for C₂₉H₂₈N₄O₃ · 0.75 H₂O: C, 70.49; H, 6.01; N, 11.33. Found: C, 70.48; H, 5.85; N, 11.54.

Example 133

Preparation of 1-Methoxycarbonylmethyl-4-methoxycarbonyl-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole.

The desired compound was prepared according to the method of Example 130, except substituting methyl bromoacetate for 2-bromoethyl ethyl ether. ¹H NMR (DMSO-*d*₆, 300 MHz) δ 2.60 (s, 3H), 3.55 (s, 3H), 3.68 (s, 3H), 5.30 (s, 2H), 5.65 (s, 2H), 7.28 (d, 1H, J = 9 Hz), 7.31-7.40 (m, 1H), 7.45 (d, 1H, J = 9 Hz), 7.62 (d, 1H, J = 6 Hz), 7.77-7.81(m, 3H), 7.99 (s, 1H), 8.31 (d, 1H, J = 6 Hz), 8.87 (s, 1H). MS (DCI/NH₃) *m/e* 497 (M+H)⁺. Anal calcd for C₂₈H₂₄N₄O₅ · 0.25 H₂O: C, 67.12; H, 4.92; N, 11.18. Found: C, 67.17; H, 5.05; N, 10.79.

107

Example 134

Preparation of 1-(2-Propanesulfonyl)-4-methoxycarbonyl-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole.

The desired compound was prepared according to the method of Example 130, except substituting 2-propanesulfonyl chloride for 2-bromoethyl ethyl ether. ¹H NMR (DMSO-d₆, 300 MHz) δ 1.25 (d, 6H, J = 6 Hz), 2.58 (s, 3H), 3.43 (s, 3H), 3.97-4.08 (m, 1H), 5.65 (s, 2H), 7.28 (d, 2H, J = 9 Hz), 7.55-7.60 (m, 2H), 7.70 (d, 1H, J = 8 Hz), 7.84 (d, 2H, J = 9 Hz), 8.04 (s, 1H), 8.18 (d, 1H, J = 9 Hz), 8.30 (d, 1H, J = 6 Hz), 8.88 (s, 1H). MS (DCI/NH₃) 531 (M⁺). Anal calcd for C₂₈H₂₆N₄O₅S · 0.5 H₂O: C, 62.32; H, 5.04; N, 10.38. Found: C, 62.55; H, 5.02; N, 10.12.

Example 135

Preparation of 1-(1-Pinacolyl)-4-methoxycarbonyl-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole.

The desired compound was prepared according to the method of Example 130, except substituting 1-chloropinacolone for 2-bromoethyl ethyl ether. mp 122-127 °C. ¹H NMR (DMSO-d₆, 300 MHz) δ 1.23 (s, 9H), 2.60 (s, 3H), 3.58 (s, 3H), 5.57 (s, 2H), 5.65 (s, 2H), 7.30 (d, 2H, J = 9 Hz), 7.35 (d, 1H, J = 9 Hz), 7.43 (d, 1H, J = 6 Hz), 7.54 (d, 1H, J = 9 Hz), 7.62 (d, 1H, J = 6 Hz), 7.80 (d, 2H, J = 9 Hz), 7.88 (s, 1H), 8.30 (bs, 1H), 8.87 (bs, 1H). MS (DCI/NH₃) m/e 523 (M⁺). Anal calcd for C₃₁H₃₀N₄O₄ · 0.75 H₂O: C, 69.45; H, 5.92; N, 10.45. Found: C, 69.45; H, 6.17; N, 10.14.

Example 136

Preparation of 1-Carbamoyl-4-methoxycarbonyl-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole.

Step 1: 1-(4-Nitrophenoxycarbonyl)-4-methoxycarbonyl-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole.

The desired compound was prepared by addition of NaH and 4-nitrophenyl chloroformate to a solution in DMF of 4-methoxycarbonyl-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole, prepared as in Example 115.

Step 2: 1-Carbamoyl-4-methoxycarbonyl-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole.

Liquid ammonia (10 drops) was condensed into a -78 °C solution in THF (12 mL) of 1-(4-nitrophenoxycarbonyl)-4-methoxycarbonyl-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole (259 mg), prepared as in step

108

1. The resulting clear-yellow solution was stirred for 20 minutes at -78 °C, then saturated aqueous NH₄Cl was added and the reaction mixture was warmed to ambient temperature and extracted with ethyl acetate. The organic phase was dried over MgSO₄, filtered, and concentrated *in vacuo* to give 32 mg of 1-carbamoyl-4-methoxycarbonyl-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole as a white solid. ¹H NMR (DMSO-d₆, 300 MHz) δ 2.58 (s, 3H), 3.45 (s, 3H), 5.65 (s, 2H), 7.29 (d, 2H, J = 9 Hz), 7.45 (t, 1H, J = 9 Hz), 7.58 (t, 2H, J = 6 Hz), 8.3-7.9 (m, 4H), 8.3 (d, 1H, J = 6 Hz), 8.34 (s, 1H), 8.55 (dd, 1H, J = 3, 9 Hz), 8.86 (s, 1H). MS (FAB) m/e 468 (M+H)⁺.

Example 137

Preparation of 1-N-Methylcarbamoyl-4-methoxycarbonyl-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole.

The desired compound was prepared according to the method of Example 136, except substituting methylamine for ammonia. ¹H NMR (DMSO-d₆, 300 MHz) δ 2.60 (s, 3H), 2.82 (d, 3H, J = 6 Hz), 3.46 (s, 3H), 5.65 (s, 2H), 7.30 (d, 2H, J = 9 Hz), 7.48 (t, 1H, J = 9 Hz), 7.59 (dd, 1H, J = 3, 9 Hz), 7.61 (d, 1H, J = 6 Hz), 7.87 (d, 2H, J = 9 Hz), 8.28 (s, 1H), 8.31 (d, 1H, J = 6 Hz), 8.44 (d, 1H, J = 6 Hz), 8.52 (dd, 1H, J = 3, 9 Hz), 8.90 (bs, 1H). MS (DCI/NH₃) m/e 425.

Example 138

Preparation of 1-(2-Ethoxyethyl)-4-chloro-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole.

Step 1: 4-Chloro-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole.

The desired compound was prepared according to the method of Example 90, except substituting 4-chloroindole for 4,7-dimethoxycarbonylindole.

Step 2: 1-(2-Ethoxyethyl)-4-chloro-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole.

The desired compound was prepared according to the method of Example 130, except substituting 4-chloro-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole, prepared as in step 1, for 4-methoxycarbonyl-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole. ¹H NMR (DMSO-d₆, 300 MHz) δ 0.95 (t, 3H, J = 9 Hz), 2.57 (s, 3H), 3.2-3.3 (m, 2H), 3.68 (t, 2H, J = 6 Hz), 4.4 (t, 2H, J = 6 Hz), 5.65 (s, 2H), 7.2-7.31 (m, 4H), 7.6 (d, 1H, J = 6 Hz),

109

7.65 (d, 1H, J = 9 Hz), 7.8 (d, 2H, J = 9 Hz), 7.84 (s, 1H), 8.3 (d, 1H, J = 6 Hz), 7.86 (s, 1H). MS (DCI/NH₃) m/e 473 (M+H)⁺. Anal calcd for C₂₇H₂₅ClN₄O₂ · 0.75 H₂O: C, 66.66; H, 5.49; N, 11.51. Found: C, 66.95; H, 5.33; N, 11.60.

5

Example 139

Preparation of 1-N, N-Dimethylcarbamoyl-4-methoxycarbonyl-3-{3-methoxy-4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole.

The desired compound was prepared according to the method of Example 96, except substituting 3-methoxy-4-bromomethylbenzoic acid for 4-chloromethylbenzoic acid. Chromatography on silica gel (CH₂Cl₂, then 2% methanol/CH₂Cl₂) gave 1-N, N-dimethylcarbamoyl-4-methoxycarbonyl-3-{3-methoxy-4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole (120 mg). ¹H NMR (DMSO-d₆, 300 MHz) δ 8.84 (s, 1H), 8.28-8.26 (d, 1H, J = 5.5 Hz), 8.17 (s, 1H), 7.87-7.85 (d, 1H, J = 8.1 Hz), 7.57-7.51 (m, 3H), 7.48-7.45 (d, 1H, J = 8.1 Hz), 7.41-7.38 (d, 1H, J = 7.4 Hz), 5.52 (s, 2H), 3.87 (s, 3H), 3.51 (s, 3H), 3.03 (s, 6H), 2.57 (s, 3H). MS (DCI/NH₃) m/e 526 (M+H)⁺. IR (KBr) 3450, 1700, 1395, 1320, 1300, 1200, 750 cm⁻¹. Anal calcd for C₂₉H₂₇N₅O₅ · 1.0 H₂O: C, 64.07; H, 5.37; N, 12.88. Found: C, 63.91; H, 5.30; N, 12.59.

20

Example 140

Preparation of 1-N, N-Dimethylcarbamoyl-4-methoxycarbonyl-3-{3-methoxy-4-[(3H-2-methylimidazo[4.5-c]pyrid-3-yl)methyl]benzoyl}indole.

The desired compound (230 mg) was isolated from the chromatography described in Example 139. ¹H NMR (DMSO-d₆, 300 MHz) δ 8.80 (s, 1H), 8.29-8.27 (d, 1H, J = 5.5 Hz), 8.17 (s, 1H), 7.88-7.85 (d, 1H, J = 8.5 Hz), 7.56-7.51 (t, 1H, J = 5.4 Hz), 7.48-7.45 (d, 1H, J = 5.4 Hz), 7.43-7.41 (d, 1H, J = 7.5 Hz), 5.58 (s, 2H), 3.87 (s, 3H), 3.51 (s, 3H), 3.03 (s, 6H), 2.60 (s, 3H). MS (DCI/NH₃) m/e 526 (M+H)⁺. Anal calcd for C₂₉H₂₇N₅O₅ · 0.25 H₂O: C, 65.71; H, 5.22; N, 13.21. Found: C, 65.95; H, 5.15; N, 13.53.

30

Example 141

Preparation of 1-N, N-Dimethylcarbamoyl-4-methoxycarbonyl-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]phenylsulfonyl}indole.

Step 1: 3-(4-Methylthiophenyl)-4-methoxycarbonylindole.

35

The desired compound was prepared according to the method of Example 57, step 1, except substituting 4-methoxycarbonylindole for indole.

Step 2: 1-*N,N*-Dimethylcarbamoyl-3-(4-methylthiophenyl)-4-methoxycarbonylindole.

The desired compound was prepared by reaction of 3-(4-methylthiophenyl)-4-methoxycarbonylindole with KOH and *N,N*-dimethylcarbamoyl chloride as described in Example 2.

Step 3: 1-*N,N*-Dimethylcarbamoyl-3-(4-methylphenylsulfonyl)-4-methoxycarbonylindole.

To a solution in acetic acid (50 mL) of 1-*N,N*-dimethylcarbamoyl-3-(4-methylthiophenyl)-4-methoxycarbonylindole (3.5 g, 9.5 mmol), prepared as in step 2, was added OXONE (potassium peroxymonosulfate, 6.2 g, 10 mmol) and the reaction mixture was stirred for 14 hours at ambient temperature. NaIO₄ (1.5 g) was added and the reaction was stirred for 4 hours and then quenched with saturated aqueous Na₂SO₃. Solid Na₂SO₃ was added to the reddish reaction mixture until it remained bright yellow in color. The reaction mixture was diluted with H₂O, made basic with saturated aqueous Na₂CO₃, and extracted three times with CH₂Cl₂. The combined organic extracts were washed with saturated aqueous Na₂CO₃ and brine, dried over MgSO₄, filtered, and concentrated *in vacuo*. Chromatography on silica gel (3%, then 20% methanol/CH₂Cl₂) gave 1.2 g of impure material which was chromatographed again (CH₂Cl₂) to give 1-*N,N*-dimethylcarbamoyl-3-(4-methylphenylsulfonyl)-4-methoxycarbonylindole (0.52 g).

Step 4: 1-*N,N*-Dimethylcarbamoyl-3-[(4-bromomethyl)phenylsulfonyl]-4-methoxycarbonylindole.

To a solution in CCl₄ (50 mL) of 1-*N,N*-dimethylcarbamoyl-3-(4-methylphenylsulfonyl)-4-methoxycarbonylindole (1.9 g, 4.7 mmol), prepared as in step 3, was added *N*-bromosuccinimide (0.85 g, 4.8 mmol) and catalytic benzoyl peroxide. The reaction mixture was stirred at reflux for 14 hours, then cooled to ambient temperature and concentrated *in vacuo*. Chromatography on silica gel (1%, then 3% methanol/CH₂Cl₂) gave 1-*N,N*-dimethylcarbamoyl-3-[(4-bromomethyl)phenylsulfonyl]-4-methoxycarbonylindole (1.5 g) of sufficient purity to use in the next step.

111

Step 5: 1-*N,N*-Dimethylcarbamoyl-4-methoxycarbonyl-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]phenylsulfonyl}indole.

The desired compound was prepared according to the method of Example 90, step 3, except substituting 1-*N,N*-dimethylcarbamoyl-3-[(4-bromomethyl)phenylsulfonyl]-4-methoxycarbonylindole, prepared as in step 4, for 4,7-dimethoxycarbonyl-3-(4-chloromethylbenzoyl)indole. Chromatography on silica gel (1%, then 2% methanol/CH₂Cl₂) gave 1-*N,N*-dimethylcarbamoyl-4-methoxycarbonyl-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]phenylsulfonyl}indole (180 mg). ¹H NMR (DMSO-*d*₆, 300 MHz) δ 8.83 (s, 1H), 8.56 (s, 1H), 8.27-8.25 (d, 1H, *J* = 5.5 Hz), 7.88-7.83 (m, 4H), 7.54-7.52 (d, 1H, *J* = 5.5 Hz), 7.47-7.45 (d, 2H, *J* = 5.1 Hz), 7.31-7.28 (d, 2H, *J* = 8.5 Hz), 5.63 (s, 2H), 3.51 (s, 3H), 3.02 (s, 6H), 2.56 (s, 3H). MS (DCI/NH₃) *m/e* 532 (M+H)⁺. IR (KBr) 3950, 1700, 1600, 1400, 1290 cm⁻¹. Anal calcd for C₂₇H₂₅N₅O₅S · 1.75 H₂O: C, 57.13; H, 5.14; N, 12.33. Found: C, 57.09; H, 4.63; N, 11.76.

Example 142

Preparation of 1-*N,N*-Dimethylcarbamoyl-4-methoxycarbonyl-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]phenylsulfonyl}indole.

The desired compound (130 mg) was isolated from the chromatography described in Example 141. ¹H NMR (DMSO-*d*₆, 300 MHz) δ 8.56 (s, 1H), 8.29-8.27 (d, 1H, *J* = 5.8 Hz), 7.89-7.86 (d, 1H, *J* = 8.5 Hz), 7.84-7.81 (d, 1H, *J* = 5.5 Hz), 7.56-7.54 (d, 1H, *J* = 5.5 Hz), 7.48-7.45 (d, 2H, *J* = 8.0 Hz), 7.36-7.33 (d, 2H, *J* = 8.5 Hz), 5.69 (s, 2H), 3.51 (s, 3H), 3.02 (s, 6H), 2.56 (s, 3H). MS (DCI/NH₃) *m/e* 532 (M+H)⁺. Anal calcd for C₂₇H₂₅N₅O₅S · 1.75 H₂O: C, 57.59; H, 5.10; N, 12.43. Found: C, 57.57; H, 4.75; N, 13.05.

Example 143

Preparation of 1-*N,N*-Dimethylcarbamoyl-4-ethynyl-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole.

The desired compound was prepared by catalytic hydrogenolysis (1 atm. H₂, 10% palladium on carbon, ethanol) of 1-*N,N*-dimethylcarbamoyl-4-ethynyl-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole, prepared as in Example 107. ¹H NMR (DMSO-*d*₆, 300 MHz) δ 1.02 (t, 3H, *J* = 9 Hz), 2.58 (s, 3H), 2.98 (bs, 8H), 5.65 (s, 2H), 7.13 (d, 1H, *J* = 9 Hz), 7.28-7.33 (m, 3H), 7.47 (d, 1H, *J* = 9 Hz), 7.60 (d, 1H, *J* = 6 Hz), 7.85-7.90 (m, 3H), 8.30 (m, 3H), 8.86

112

(s, 1H). MS (DCI/NH₃) m/e 466 (M+H)⁺. Anal calcd for C₂₈H₂₇N₅O₂ · 0.75 H₂O. C, 70.54; H, 6.03; N, 14.27. Found: C, 70.20; H, 5.99; N, 14.61.

Example 144

5 Preparation of 1-*N,N*-Dimethylcarbamoyl-4-hydroxy-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole.

To a solution in CH₂Cl₂ (10 mL) at -78 °C of 1-*N,N*-dimethylcarbamoyl-4-methoxy-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole (94 mg, 0.20 mmol), prepared as in Example 121, was added BBr₃ (1.0 M in CH₂Cl₂, 240 μL, 0.24 mmol), and the reaction mixture was stirred for 30 minutes at -78 °C. The cold bath was removed and the reaction mixture was stirred overnight at ambient temperature. The reaction was quenched by addition of H₂O (5 mL) and the resulting slightly turbid yellow solution was extracted with CH₂Cl₂. The organic phase was washed with brine, dried over MgSO₄, filtered, and concentrated *in vacuo*. The resulting yellow solid was dissolved in acetone (15 mL) and aqueous 1 M HCl (5 mL) was added. The solution was shaken for 5-10 minutes, neutralized with saturated aqueous NaHCO₃, and extracted twice with ethyl acetate. The combined organic extracts were washed with brine, dried over MgSO₄, filtered, and concentrated *in vacuo* to give 1-*N,N*-dimethylcarbamoyl-4-hydroxy-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole (48 mg) as an amorphous yellow solid. mp 99-108 °C. ¹H NMR (DMSO-d₆, 300 MHz) δ 2.60 (s, 3H), 2.98 (s, 6H), 5.68 (s, 2H), 6.68 (d, 1H, J = 9 Hz), 7.03 (d, 1H, J = 9 Hz), 7.25 (d, 1H, J = 9 Hz), 7.28-7.36 (m, 2H), 7.64 (d, 1H, J = 6 Hz), 7.86 (d, 2H, J = 9Hz), 8.15 (s, 1H), 8.34 (bs, 1H), 8.88 (bs, 1H). MS (DCI/NH₃) m/e 454 (M⁺).

25

Example 145

Preparation of 1-*N,N*-Dimethylcarbamoyl-6-bromo-4-methoxycarbonyl-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole.

30 Step 1: 1-*N,N*-Dimethylcarbamoyl-6-bromo-4-methoxycarbonyl-3-(4-(*N*-3-nitropyridin-4-yl)aminomethylbenzoyl)indole.

The desired compound was prepared according to the method of Example 102, steps 1-4, except substituting 6-bromo-4-methoxycarbonylindole for 4-bromoindole.

35

113

Step 2: 1-*N,N*-Dimethylcarbamoyl-6-bromo-4-methoxycarbonyl-3-(4-(*N*-3-aminopyridin-4-yl)aminomethylbenzoyl)indole.

The desired compound was prepared by catalytic hydrogenolysis (4 atm H₂, Raney nickel, THF) of 1-*N,N*-dimethylcarbamoyl-6-bromo-4-methoxycarbonyl-3-(4-(*N*-3-nitropyridin-4-yl)aminomethylbenzoyl)indole, prepared as in step 1.

Step 3: 1-*N,N*-Dimethylcarbamoyl-6-bromo-4-methoxycarbonyl-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole.

The desired compound was prepared by heating a solution of 1-*N,N*-dimethylcarbamoyl-6-bromo-4-methoxycarbonyl-3-(4-(*N*-3-aminopyridin-4-yl)aminomethylbenzoyl)indole (2.53 g), prepared as in step 2, in acetic acid (20 mL) and acetic anhydride (20 mL) as described in Example 57, step 8. ¹H NMR (DMSO-d₆, 300 MHz) δ 2.57 (s, 3H), 3.01 (s, 6H), 3.50 (s, 3H), 5.64 (s, 2H), 7.28 (d, 2H, J = 8.4 Hz), 7.59 (dd, 1H, J = 5.7, 0.6 Hz), 7.67 (d, 1H, J = 2.1 Hz), 7.84 (d, 2H, J = 8.4 Hz), 8.07 (d, 1H, J = 2.1 Hz), 8.17 (s, 1H), 8.30 (d, 1H, J = 5.7 Hz), 8.86 (s, 1H). MS (DCI/NH₃) m/e 576 (M+H)⁺, 574. Anal calcd for C₂₈H₂₄N₅O₄Br · 0.4 ethyl acetate: C, 58.31; H, 4.50; N, 11.49. Found: C, 58.44; H, 4.35; N, 11.21.

Example 146

Preparation of 1-*N,N*-Dimethylcarbamoyl-6-(benzo[b]fur-2-yl)-4-methoxycarbonyl-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole.

The desired compound was prepared according to the method of Example 105, except substituting 1-*N,N*-dimethylcarbamoyl-6-bromo-4-methoxycarbonyl-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole, prepared as in Example 145, for 1-*N,N*-dimethylcarbamoyl-4-bromo-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole. ¹H NMR (DMSO-d₆, 300 MHz) δ 2.57 (s, 3H), 3.07 (s, 6H), 3.53 (s, 3H), 5.66 (s, 2H), 7.29 (t, 1H, J = 8.4 Hz), 7.30 (d, 2H, J = 8.7 Hz), 7.35 (t, 1H, J = 8.4 Hz), 7.62 (d, 1H, J = 5.4 Hz), 7.63 (s, 1H), 7.67 (d, 1H, J = 8.4 Hz), 7.69 (d, 1H, J = 8.4 Hz), 7.88 (d, 2H, J = 8.7 Hz), 8.11 (d, 1H, J = 1.5 Hz), 8.23 (s, 1H), 8.32 (d, 1H, J = 5.4 Hz), 8.35 (d, 1H, J = 1.5 Hz), 8.87 (s, 1H). MS (DCI/NH₃) m/e 612 (M+H)⁺. Anal calcd for C₃₆H₂₉N₅O₃ · 0.4 ethyl acetate · 0.4 H₂O: C, 69.04; H, 5.08; N, 10.71. Found: C, 69.25; H, 4.94; N, 10.69.

114

Example 147

Preparation of 1-*N,N*-Dimethylcarbamoyl-6-(fur-2-yl)-4-methoxycarbonyl-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole.

The desired compound was prepared according to the method of Example 104, except substituting 1-*N,N*-dimethylcarbamoyl-6-bromo-4-methoxycarbonyl-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole, prepared as in Example 145, for 1-*N,N*-dimethylcarbamoyl-4-bromo-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole. ¹H NMR (DMSO-*d*₆, 300 MHz) δ 2.58 (s, 3H), 3.06 (s, 6H), 3.51 (s, 3H), 5.65 (s, 2H), 6.63 (dd, 1H, J = 2.4, 3.6 Hz), 7.11 (d, 1H, J = 3.6 Hz), 7.29 (d, 2H, J = 8.4 Hz), 7.60 (d, 1H, J = 6.3 Hz), 7.79 (d, 1H, J = 1.2 Hz), 7.87 (d, 2H, J = 8.4 Hz), 7.89 (d, 1H, J = 1.2 Hz), 8.10 (d, 1H, J = 2.4 Hz), 8.14 (s, 1H), 8.30 (d, 1H, J = 6.3 Hz), 8.86 (s, 1H). MS (DCI/NH₃) *m/e* 562 (M+H)⁺. Anal calcd for C₃₂H₂₇N₅O₅ · 0.5 ethyl acetate · 0.1 H₂O: C, 67.23; H, 5.18; N, 11.53. Found: C, 67.24; H, 5.03; N, 11.57.

Example 148

Preparation of 1-*N,N*-Dimethylcarbamoyl-4-(*N,N*-dimethylaminocarbonyloxy)-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole.

Step 1: 1-*N,N*-Dimethylcarbamoyl-4-(*N,N*-dimethylaminocarbonyloxy)indole.

The desired compound was prepared by treating 4-hydroxyindole with 2 equivalents of NaH and 2 equivalents of dimethylcarbamyl chloride according to the method of Example 130.

Step 2: 1-*N,N*-Dimethylcarbamoyl-4-(*N,N*-dimethylaminocarbonyloxy)-3-(4-chloromethylbenzoyl)indole.

The desired compound was prepared according to the method of Example 4, step 2, except substituting 1-*N,N*-dimethylcarbamoyl-4-(*N,N*-dimethylaminocarbonyloxy)indole, prepared as in step 1, for 6-(4-fluorophenyl)indole-1-carboxylic acid diamide.

Step 3: 1-*N,N*-Dimethylcarbamoyl-4-(*N,N*-dimethylaminocarbonyloxy)-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole.

The desired compound was prepared according to the method of Example 102, steps 2-5, except substituting 1-*N,N*-dimethylcarbamoyl-4-(*N,N*-dimethylaminocarbonyloxy)-3-(4-chloromethylbenzoyl)indole, prepared as in step 2, for 1-*N,N*-dimethylcarbamoyl-4-bromo-3-(4-chloromethylbenzoyl)indole. ¹H NMR

115

(DMSO-d₆, 300 MHz) δ 2.58 (s, 3H), 2.70 (s, 3H), 2.85 (s, 3H), 3.0 (s, 6H), 5.65 (s, 2H), 6.96 (d, 1H, J = 8 Hz), 7.28 (d, 2H, J = 9 Hz), 7.30-7.38 (m, 1H), 7.50 (d, 1H, J = 9 Hz), 7.60 (d, 1H, J = 6 Hz), 7.80 (d, 2H, J = 9 Hz), 7.94 (s, 1H), 8.30 (d, 1H, J = 6 Hz), 8.87 (s, 1H). MS (DCI/NH₃) m/e 525 (M⁺). Anal calcd for C₂₉H₂₈N₆O₄ · 1.0 H₂O: C, 64.19; H, 5.57; N, 15.48. Found: C, 64.40; H, 5.33; N, 15.38.

Example 149

Preparation of 1-*N,N*-Dimethylcarbamoyl-4-(*N,N*-dimethylaminocarbonylamino)-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole.

10 Step 1: 1-*N,N*-Dimethylcarbamoyl-4-(*N,N*-dimethylaminocarbonylamino)indole.

To a solution of 4-aminoindole (1.0 g, 7.6 mmol) in THF (30 mL) at -78 °C was added lithium hexamethyldisilazide (1.0 M in THF, 7.6 mL, 7.6 mmol). The reaction mixture was stirred for 5 minutes at -78 °C and *N,N*-dimethylcarbamyl chloride (0.74 mL, 8.0 mmol) was added. The cold bath was removed and the reaction mixture was stirred for 80 minutes. The reaction mixture was cooled back to -78 °C and lithium hexamethyldisilazide (1.0 M in THF, 7.6 mL, 7.6 mmol) was added. The reaction mixture was stirred for 10 minutes at -78 °C and *N,N*-dimethylcarbamyl chloride (0.74 mL, 8.0 mmol) was added. The reaction mixture was stirred for 15 minutes at -78 °C, the cold bath was removed and the reaction mixture was warmed to ambient temperature. The reaction was quenched with saturated aqueous NH₄Cl and the mixture was extracted twice with ethyl acetate. The combined organic layers were washed with brine, dried over MgSO₄, filtered, and concentrated *in vacuo*. Chromatography on silica gel (ethyl acetate) gave 1-*N,N*-dimethylcarbamoyl-4-(*N,N*-dimethylaminocarbonylamino)indole (0.96 g).

25

Step 2: 1-*N,N*-Dimethylcarbamoyl-4-(*N,N*-dimethylaminocarbonylamino)-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole.

The desired compound was prepared according to the method of Example 4, steps 2 and 3, except substituting 1-*N,N*-dimethylcarbamoyl-4-(*N,N*-dimethylaminocarbonylamino)indole, prepared as in step 1, for 6-(4-fluorophenyl)indole -1-carboxylic acid diamide. ¹H NMR (DMSO-d₆, 300 MHz) δ 2.58 (s, 3H), 2.93 (s, 6H), 3.00 (s, 6H), 5.63 (s, 2H), 7.13 (d, 1H, J = 6 Hz), 7.28-7.33 (m, 3H), 7.60 (d, 1H, J = 3 Hz), 7.83 (d, 2H, J = 6 Hz), 7.97 (s, 1H), 8.03 (d, 1H, J = 6 Hz), 8.30 (d, 1H, J = 3 Hz), 8.85 (s, 1H), 10.34 (s, 1H). MS (DCI/NH₃) m/e 524 (M+H)⁺. Anal calcd for C₂₉H₂₉N₇O₃ · 1.75 H₂O: C, 62.74; H, 5.90; N, 17.66. Found: C, 62.70; H, 5.57; N, 16.04.

35

Example 150

Preparation of 1-*N,N*-Dimethylcarbamoyl-4-cyano-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole hydrochloride.

5 Step 1: 1*H*-1-(4-Bromobenzyl)-2-methylimidazo[4.5-*c*]pyridine.

The desired compound was prepared according to the method of Example 57, steps 7 and 8, except substituting 4-bromobenzylamine for 1-phenylsulfonyl-3-[(4-aminomethyl)phenylsulfonyl]indole.

10 Step 2: 1*H*-1-(4-Trimethylstannylbenzyl)-2-methylimidazo[4.5-*c*]pyridine.

To a solution under N₂ of 1*H*-1-(4-bromobenzyl)-2-methylimidazo[4.5-*c*]pyridine (3.48 g, 11.5 mmol), prepared as in step 1, and hexamethylditin (7.73 g, 23.6 mmol) in dimethoxyethane (150 mL) was added tetrakis(triphenylphosphine) palladium(0) (660 mg, 0.57 mmol) and the reaction mixture was stirred at reflux for
15 3.5 hours. The reaction mixture was cooled to ambient temperature and filtered. The filtrate was concentrated *in vacuo* and taken up in ethyl acetate. The ethyl acetate solution was washed twice with pH 7 buffer and once with brine. The combined aqueous washings were extracted twice with ethyl acetate. The combined organic extracts were dried over Na₂SO₄, filtered, and concentrated *in vacuo*.
20 Chromatography on silica gel (4% methanol/CHCl₃) followed by trituration with hexane gave 1*H*-1-(4-trimethylstannylbenzyl)-2-methylimidazo[4.5-*c*]pyridine (3.74 g) as soft crystals, mp 123-126 °C.

25 Step 3: 1-*N,N*-Dimethylcarbamoyl-4-cyano-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole hydrochloride.

To a solution of 1-*N,N*-dimethylcarbamoyl-4-cyanoindole-3-carbonyl chloride (prepared by treatment of 566 mg of 1-*N,N*-dimethylcarbamoyl-4-cyanoindole-3-carboxylic acid with thionyl chloride) in THF (20 mL) was added allylpalladium chloride dimer (52 mg, 0.14 mmol) and 1*H*-1-(4-trimethylstannylbenzyl)-2-
30 methylimidazo[4.5-*c*]pyridine (850 mg, 2.2 mmol), prepared as in step 2. The reaction mixture was heated at reflux for 4 hours, and then was cooled to ambient temperature, diluted with CH₂Cl₂, and filtered. The filtrate was washed with 5% aqueous NaHCO₃, H₂O, and brine. The combined aqueous washings were extracted with CH₂Cl₂. The combined organic extracts were dried over Na₂SO₄, filtered, and
35 concentrated *in vacuo*. The crude material was chromatographed three times (twice with 4-8% methanol/CHCl₃; then 7% methanol/CH₂Cl₂). The material obtained after

117

the chromatographies was dissolved in THF (3 mL) and 2 drops of 4 N HCl/dioxane was added. The resulting fine solid was filtered and washed with ether to give 1-*N,N*-dimethylcarbamoyl-4-cyano-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole hydrochloride (13 mg). mp 179-181 °C. ¹H NMR (DMSO-*d*₆, 300 MHz) δ 2.70 (s, 3H), 3.01 (s, 6H), 5.88 (s, 2H), 7.39 (d, 2H, *J* = 8.1 Hz), 7.56 (t, 1H, *J* = 8.1 Hz), 7.84 (dd, 1H, *J* = 8.1, 1.2 Hz), 7.94 (d, 2H, *J* = 8.1 Hz), 8.02 (dd, 1H, *J* = 8.1, 1.2 Hz), 8.27 (s, 1H), 8.32 (d, 1H, *J* = 6.3 Hz), 8.68 (d, 1H, *J* = 6.3 Hz), 9.44 (s, 1H). MS (DCI/NH₃) *m/e* 463 (M+H)⁺. Anal calcd for C₂₇H₂₃N₆O₂Cl · 1.4 H₂O: C, 61.87; H, 4.96; N, 16.03. Found: C, 61.89; H, 4.84; N, 16.00.

Example 151

Preparation of 1-*N,N*-Dimethylcarbamoyl-4-methoxycarbonyl-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzyl}indole.

Step 1: 4-Methoxycarbonyl-3-[(4-chloromethyl)benzyl]indole.

To a 0 °C solution of trifluoroacetic acid (0.65 mL, 8.6 mmol) and triethylsilane (2.7 mL, 17 mmol) in CH₂Cl₂ (17 mL) was added dropwise a solution of 4-methoxycarbonylindole (1.0 g, 5.7 mmol) and 4-chloromethylbenzaldehyde (0.97 g, 6.3 mmol) in CH₂Cl₂ (29 mL). The reaction mixture was stirred for 1 hour at 0 °C and 20 hours at ambient temperature and then was partitioned between CH₂Cl₂ and saturated aqueous NaHCO₃. The aqueous phase was extracted with CH₂Cl₂. The combined organic layers were washed with saturated aqueous NaHCO₃, dried over MgSO₄, filtered, and concentrated *in vacuo*. Chromatography on silica gel (25% hexane/CH₂Cl₂, then CH₂Cl₂) gave 4-methoxycarbonyl-3-[(4-chloromethyl)benzyl]indole (1.06 g).

Step 2: 1-*N,N*-Dimethylcarbamoyl-4-methoxycarbonyl-3-[(4-chloromethyl)benzyl]indole.

The desired compound was prepared according to the method of Example 130, except substituting 4-methoxycarbonyl-3-[(4-chloromethyl)benzyl]indole, prepared as in step 1, for 4-methoxycarbonyl-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole, and substituting *N,N*-dimethylcarbamyl chloride for 2-bromoethyl ethyl ether.

118

Step 3: 1-*N,N*-Dimethylcarbamoyl-4-methoxycarbonyl-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzyl}indole.

The desired compound was prepared according to the method of Example 90, step 3, except substituting 1-*N,N*-dimethylcarbamoyl-4-methoxycarbonyl-3-[(4-chloromethyl)benzyl]indole, prepared as in step 2, for 4,7-dimethoxycarbonyl-3-(4-chloromethylbenzoyl)indole. ¹H NMR (DMSO-*d*₆, 300 MHz) δ 2.52 (s, 3H), 3.00 (s, 6H), 3.56 (s, 3H), 4.13 (s, 2H), 5.43 (s, 2H), 7.03 (s, 4H), 7.2-7.3 (m, 1H), 7.43 (dd, 1H, *J* = 7.5, 1.2 Hz), 7.50-7.55 (m, 2H), 7.83 (dd, 1H, *J* = 8.1, 1.2 Hz) 8.25 (d, 1H, *J* = 5.4 Hz), 8.81 (d, 1H, *J* = 1.2 Hz). MS (DCI/NH₃) *m/e* 482 (M+H)⁺.

Example 152

Preparation of 1-*N,N*-Dimethylcarbamoyl-4-chloro-3-{4-[(1*H*-2-methylimidazo[4.5-*b*]pyrid-1-yl)methyl]benzoyl}indole.

The desired compound was prepared according to the method of Example 109, except substituting 1*H*-2-methylimidazo[4,5-*b*]pyridine, prepared as is Example 27, step 1, for 1*H*-2-methylimidazo[4,5-*c*]pyridine. ¹H NMR (DMSO-*d*₆, 300 MHz) δ 2.59 (s, 3H), 3.00 (s, 3H), 5.65 (s, 2H), 7.18-7.22 (m, 1H), 7.25-7.40 (m, 4H), 7.65 (d, 1H, *J* = 9 Hz), 7.86 (d, 2H, *J* = 9 Hz), 7.93 (d, 1H, *J* = 9 Hz), 8.05 (s, 1H), 8.35 (d, 1H, *J* = 6 Hz). MS (DCI/NH₃) 472 (M⁺).

Example 153

Preparation of 1-*N,N*-Dimethylcarbamoyl-4-methoxycarbonyl-3-{4-[(3*H*-2-methylimidazo[4.5-*b*]pyrid-3-yl)methyl]benzoyl}indole.

The desired compound was prepared according to the method of Example 43, except substituting 1*H*-2-methylimidazo[4,5-*b*]pyridine, prepared as is Example 27, step 1, for 1*H*-2-methylimidazo[4,5-*c*]pyridine. 1-*N,N*-dimethylcarbamoyl-4-methoxycarbonyl-3-{4-[(3*H*-2-methylimidazo[4.5-*b*]pyrid-3-yl)methyl]benzoyl}indole (286 mg) was isolated by chromatography on silica gel (CH₂Cl₂, then 2%, then 4%, then 5% methanol/CH₂Cl₂). ¹H NMR (DMSO-*d*₆, 300 MHz) δ 2.55 (s, 3H), 3.02 (s, 6H), 3.48 (s, 3H), 5.62 (s, 2H), 7.27 (dd, 1H, *J* = 8.1, 4.8 Hz), 7.34 (apparent d, 2H, *J* = 8.1 Hz), 7.4-7.5 (m, 1H), 7.56 (dd, 1H, *J* = 7.2, 1.2 Hz), 7.85 (apparent d, 2H, *J* = 8.4 Hz), 7.86 (dd, 1H, *J* = 8.4, 1.2 Hz), 8.00 (dd, 1H, *J* = 8.1, 1.5 Hz), 8.12 (s, 1H), 8.31 (dd, 1H, *J* = 5.1, 1.5 Hz). MS (DCI/NH₃) *m/e* 496 (M+H)⁺. Anal calcd for C₂₈H₂₅N₅O₄ · 0.8 H₂O: C, 65.95; H, 5.26; N, 13.73. Found: C, 65.63; H, 4.86; N, 13.47.

Example 154Preparation of 1-*N,N*-Dimethylcarbamoyl-4-methoxycarbonyl-3-{4-[(1*H*-2-methylimidazo[4.5-*b*]pyrid-1-yl)methyl]benzoyl}indole.

- The desired compound (45 mg) was isolated from the chromatography described in Example 153. ¹H NMR (DMSO-*d*₆, 300 MHz) δ 2.59 (s, 3H), 3.02 (s, 6H), 3.47 (s, 3H), 5.65 (s, 2H), 7.21 (dd, 1H, *J* = 8.1, 4.8 Hz), 7.29 (apparent d, 2H, *J* = 8.1 Hz), 7.4-7.5 (m, 1H), 7.57 (dd, 1H, *J* = 7.5, 1.0 Hz), 7.85 (apparent d, 2H, *J* = 8.4 Hz), 7.86 (dd, 1H, *J* = 8.1, 1.2 Hz), 7.95 (dd, 1H, *J* = 8.1, 1.5 Hz), 8.11 (s, 1H), 8.36 (dd, 1H, *J* = 4.8, 1.5 Hz). MS (DCI/NH₃) *m/e* 496 (M+H)⁺.
- Anal calcd for C₂₈H₂₅N₅O₄ · 1.0 H₂O: C, 65.49; H, 5.30; N, 13.64. Found: C, 65.45; H, 5.06; N, 13.50.

Example 155Preparation of 1-*N,N*-Dimethylcarbamoyl-4-methoxycarbonyl-3-{4-[(5*H*-2-methylimidazo[4.5-*c*]pyrid-5-yl)methyl]benzoyl}indole.

- The desired compound was prepared according to the method of Example 43. 1-*N,N*-dimethylcarbamoyl-4-methoxycarbonyl-3-{4-[(5*H*-2-methylimidazo[4.5-*c*]pyrid-5-yl)methyl]benzoyl}indole (143 mg) was isolated by chromatography on silica gel (5%, then 10%, then 12% methanol/CH₂Cl₂). ¹H NMR (DMSO-*d*₆, 300 MHz) δ 2.51 (s, 3H), 3.02 (s, 6H), 3.46 (s, 3H), 5.76 (s, 2H), 7.4-7.65 (m, 3H), 7.54 (d, 2H, *J* = 8.1 Hz), 7.87 (dd, 1H, *J* = 9.3, 1.2 Hz), 7.90 (d, 2H, *J* = 8.1 Hz), 8.13 (s, 1H), 8.18 (dd, 1H, *J* = 6.9, 1.8 Hz), 8.97 (d, 1H, *J* = 1.5 Hz). MS (DCI/NH₃) *m/e* 496 (M+H)⁺. Anal calcd for C₂₈H₂₅N₅O₄ · 1.6 H₂O: C, 64.14; H, 5.42; N, 13.36. Found: C, 64.17; H, 5.03; N, 13.36.

Example 156Preparation of 1-*N,N*-Dimethylcarbamoyl-4-methoxycarbonyl-3-{4-[1-(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)eth-1-yl]benzoyl}indole.Step 1: 1-*N,N*-Dimethylcarbamoyl-4-methoxycarbonyl-3-(4-acetylbenzoyl)indole.

- To a solution in dichloroethane (10 mL) of 4-acetylbenzoyl chloride (3.0 mmol), prepared by treatment of 4-acetylbenzoic acid with oxalyl chloride, was added AlCl₃ (1.2 g, 9.0 mmol) and the brown solution was heated at 50 °C for 10 minutes. 1-*N,N*-dimethoxycarbonyl-4-methoxycarbonylindole (738 mg, 3.0 mmol) was added and the reaction mixture was heated at 65 °C for 8 hours. The reaction mixture was cooled to ambient temperature and poured into aqueous 3 *N* HCl. The aqueous phase was extracted three times with CH₂Cl₂. The combined organic extracts were washed with aqueous 1 *N* NaOH and brine, dried over MgSO₄, filtered, and concentrated *in*

120

vacuo. Chromatography on silica gel (40% to 80% ethyl acetate/hexane) gave 1-*N,N*-dimethylcarbamoyl-4-methoxycarbonyl-3-[(4-acetyl)benzoyl]indole (620 mg).

5 Step 2: 1-*N,N*-Dimethylcarbamoyl-4-methoxycarbonyl-3-[4-(1-hydroxyethyl)benzoyl]indole.

To a solution in 3:1 ethanol-CH₂Cl₂ (8 mL) of 1-*N,N*-dimethylcarbamoyl-4-methoxycarbonyl-3-[(4-acetyl)benzoyl]indole (260 mg, 0.663 mmol), prepared as in step 1, was added NaBH₄ (28.2 mg, 0.742 mmol) in portions. After 5 minutes, the reaction was quenched with saturated aqueous NH₄Cl and concentrated *in vacuo*. The
10 residue was taken up in CH₂Cl₂ and washed with brine. The aqueous phase was extracted with CH₂Cl₂. The combined organic layers were dried over MgSO₄, filtered, and concentrated *in vacuo* to give a yellow oil (260 mg) which was used without further purification.

15 Step 3: 1-*N,N*-Dimethylcarbamoyl-4-methoxycarbonyl-3-[4-(1-methanesulfonyloxyethyl)benzoyl]indole.

To a 0 °C solution in CH₂Cl₂ (10 mL) of the 1-*N,N*-dimethylcarbamoyl-4-methoxycarbonyl-3-[4-(1-hydroxyethyl)benzoyl]indole prepared in step 2 (260 mg) was added triethylamine (138 µL, 0.99 mmol) and methanesulfonyl chloride (61.3
20 µL, 0.79 mmol) and the reaction mixture was stirred for 20 minutes. The cold bath was removed and stirring was continued for 10 minutes. The reaction mixture was poured into a mixture of brine and saturated aqueous NaHCO₃ and extracted three times with CH₂Cl₂. The combined organic extracts were dried over MgSO₄, filtered, and concentrated *in vacuo* to give 1-*N,N*-dimethylcarbamoyl-4-methoxycarbonyl-3-
25 [4-(1-methanesulfonyloxyethyl)benzoyl]indole which was used without further purification.

Step 4: 1-*N,N*-Dimethylcarbamoyl-4-methoxycarbonyl-3-[4-(1-azidoethyl)benzoyl]indole.

30 To a solution in DMF (8 mL) of the 1-*N,N*-dimethylcarbamoyl-4-methoxycarbonyl-3-[4-(1-methanesulfonyloxyethyl)benzoyl]indole prepared in step 3 was added sodium azide (429 mg, 6.6 mmol) and the reaction mixture was heated at 60 °C for 1 hour. The reaction mixture was poured into brine and the aqueous phase was extracted three times with ethyl acetate. The combined organic extracts were
35 washed with brine, dried over MgSO₄, filtered, and concentrated *in vacuo*.

121

Chromatography on silica gel (40-60% ethyl acetate/hexane) gave 1-*N,N*-dimethylcarbamoyl-4-methoxycarbonyl-3-[4-(1-azidoethyl)benzoyl]indole (250 mg).

Step 5: 1-*N,N*-Dimethylcarbamoyl-4-methoxycarbonyl-3-[4-[1-(1H-2-methylimidazo[4.5-c]pyrid-1-yl)ethyl]benzoyl]indole.

The desired compound was prepared according to the method of Example 29, steps 5 and 6, except substituting 1-*N,N*-dimethylcarbamoyl-4-methoxycarbonyl-3-[4-(1-azidoethyl)benzoyl]indole, prepared as in step 4, for 1-*N,N*-dimethylcarbamoyl-3-(4-aminomethylbenzoyl)indole. ¹H NMR (DMSO-d₆, 300 MHz) δ 1.97 (d, 3H, J = 6.9 Hz), 2.64 (s, 3H), 3.03 (s, 6H), 3.46 (s, 3H), 6.07 (q, 1H, J = 6.9 Hz), 7.26 (dd, 1H, J = 0.9, 5.7 Hz), 7.43 (d, 2H, J = 8.1 Hz), 7.46 (t, 1H, J = 8.4 Hz), 7.58 (dd, 1H, J = 1.2, 7.5 Hz), 7.86 (d, 2H, J = 8.1 Hz), 7.88 (dd, 1H, J = 0.6, 7.5 Hz), 8.12 (s, 1H), 8.17 (d, 1H, J = 5.7 Hz), 8.83 (s, 1H). MS (DCI/NH₃) m/e 511 (M+2)⁺, 510 (M+1)⁺, 378, 277, 205.

Example 157

Preparation of 1-*N,N*-Dimethylcarbamoyl-4-methoxycarbonyl-3-[4-[1-(1H-imidazo[4.5-c]pyrid-1-yl)ethyl]benzoyl]indole.

The desired compound was prepared according to the method of Example 30, except substituting 1-*N,N*-dimethylcarbamoyl-4-methoxycarbonyl-3-[4-(1-(*N*-3-aminopyridin-4-yl)ethyl)benzoyl]indole, prepared as in Example 156, for 1-*N,N*-dimethylcarbamoyl-3-[4-(*N*-3-aminopyridin-4-yl)aminomethylbenzoyl]indole. ¹H NMR (DMSO-d₆, 300 MHz) δ 2.3 (d, 3H, J = 6.9 Hz), 3.1 (s, 6H), 3.43 (s, 3H), 6.04 (q, 1H, J = 6.9 Hz), 7.45 (t, 1H, J = 8.4 Hz), 7.51-7.57 (m, 3H), 7.84-7.89 (m, 3H), 8.11 (s, 1H), 8.30 (d, 1H, J = 5.2 Hz), 8.79 (s, 1H), 8.99 (s, 1H). MS (DCI/NH₃) m/e 496 (M+H)⁺, 378, 167.

Example 158

Preparation of 1-*N,N*-Dimethylcarbamoyl-4-methoxycarbonyl-3-[4-[(1H-2-methyl-5- and 6-chlorobenzimidazolyl)methyl]benzoyl]indole.

Step 1: 5-chloro-1,2-phenylenediamine.

To a suspension in diethyl ether (50 mL) of 5-chloro-2-nitroaniline (2.70 g, 15.6 mmol) was added zinc powder (10.2 g, 156 mmol) in portions. The reaction mixture was filtered and concentrated *in vacuo* to give 5-chloro-2-aminoaniline which was used without further purification.

122

Step 2: 5- and 6-Chloro-2-methylbenzimidazole.

The 5-chloro-1,2-phenylenediamine prepared in step 1 was dissolved in acetic acid (10 mL) and the solution was heated at 95 °C for 4 hours. The reaction mixture was then cooled in an ice bath and taken to pH = 8-9 with concentrated NH₄OH. The resulting precipitate was filtered, washed with H₂O, and dried in a vacuum oven to give a mixture of 5- and 6-chloro-2-methylbenzimidazole (2.25 g).

Step 3: 1-*N,N*-Dimethylcarbamoyl-4-methoxycarbonyl-3-{4-[(1H-2-methyl-5- and 6-chlorobenzimidazolyl)methyl]benzoyl}indole.

Sodium hydride (60% oil dispersion, 22.5 mg, 0.563 mmol) was washed three times with hexane and suspended in DMF (3 mL). A mixture of mixture of 5- and 6-chloro-2-methylbenzimidazole (75 mg, 0.450 mmol), prepared as in step 1, was added, the reaction mixture was stirred for 5 minutes, and LiBr (20 mg) and 1-*N,N*-dimethylcarbamoyl-4-methoxycarbonyl-3-(4-chloromethylbenzoyl)indole (150 mg, 0.373 mmol) were added. The reaction mixture was stirred for 7.5 hours at ambient temperature and then was poured into H₂O and extracted three times with ethyl acetate. The combined organic layers were washed with brine, dried over MgSO₄, filtered, and concentrated *in vacuo*. Chromatography on silica gel (60% ethyl acetate/hexane, then 10% methanol/CH₂Cl₂), followed by HPLC (20-70% CH₃CN/H₂O) gave a mixture of 1-*N,N*-dimethylcarbamoyl-4-methoxycarbonyl-3-{4-[(1H-2-methyl-5- and 6-chlorobenzimidazolyl)methyl]benzoyl}indole in about a 1:1 ratio of Cl regioisomers. ¹H NMR (DMSO-d₆, 300 MHz) δ 2.52 (s, 3H), 2.54 (s, 3H), 3.02 (s, 6H), 3.02 (s, 6H), 3.27 (s, 3H), 3.28 (s, 3H), 5.62 (s, 2H), 5.62 (s, 2H), 7.18-7.22 (m, 1H), 7.18-7.22 (m, 1H), 7.25 (d, 2H, J = 8.4 Hz), 7.25 (d, 2H, J = 8.4 Hz), 7.43 (t, 1H, J = 8.7 Hz), 7.43 (t, 1H, J = 8.7 Hz), 7.52-7.58 (m, 2H), 7.52-7.58 (m, 2H), 7.62 (d, 1H, J = 2.6 Hz), 7.68 (d, 1H, J = 2.6 Hz), 7.82-7.88 (m, 3H), 7.82-7.88 (m, 3H), 8.09 (s, 1H), 8.10 (s, 1H). MS (DCI/NH₃) m/e 529 (M+H)⁺, 364, 182, 167. Anal calcd for C₂₉H₂₅ClN₄O₄ · 0.75 CH₃OH · 0.25 CF₃CO₂H: C, 62.47; H, 4.89; N, 9.63. Found: C, 62.43; H, 4.86; N, 9.59.

Example 159Preparation of 1-*N,N*-Dimethylcarbamoyl-4-chloro-3-{4-[(1H-2-methyl-5- and 6-chlorobenzimidazolyl)methyl]benzoyl}indole.

The desired compound was prepared as a mixture of chlorine regioisomers according to the method of Example 158, except substituting 1-*N,N*-dimethylcarbamoyl-4-chloro-3-(4-chloromethylbenzoyl)indole, prepared as in

123

Example 109, step 2, for 1-*N,N*-dimethylcarbamoyl-4-methoxycarbonyl-3-(4-chloromethylbenzoyl)indole. ¹H NMR (DMSO-d₆, 300 MHz) δ 2.51 (s, 3H), 2.52 (s, 3H), 3.0 (s, 6H), 3.0 (s, 6H), 5.62 (s, 2H), 5.62 (s, 2H), 7.17-7.39 (m, 0.5H), 7.17-7.39 (m, 0.5H), 7.52 (d, 1H, J = 8.6 Hz), 7.57 (d, 1H, J = 8.6 Hz), 7.62-7.67 (m, 2H), 7.62-7.67 (m, 2H), 7.85 (d, 2H, J = 8.4 Hz), 7.87 (d, 2H, J = 8.4 Hz), 8.04 (s, 1H), 8.05 (s, 1H). MS (DCI/NH₃) m/e 505 (M+H)⁺, 140, 167.

Example 160

Preparation of 1-(2-Ethoxyethyl)-4-methoxycarbonyl-3-{4-[(1H-2-methyl-5- and 6-chlorobenzimidazolyl)methyl]benzoyl}indole.

Step 1: 1-(2-Ethoxyethyl)-4-methoxycarbonylindole.

The desired compound was prepared according to the method of Example 130, except substituting 4-methoxycarbonylindole, prepared as in Example 43, step 1, for 4-methoxycarbonyl-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole.

Step 2: 1-(2-Ethoxyethyl)-4-methoxycarbonyl-3-(4-chloromethylbenzoyl)indole.

The desired compound was prepared according to the method of Example 4, step 2, except substituting 1-(2-ethoxyethyl)-4-methoxycarbonylindole, prepared as in step 1, for 6-(4-fluorophenyl)indole-1-carboxylic acid dimethylamide.

Step 3: 1-(2-Ethoxyethyl)-4-methoxycarbonyl-3-{4-[(1H-2-methyl-5- and 6-chlorobenzimidazolyl)methyl]benzoyl}indole.

The desired compound was prepared as a mixture of chlorine regioisomers according to the method of Example 158, except substituting 1-(2-ethoxyethyl)-4-methoxycarbonyl-3-(4-chloromethylbenzoyl)indole, prepared as in step 2, for 1-*N,N*-dimethylcarbamoyl-4-methoxycarbonyl-3-(4-chloromethylbenzoyl)indole. ¹H NMR (DMSO-d₆, 300 MHz) δ 0.97 (t, 3H, J = 7.4 Hz), 0.97 (t, 3H, J = 7.4 Hz), 2.53 (s, 3H), 2.56 (s, 3H), 3.35 (q, 2H, J = 7.4 Hz), 3.35 (q, 2H, J = 7.4 Hz), 3.55 (s, 3H), 3.56 (s, 3H), 3.69 (t, 2H, J = 5.8 Hz), 3.69 (t, 2H, J = 5.8 Hz), 4.44 (t, 2H, J = 5.8 Hz), 4.44 (t, 2H, J = 5.8 Hz), 5.61 (s, 2H), 5.61 (s, 2H), 7.18-7.27 (m, 3H), 7.18-7.27 (m, 3H), 7.33-7.43 (m, 2H), 7.33-7.43 (m, 2H), 7.57 (t, 1H, J = 8.7 Hz), 7.57 (t, 1H, J = 8.7 Hz), 7.63 (d, 1H, J = 2.4 Hz), 7.70 (d, 1H, J = 2.5 Hz), 7.80 (dd, 2H, J = 6.5, 8.8 Hz), 7.80 (dd, 2H, J = 6.5, 8.8 Hz), 7.85 (dd, 1H, J = 1.2, 8.8 Hz), 7.85 (dd, 1H, J = 1.2, 8.8 Hz), 7.92 (s, 1H), 7.93 (s, 1H). MS

124

(DCI/NH₃) m/e 530 (M+H)⁺, 365, 248, 181, 169. Anal calcd for C₃₀H₂₈ClN₃O₄ · 0.475 H₂O: C, 66.78; H, 5.41; N, 7.80. Found: C, 66.81; H, 5.36; N, 7.88.

Example 161

5 Preparation of 1-(Pyrrolidin-1-ylcarbonyl)-4-methoxycarbonyl-3-{4-[(1H-2-methyl-5- and 6-chlorobenzimidazolyl)methyl]benzoyl}indole.

The desired compound was prepared as a mixture of chlorine regioisomers according to the method of Example 160, except substituting 1-pyrrolidine carbonyl chloride, for 2-bromoethyl ethyl ether. ¹H NMR (DMSO-d₆, 300 MHz) δ 1.87 (bs, 2H), 1.87 (bs, 2H), 2.52 (s, 3H), 2.54 (s, 3H), 3.30 (s, 3H), 3.47 (s, 3H), 3.52 (bs, 2H), 3.52 (bs, 2H), 5.61 (s, 2H), 5.61 (s, 2H), 7.18-7.23 (m, 1H), 7.18-7.23 (m, 1H), 7.26 (d, 2H, J = 8.4 Hz), 7.44 (t, 1H, J = 8.0 Hz), 7.44 (t, 1H, J = 8.0 Hz), 7.52-7.59 (m, 2H), 7.52-7.59 (m, 2H), 7.63 (d, 1H, J = 2.0 Hz), 7.68 (d, 1H, J = 2.0 Hz), 7.83 (d, 2H, J = 8.4 Hz), 7.85 (d, 2H, J = 8.4 Hz), 7.98 (d, 1H, J = 8.0 Hz), 7.98 (d, 1H, J = 8.0 Hz), 8.18 (s, 1H), 8.19 (s, 1H). MS (DCI/NH₃) m/e 555 (M+H)⁺, 169. Anal calcd for C₃₁H₂₇ClN₄O₄ · 0.8 H₂O · 0.2 DMF: C, 65.01; H, 5.17; N, 10.06. Found: C, 64.95; H, 4.91; N, 10.00.

Example 162

20 Preparation of 1-N,N-Dimethylcarbamoyl-4-methoxycarbonyl-3-{4-[(1H-2-(trifluoromethyl)benzimidazolyl)methyl]benzoyl}indole.

Step 1: 1H-2-(Trifluoromethyl)benzimidazole.

A mixture of 1,2-diaminobenzene (1.0 g), trifluoroacetic acid (1 mL) and trifluoroacetic anhydride (1 mL) was heated at 60 °C for 10 hours. The reaction mixture was then cooled in an ice bath and taken to pH = 7-8 with concentrated NH₄OH. The resulting white solid was filtered and recrystallized from ethanol to give 400 mg of 1H-2-(trifluoromethyl)benzimidazole as colorless crystals.

30 Step 2: 1-N,N-Dimethylcarbamoyl-4-methoxycarbonyl-3-{4-[(1H-2-(trifluoromethyl)benzimidazolyl)methyl]benzoyl}indole.

The desired compound was prepared according to the method of Example 158, step 3, except substituting 1H-2-(trifluoromethyl)benzimidazole, prepared as in step 1, for 5- and 6-chloro-2-methylbenzimidazole. ¹H NMR (CDCl₃, 300 MHz) δ 3.11 (s, 6H), 3.53 (s, 3H), 5.61 (s, 2H), 7.17 (d, 2H, J = 8.4 Hz), 7.27-7.30 (m, 1H), 7.39-7.45 (m, 3H), 7.69 (s, 1H), 7.73 (d, 1H, J = 7.6 Hz), 7.82-7.86 (m, 3H),

125

7.91-7.95 (m, 1H). MS (DCI/NH₃) m/e 550 (M+2)⁺, 549 (M+H)⁺, 364, 277, 204, 187.

Example 163

Preparation of 1-*N,N*-Dimethylcarbamoyl-4-methoxycarbonyl-3-{4-[(1H-2-methyl-5- and 6-methylbenzimidazolyl)methyl]benzoyl}indole.

Step 1: 5- and 6-Methyl-2-methylbenzimidazole.

A mixture of 3,4-diaminotoluene (1.0 g), acetic anhydride (1.5 mL) and acetic acid (2.0 mL) was heated at 85 °C for 12 hours. The reaction mixture was cooled in an ice bath and taken to pH = 8 with concentrated NH₄OH. The resulting solid was filtered and dried in a vacuum oven to give 1.2 g of 5- and 6-methyl-2-methylbenzimidazole as light-brown crystals.

Step 2: 1-*N,N*-Dimethylcarbamoyl-4-methoxycarbonyl-3-{4-[(1H-2-methyl-5- and 6-methylbenzimidazolyl)methyl]benzoyl}indole.

The desired compound was prepared as a mixture of methyl regioisomers according to the method of example 158, step 3, except substituting 5- and 6-methyl-2-methylbenzimidazole, prepared as in step 1, for 5- and 6-chloro-2-methylbenzimidazole. ¹H NMR (DMSO-d₆, 300 MHz) δ 2.39 (s, 3H), 2.39 (s, 3H), 2.50 (s, 3H), 2.50 (s, 3H), 3.02 (s, 6H), 3.02 (s, 6H), 3.47 (s, 3H), 3.47 (s, 3H), 5.55 (s, 2H), 5.55 (s, 2H), 6.98-7.00 (m, 1H), 6.98-7.00 (m, 1H), 7.24 (d, 2H, J = 8.8 Hz), 7.24 (d, 2H, J = 8.8 Hz), 7.29 (s, 1H), 7.35 (s, 1H), 7.36 (d, 1H, J = 8.4 Hz), 7.44 (d, 1H, J = 8.4 Hz), 7.45 (t, 1H, J = 8.4 Hz), 7.45 (t, 1H, J = 8.4 Hz), 7.56 (d, 1H, J = 8.4 Hz), 7.56 (d, 1H, J = 8.4 Hz), 7.82 -7.88 (m, 3H), 7.82 -7.88 (m, 3H), 8.11 (s, 1H), 8.12 (s, 1H). MS (DCI/NH₃) m/e 509 (M+H)⁺, 364.

Example 164

Preparation of 1-*N,N*-Dimethylcarbamoyl-4-methoxycarbonyl-3-{4-[(1H-2-methyl-4- and 7-methylbenzimidazolyl)methyl]benzoyl}indole.

The desired compound was prepared as a mixture of methyl regioisomers according to the method of Example 163, except substituting 2,3-diaminotoluene for 3,4-diaminotoluene. ¹H NMR (DMSO-d₆, 300 MHz) δ 2.39 (s, 3H), 2.39 (s, 3H), 2.50 (s, 3H), 2.50 (s, 3H), 3.02 (s, 6H), 3.02 (s, 6H), 3.48 (s, 3H), 3.48 (s, 3H), 5.56 (s, 2H), 5.56 (s, 2H), 6.99 (d, 1H, J = 8.6 Hz), 6.99 (d, 1H, J = 8.6 Hz), 7.24 (d, 2H, J = 8.4 Hz), 7.24 (d, 2H, J = 8.4 Hz), 7.29 (s, 1H), 7.55 (d, 1H, J = 7.8 Hz), 7.56 (s, 1H), 7.44 (d, 1H, J = 7.9 Hz), 7.45 (t, 1H, J = 8.0 Hz), 7.45 (t, 1H, J = 8.0 Hz), 7.57 (d, 1H, J = 8.0 Hz), 7.57 (d, 1H, J = 8.0 Hz), 7.82-7.88 (m, 3H),

126

7.82-7.88 (m, 3H), 8.11 (s, 1H), 8.12 (s, 1H). MS (DCI/NH₃) m/e 509 (M+H)⁺, 161. Anal calcd for C₃₀H₂₈N₄O₄ · 0.6 H₂O · 0.3 EtOH; C, 68.86; H, 5.96; N, 10.49. Found: C, 68.93; H, 5.98; N, 10.17.

5

Example 165

Preparation of 1-*N,N*-Dimethylcarbamoyl-4-methoxycarbonyl-3-{4-[(1*H*-2-methyl-5- and 6-fluorobenzimidazolyl)methyl]benzoyl}indole.

The desired compound was prepared as a mixture of fluorine regioisomers according to the method of Example 158, except substituting 4-fluoro-2-nitroaniline for 5-chloro-2-nitroaniline. ¹H NMR (DMSO-d₆, 300 MHz) δ 2.51 (s, 3H), 2.54 (s, 3H), 3.02 (s, 6H), 3.02 (s, 6H), 3.48 (s, 3H), 3.48 (s, 3H), 5.59 (s, 2H), 5.61 (s, 2H), 7.02 (dt, 1H, J = 2.4, 10.2 Hz), 7.04 (dt, 1H, J = 2.4, 10.2 Hz), 7.27 (d, 2H, J = 8.4 Hz), 7.27 (d, 2H, J = 8.4 Hz), 7.38 (dd, 1H, J = 2.7, 10.2 Hz), 7.45 (t, 1H, J = 8.0 Hz), 7.45 (t, 1H, J = 8.0 Hz), 7.45 (dd, 1H, J = 2.7, 10.1 Hz), 7.51 (dd, 1H, J = 5.1, 9.2 Hz), 7.56 (dd, 1H, J = 5.0, 9.2 Hz), 7.56 (d, 1H, J = 8.0 Hz), 7.56 (d, 1H, J = 8.0 Hz), 7.83-7.88 (m, 3H), 7.83-7.88 (m, 3H), 8.11 (s, 1H), 8.14 (s, 1H). MS (DCI/NH₃) m/e 513 (M+H)⁺. Anal calcd for C₂₉H₂₅FN₄O₄ · 0.2 H₂O; C, 65.69; H, 4.89; N, 10.50. Found: C, 65.53; H, 4.89; N, 10.51.

20

Example 166

Preparation of 1-*N,N*-Dimethylcarbamoyl-4-methoxycarbonyl-3-{4-[(1*H*-2-methyl-5- and 6-nitrobenzimidazolyl)methyl]benzoyl}indole.

The desired compound was prepared as a mixture of nitro regioisomers according to the method of Example 158, step 3, except substituting 5-nitro-2-methylbenzimidazole for 6-chloro-2-methylbenzimidazole. ¹H NMR (DMSO-d₆, 300 MHz) δ 2.60 (s, 3H), 2.61 (s, 3H), 3.02 (s, 6H), 3.02 (s, 6H), 3.46 (s, 3H), 3.47 (s, 3H), 5.73 (s, 2H), 5.80 (s, 2H), 7.29 (d, 2H, J = 8.7 Hz), 7.29 (d, 2H, J = 8.2 Hz), 7.45 (t, 1H, J = 8.7 Hz), 7.45 (t, 1H, J = 8.7 Hz), 7.55-7.58 (m, 1H), 7.55-7.58 (m, 1H), 7.78 (d, 1H, J = 8.7 Hz), 7.78 (d, 1H, J = 8.7 Hz), 7.83-7.88 (m, 3H), 7.83-7.88 (m, 3H), 8.10-8.17 (m, 2H), 8.10-8.17 (m, 2H), 8.47 (d, 1H, J = 2.6 Hz), 8.60 (d, 1H, J = 2.6 Hz). MS (DCI/NH₃) m/e 540 (M+H)⁺, 178.

35

127

Example 167

Preparation of 1-*N,N*-Dimethylcarbamoyl-4-methoxycarbonyl-3-{4-[(1*H*-2-methyl-5,6-dichlorobenzimidazolyl)methyl]benzoyl}indole.

The desired compound was prepared according to the method of Example 158, steps 2 and 3, except substituting 4,5-dichloro-1,2-phenylenediamine for 5-chloro-1,2-phenylenediamine. ¹H NMR (DMSO-d₆, 300 MHz) δ 2.52 (s, 3H), 3.02 (s, 6H), 3.48 (s, 3H), 6.63 (s, 2H), 7.25 (d, 2H, J = 8.4 Hz), 7.45 (t, 1H, J = 7.8 Hz), 7.57 (dd, 1H, J = 7.8, 0.6 Hz), 7.85 (d, 2H, J = 8.4 Hz), 7.86 (s, 1H), 7.87 (dd, 1H, J = 0.6, 7.8 Hz), 7.95 (s, 1H), 8.12 (s, 1H). MS (DCI/NH₃) m/e 563 (M+H)⁺.

10

Example 168

Preparation of 1-*N,N*-Dimethylcarbamoyl-4-methoxycarbonyl-3-{4-[(1*H*-2-methyl-5- and 6-methoxycarbonylbenzimidazolyl)methyl]benzoyl}indole.

The desired compound was prepared as a mixture of ester regioisomers according to the method of Example 158, steps 2 and 3, except substituting methyl 3,4-diaminobenzoate for 5-chloro-1,2-phenylenediamine. ¹H NMR (DMSO-d₆, 300 MHz) δ 2.57 (s, 3H), 2.58 (s, 3H), 3.02 (s, 6H), 3.02 (s, 6H), 3.47 (s, 3H), 3.48 (s, 3H), 3.84 (s, 3H), 3.86 (s, 3H), 5.67 (s, 2H), 5.73 (s, 2H), 7.23 (d, 2H, J = 8.4 Hz), 7.27 (d, 2H, J = 8.4 Hz), 7.45 (t, 1H, J = 8.0 Hz), 7.45 (t, 1H, J = 8.0 Hz), 7.56 (d, 1H, J = 8.0 Hz), 7.56 (d, 1H, J = 8.0 Hz), 7.64 (d, 1H, J = 9.5 Hz), 7.68 (d, 1H, J = 9.5 Hz), 7.81-7.88 (m, 4H), 7.81-7.88 (m, 4H), 8.11 (s, 1H), 8.12 (s, 1H), 8.15 (d, 1H, J = 1.8 Hz), 8.18 (d, 1H, J = 1.8 Hz). MS (DCI/NH₃) m/e 553 (M+H)⁺, 364, 191.

20

Example 169

Preparation of 1-(Pyrrolidin-1-ylcarbonyl)-4-methoxycarbonyl-3-{4-[(1*H*-2-methyl-5- and 6-methoxycarbonylbenzimidazolyl)methyl]benzoyl}indole.

The desired compound was prepared as a mixture of ester regioisomers according to the method of Example 160, except substituting 1-pyrrolidine carbonyl chloride, for 2-bromoethyl ethyl ether in step 1, and substituting 5- and 6-methoxycarbonyl-2-methylbenzimidazole, prepared as in Example 168, for 5- and 6-chloro-2-methylbenzimidazole in step 3. ¹H NMR (DMSO-d₆, 300 MHz) δ 1.87 (bs, 4H), 1.87 (bs, 4H), 2.58 (s, 3H), 2.58 (s, 3H), 3.37 (s, 3H), 3.37 (s, 3H), 3.51 (bs, 4H), 3.51 (bs, 4H), 3.84 (s, 3H), 3.86 (s, 3H), 5.66 (s, 2H), 5.74 (s, 2H), 7.24 (d, 2H, J = 8.4 Hz), 7.28 (d, 2H, J = 8.4 Hz), 7.44 (t, 1H, J = 8.0 Hz), 7.44 (t, 1H, J = 8.0 Hz), 7.56 (d, 1H, J = 8.0 Hz), 7.56 (d, 1H, J = 8.0 Hz), 7.63 (d, 1H, J = 8.6 Hz), 7.67 (d, 1H, J = 8.4 Hz), 7.82-7.84 (m, 3H), 7.82-7.84 (m, 3H),

30

35

128

7.98 (d, 1H, J = 8.0 Hz), 7.98 (d, 1H, J = 8.0 Hz), 8.14 (s, 1H), 8.18 (s, 1H), 8.18 (s, 1H), 8.19 (s, 1H). MS (DCI/NH₃) m/e 579 (M+H)⁺, 390, 280, 191. Anal calcd for C₃₃H₃₀N₄O₆ · 0.6 H₂O: C, 66.43; H, 5.40; N, 9.39. Found: C, 66.45; H, 5.39; N, 9.39.

5

Example 170

Preparation of 1-(Pyrrolidin-1-ylcarbonyl)-4-methoxycarbonyl-3-{4-[(1H-2-methyl-5- and 6-methylbenzimidazolyl)methyl]benzoyl}indole.

The desired compound was prepared as a mixture of methyl regioisomers according to the method of Example 169, except substituting 5- and 6-methyl-2-methylbenzimidazole, prepared as in Example 163, step 1, for 5- and 6-methoxycarbonyl-2-methylbenzimidazole. ¹H NMR (DMSO-d₆, 300 MHz) δ 1.86 (bs, 2H), 1.86 (bs, 2H), 2.40 (s, 3H), 2.50 (s, 3H), 3.31 (s, 3H), 3.47 (s, 3H), 3.51 (bs, 2H), 3.51 (bs, 2H), 5.56 (s, 2H), 5.56 (s, 2H), 6.99 (d, 1H, J = 8.4 Hz), 6.99 (d, 1H, J = 8.4 Hz), 7.24 (d, 2H, J = 8.4 Hz), 7.24 (d, 2H, J = 8.4 Hz), 7.28 (s, 1H), 7.34 (d, 1H, J = 8.4 Hz), 7.36 (s, 1H), 7.43 (t, 1H, J = 8.0 Hz), 7.43 (t, 1H, J = 8.0 Hz), 7.43 (d, 1H, J = 8.4 Hz), 7.56 (d, 1H, J = 8.0 Hz), 7.56 (d, 1H, J = 8.0 Hz), 7.73 (d, 2H, J = 8.4 Hz), 7.74 (d, 2H, J = 8.4 Hz), 7.98 (d, 1H, J = 8.0 Hz), 7.98 (d, 1H, J = 8.0 Hz), 8.18 (s, 1H), 8.19 (s, 1H). MS (DCI/NH₃) m/e 535 (M+H)⁺, 390. Anal calcd for C₃₂H₃₀N₄O₄ · 0.6 H₂O · 0.2 Ac₂O: C, 69.99; H, 5.87; N, 9.95. Found: C, 69.92; H, 5.79; N, 9.88.

20

Example 171

Preparation of 1-N,N-Dimethylcarbamoyl-4-methoxycarbonyl-3-{4-[(3H-2,4,6-trimethylimidazo[4,5-c]pyrid-3-yl)methyl]benzoyl}indole.

25 Step 1: 1-N,N-Dimethylcarbamoyl-4-methoxycarbonyl-3-(4-aminomethylbenzoyl)indole.

The desired compound was prepared according to the method of Example 102, steps 1-3, except substituting 4-methoxycarbonylindole, prepared as in Example 43, step 1, for 4-bromoindole.

30

Step 2: 1-N,N-Dimethylcarbamoyl-4-bromo-3-(4-(N-3-nitro-2,6-dimethylpyridin-4-yl)aminomethylbenzoyl)indole.

A mixture of 1-N,N-dimethylcarbamoyl-4-methoxycarbonyl-3-(4-aminomethylbenzoyl)indole (150 mg, 0.393 mmol), triethylamine (60.1 μL, 0.432 mmol), and 3-nitro-4-chloro-2,6-dimethylpyridine (110 mg, 0.589 mmol) in THF (5 mL) was heated at 60 °C for 160 hours. The reaction mixture was cooled to ambient

35

129

temperature and concentrated *in vacuo*. The residue was purified by chromatography on silica gel (ethyl acetate) to give 128 mg of 1-*N,N*-dimethylcarbamoyl-4-bromo-3-(4-(*N*-3-nitro-2,6-dimethylpyridin-4-yl)aminomethylbenzoyl)indole.

5 Step 3: 1-*N,N*-Dimethylcarbamoyl-4-methoxycarbonyl-3-{4-[(3H-2,4,6-trimethylimidazo[4.5-c]pyrid-3-yl)methyl]benzoyl}indole.

The desired compound was prepared according to the method of Example 57, step 8, except substituting 1-*N,N*-dimethylcarbamoyl-4-bromo-3-(4-(*N*-3-nitro-2,6-dimethylpyridin-4-yl)aminomethylbenzoyl)indole, prepared as in step 2, for 3-[(4-(*N*-3-nitropyrid-4-yl)aminomethyl)phenylsulfonyl]indole. ¹H NMR (DMSO-d₆, 300 MHz) δ 2.47 (s, 3H), 2.51 (s, 3H), 2.62 (s, 3H), 3.02 (s, 6H), 3.47 (s, 3H), 5.56 (s, 2H), 7.22 (s, 1H), 7.24 (d, 2H, J = 8.4 Hz), 7.45 (t, 1H, J = 8.6 Hz), 7.56 (dd, 1H, J = 8.6, 1.5 Hz), 7.83 (d, 2H, J = 8.4 Hz), 7.87 (1H, dd, J = 8.6, 1.5 Hz), 8.11 (s, 1H). MS (DCI/NH₃) m/e 584 (M+H+HOAc)⁺, 524 (M+H)⁺, 453, 364.

15 Anal calcd for C₃₀H₂₉N₅O₄ · 0.4 H₂O · 0.4 HOAc: C, 65.93; H, 5.63; N, 12.48. Found: C, 65.86; H, 5.61; N, 12.38.

Example 172

20 Preparation of 1-(Pyrrolidin-1-ylcarbonyl)-4-methoxycarbonyl-3-{4-[(1H-5-trifluoromethyl-2-methylmethylbenzimidazolyl)methyl]benzoyl}indole.

The desired compound was prepared according to the method of Example 171, except substituting 4-chloro-3-nitrobenzotrifluoride for 3-nitro-4-chloro-2,6-dimethylpyridine. ¹H NMR (DMSO-d₆, 300 MHz) δ 2.59 (s, 3H), 3.02 (s, 6H), 3.47 (s, 3H), 5.68 (s, 2H), 7.28 (d, 2H, J = 8.7 Hz), 7.45 (dd, 1H, J = 7.6, 8.8 Hz), 7.53 (dd, 1H, J = 1.6, 9.0 Hz), 7.57 (dd, 1H, J = 1.8, 7.6 Hz), 7.73 (d, 1H, J = 9.0 Hz), 7.83 (d, 2H, J = 8.7 Hz), 7.86 (dd, J = 1.6, 8.7 Hz), 7.93 (s, 1H), 8.10 (s, 1H). MS (DCI/NH₃) m/e 563 (M+H)⁺, 364, 278, 201.

25

Example 173

30 Preparation of 1-*N,N*-Dimethylcarbamoyl-4-methoxycarbonyl-3-{4-[(5-oxide-1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole.

To a 0 °C solution in CH₂Cl₂ (2 mL) of 1-*N,N*-dimethylcarbamoyl-4-methoxycarbonyl-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole (25 mg, 0.045 mmol), prepared as in Example 44, was added 3-chloroperbenzoic acid (80%, 12.5 mg, 0.045 mmol). The reaction mixture was stirred for 1 hour at 0 °C and then was partitioned between CH₂Cl₂ and saturated

35

130

aqueous NaHCO₃/NaHSO₃. The organic phase was dried over MgSO₄, filtered, and concentrated *in vacuo*. Pure 1-*N,N*-dimethylcarbamoyl-4-methoxycarbonyl-3-{4-[(5-oxide-1H-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole was obtained by HPLC (20-40% CH₃CN/H₂O). ¹H NMR (DMSO-*d*₆, 300 MHz) δ 2.55 (s, 3H), 3.02 (s, 6H), 3.48 (s, 3H), 5.65 (s, 2H), 7.31 (d, 2H, *J* = 8.4 Hz), 7.46 (t, 1H, *J* = 8.0 Hz), 7.57 (d, 1H, *J* = 8.0 Hz), 7.85 (d, 2H, *J* = 8.4 Hz), 7.87 (d, 1H, *J* = 7.6 Hz), 8.11 (s, 1H), 8.12 (dd, 1H, *J* = 7.6, 2.2 Hz), 8.68 (d, 1H, *J* = 2.2 Hz). MS (DCI/NH₃) *m/e* 512 (M+H)⁺, 496, 364.

Example 174

Preparation of 1-*N,N*-Dimethylcarbamoyl-4-methoxycarbonyl-3-{4-[(4-chloro-1H-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole.

A mixture of 1-*N,N*-dimethylcarbamoyl-4-methoxycarbonyl-3-{4-[(5-oxide-1H-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole (60 mg), prepared as in Example 173, and POCl₃ (1 mL) was heated at 100 °C for 1 hour. The reaction mixture was cooled to ambient temperature and partitioned between CH₂Cl₂ and saturated aqueous NaHCO₃. The organic phase was washed with saturated aqueous NaHCO₃, dried over MgSO₄, filtered, and concentrated *in vacuo*. The residue was purified by chromatography on silica gel (2% methanol/CH₂Cl₂) to give 1-*N,N*-dimethylcarbamoyl-4-methoxycarbonyl-3-{4-[(4-chloro-1H-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole (34 mg). ¹H NMR (DMSO-*d*₆, 300 MHz) δ 2.60 (s, 3H), 3.01 (s, 6H), 3.47 (s, 3H), 5.68 (s, 2H), 7.29 (d, 2H, *J* = 8.4 Hz), 7.45 (t, 1H, *J* = 8.6 Hz), 7.57 (d, 1H, *J* = 8.6 Hz), 7.68 (d, 1H, *J* = 6.0 Hz), 7.84 (d, 2H, *J* = 8.4 Hz), 7.87 (d, 1H, *J* = 8.6 Hz), 8.11 (s, 1H), 8.12 (d, 1H, *J* = 6.0 Hz). MS (DCI/NH₃) *m/e* 530 (M+H)⁺, 364. Anal calcd for C₂₈H₂₄ClN₄O₅ · 0.5 H₂O · 0.375 HCl: C, 61.28; H, 4.74; N, 12.29. Found: C, 61.29; H, 4.67; N, 12.29.

Example 175

Preparation of 1-*N,N*-Dimethylcarbamoyl-4-methoxycarbonyl-3-{4-[(1,5-H-2-methylimidazo[4.5-*c*]pyrid-4-one-1-yl)methyl]benzoyl}indole.

A mixture of 1-*N,N*-dimethylcarbamoyl-4-methoxycarbonyl-3-{4-[(5-oxide-1H-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole (61 mg), prepared as in Example 173, acetic anhydride (1 mL) was heated at 130 °C for 6 hours. The reaction mixture was cooled to ambient temperature and concentrated *in vacuo*. The residue was purified by chromatography on silica gel (5%, then 8% methanol/CH₂Cl₂) to give 1-*N,N*-dimethylcarbamoyl-4-methoxycarbonyl-3-{4-[(1,5-H-2-methylimidazo[4.5-

131

c]pyrid-4-one-1-yl)methyl]benzoyl}indole (42 mg). ^1H NMR (DMSO- d_6 , 300 MHz) δ 2.42 (s, 3H), 3.03 (s, 6H), 3.49 (s, 3H), 5.51 (s, 2H), 6.57 (d, 1H, $J = 6.7$ Hz), 7.13 (t, 1H, $J = 6.7$ Hz), 7.24 (d, 2H, $J = 8.4$ Hz), 7.46 (t, 1H, $J = 8.6$ Hz), 7.57 (d, 1H, $J = 8.6$ Hz), 7.86 (d, 2H, $J = 8.4$ Hz), 7.87 (d, 1H, $J = 8.6$ Hz), 8.12 (s, 1H), 11.14 (d, 1H, $J = 6.7$ Hz). MS (DCI/ NH_3) m/e 512 ($\text{M}+\text{H}$) $^+$, 441, 365, 264, 250, 236, 178.

Example 176

Preparation of 1-*N,N*-Dimethylcarbamoyl-4-ethoxycarbonyl-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole.

To a solution in DMF (4 mL) of 1-*N,N*-dimethylcarbamoyl-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole-4-carboxylic acid (200 mg, 0.42 mmol), prepared as in Example 118 was added NaHCO_3 (70 mg, 0.83 mmol) and bromoethane (62 μL , 0.83 mmol). The reaction vessel was sealed and heated at 40 $^\circ\text{C}$ for 1.5 hours. The reaction mixture was cooled to ambient temperature and partitioned between CH_2Cl_2 and brine. The aqueous phase was extracted three times with CH_2Cl_2 . The combined organic layers were dried over MgSO_4 , filtered, and concentrated *in vacuo*. The residue was purified by chromatography on silica gel (5%, then 15% methanol/ CH_2Cl_2) to give 1-*N,N*-dimethylcarbamoyl-4-ethoxycarbonyl-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole (53 mg). ^1H NMR (DMSO- d_6 , 300 MHz) δ 0.92 (t, 3H, $J = 7.4$ Hz), 2.57 (s, 3H), 3.02 (s, 6H), 3.95 (q, 2H, $J = 7.0$ Hz), 5.65 (s, 2H), 7.30 (d, 2H, $J = 7.8$ Hz), 7.4-7.5 (m, 1H), 7.5-7.6 (m, 2H), 7.87 (d, 2H, $J = 8.1$ Hz), 7.8-7.9 (m, 1H), 8.10 (s, 1H), 8.30 (d, 1H, $J = 5.7$ Hz), 8.86 (s, 1H). MS (DCI/ NH_3) m/e 572 ($\text{M}+\text{H}$) $^+$. Anal calcd for $\text{C}_{29}\text{H}_{27}\text{N}_5\text{O}_4 \cdot 0.3 \text{Et}_2\text{O} \cdot 0.5 \text{H}_2\text{O}$: C, 66.41; H, 5.83; N, 12.82. Found: C, 66.42; H, 5.59; N, 12.66.

Example 177

Preparation of 1-*N,N*-Dimethylcarbamoyl-4-(2-propyloxycarbonyl)-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole.

Step 1: 4-(2-propyloxycarbonyl)indole.

The desired compound was prepared according to the method of Example 176, except substituting indole-4-carboxylic acid for 1-*N,N*-dimethylcarbamoyl-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole-4-carboxylic acid, and substituting 2-bromopropane for bromoethane.

132

Step 2: 1-*N,N*-Dimethylcarbamoyl-4-(2-propyloxycarbonyl)-3-{4-[(1*H*-2-methylnaphtho[2,3-*d*]imidazol-1-yl)methyl]benzoyl}indole.

The desired compound was prepared according to the method of Example 109, except substituting 4-(2-propyloxycarbonyl)indole, prepared as in step 1, for 4-chloroindole. ¹H NMR (DMSO-*d*₆, 300 MHz) δ 1.02 (d, 6H, *J* = 6.3 Hz), 2.57 (s, 3H), 3.02 (s, 6H), 4.86 (apparent quint, 1H, *J* = 6.3 Hz), 5.64 (s, 2H), 7.30 (d, 2H, *J* = 8.1 Hz), 7.4-7.5 (m, 1H), 7.54-7.64 (m, 2H), 7.8-7.9 (m, 3H), 8.08 (s, 1H), 8.30 (d, *J* = 5.7 Hz), 8.86 (s, 1H). MS (DCI/NH₃) *m/e* 524 (M+H)⁺. Anal calcd for C₃₀H₂₉N₅O₄ · 1.2 H₂O: C, 66.09; H, 5.80; N, 12.85. Found: C, 66.31; H, 5.57; N, 12.47.

Example 178

Preparation of 1-*N,N*-Dimethylcarbamoyl-4-methoxycarbonyl-3-{4-[(1*H*-2-methylnaphtho[2,3-*d*]imidazol-1-yl)methyl]benzoyl}indole.

Step 1: 1*H*-2-Methylnaphtho[2,3-*d*]imidazole.

The desired compound was prepared according to the method of Example 158, step 2, except substituting 2,3-diaminonaphthalene for 5-chloro-1,2-phenylenediamine.

Step 2: 4-Methoxycarbonyl-3-{4-[(1*H*-2-methylnaphtho[2,3-*d*]imidazol-1-yl)methyl]benzoyl}indole.

The desired compound was prepared according to the method of Example 90, except substituting 4-methoxycarbonylindole, prepared as in Example 43, step 1, for 4,7-dimethoxycarbonylindole, and substituting 1*H*-2-methylnaphtho[2,3-*d*]imidazole, prepared as in step 1, for 1*H*-2-methylimidazo[4,5-*c*]pyridine.

Step 3: 1-*N,N*-Dimethylcarbamoyl-4-methoxycarbonyl-3-{4-[(1*H*-2-methylnaphtho[2,3-*d*]imidazol-1-yl)methyl]benzoyl}indole.

To a 0 °C solution in THF (5 mL) of 4-methoxycarbonyl-3-{4-[(1*H*-2-methylnaphtho[2,3-*d*]imidazol-1-yl)methyl]benzoyl}indole (38 mg, 0.098 mmol), prepared as in step 2, was added NaH (95%, 3.00 mg, 0.118 mmol). After 10 minutes, dimethylcarbamyl chloride (11.5 μ L, 0.137 mmol) was added and the reaction mixture was stirred for 15 minutes, then the cold bath was removed and stirring was continued for 15 minutes. The reaction mixture was quenched with saturated aqueous NH₄Cl and extracted with ethyl acetate. The organic phase was washed with brine, dried over MgSO₄, filtered, and concentrated *in vacuo*. Chromatography on silica gel (CH₂Cl₂, then 5% methanol/CH₂Cl₂) gave 1-*N,N*-

133

dimethylcarbamoyl-4-methoxycarbonyl-3-{4-[(1H-2-methylnaphtho[2,3-d]imidazol-1-yl)methyl]benzoyl}indole (21 mg) as an amorphous solid. ¹H NMR (DMSO-d₆, 300 MHz) δ 2.64 (s, 3H), 3.02 (s, 6H), 3.45 (s, 3H), 5.70 (s, 2H), 7.30 (d, 2H, J = 9 Hz), 7.35-7.44 (m, 3H), 7.55 (d, 1H, J = 7 Hz), 7.84 (d, 3H, J = 9 Hz), 7.90-8.05 (m, 3H), 8.10 (d, 2H, J = 7 Hz). MS (DCI/NH₃) m/e 545 (M⁺). Anal calcd for C₃₃H₂₈N₄O₄ · 0.5 H₂O: C, 71.59; H, 5.28; N, 10.12. Found: C, 71.32; H, 5.36; N, 9.70.

Example 179

10 Preparation of 1-N, N-dimethylcarbamoyl-4-(N, N-dimethylaminocarbonyloxy)-3-{3-fluoro-4-[(1H-2-methylimidazo[4,5-c]pyrid-1-yl)methyl]benzoyl}indole.

The desired compound was prepared according to the method of example 96, steps 1, 2, 3, and 4, except substituting 4-(N, N-dimethylaminocarbonyloxy)indole for 4,7-dimethoxycarbonylindole. ¹H NMR (DMSO-d₆, 300 MHz) δ 2.59 (s, 3H), 2.73 (s, 3H), 2.91 (s, 3H), 3.00 (s, 6H), 5.69 (s, 2H), 6.97-7.00 (d, 1H, J=8.8Hz), 7.13 (t, 1H), 7.33-7.38 (t, 1H, J=8.5Hz), 7.49-7.52 (d, 1H, J=8.1Hz), 7.59-7.67 (m, 3H), 8.02 (s, 1H), 8.29-8.31 (d, 1H, J=8.0Hz), 8.86 (s, 1H). MS (DCI/NH₃) m/z = 543(M+1)⁺. Anal calcd for C₂₉H₂₇FO₄N₆: C, 63.14; H, 5.11; N, 15.23.

20 Found C, 63.01; H, 5.39; N, 13.75.

Example 180

Preparation of 1-N, N-dimethylcarbamoyl-4-ethynyl-3-{3-fluoro-4-[(1H-2-methylimidazo[4,5-c]pyrid-1-yl)methyl]benzoyl}indole.

25

Step 1: 1-N, N-dimethylcarbamoyl-4-bromo-3-{3-fluoro-4-[(1H-2-methylimidazo[4,5-c]pyrid-1-yl)methyl]benzoyl}indole.

The desired compound was prepared according to the method of example 96, steps 1, 2, 3, and 4, except substituting 4-bromoindole for 4,7-dimethoxycarbonylindole.

30

Step 2: 1-N, N-dimethylcarbamoyl-4-(trimethylsilylethynyl)-3-{3-fluoro-4-[(1H-2-methylimidazo[4,5-c]pyrid-1-yl)methyl]benzoyl}indole.

The desired compound was prepared according to example 106 except substituting 1-N, N-dimethylcarbamoyl-4-bromo-3-{3-fluoro-4-

35

134

[(1H-2-methylimidazo-[4,5-c]pyrid-1-yl)methyl]benzoyl}indole for 1-*N,N*-dimethylcarbamoyl-4-bromo-3-{4-[(1H-2-methylimidazo-[4,5-c]pyrid-1-yl)methyl]benzoyl}indole.

5 Step 3: 1-*N,N*-dimethylcarbamoyl-4-ethynyl-3-{3-fluoro-4-


[(1H-2-methylimidazo-[4,5-c]pyrid-1-yl)methyl]benzoyl}indole.

- The desired compound was prepared according to example 107 except substituting 1-*N,N*-dimethylcarbamoyl-4-(trimethylsilylethynyl)-3-{3-fluoro-4-[(1H-2-methylimidazo-[4,5-c]pyrid-1-yl)methyl]benzoyl}indole for 1-*N,N*-
- 10 dimethylcarbamoyl-4-(trimethylsilylethynyl)-3-{4-[(1H-2-methylimidazo-[4,5-c]pyrid-1-yl)methyl]benzoyl}indole. ¹H NMR (DMSO-d₆, 300 MHz): δ 2.57 (s, 3H), 3.01 (s, 6H), 4.07 (s, 1H), 5.69 (s, 2H), 7.05-7.15 (m, 1H), 7.30-7.45 (m, 2H), 7.55-7.75 (m, 4H), 8.18 (s, 1H), 8.29 (d, J=5.7 Hz, 1H), 8.85 (s, 1H). MS (DCI/NH₃) m/e 480 (M+1)⁺. Anal calcd for C₂₈H₂₂N₅O₂F•0.1 CH₂Cl₂: C, 69.16;
- 15 H, 4.59; N, 14.35. Found: C, 69.28; H, 4.43; N, 13.79.

135

WE CLAIM:

1. A compound of formula



- 5 or a pharmaceutically acceptable salt thereof wherein
R¹ is one or more groups independently selected from the group consisting of
hydrogen,
halogen,
hydroxy,
10 cyano,
alkyl of one to six carbon atoms,
alkynyl of two to four carbon atoms,
alkoxy of one to six carbon atoms,
alkanoyl of one to seven carbon atoms,
15 -COOR⁶, wherein R⁶ is hydrogen, alkyl of one to ten carbon atoms, or
phenylalkyl wherein the alkyl portion is of one to four carbon
atoms,
unsubstituted phenyl,
phenyl, substituted with
20 alkyl of one to six carbon atoms,
alkoxy of one to six carbon atoms,
halogen,
-NR⁴R⁵, where R⁴ and R⁵ are independently selected from
hydrogen and alkyl of one to six carbon atoms, or R⁴
25 and R⁵ together with the nitrogen atom to which they
are attached form a pyrrolidinyl, piperidinyl,
piperazinyl, or morpholinyl ring,
-COOR⁶,
-C(O)NR⁴R⁵, or
30 -SO₂NR⁴R⁵,
-C(O)NR⁴R⁵,
-OC(O)NR⁴R⁵,



136

-NHC(O)NR⁴R⁵,
2- or 3-furyl,
35 2- or 3-thienyl,
2-, 4-, or 5-thiazolyl,
2-, 3-, or 4-pyridyl,
2-, or 4-pyrimidyl,
phenylalkyl in which the alkyl portion is of one to six carbon atoms,
40 phenylalkyl, in which the alkyl portion is of one to six carbon atoms
and the phenyl moiety is substituted with
halogen,
alkyl of from one to six carbon atoms, or
alkoxy of from one to six carbon atoms,
45 unsubstituted benzyoyl,
benzoyl substituted with
halogen,
alkyl of from one to six carbon atoms, or
alkoxy of from one to six carbon atoms,
50 unsubstituted phenoxy,
phenoxy substituted with
halogen,
alkyl of from one to six carbon atoms, or
alkoxy of from one to six carbon atoms,
55 unsubstituted phenylalkyloxy, in which the alkyl portion is of one to
six carbon atoms,
phenylalkyloxy in which the alkyl portion is of one to six carbon
atoms and the phenyl moiety is substituted with
halogen,
60 alkyl of from one to six carbon atoms, or
alkoxy of from one to six carbon atoms, and
unsubstituted phenylalkanoyl, in which the alkanoyl portion is of one
to seven carbon atoms,
phenylalkanoyl, in which the alkanoyl portion is of one to seven
65 carbon atoms and the phenyl moiety is substituted with;
halogen,
alkyl of from one to six carbon atoms, or
alkoxy of from one to six carbon atoms;

- 70 **R²** is selected from the group consisting of
hydrogen,
alkyl of one to six carbon atoms;
-(CH₂)_pCOOR⁶, where p 0, 1, 2, 3, or 4,
-(CH₂)_qNR⁴R⁵, where q 2, 3, or 4,
75 -(CH₂)_pCOR⁶
-(CH₂)_qOR⁶,
-(CH₂)_pSO₂R⁶,
-(CH₂)_pSO₂NR⁴R⁵,
-(CH₂)_pCONR⁷R⁸, where R⁷ and R⁸ are independently selected from
80 the group consisting of
hydrogen,
alkyl of one to six carbon atoms,
-(CH₂)_rCOOR⁶, where r is 1, 2, 3, or 4,
-(CH₂)_rNR⁴R⁵,
85 -(CH₂)_rOH,
-(CH₂)_rSO₂R⁶, and
-(CH₂)_rSO₂NR⁴R⁵,
-(CH₂)_pCN
-(CH₂)_p-1*H*-tetrazol-5-yl
90 -CONHNH₂, and;
unsubstituted phenylalkyl wherein the alkyl portion is of one to four
carbon atoms, and
phenylalkyl wherein the alkyl portion is of one to four carbon atoms
and the phenyl moiety is substituted with
95 halogen,
alkyl of from one to six carbon atoms, or
alkoxy of from one to six carbon atoms; or
R⁷ and R, taken together with the nitrogen atom to which they are
attached, for a pyrrolidinyl or morpholinyl ring;
100
- R³** is selected from the group consisting of hydrogen and alkyl of one to six
carbon atoms;


138

105 **L¹** is selected from the group consisting of




110 alkyl of one to six carbon atoms,
alkoxycarbonyl of from one to six carbon atoms,
aminocarbonyl,
alkylaminocarbonyl of one to six carbon atoms,
dialkylaminocarbonyl in which the alkyl groups are
115 independently of one to six carbon atoms,
alkanoyl of one to six carbon atoms,
unsubstituted phenyl, and
phenyl substituted with

120 halogen,
alkyl of from one to six carbon atoms, or
alkoxy of from one to six carbon atoms; and



125

Ar¹ is a valence bond or a radical of formula



130

where Y is O, S, or $-\text{CH}=\text{CH}-$, Z is N or CH, and R^{11} is selected
from the group consisting of
hydrogen,

alkyl of one to six carbon atoms,
alkenyl of two to six carbon atoms,
alkoxy of one to six carbon atoms, and
135 halogen;

139

L^2 is selected from the group consisting of

a valence bond,

unsubstituted straight-chain alkylene of one to six carbon atoms,

140 straight-chain alkylene of one to six carbon atoms substituted with one

or more groups selected from

alkyl of one to six carbon atoms,

alkenyl of two to six carbon atoms,

alkoxycarbonyl of one to six carbon atoms,

145 alkoxy of one to six carbon atoms,

alkylthio of one to six carbon atoms,

alkoxyalkyl in which the two alkyl portions each are of

one to six carbon atoms,

alkylthioalkyl in which the alkoxy and alkyl portions

150 are independently of one to six carbon atoms,

unsubstituted phenylalkyl wherein the alkyl portion is of one to six carbon atoms,

phenylalkyl wherein the alkyl portion is of one to six carbon atoms, and the phenyl ring is substituted with

155 alkyl of one to six carbon atoms,

haloalkyl of one to six carbon atoms,

alkoxy of one to six carbon atoms,

hydroxy, or

halogen,

160 unsubstituted thiophenyl, and

thiophenyl substituted with

alkyl of one to six carbon atoms,

haloalkyl of one to six carbon atoms,

alkoxy of one to six carbon atoms,


165 hydroxy, or

halogen,

with the proviso that L^2 is unsubstituted alkylene or alkylene substituted alkyl when Ar^1 is a valence bond;

140

170

Ar² is selected from the group consisting of

175

180

where R¹³ is selected from the group consisting of

alkyl of one to six carbon atoms,
 alkenyl of two to six carbon atoms,
 alkoxy of one to six carbon atoms,
 alkylthio of one to six carbon atoms,

185

alkoxyalkyl in which the alkoxy and alkyl portions are independently
 of one to six carbon atoms,

141

alkylthioalkyl in which the alkyl portions each independently of one to six carbon atoms,

haloalkyl of one to six carbon atoms,

190 unsubstituted phenylalkyl wherein the alkyl portion is of one to six carbon atoms,

phenylalkyl wherein the alkyl portion is of one to six carbon atoms and the phenyl is substituted with

alkyl of one to six carbon atoms,

195 haloalkyl of one to six carbon atoms,

alkoxy of one to six carbon atoms,

hydroxy, or

halogen,

cycloalkyl of three to eight carbon atoms,

200 unsubstituted thiophenyl, and

thiophenyl substituted with

alkyl of one to six carbon atoms,

haloalkyl of one to six carbon atoms,

alkoxy of one to six carbon atoms,

205 hydroxy, or

halogen, and

R¹⁴ and R¹⁵ are independently selected from the group consisting of

hydrogen,

alkyl of one to six carbon atoms,

210 alkenyl of two to six carbon atoms,

halogen,

cyano,

carboxyl,

alkoxycarbonyl of two to six carbon atoms,

215 aminocarbonyl,

alkylaminocarbonyl of two to six carbon atoms,

dialkylaminocarbonyl in which the alkyl groups are

independently of one to six carbon atoms,

alkanoyl,

220 hydroxyalkyl,

haloalkyl,

alkoxy of one to six carbon atoms,

142

alkylthio of one to six carbon atoms,
alkylsulfinyl of one to six carbon atoms,
225 alkylsulfonyl of one to six carbon atoms,
amino,
alkonylamino, of one to six carbon atoms, and
nitro, or

230 R^{14} and R^{15} , together with the carbon atoms to which they are
attached define a phenyl ring or 5- to 7-membered
cycloalkylene ring.

2. A compound as defined by Claim 1, or the pharmaceutically acceptable salt thereof wherein

R^1 is one or more groups independently selected from the group consisting of

5 hydrogen,
halogen,
alkyl of one to six carbon atoms,
alkynyl of two to four carbon atoms,
alkoxy of one to six carbon atoms,
10 $-COOR^6$, wherein R^6 is hydrogen, alkyl of one to ten carbon atoms, or
phenylalkyl wherein the alkyl portion is of one to four carbon
atoms,
 $-OC(O)NR^4R^5$, wherein R^4 and R^5 are independently selected from
hydrogen and alkyl of one to six carbon atoms, or R^4 and R^5
15 together with the nitrogen atom to which they are attached form
a pyrrolidinyl, piperidinyl, piperazinyl, or morpholinyl ring,
phenyl,
phenyl, optionally substituted with
alkyl of one to six carbon atoms,
20 alkoxy of one to six carbon atoms, or
halogen,
phenylalkyl wherein the alkyl portion is of one to four carbon
atoms,

25

143

phenylalkyl wherein the alkyl portion is of one to four carbon atoms, and the phenyl moiety is substituted with halogen,

30

alkyl of one to six carbon atoms, or alkoxy of one to six carbon atoms,

phenoxy, and

phenoxy substituted with

halogen,

35


alkyl of one to six carbon atoms, or alkoxy of one to six carbon atoms;

R^3 is hydrogen;

40

L^1 is $>C=O$ or $-SO_2-$;

Ar^1 is



wherein

45


Y is O, S, or $-CH=CH-$,

Z is N or CH;


L^2 is straight chain alkylene of one to six carbon atoms; and

50

Ar^2 is selected from the group consisting of




144



, and

55



wherein R¹³ is methyl and R¹⁴ and R¹⁵ are hydrogen.

60

3. A compound as defined by Claim 2, or the pharmaceutically acceptable salt thereof wherein Ar¹ is selected from the group consisting of unsubstituted phenyl and phenyl substituted with

5

alkyl of one to six carbon atoms,
alkoxy of one to six carbon atoms, or
halogen.

4. A compound as defined by Claim 3, or the pharmaceutically acceptable salt thereof wherein

R¹ is one or more groups independently selected from the group consisting of

5

hydrogen,
alkyl of one to six carbon atoms,
alkynyl of two to four carbon atoms,
-COOR⁶, wherein R⁶ is hydrogen, alkyl of one to ten carbon atoms, or
phenylalkyl wherein the alkyl portion is of one to four carbon
atoms,

10

145

-OC(O)NR⁴R⁵, wherein R⁴ and R⁵ are independently selected from hydrogen and alkyl of one to six carbon atoms, or R⁴ and R⁵ together with the nitrogen atom to which they are attached form a pyrrolidinyl, piperidinyl, piperazinyl, or morpholinyl ring, phenylmethyl, 4-fluorophenyl, and 4-fluorophenoxy;

R² is -C(O)N(CH₃)₂ or -(CH₂)_qOR⁶ where q is 1, 2, 3, or 4, and

L¹ is >C=O or -SO₂-.

5. A compound as defined by Claim 4, or the pharmaceutically acceptable salt thereof wherein L² is methylene.
6. A compound as defined by Claim 4, or the pharmaceutically acceptable salt thereof wherein L² is a valence bond.
7. A compound as defined by Claim 4, or the pharmaceutically acceptable salt thereof wherein Ar¹ is a valence bond.
8. A compound as defined by Claim 1 selected from the group consisting of:
 6-(4-fluorophenyl)-3-{4-[(1H-2-ethylbenzimidazolyl)methyl]benzoyl}indole,
 1-*N,N*-dimethylcarbamoyl-6-(4-fluorophenyl)-3-{4-[(1H-2-methylbenzimidazolyl)methyl]benzoyl}indole,
 6-(4-fluorophenyl)-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole,
 1-*N,N*-dimethylcarbamoyl-6-(4-fluorophenyl)-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole,
 1-*N,N*-dimethylcarbamoyl-6-(4-fluorophenyl)-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole hydrochloride,
 6-(4-fluorophenyl)-3-{4-[(3H-2-methylimidazo[4.5-c]pyrid-3-yl)methyl]benzoyl}indole,
 1-*N,N*-dimethylcarbamoyl-6-(4-fluorophenyl)-3-{4-[(3H-2-methylimidazo[4.5-c]pyrid-3-yl)methyl]benzoyl}indole,

146

- 15 1-*N,N*-dimethylcarbamoyl-6-(4-fluorophenyl)-3-[4-(5H-2-methylimidazo[4.5-c]pyrid-5-ylmethyl)benzoyl]indole,
6-(4-fluorophenyl)-3-[4-(1H-2-methylimidazo[4.5-c]pyridyl)benzoyl]indole,
1-*N,N*-dimethylcarbamoyl-6-(4-fluorophenyl)-3-[4-(1H-2-methylimidazo[4.5-c]pyrid-1-yl)benzoyl]indole,
- 20 6-(4-fluorophenyl)-3-{3-[(1H-2-methylimidazo[4.5-c]pyridyl)methyl]benzoyl}indole,
1-*N,N*-dimethylcarbamoyl-6-(4-fluorophenyl)-3-{3-[(1H-2-methylimidazo[4.5-c]pyridyl)methyl]benzoyl}indole,
3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole,
- 25 1-*N,N*-dimethylcarbamoyl-3-{4-[(1H-2-methylimidazo[4.5-c]pyridyl)methyl]benzoyl}indole,
3-[4-(5H-2-methylimidazo[4.5-c]pyrid-5-ylmethyl)benzoyl]indole,
1-*N,N*-dimethylcarbamoyl-3-[4-(5H-2-methylimidazo[4.5-c]pyrid-5-ylmethyl)benzoyl]indole,
- 30 3-{3-[(1H-2-methylimidazo[4.5-c]pyridyl)methyl]benzoyl}indole,
1-*N,N*-dimethylcarbamoyl-3-{3-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole,
3-{3-[(3H-2-methylimidazo[4.5-c]pyridyl)methyl]benzoyl}indole,
1-*N,N*-dimethylcarbamoyl-3-{3-[(3H-2-methylimidazo[4.5-c]pyridyl)methyl]benzoyl}indole,
- 35 3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)]benzoyl}indole,
1-*N,N*-dimethylcarbamoyl-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)benzoyl}indole,
1-*N,N*-dimethylcarbamoyl-6-(4-fluorophenyl)-3-[(3H-2-methylimidazo[4.5-c]pyrid-3-yl)methylcarbonyl]indole,
- 40 1-*N,N*-dimethylcarbamoyl-6-(4-fluorophenyl)-3-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methylcarbonyl]indole,
1-*N,N*-dimethylcarbamoyl-3-[(3H-2-methylimidazo[4.5-c]pyrid-3-yl)methylcarbonyl]indole,
- 45 1-*N,N*-dimethylcarbamoyl-3-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methylcarbonyl]indole,
1-*N,N*-dimethylcarbamoyl-3-{4-[(3H-2-methylimidazo[4.5-b]pyrid-3-yl)methyl]benzoyl}indole,
1-*N,N*-dimethylcarbamoyl-3-{4-[(1H-2-methylimidazo[4.5-b]pyrid-1-yl)methyl]benzoyl}indole,
- 50

147

- 1-*N,N*-dimethylcarbamoyl-3-{4-[1H-2-trifluoromethylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole,
1-*N,N*-dimethylcarbamoyl-3-{4-[1H-imidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole,
55 1-*N,N*-dimethylcarbamoyl-3-{4-[1H-2-(2-propyl)imidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole,
1-*N,N*-dimethylcarbamoyl-3-{4-[1H-2-phenylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole,
1-*N,N*-dimethylcarbamoyl-3-{4-[1H-2-ethylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole,
60 3-{3-[(5H-2-methylimidazo[4.5-c]pyrid-5-yl)methyl]benzoyl}indole,
1-*N,N*-dimethylcarbamoyl-3-{3-[(5H-2-methylimidazo[4.5-c]pyrid-5-yl)methyl]benzoyl}indole,
1-*p*-toluenesulfonyl-6-(4-fluorophenyl)-3-{4-[(1H-2-methylimidazo[4.5-c]pyridyl)methyl]benzoyl}indole,
65 1-*N,N*-dimethylcarbamoyl-6-(4-fluorophenyl)-3-[(3H-2-methylimidazo[4.5-c]pyrid-3-yl)pent-5-ylcarbonyl]indole,
1-*N,N*-dimethylcarbamoyl-6-(4-fluorophenyl)-3-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)pent-5-ylcarbonyl]indole,
70 1-*N,N*-dimethylcarbamoyl-6-(4-fluorophenyl)-3-[(5H-2-methylimidazo[4.5-c]pyrid-5-yl)pent-5-ylcarbonyl]indole,
1-*N,N*-dimethylcarbamoyl-6-(4-fluorophenoxy)-3-{4-[(3H-2-methylimidazo[4.5-c]pyrid-3-yl)methyl]benzoyl}indole,
1-*N,N*-dimethylcarbamoyl-6-(4-fluorophenoxy)-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole,
75 1-*N,N*-dimethylcarbamoyl-6-phenylmethyl-3-{4-[(3H-2-methylimidazo[4.5-c]pyrid-3-yl)methyl]benzoyl}indole,
1-*N,N*-dimethylcarbamoyl-6-phenylmethyl-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole,
80 1-*N,N*-dimethylcarbamoyl-4-methoxycarbonyl-3-{4-[(3H-2-methylimidazo[4.5-c]pyrid-3-yl)methyl]benzoyl}indole,
1-*N,N*-dimethylcarbamoyl-4-methoxycarbonyl-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole,
1-*N,N*-dimethylcarbamoyl-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]phenylsulfonyl}indole,
85

148

- 1-(morpholin-4-ylcarbonyl)-6-(4-fluorophenyl)-3-{4-[(1H-2-methylimidazo[4.5-c]pyridyl)methyl]benzoyl}indole,
1-(*N,N*-dimethylcarbamoylmethyl)-6-(4-fluorophenyl)-3-{4-[(1H-2-methylimidazo[4.5-c]pyridyl)methyl]benzoyl}indole,
90 4,7-dimethoxycarbonyl-3-{4-[(1H-2-methylimidazo[4,5-c]pyrid-1-yl)methyl]benzoyl}indole,
4,7-dimethyl-3-{4-[(1H-2-methylimidazo[4,5-c]pyrid-1-yl)methyl]benzoyl}indole,
4,7-dimethyl-3-{4-[(3H-2-methylimidazo[4,5-c]pyrid-3-yl)methyl]benzoyl}indole,
95 7-benzyloxy-3-{4-[(1H-2-methylimidazo[4,5-c]pyrid-1-yl)methyl]benzoyl}indole,
7-(4-fluorophenyl)-3-{4-[(1H-2-methylimidazo[4,5-c]pyrid-1-yl)methyl]benzoyl}indole,
100 6-(4-fluorophenyl)-3-{*N*-[3-(1H-2-methylimidazo[4.5-c]pyrid-1-yl)propyl]sarcosyl}indole-1-carboxylic acid dimethyl amide,
1-*N,N*-dimethylcarbamoyl-4-methoxycarbonyl-3-{3-fluoro-4-[(1H-2-methylimidazo[4,5-c]pyrid-1-yl)methyl]benzoyl}indole,
1-*N,N*-dimethylcarbamoyl-6-benzyloxy-3-{4-[(1H-2-methylimidazo[4,5-c]pyrid-1-yl)methyl]benzoyl}indole,
105 1-*N,N*-dimethylcarbamoyl-4-methoxycarbonyl-3-{5-[(1H-2-methylimidazo[4,5-c]pyrid-1-yl)methyl]thien-2-oyl}indole,
1-*N,N*-dimethylcarbamoyl-6-(4-fluorophenyl)-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]phenylaminocarbonyl}indole
hydrochloride,
110 1-*N,N*-dimethylcarbamoyl-5-(4-fluorophenyl)-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole,
1-*N,N*-dimethylcarbamoyl-6-(4-fluorophenyl)-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]phenylsulfonyl}indole,
115 1-*N,N*-dimethylcarbamoyl-4-bromo-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole,
1-*N,N*-dimethylcarbamoyl-4-acetyl-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole,
1-*N,N*-dimethylcarbamoyl-4-(fur-2-yl)-3-{4-[(1H-2-methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole,
120

149

- 1-*N,N*-dimethylcarbamoyl-4-(benzo[b]fur-2-yl)-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole,
1-*N,N*-dimethylcarbamoyl-4-(trimethylsilylethynyl)-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole,
125 1-*N,N*-dimethylcarbamoyl-4-ethynyl-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole,
4-(4-fluorophenyl)-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole,
1-*N,N*-dimethylcarbamoyl-4-chloro-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole,
130 1-*N,N*-dimethylcarbamoyl-4-fluoro-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole,
1-*N,N*-dimethylcarbamoyl-2-methyl-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole,
135 1,4-di-*N,N*-dimethylcarbamoyl-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole,
1-*N,N*-dimethylcarbamoyl-5-methoxycarbonyl-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole,
1-*N,N*-dimethylcarbamoyl-4-methoxycarbonyl-6-(4-fluorophenyl)-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole,
140 4-methoxycarbonyl-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole,
4-methoxycarbonyl-1-(pyrrolidin-1-ylcarbonyl)-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole,
145 1-*N,N*-dimethylcarbamoyl-4-benzyloxycarbonyl-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole,
1-*N,N*-dimethylcarbamoyl-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole-4-carboxylic acid,
1-*N,N*-dimethylcarbamoyl-4-(*N*-nonylcarbamoyl)-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole,
150 1-*N,N*-dimethylcarbamoyl-4-(dec-1-yloxycarbonyl)-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole,
1-*N,N*-dimethylcarbamoyl-4-methoxy-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole,
155 1-*N,N*-dimethylcarbamoyl-4-methyl-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole,

150

- 1-*N,N*-dimethylcarbamoyl-4-methoxycarbonyl-3-[(1*H*-2-methylimidazo[4.5-
c]pyrid-1-yl)hex-6-ylcarbonyl]indole,
1-*N,N*-dimethylcarbamoyl-4-methoxycarbonyl-3-{4-[(1*H*-2-
methylbenzimidazolyl)methyl]benzoyl}indole,
4-methoxycarbonyl-1-(pyrrolidin-1-ylcarbonyl)-3-{4-[(1*H*-2-
methylbenzimidazolyl)methyl]benzoyl}indole,
1-*N,N*-dimethylcarbamoyl-4-methoxycarbonyl-3-[(1*H*-2-methylimidazo[4.5-
c]pyrid-1-yl)pent-5-ylcarbonyl]indole,
1-*N,N*-dimethylcarbamoylmethyl-4-methoxycarbonyl-3-[(1*H*-2-
methylimidazo[4.5-c]pyrid-1-yl)pent-5-ylcarbonyl]indole,
1-*N,N*-dimethylcarbamoyl-4-methoxycarbonyl-3-[(1*H*-2-methylimidazo[4.5-
c]pyrid-1-yl)pent-5-ylcarbonyl]indole,
1-*N,N*-dimethylcarbamoyl-4-methoxycarbonyl-3-{4-[(2-methyl-4-
(3*H*)quinazolinone-3-yl)methyl]benzoyl}indole,
1-(2-ethoxyethyl)-4-methoxycarbonyl-3-{4-[(1*H*-2-methylimidazo[4.5-
c]pyrid-1-yl)methyl]benzoyl}indole,
1-*N,N*-dimethylsulfamoyl-4-methoxycarbonyl-3-{4-[(1*H*-2-
methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole,
1-*N,N*-dimethylsulfamoyl-4-methoxycarbonyl-3-{4-[(1*H*-2-
methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole,
1-acetoxymethyl-4-methoxycarbonyl-3-{4-[(1*H*-2-methylimidazo[4.5-c]pyrid-
1-yl)methyl]benzoyl}indole,
1-(2-propanesulfonyl)-4-methoxycarbonyl-3-{4-[(1*H*-2-methylimidazo[4.5-
c]pyrid-1-yl)methyl]benzoyl}indole,
1-(1-pinacolyl)-4-methoxycarbonyl-3-{4-[(1*H*-2-methylimidazo[4.5-c]pyrid-
1-yl)methyl]benzoyl}indole,
1-carbamoyl-4-methoxycarbonyl-3-{4-[(1*H*-2-methylimidazo[4.5-c]pyrid-1-
yl)methyl]benzoyl}indole,
1-*N*-methylcarbamoyl-4-methoxycarbonyl-3-{4-[(1*H*-2-methylimidazo[4.5-
c]pyrid-1-yl)methyl]benzoyl}indole,
1-(2-ethoxyethyl)-4-chloro-3-{4-[(1*H*-2-methylimidazo[4.5-c]pyrid-1-
yl)methyl]benzoyl}indole,
1-*N,N*-dimethylcarbamoyl-4-methoxycarbonyl-3-{3-methoxy-4-[(1*H*-2-
methylimidazo[4.5-c]pyrid-1-yl)methyl]benzoyl}indole,
1-*N,N*-dimethylcarbamoyl-4-methoxycarbonyl-3-{3-methoxy-4-[(3*H*-2-
methylimidazo[4.5-c]pyrid-3-yl)methyl]benzoyl}indole,

151

- 195 1-*N,N*-dimethylcarbamoyl-4-methoxycarbonyl-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]phenylsulfonyl}indole,
1-*N,N*-dimethylcarbamoyl-4-methoxycarbonyl-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]phenylsulfonyl}indole,
1-*N,N*-dimethylcarbamoyl-4-ethynyl-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole,
200 1-*N,N*-dimethylcarbamoyl-4-hydroxy-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole,
1-*N,N*-dimethylcarbamoyl-6-bromo-4-methoxycarbonyl-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole,
1-*N,N*-dimethylcarbamoyl-6-(benzo[*b*]fur-2-yl)-4-methoxycarbonyl-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole,
205 1-*N,N*-dimethylcarbamoyl-6-(fur-2-yl)-4-methoxycarbonyl-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole,
1-*N,N*-dimethylcarbamoyl-4-(*N,N*-dimethylaminocarbonyloxy)-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole,
1-*N,N*-dimethylcarbamoyl-4-(*N,N*-dimethylaminocarbonylamino)-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole,
210 1-*N,N*-dimethylcarbamoyl-4-cyano-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole hydrochloride,
1-*N,N*-dimethylcarbamoyl-4-methoxycarbonyl-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzyl}indole,
215 1-*N,N*-dimethylcarbamoyl-4-chloro-3-{4-[(1*H*-2-methylimidazo[4.5-*b*]pyrid-1-yl)methyl]benzoyl}indole,
1-*N,N*-dimethylcarbamoyl-4-methoxycarbonyl-3-{4-[(3*H*-2-methylimidazo[4.5-*b*]pyrid-3-yl)methyl]benzoyl}indole,
1-*N,N*-dimethylcarbamoyl-4-methoxycarbonyl-3-{4-[(1*H*-2-methylimidazo[4.5-*b*]pyrid-1-yl)methyl]benzoyl}indole,
220 1-*N,N*-dimethylcarbamoyl-4-methoxycarbonyl-3-{4-[(5*H*-2-methylimidazo[4.5-*c*]pyrid-5-yl)methyl]benzoyl}indole,
1-*N,N*-dimethylcarbamoyl-4-methoxycarbonyl-3-{4-[1-(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)eth-1-yl]benzoyl}indole,
225 1-*N,N*-dimethylcarbamoyl-4-methoxycarbonyl-3-{4-[1-(1*H*-imidazo[4.5-*c*]pyrid-1-yl)eth-1-yl]benzoyl}indole,
1-*N,N*-dimethylcarbamoyl-4-methoxycarbonyl-3-{4-[(1*H*-2-methyl-5-, and 6-chlorobenzimidazolyl)methyl]benzoyl}indole,

152

- 230 1-*N,N*-dimethylcarbamoyl-4-chloro-3-{4-[(1*H*-2-methyl-5-, and 6-chlorobenzimidazolyl)methyl]benzoyl}indole,
1-(2-ethoxyethyl)-4-methoxycarbonyl-3-{4-[(1*H*-2-methyl-5-, and 6-chlorobenzimidazolyl)methyl]benzoyl}indole,
1-(pyrrolidin-1-ylcarbonyl)-4-methoxycarbonyl-3-{4-[(1*H*-2-methyl-5-, and 6-chlorobenzimidazolyl)methyl]benzoyl}indole,
- 235 1-*N,N*-dimethylcarbamoyl-4-methoxycarbonyl-3-{4-[(1*H*-2-(trifluoromethyl)benzimidazolyl)methyl]benzoyl}indole,
1-*N,N*-dimethylcarbamoyl-4-methoxycarbonyl-3-{4-[(1*H*-2-methyl-5- and 6-methylbenzimidazolyl)methyl]benzoyl}indole,
1-*N,N*-dimethylcarbamoyl-4-methoxycarbonyl-3-{4-[(1*H*-2-methyl-4- and 7-methylbenzimidazolyl)methyl]benzoyl}indole,
- 240 1-*N,N*-dimethylcarbamoyl-4-methoxycarbonyl-3-{4-[(1*H*-2-methyl-5- and 6-methylbenzimidazolyl)methyl]benzoyl}indole,
1-*N,N*-dimethylcarbamoyl-4-methoxycarbonyl-3-{4-[(1*H*-2-methyl-5- and 6-nitrobenzimidazolyl)methyl]benzoyl}indole,
- 245 1-*N,N*-dimethylcarbamoyl-4-methoxycarbonyl-3-{4-[(1*H*-2-methyl-5, 6-dichlorobenzimidazolyl)methyl]benzoyl}indole,
1-*N,N*-dimethylcarbamoyl-4-methoxycarbonyl-3-{4-[(1*H*-2-methyl-5- and 6-methoxycarbonylbenzimidazolyl)methyl]benzoyl}indole,
1-(pyrrolidin-1-ylcarbonyl)-4-methoxycarbonyl-3-{4-[(1*H*-2-methyl-5- and 6-methoxycarbonylbenzimidazolyl)methyl]benzoyl}indole,
- 250 1-(pyrrolidin-1-ylcarbonyl)-4-methoxycarbonyl-3-{4-[(1*H*-2-methyl-5- and 6-methylbenzimidazolyl)methyl]benzoyl}indole,
1-*N,N*-dimethylcarbamoyl-4-methoxycarbonyl-3-{4-[(3*H*-2, 4, 6-trimethylimidazo[4.5-*c*]pyrid-3-yl)methyl]benzoyl}indole,
- 255 1-(pyrrolidin-1-ylcarbonyl)-4-methoxycarbonyl-3-{4-[(1*H*-5-trifluoromethyl-2-methylmethylbenzimidazolyl)methyl]benzoyl}indole,
1-*N,N*-dimethylcarbamoyl-4-methoxycarbonyl-3-{4-[(5-oxide-1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole,
1-*N,N*-dimethylcarbamoyl-4-methoxycarbonyl-3-{4-[(4-chloro-1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole,
- 260 1-*N,N*-dimethylcarbamoyl-4-methoxycarbonyl-3-{4-[(1,5-*H*-2-methylimidazo[4.5-*c*]pyrid-4-one-1-yl)methyl]benzoyl}indole,
1-*N,N*-dimethylcarbamoyl-4-ethoxycarbonyl-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole,

153

- 265 1-*N,N*-dimethylcarbamoyl-4-(2-propyloxycarbonyl)-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole, and
1-*N,N*-dimethylcarbamoyl-4-methoxycarbonyl-3-{4-[(1*H*-2-methylnaphtho[2,3-*d*]imidazol-1-yl)methyl]benzoyl}indole.
9. A compound or pharmaceutically acceptable salt thereof selected from the group consisting of
1-*N,N*-dimethylcarbamoyl-4-(*N,N*-dimethylaminocarbonyloxy)-3-{3-fluoro-4-[(1*H*-2-methylimidazo[4,5-*c*]pyrid-1-yl)methyl]benzoyl}indole,
5 1-*N,N*-dimethylcarbamoyl-4-ethynyl-3-{3-fluoro-4-[(1*H*-2-methylimidazo[4,5-*c*]pyrid-1-yl)methyl]benzoyl}indole,
1-*N,N*-dimethylcarbamoyl-4-ethynyl-3-{4-[(1*H*-2-methylimidazo[4,5-*c*]pyrid-1-yl)methyl]benzoyl}indole,
10 1-*N,N*-dimethylcarbamoyl-4-(*N,N*-dimethylaminocarbonyloxy)-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole, and
1-*N,N*-Dimethylcarbamoyl-4-methoxycarbonyl-3-{4-[(1*H*-2-methylimidazo[4.5-*c*]pyrid-1-yl)methyl]benzoyl}indole.
10. A pharmaceutical composition useful for inhibiting PAF in a mammal in need of such treatment comprising a PAF-inhibitive effective amount of a compound as defined by Claim 1 in combination with a pharmaceutically acceptable carrier.
- 5 11. A method of treating PAF-mediated disorders comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound as defined by Claim 1.

INTERNATIONAL SEARCH REPORT

National Application No.
PCT/US 94/14112

A. CLASSIFICATION OF SUBJECT MATTER

C 07 D 471/04, C 07 D 403/10, C 07 D 405/14,
C 07 D 409/14, C 07 D 413/14, C 07 D 417/14,

According to International Patent Classification (IPC) or to both national classification and IPC 6

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

C 07 D, A 61 K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO, A, 93/01 813 (ABBOTT) 04 February 1993 (04.02.93), claims 1,5-7 (cited in the application). --	1, 10, 11
A	DE, A, 2 427 207 (CIBA-GEIGY) 09 January 1975 (09.01.75), claims 1,43,50. --	1, 10
A	EP, A, 0 171 037 (STERLING DRUG) 12 February 1986 (12.02.86), claims 1,10. --	1, 10
A	DE, A, 3 200 705 (AGFA-GEVAERT) 21 July 1983 (21.07.83),	1

☒ Further documents are listed in the continuation of box C.☐ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search
15 February 1995

Date of mailing of the international search report

- 6. 03. 95

Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

HAMMER e.h.

INTERNATIONAL SEARCH REPORT

-2-

Inventor's Application No
PCT/US 94/14112

A. CLASSIFICATION OF SUBJECT MATTER

C 07 D 487/04, A 61 K 31/435, A 61 K 31/50
According to International Patent Classification (IPC) or to both national classification and IPC 6

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>page 44, line 7. --</p> <p>EP, A, 0 444 451 (STERLING DRUG) 04 September 1991 (04.09.91), claim 1; formula VII. --</p>	1
A	<p>CHEMICAL ABSTRACTS, vol. 113, no. 1, issued 1990, July 02, (Columbus, Ohio, USA), FUJISAWA PHARMACEUTICAL CO., LTD. "Preparation of imida- zolidine derivatives as platelet activating factor (PAF) antagonists", page 618, no. 6 344p; & JP, A, 02 015 068. --</p>	1, 10



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search
15 February 1995

Date of mailing of the international search report

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+ 31-70) 340-3016

Authorized officer

HAMMER e.h.

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>--- CHEMICAL ABSTRACTS, vol. 96, no. 14, issued 1982, April 05 (Columbus, Ohio, USA), Nagarajan, K. et al. "Structure-activity relations among cyclic and acyclic S-(3-indolyl) isothioureas - development of a potent vasoconstrictor, tinazoline, 3-(2-imidazolin-2-yl-thio) indole", page 20, no.115 505t; & Indian J. Exp. Biol. 1981, 19(12), 1150-3 (Eng).</p>	1
A	<p>--- CHEMICAL ABSTRACTS, vol. 108, no. 7, issued 1988, February 15, (Columbus, Ohio, USA), HELBECQUE N. et al. "Grossularine-1 and grossula- rine-2, alpha-carbolines from Dendrodoa grossularia, as possible intercalative agents", page 16, no. 48 713k; & Cancer Biochem. Biophys. 1987, 9(3), 271-9 (Eng).</p>	1
A	<p>--- CHEMICAL ABSTRACTS, vol. 111, no. 17, issued 1989, October 23, (Columbus, Ohio, USA), MOQUIN-PATTEY, CAROLE et al. "Grossularine-1 and grossula- rine-2, cytotoxic alpha-carbolines from the tunicate Dendrodoa grossularia", page 440, no. 150 783p; & Tetrahedron 1989, 45(11), 3445-50 (Eng).</p>	1
A	<p>--- CHEMICAL ABSTRACTS, vol. 102, no. 11, issued 1985, March 18 (Columbus, Ohio, USA), MOQUIN, CAROLE et al. "Grossularine, a novel indole derivative from the marine tunicate, Dendrodoa grossularia", page 360, no. 93 257b;</p>	1

INTERNATIONAL SEARCH REPORT

-4-

International Application No
PCT/US 94/14112

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
	<p>& Tetrahedron Lett. 1984, 25(44), 5047-8 (Eng). -----</p>	

ANHANG

ANNEX

ANNEXE

zum internationalen Recherchenbericht über die internationale Patentanmeldung Nr.

to the International Search Report to the International Patent Application No.

au rapport de recherche international relatif à la demande de brevet international n°

PCT/US 94/14112 SAE 101584

In diesem Anhang sind die Mitglieder der Patentfamilien der im obengenannten internationalen Recherchenbericht angeführten Patentedokumente angegeben. Diese Angaben dienen nur zur Unterrichtung und erfolgen ohne Gewähr.

This Annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The Office is in no way liable for these particulars which are given merely for the purpose of information.

La présente annexe indique les membres de la famille de brevets relatifs aux documents de brevets cités dans le rapport de recherche international visé ci-dessus. Les renseignements fournis sont donnés à titre indicatif et n'engagent pas la responsabilité de l'Office.

Im Recherchenbericht angeführtes Patentedokument Patent document cited in search report Document de brevet cité dans le rapport de recherche	Datum der Veröffentlichung Publication date Date de publication	Mitglied(er) der Patentfamilie Patent family member(s) Membre(s) de la famille de brevets	Datum der Veröffentlichung Publication date Date de publication
WO A1 9301813	04-02-93	AU A1 23391/92	23-02-93
		AU B2 651243	14-07-94
		CA AA 2112562	04-02-93
		EP A1 595924	11-05-94
		EP A4 595924	24-08-94
		IL A0 102494	14-01-93
		JP T2 6510027	10-11-94
		PT A 100698	29-10-93
DE A1 2427207	09-01-75	AT A 4847/74	15-03-76
		AT B 333267	10-11-76
		BE A1 816262	13-12-74
		CH A 574441	15-04-76
		DD C 112132	20-03-75
		DK A 3166/74	17-02-75
		DK B 142701	22-12-80
		DK C 142701	21-09-81
		ES A1 427269	01-07-76
		FR A1 2233047	10-01-75
		FR B1 2233047	04-11-77
		IE B 39495	25-10-78
		IL A0 44876	31-07-74
		IL A1 44876	31-01-78
		JP A2 50035160	03-04-75
		JP B4 58049557	05-11-83
		LU A 70309	13-04-76
		NL A 7407614	17-12-74
		SE A 7407175	16-12-74
		SE B 408709	02-07-79
		SE C 408709	11-10-79
		US A 3954757	04-05-76
		US A 4055647	25-10-77
		YU A 1647/74	31-08-82
EP A2 171037	12-02-86	AT E 77371	15-07-92
		AU A1 45764/85	13-02-86
		AU B2 574817	14-07-88
		CA A1 1246563	13-12-88
		CA A2 1255305	06-06-89
		CA A2 1255312	06-06-89
		CA A2 1255316	06-06-89
		CA A2 1258069	01-08-89
		CA A2 1258070	01-08-89
		DE C0 3586224	23-07-92
		DE T2 3586224	28-01-93
		DK A0 3544/85	05-08-85
		DK A 3544/85	07-02-86
		EP A3 171037	26-08-87
		EP B1 171037	17-06-92
		ES A1 545894	16-07-86
		ES A5 545894	16-08-86
		ES A1 8609246	16-12-86
		ES A1 552912	16-10-87
		ES A5 552912	16-11-87
		ES A1 552909	01-12-87
		ES A1 552911	01-12-87
		ES A1 552910	16-12-87
		ES A5 552909	29-12-87
		ES A5 552911	29-12-87
		ES A1 8800149	01-01-88
		ES A5 552910	15-01-88
		ES A1 8800901	16-02-88
		ES A1 8800902	16-02-88
		ES A1 8801203	01-03-88

FI	AO	85297	01-08-85
FI	A	85297	07-02-86
FI	A	893254	04-07-89
FI	A	893255	04-07-89
FI	A	893255	04-07-89
FI	A	893256	04-07-89
FI	A	893257	04-07-89
FI	AO	893253	04-07-89
FI	AO	893254	04-07-89
FI	AO	893255	04-07-89
FI	AO	893256	04-07-89
FI	AO	893257	04-07-89
GR	A	851937	05-12-85
IE	B	57863	05-05-93
IL	AO	75966	31-12-85
IL	A1	75966	15-08-89
JP	A2	61047463	07-03-86
JP	B4	6070010	07-09-94
KR	B1	8700548	18-03-87
MX	A	160612	28-03-90
NO	A	853066	07-02-86
NO	A	903304	07-02-86
NO	A	903305	07-02-86
NO	A	903306	07-02-86
NO	AO	903304	25-07-90
NO	AO	903305	25-07-90
NO	AO	903306	25-07-90
NO	B	169067	27-01-92
NO	C	169067	06-05-92
NZ	A	212953	26-02-90
NZ	A	225464	26-02-90
NZ	A	225465	26-02-90
NZ	A	225466	26-02-90
NZ	A	225467	26-02-90
PH	A	23498	16-08-89
PT	A	80919	01-09-85
PT	B	80919	30-09-87
ZA	A	8505923	26-03-86
US	A	4581354	08-04-86
US	A	4634776	06-01-87
US	E	32761	04-10-88
US	A	4885295	05-12-89
US	A	4978664	18-12-90
US	A	5013732	07-05-91

DE	A1	3200705	21-07-83
GB	AO	8300702	16-02-83
GB	A1	2128349	26-04-84
GB	B2	2128349	29-08-85
JP	A2	58123537	22-07-83
US	A	4461827	24-07-84

EP	A2	444451	04-09-91
AU	A1	71222/91	29-08-91
AU	B2	638795	08-07-93
CA	AA	2035711	27-08-91
EP	A3	444451	08-04-92
FI	AO	910851	22-02-91
FI	A	910851	27-08-91
HU	AO	910400	28-08-91
HU	A2	56565	30-09-91
HU	B	208132	30-08-93
IL	AO	97313	25-05-92
NO	AO	910731	25-02-91
NO	A	910731	27-08-91
NZ	A	237041	25-11-92
PT	A	96871	31-10-91
US	A	5068234	26-11-91
US	A	5324737	28-06-94

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☒ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☒ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.